Cardiopulmonary interactions of hypoxia and hypercapnia and the role of vasoactive mediators in the pulmonary circulation in man by Kiely, David Gerard
CARDIOPULMONARY INTERACTIONS OF HYPOXIA AND
HYPERCAPNIA AND THE ROLE OF VASOACTIVE
MEDIATORS IN THE PULMONARY CIRCULATION IN MAN
David Gerard Kiely BSc (Hons) MB ChB MRCP (UK)
Thesis submitted to the University of Edinburgh for the degree of
Doctor of Medicine August 1999
To Jane, Emma, Laura
and my parents
This thesis has been composed by David Gerard Kiely and represents the
culmination of two years work at the Department of Clinical Pharmacology,
Ninewells Hospital, Dundee. The work on which this thesis is based is the
candidates own although he was assisted by other members of the department
during the conduct ofsome of the initial studies. This thesis has not been
submitted in candidaturefor any other degree, diploma or qualification.
2
ACKNOWLEDGEMENTS
I would like to thank all those who helped me during my two years at the Department
of Clinical Pharmacology, Ninewells Hospital, Dundee and in the following years
which culminated in the eventual submission of my work. Brian Lipworth offered
endless encouragement. I am indebted to him for his concern, support, patience and
interest over several years that has enabled me to pursue an enjoyable career in
respiratory medicine. Robert Cargill "blooded" me in the art of Doppler
echocardiography and helped make the transition from a clinical to research job less
painful. Many thanks to Soong Tan, Dave Clark, Alison Lee, Martin Devlin and Pete
Clarkson amongst others, for frequent cups of coffee and fun nights out in
Barcelona, Stockholm and York to name a few. To technical help from Harry and
Gordon and their help to pass the hours discussing Scotland's lack of progress in all
things sporting. I am indebted to Lesley and Wendy for all their help in the lab and
performing the overwhelming bulk of the assays, and to Steve for being generous
with the purse strings. To Jenny and Joy for helping with the admin, to Jess for help
with patients and for Mrs Rice for being Mrs Rice. Thanks also to Andrew for morale
boosting chats and for help printing the figures.
It goes without saying that none of this would have been possible without the help of
my parents. My principal thanks go to Jane who has supported me throughout and
has given me a wonderful family that I have been able to use on numerous occasions
as an excuse for the late submission of this thesis. A final word of thanks to Edwin




We have examined the cardiopulmonary effects of hypoxia and hypercapnia in the
integrated physiological system of normal man using non-invasive pulsed-wave
Doppler echocardiography and phonocardiography and have extended this work to
study the role vasoactive mediators in the pulmonary circulation in man.
We have demonstrated that systolic and diastolic function are unaffected by acute
hypercapnia in normal man. Acute hypoxaemia significantly impairs both right and
left ventricular diastolic function, in a dose dependant manner, although systolic
function remains well preserved. In addition to confirming that hypoxia is a potent
pulmonary vasoconstrictor we have demonstrated that hypercapnia is a weak
pulmonary vasoconstrictor, suggesting a possible role in ventilation perfusion
matching in health and disease. We have also shown potentially adverse
electrophysiological effects of both hypoxia and hypercapnia, the clinical significance
of which is unknown.
The second part of this thesis examines the role of vasoactive mediators in the
pulmonary circulation. In a series of placebo controlled studies we have demonstrated
for the first time in normal man that angiotensin II is capable of modulating the acute
hypoxic pulmonary vasoconstrictor response, using infusions of the non selective
angiotensin II receptor blocker saralasin and the orally active type 1 angiotensin II
receptor blocker losartan. We have extended this work to patients with hypoxaemic
cor pulmonale secondary to chronic obstructive pulmonary disease (COPD) and have
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shown beneficial haemodynamic and endocrine sequelae of type 1 angiotensin II
receptor blockade in these patients with a vasoreactive pulmonary circulation. These
results suggest that manipulation of the renin-angiotensin system may be of
therapeutic benefit in this patient group.
We have shown that acute hypoxaemia is a stimulus to endothelin-1 release in normal
man and that levels of this peptide are elevated in patients with hypoxaemic cor
pulmonale due to COPD. We have demonstrated in a double blind placebo controlled
crossover study that systemic infusions of this peptide are capable of causing
pulmonary vasoconstriction in a dose dependant manner in addition to having adverse
effects on both inotropicity and lusitropicity in normal man. These novel findings may
be important in considering the pathophysiological role of endothelin-1 in both
cardiovascular and cardiopulmonary disease. Using an infusion of the nitric oxide
inhibitor NG-monomethyl-L-arginine we have shown for the first time in a double blind
placebo controlled crossover study that basal nitric oxide generation is important in
maintaining basal pulmonary vascular tone in normal man.
Finally in a study encompassing 114 events of suspected pulmonary thromboembolism
(PTE) we have reported for the first time elevated levels of atrial, B-type and N-
terminal atrial natriuretic peptides in patients with pulmonary thromboembolism,
presumably reflecting the cardiopulmonary sequelae. In addition we have shown
significantly elevated levels of these peptides in patients dying of PTE compared to
survivors. The results of this pilot study suggest that further work is required to more
fully evaluate the diagnostic role of these peptides in PTE and whether they may be
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useful in risk stratification and the identification of patients most likely to benefit from
thrombolysis.
Our findings from this series of studies are consistent with an important role for
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The pulmonary vascular bed has often been regarded as a passive conduit for the
transport of blood from the right side of the heart to the left. Although under normal
conditions vasomotor control is minimal and gaseous exchange occurs as a relatively
passive process this can be disrupted by a variety of different disease processes. In
recent years much interest has been directed towards different cellular elements of the
pulmonary vascular tree and the role of endothelial cells in the synthesis and
metabolism of vasoactive substances, growth factors and in the regulation of cell
growth.
In terms of morbidity and mortality chronic bronchitis and emphysema and pulmonary
thromboembolism represent the commonest causes of pulmonary hypertension seen in
the general medical setting. The aetiology and pathogenesis of pulmonary
hypertension in these conditions is different and although incompletely understood is
likely to reflect abnormalities in gaseous exchange, ablation of the pulmonary vascular
bed and changes in endothelial function. The discovery of new vasoactive peptides
and the characterisation of receptor ligand interactions has given us insight into a
variety of different pathophysiological processes and provided us with therapeutic
options and diagnostic tests in conditions such congestive cardiac failure. The role
and importance of these peptides in the pulmonary vascular bed is incompletely
understood.
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This MD Thesis firstly examines the cardiopulmonary effects of hypoxia and
hypercapnia in the integrated physiological system of man. Although these
abnormalities of gaseous exchange have been extensively investigated in the past the
advent of new non invasive methodology has allowed us to more completely elucidate
their effects in normal man.
Secondly we have examined the role of vasoactive peptides in the pulmonary
circulation. In this respect the interaction of hypoxia with the renin angiotensin
system has been of considerable interest and we have examined for the first time the
role of angiotensin II in modulating the acute hypoxic pulmonary vasoconstrictor
response in normal man and the haemodynamic and endocrine effects of selective
angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. The
discovery of endothelin-1 as the most potent vasoconstrictor known to man has
heralded much research into its role in conditions characterised by abnormal
vasoconstriction. We have examined the interaction between hypoxia and endothelin-
1 release and in addition have studied the effects of this hormone on both the
pulmonary and cardiovascular systems in normal man. In addition to examining the
role of different vasoconstrictors in the pulmonary circulation we have examined
whether basal generation of a potent vasodilator, nitric oxide, is essential for
maintenance of low pulmonary vascular tone, where conflicting results exist in the
current literature.
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The final chapter in this thesis examines some of the endocrine sequelae of pulmonary
thromboembolism and their possible physiological and diagnostic roles in this
condition.
The remainder of this chapter reviews our current understanding of the
cardiopulmonary effects of hypoxia and hypercapnia and the role of vasoactive
peptides in the pulmonary circulation in man with particular reference to their possible
therapeutic and diagnostic value.
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1.2 Cardiopulmonary effects of hypoxaemia
1.2.1 Hypoxic pulmonary vasoconstriction
Hypoxaemia usually arises in man as a consequence of adverse environmental
conditions (eg altitude) or due to acute or chronic pulmonary diseases. Since the first
description of the phenomenon of acute hypoxic pulmonary vasoconstriction by Von
Euler and Liljestrand in 1946 (von Euler US et al, 1946) the effects of hypoxia on the
pulmonary circulation have been extensively studied. The mechanism of this response
is incompletely understood although teleologically it has beneficial effects regulating
foetal blood flow and after birth acting as a homeostatic mechanism to divert blood
from areas of alveolar hypoxia and thus maintaining ventilation perfusion
homogeneity. The importance of ventilation perfusion matching has been
demonstrated in healthy volunteers by Hales (Hales CA et al, 1978) who showed a
significant reduction in arterial p02 after the intake of a small dose of the vasodilator
nitroglycerin. The central regulatory role of this response is reflected by its presence
in most animal species (Satchell G, 1962, Millard R et al, 1974, Cueva S et al, 1974).
Although the acute effects of this response are undoubtedly beneficial the presence of
chronic hypoxaemia can result in elevation of pulmonary arterial pressure, vascular
remodelling and over time the development of cor pulmonale. A consequence not
uncommonly seen in the context of chronic bronchitis and emphysema.
Pulmonary vasoconstriction is initiated within seconds of the onset of alveolar hypoxia
(Jensen K et al, 1992) and is known to be a more effective stimulus to the small
pulmonary arteries (the main site of hypoxic pulmonary vasoconstriction) than the
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oxygen content of the pulmonary artery perfusate (Marshall C et al, 1983, Bergofsky
E et al, 1968). Considerable individual and ethnic differences are seen in the response
of the pulmonary vascular tree to hypoxia with the relationship of the curve of
pulmonary artery pressure to hypoxaemia being less steep in Himalayan people
compared to Andean counterparts who in turn appear to be better adapted to the
effects of hypobaric oxygen than their North American counterparts (Williams D,
1994). This is thought to be a reflection of genetic adaptation to hypobaric hypoxia.
The inability of some individuals to adapt to hypobaric hypoxia results in a wide
variety of disturbances in functions of most organs of the body resulting in the
development of "mountain sickness" (Anand IS, 1994).
Nagasaka (Nagasaka Y et al, 1984) showed that hypoxia increased pulmonary
vascular resistance in arterial segments upstream from arterioles. Further work with
laser technology confirmed hypoxic pulmonary vasoconstriction to small arterioles 30-
200pm in diameter (Koyama T et al, 1983). Although the major site of pulmonary
vasoconstriction is known the mechanism of this response and how vascular smooth
muscles sense hypoxia is poorly understood. Alveolar hypoxia results in calcium
influx through voltage dependent calcium channels as a consequence of depolarisation
of the resting membrane potential of the smooth muscle cells (Madden J et al, 1985).
A number of different vasoactive substances such as angiotensin II (ANG II) (Berkov
S, 1974, McMurty I et al, 1984), histamine (Tucker A et al, 1976), serotonin (Miller
M et al, 1979), prostaglandins (Weir E et al, 1974) and leukotrienes (McDonnell T et
al, 1990) have all been proposed as possible mediators although current interest
surrounds the hypothesis that the smooth muscle cells may directly sense changes in
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oxygen tension via potassium channels (Post JM et al, 1992). They demonstrated that
hypoxaemia inhibited outward potassium current in pulmonary arterial smooth
muscles resulting in depolarisation of the membrane potential providing a stimulus for
calcium influx through voltage dependent calcium channels and consequently resulting
in vasoconstriction.
Although different vasoactive peptides have been excluded as sole mediators of
hypoxic pulmonary vasoconstriction (HPV) the interaction between hypoxia and
hormonal systems has been of much interest. In this respect the interaction between
hypoxaemia and the renin-angiotensin system (RAS) is of considerable interest
(Cargill RI et al, 1994). Not only has ANG II been shown to be a potent pulmonary
vasoconstrictor (Segel N et al, 1960) but aldosterone may also be important in
determining changes in sodium and water homeostasis. This may be particularly
relevant where activation of the RAS accompanies chronic hypoxic lung disease, such
as occurs in cor pulmonale (Farber MO et al, 1977, Farber MO et al, 1982), where
manipulation of the RAS may have therapeutic benefit.
1.2.2 Cardiovascular effects of hypoxia
In addition to effects on the pulmonary vasculature hypoxia affects a variety of other
physiological systems. Although the effects of myocardial ischaemia have been
extensively investigated much less is known of the effects of arterial hypoxaemia
where the majority of studies have examined the effects of hypoxia on isolated heart
and muscle preparations. Although acute hypoxaemia has been reported as increasing
(Doyle JT et al, 1952, Vogel JA et al, 1967), decreasing (Motley HL et al, 1947) or
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having no effect (Fletcher EC et al, 1983) on cardiac output in humans it is now
generally accepted that cardiac output rises in a dose dependent fashion with
increasing hypoxaemia in healthy men (Phillips BA et al, 1988) and in contrast to its
effects on the pulmonary vasculature hypoxia is a weak systemic vasodilator. The
time course of cardiovascular response to hypoxaemia is brisk with one study
reporting 95% of subjects attaining 85% of maximum cardiac output within 5 minutes
(Phillips BA et al, 1988). In this study the increase in cardiac output resulted entirely
from an increase in heart rate with no significant changes seen in stroke volume.
Indeed this increase in cardiac output is a physiologically predictable response.
During hypoxaemia oxygen delivery to the tissues decreases and since oxygen supply
to the tissues is a function of arterial oxygenation, cardiac output and haemoglobin,
increased cardiac output at least in the acute situation is a teleologically appropriate
response. Interestingly ascent to altitude results in an acute increase in cardiac output
and heart rate (Vogel JA et al, 1967), however, over a period of 1-10 days heart rate
returns to levels slightly above pre-ascent levels, cardiac output and stroke volume
decrease to reach a steady state with values 20% below resting levels at sea level
(Alexander JK et al, 1967). It is not clear whether this reduction represents a
physiological adaptation to improved oxygen delivery to the tissues caused by an
increased haematocrit and changes in the oxygen-haemoglobin dissociation curve or
reflects impairment of myocardial function. Echocardiography shows a reduction in
left ventricular end diastolic and end-systolic diameters although ejection fraction
remains normal suggesting a physiological adaptation rather than impaired myocardial
function (Alexander JK et al, 1983).
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Observational studies in patients have shown that in chronic hypoxic lung disease that
left ventricular function at rest is usually normal or increased as judged by left
ventricular ejection fraction, cardiac output and pulmonary capillary wedge pressure
(Fishman AP et al, 1971, Christianson LC et al, 1979, Anand IS et al, 1992).
Interestingly, however, patients with hypoxaemic cor pulmonale have a
proportionately smaller increase in cardiac output in response to exercise than do their
counterparts with no evidence of pulmonary hypertension (Khaja F et al, 1971). In
addition post mortem studies have shown patchy fibrosis and left ventricular
hypertrophy in patients with hypoxaemic cor pulmonale (Michelson N, 1980, Kohama
A et al, 1990). The functional consequences and of these changes are unknown
although one would imaging that they would reduce ventricular compliance and result
in impairment of left ventricular diastolic function, changes which have been
demonstrated in vivo (Marangoni S et al, 1992).
Studies in healthy humans have demonstrated a significant increase in coronary artery
blood flow in response to hypoxaemia with a reduction in inspired oxygen to 10%
resulting in a 2 fold increase in coronary blood flow, possibly mediated by
prostaglandins (Hellems HK et al, 1957). Ascent to high altitude although resulting in
an acute increase in coronary blood flow results in a 25% reduction over the following
7-10 days, presumably reflecting adaptation to improved oxygen delivery (Groover
RF et al, 1976). During myocardial ischaemia myocardial performance is dependent
on oxygen delivery as well as the build up of metabolites. Left ventricular
performance is impaired most by a combination of hypoxaemia and the build up of
metabolites as demonstrated by occluding an artery with a percutaneous transluminal
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coronary angioplasty balloon. Whereas left ventricular performance is less affected by
pacing induced ischaemia (Bruyne B et al, 1993). In patients with chronic lung
disease and underlying coronary artery disease the addition of hypoxia to underlying
myocardial ischaemia may be enough to precipitate left ventricular failure particularly
in the presence of hypercapnia and acidosis. It is not surprising therefore that in
addition arrhythmias are common in chronic hypoxic lung disease (Terlapur VG et al,
1982, Holford Fo et al, 1973, Kleiger RE et al, 1974) possibly reflecting direct effects
of hypoxia and hypercapnia on the heart as well as myocardial ischaemia. The
electrophysiological effects of hypoxaemia in normal humans are not well documented
although it is well recognised that there is a close correlation between the level of
hypoxaemia and the occurrence of ventricular extrasystoles (Shepard JW Jr et al,
1985). Certainly uncomplicated ascent to altitude and short exposure to hypoxia does
not appear to be associated with significant arrhythmias (Vogel JA et al, 1967).
1.3 Cardiopulmonary effects of hypercapnia
Hypercapnia occurs in a variety of different disease states commonly occurring in the
context of chronic bronchitis and emphysema and also in diseases involving
neurological and musculoskeletal systems. It reflects inadequate alveolar ventilation
and consequently is usually accompanied by hypoxaemia. However, hypercapnia also
occurs in anaesthetic practice in the absence of hypoxia as so called "permissive
hypercapnia". This reflects recent work suggesting that mechanical ventilation may
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contribute to barotrauma (Dreyfuss D et al, 1985) resulting in a volume and pressure
limited ventilation strategy and higher levels of carbon dioxide (C02) as a
consequence (Hickling KG et al, 1990, Pesenti A, 1990). In addition to profound
effects on the cardiovascular system hypercapnia also affects the respiratory system,
central nervous system as well as renal and acid-base physiology. Although
hypercapnia may have deleterious consequences patients with respiratory insufficiency
can excrete metabolically produced carbon dioxide with a relatively low alveolar
ventilation, diminishing ventilatory requirements and thus reducing the work of
breathing.
1.3.1 "Direct" and "indirect" effects of hypercapnia
Carbon dioxide can be regarded as having both "direct" " indirect" circulatory effects
in man. Although C02 causes dilation of peripheral arterioles and depresses
myocardial contractility (Butcher RL et al, 1972, Nejad NS et al, 1967, Price HL,
1960) it stimulates the central nervous system at different levels evoking a variety of
sympathoadrenal responses (Cross BA et al, 1962). Firstly we will consider the direct
effects of C02 on end organs. In isolated guinea pig (McElroy WT Jr et al, 1958),
rabbit (Williams EM et al, 1958) and dog heart preparations (Price FIL et al, 1955)
increased C02 concentration results in a reduced rate and force of contraction. The
ability of C02 to reduce pH of the perfusate ie the ability of C02 to form carbonic acid
was believed to be primarily responsible for the observed effects, since in the absence
of external pH changes force and rate of contraction was independent of C02
concentration. A similar effect has been in peripheral blood vessels (Diji A, 1959)
although interestingly, pulmonary vessels seem to be the exception to the rule that
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acidosis causes vasodilatation (Duke HN, 1949, Bergofsky EH et al, 1962). It has
been observed that CO2 causes vasoconstriction in isolated lungs and this may act as a
protective mechanism to direct blood from poorly ventilated areas of the lung in much
the same way as hypoxia. The ability of carbon dioxide to dilate capillaries and veins
more than arteries and arterioles (Fleishman M et al, 1957) allows control of venous
return to the heart and some control over cardiac output. In addition to direct effects,
the cardiovascular effects of C02 depend on indirect actions mediated via the
autonomic nervous system.
It is well known that chemoreceptors in the carotid and aortic bodies are exquisitely
sensitive to changes in C02 concentration resulting in stimulation of a variety of
subcortical areas which themselves can be stimulated directly by C02 (Gellhorn E,
1953). The end result is one of cortical stimulation, increased sympathetic discharge
and hyperventilation (Price HL, 1960). The indirect effects of C02 can therefore
antagonise the direct effects with the increased sympathetic discharge mediated
centrally having positively chronotropic and inotropic effects in addition to causing
arteriolar vasoconstriction. Although breathing low concentrations of inhaled C02
5% had no significant effects on cardiac output in normal man (Burnum JF et al,
1954) an increase was observed with higher concentrations of carbon dioxide (Kilburn
KH et al, 1969). This effect is thought to be due to the central nervous system actions
of C02 mediated via the sympathetic nervous system since blockade of this system
with subarachnoid procaine resulted in hypotension and cardiac failure in response to
C02 inhalation (Lurie AA et al, 1958). Although hypercapnia invariably causes
arterial hypertension in the integrated physiological system of man the effects are less
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marked than those on cardiac output resulting in a reduction of systemic vascular
resistance. This suggests predominance of locally mediated vasodilator over centrally
mediated vasoconstrictor effects.
1.3.2 Hypercapnia and the pulmonary circulation
There is some debate concerning the effect of C02 on the pulmonary vasculature. The
early work ofFishman and colleagues (Fishman AP et al, 1960) examined the effect of
inhalation of 3-5% C02 on both normal volunteers and patients with chronic
bronchitis and emphysema and concluded that in contrast to hypoxia that hypercapnia
had no significant effects on the pulmonary vasculature. This work contrasted sharply
with animal studies (Duke HN et al, 1949, Bergofsky EH et al, 1962) and the
dichotomy was explained by Kilburn and his colleagues (Kilburn KH et al, 1969) who
demonstrated pulmonary vasoconstriction in patients with more severe hypercapnia.
These findings have been corroborated in other patient studies providing strong
evidence for a pulmonary vasoconstrictor effect of hypercapnia (Rosketh R, 1966,
Paul G et al, 1964). Breathing 5% C02 would appear to be an inadequate stimulus to
conscious human subjects due to negation of the effects of carbon dioxide as a
consequence of augmented ventilation. One could postulate, however, that inhaling
C02 in concentrations sufficient to increase arterial C02 concentration may cause
pulmonary vasoconstriction and be another mechanism in healthy man for
maintenance of ventilation perfusion homogeneity.
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1.3.3 Arrhythmogenesis
Hypercapnia is known to be arrhythmogenic although in conscious subjects it is well
tolerated until CO2 concentrations exceed twice the normal concentration (Secher PH
et al, 1960). It is well known that anaesthetics can change the threshold at which
arrhythmias occur in response to CO2 (Price HL, 1958). Interestingly anaesthetics
that increase the sympatheticoadrenal response lower the arrhythmia threshold to C02
(Lurie AA et al, 1958). This finding in conjunction with the observation that
arrhythmias observed during C02 inhalation can be reproduced by direct stimulation
of cardiac nerves or the addition of adrenaline, suggests that it is the sympathoadrenal
stimulation caused by CO2 that is responsible for its arrhythmogenic potential (Price
HL, 1958). Although asystole has been observed in the context of hypercapnia it is
known that hypercapnia is itself not responsible for this phenomenon but that it
exaggerates the cardiac response to vagal stimulation (Clowes G Jr et al, 1955).
Although arrhythmias are common in patients with hypercapnia who have underlying
chronic bronchitis and emphysema the importance of hypercapnia per se and the
possible synergism between hypoxia and hypercapnia has not been fully investigated.
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1.4 The endothelium and modulation of pulmonary vascular tone
during normoxaemia and hypoxaemia.
The vascular endothelium acts not only as a barrier between vascular smooth muscle
and blood but has a variety of well defined functions. These include processing of
circulating hormones, preservation of a non-thrombotic surface and regulation of
pulmonary vascular tone and smooth muscle proliferation (Vane JR et al, 1990, Dzau
VJ et al, 1991, Ogawa S et al, 1990, Scott-Burden T et al, 1993). Evidence suggests
that endothelial dysfunction plays a central role in contributing to the development of
pulmonary hypertension due to an imbalance of vasodilators/vasoconstrictors
(Christman BW et al, 1992) and growth inhibiting/promoting factors (Dzau VJ et al,
1991). A variety of different stimuli such as hypoxia and shear stress are known to
cause endothelial dysfunction and pulmonary hypertension is likely to represent a
combination of both endothelial initiated and mediated responses. It is currently
thought that basal generation of vasodilators maintains the low pressure pulmonary
circulation and protects it from the development of pulmonary hypertension and that
under normal conditions this vascular bed is well protected from vasoconstrictor
substances. Indeed the observation that in the development of hypoxic pulmonary
hypertension levels of endothelial derived constricting factors such as ET-1 (Giadi et
al, 1993) and ANG II are increased whilst the production and or effects of
vasodilators such as nitric oxide (NO) (Dinh-Xuan AT et al, 1991, Adnot S et al,




Prostacyclin was the first identified vasodilator synthesised by endothelial cells and its
release has been shown to be stimulated by hypoxaemia. Interestingly inhibition of
prostaglandin synthesis has been shown to enhance the acute HPV response to
alveolar hypoxia in an animal model (Weir EK et al, 1978) and increase pulmonary
vascular resistance in patients with chronic bronchitis and emphysema (Adnot S et al,
1987). This suggests that prostaglandins may play a role in modulating HPV.
Furchgott and Zawadaki (Furchgott RF et al, 1980) isolated a second endothelial
derived relaxing factor in 1980 which has subsequently been identified as NO.
Although it is well established that impairment of endogenous NO release whether
induced pharmacologically or due to structural endothelial disease is associated with
an increased response to vasoconstrictor substances (Adnot S et al, 1991, Dinh-Xuan
AT et al, 1991) there is still some debate regarding whether basal generation of NO is
essential for maintenance of low pulmonary vascular tone where conflicting results
exist suggesting the possibility of species specificity. In the cat (McMahon TJ et al,
1991) and lamb (Fineman JR et al, 1991, Fineman JR et al, 1992) inhibition of NO
synthesis is associated with an increase in pulmonary vascular tone whereas studies in
the rat (Hasunuma K et al, 199), dog (Archer SL et al, 1990, Nishiwaki K et al, 1992)
and rabbit (Cherry PD et al, 1987) have shown either no or variable effect. To date
only one study in normal man has been performed suggesting an important role for
basal NO synthesis in maintenance of both systemic and pulmonary vascular tone with
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an infusion of bP-monomethyl-L-arginine significantly increasing both systemic and
pulmonary vascular resistance (Stammler JS et al, 1994).
Nitric oxide also plays an important role in modulating HPV. Animal studies using
isolated lungs from rats have shown that inhibitors of NO such as methylene blue and
L-arginine potentiate hypoxic pulmonary vasoconstriction (Brashers VL et al, 1988)
and endothelium derived relaxing factor inhibits HPV in rats (Liu S et al, 1993).
Studies in normal man have shown that inhaled NO selectively reverses HPV (Frostell
CG et al, 1993) and this coupled with the well documented increase in NO production
in response to hypoxaemia (Busse R et al, 1993) suggests an important role for NO in
modulating the acute HPV response. Impairment of endothelium dependent
pulmonary artery relaxation has been demonstrated in arteries from patients with end
stage chronic obstructive pulmonary disease (COPD) (Dinh-Xuan AT et al, 1991).
Compared to control subjects removal of endothelial production of NO eliminates the
difference in tension in the arterial rings increasing the tension in control rings but not
in patients, suggesting that NO release which normally acts as a brake on
vasoconstriction is reduced in arterial rings from patients with chronic obstructive
airways disease favouring not only impaired relaxation but also favouring excessive
constriction of pulmonary arteries in these patients. Pepke-Zaba has demonstrated that
inhaled NO can be used as a selective pulmonary vasodilator in patients with
moderately severe pulmonary hypertension (Pepke-Zaba et al, 1991) and studies are
currently underway examining whether inhaled NO may have a role to play in the
treatment of patients with end stage COPD. In addition a complex interplay also exists
between NO and ET-1 and NO may play an important role in modulating pulmonary
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vascular tone by reducing ET-1 synthesis and release (Boulanger C et al, 1990). This
may be of particular importance in disease states characterised by excessive
vasoconstriction and elevated levels of this peptide.
In addition to locally generated vasodilators a number of other substances produced at
distant sites are known to have important effects on the pulmonary vascular bed. Of
particular interest is a family of peptides known as the natriuretic peptides which
cause natriuresis, vasodilatation and suppression of the renin angiotensin system
(Struthers AD et al, 1994). ANP or atrial natriuretic peptide and BNP or B-type
natriuretic peptide are synthesised from primarily atrial and ventricular myocytes
respectively and are secreted in response to changes in wall tension (Yasue H et al,
1994) and hypoxaemia and may play an important role in autoregulation particularly in
the context of pulmonary hypertension. Levels of ANP have been shown to be
elevated during acute hypoxaemia in normal man (Lawrence DL et al, 1990), in
primary pulmonary hypertension (Morice AH et al 1990) and hypoxaemic cor
pulmonale (Lang CC et al, 1992).
In terms of modulating the pulmonary vascular response to hypoxaemia ANP has been
shown to cause potent inhibition of HPV in isolated perfused rat lungs (Ou LC et al,
1989, Zhao L et al, 1992) and ANP has been shown to prevent the pulmonary
vascular remodelling seen in response to chronic hypoxia in rats (Zhao L et al, 1991).
This response again appears to be species related with no effect seen on HPV in dogs.
Studies in have shown that both ANP and BNP cause pulmonary vasodilatation in
normal man in response to pressor agents (Cargill RI et al, 1996) and BNP but not
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ANP was able to attenuate the acute HPV response in normal man (Cargill RI et al,
1995). In patients with COPD infusions of ANP have been shown to cause
vasodilatation (RogersTK et al, 1994, Adnot S et al, 1989). In the same way as NO
production may ameliorate the effects of other vasoconstrictors it has been proposed
that the vasorelaxant and natriuretic properties of the natriuretic peptide system may
antagonise the effects of RAS activation which is commonly seen in the context of
hypoxaemic cor pulmonale secondary to COPD.
1.4.2 Vasoconstrictors
Following the identification of endothelial derived relaxing factors investigators turned
their attention to searching for endothelial derived constricting factors. This resulted
in the identification of a 21 amino acid peptide which was isolated and sequenced by
Yanagisawa in 1988 and called endothelin (Yanagisawa M et al, 1988). This peptide
causes long acting vasoconstriction and is the most potent pressor agent known to
man. Further work identified two other structurally related peptides. ET-1 and
endothelin-2 (ET-2) exhibit the closest structural similarity and are more potent
vasoconstrictors than endothelin-3 (ET-3) (Inoue A et al, 1989). In the lung both ET-
1 and ET-3 are abundantly expressed (Giad A et al, 1991, Filep JG, 1993) and both
have been shown to constrict pulmonary arteries and veins from various animal
species (Filep JG, 1993) and ET-1 has been shown to have mitogenic properties on
vascular smooth muscle cells, consistent with the hypothesis that ET-1 plays a role in
vascular remodelling (Janakidevi K et al, 1992). Receptors have been isolated in
smooth muscle cells (Hirata Y et al, 1988, Hosoda K et al, 1991) where stimulation of
the type A endothelin receptor results in gradual onset but long lasting constriction
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whilst stimulation of the type B receptor causes transient vasodilatation although it is
also involved in the vasoconstrictor response (Bigaud M et al, 1992, Clozel M et al,
1992). Synthesis of ET-1 on the basis of induction of mRNA or increased levels of
ET-1 is stimulated by a variety of physical and chemical stimuli in vitro including
exposure to adrenaline, thrombin, vasoactive peptides such as ANG II and by physical
stimuli including hypoxia and shear stress (Haynes WG et al, 1993). In rats hypoxia
stimulates ET-1 mRNA expression (Kourembanas S et al, Elton TS et al, 1992) and
release of ET-1 from perfused resistance vessels (Rakugi H et al, 1990). In vitro ET-
1 has been shown to cause pulmonary vasoconstriction in rat and human pulmonary
artery resistance vessels (Crawlwy D et al, 1989, MacLean MR et al, 1994) and ET-1
has been shown to have both vasoconstrictor and vasodilator properties in the rat lung
(Hasanuma K et al, 1990). An important role for ET-1 in modulating the acute HPV
response in rats has been shown by Oparil and workers (Oparil S et al, 1995) who
have shown that endothelin receptor blockers attenuate this response and Eddahibi
and colleagues (Eddahibi S et al, 1995) have shown that endothelin receptor blockade
can attenuate the development of pulmonary hypertension in chronically hypoxic rats.
Interestingly the hypoxia induced contraction of canine pulmonary artery rings was
not antagonised by the selective type A endothelin antagonist BQ-123 (Douglas SA et
al, 1993) suggesting species specificity.
It is thought that ET-1 is not stored intracellularly reflected by the observation that
production of ET-1 by cultured endothelial cells is not detected until at least 30
minutes stimulation with thrombin (Yanagisawa M et al, 1988). It would seem
unlikely therefore that ET-1 is a mediator of hypoxic pulmonary vasoconstriction
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particularly given the long time course of its actions (Vanhoutte PM et al, 1989).
However, evidence does suggest that it is capable of modulating the acute HPV
response as a consequence of both hypoxia mediated ET-1 release and hypoxia
mediated increases in maximum ET-1 binding (Liu J et al, 1990). These interactions
as well as the interactions of ET-1 with other vasoconstrictors (Emoriti CI et al,
1991) and vasodilators (Suzuki S et al, 1991, Warner TD et al, 1989) suggests that
ET-1 may play an important role in modulating the vascular response to hypoxaemia
particularly in conditions where ET-1 levels are elevated. However, further studies
need to be performed in man to evaluate more fully the role of ET-1. In particular
although levels of ET-1 are known to be elevated in primary pulmonary hypertension
(Stewart DJ et al, 1991), the effects of hypoxaemia on ET-1 release and the effects of
ET-1 on the pulmonary vascular bed in normal man are not known. It has still not
been established whether levels of ET-1 are elevated in hypoxaemic cor pulmonale
where conceivably they could enhance pulmonary vasoconstriction and increase right
ventricular afterload.
The octapeptide ANG II is a potent systemic and pulmonary vasoconstrictor (Segel N
et al, 1960) and is formed form angiotensin I (ANG I) by the action of angiotensin
converting enzyme (ACE). This enzyme is predominantly a tissue enzyme and is
localised mainly to the surface of endothelial cells in the systemic and pulmonary
circulations. Highest concentrations of this enzyme are found in the lung (Ryan JW et
al, 1975) on the luminal surface of the pulmonary vascular endothelium. Just under
half of arterial ANG II is formed by the pulmonary circulation with approximately 60-
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80% of circulating ANG I being converted to ANG II by a single pass through the
lungs (Ng KKF et al, 1967, Ng KKF et al, 1968). During hypoxaemia, blood flow
through the lungs is accelerated and the conversion of ANG I becomes less efficient
(Szidon et al, 1980). ANG II receptors have been demonstrated in the pulmonary
circulation. Although a number of ANG II receptors have been identified most of the
vascular effects are thought to be modulated via the ATi receptor (Timmermans
PBMWM et al, 1991). The close association of ACE with the endothelial cells of the
pulmonary circulation, resulting in the conversion of ANG I to its active metabolite, is
ideally suited to regulate blood flow to the lung. If the rate of conversion of ANG I to
ANG II can be controlled then the blood flow to that area could be regulated by the
amount of ANG II produced. Although it has been demonstrated that ACE activity in
the lung can be enhanced after short term exposure of rat pulmonary artery to
hypoxaemia (Krulewitz AH et al, 1984) these results are in sharp contrast to longer
term studies showing a reduction in ACE activity at 14 and 28 days (Jin H et al,
1987). Interestingly although there is a reduced pressor response to ANG I, there is
restoration of the response to infused ANG II reflecting receptor up regulation in the
face of reduced enzymatic activity.
ANG II in addition to direct pulmonary vasoconstrictor effects has been shown to
potentiate the HPV response in isolated perfusd rat lung. Berkov postulated that ANG
II was required to facilitate hypoxic pulmonary vasoconstriction (Berkov S, 1974)
although McMurty subsequently showed that other pulmonary pressor agents also
possessed the ability to restore HPV in saline perfused rat lung (McMurty IF, 1884).
In vivo studies have shown that ANG II potentiated acute hypoxic pulmonary
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vasoconstriction in dogs (Alexander JM et al, 1976) although other workers have
found that chronic infusion of ANG II paradoxically attenuated pulmonary
hypertension and vascular remodelling in chronically hypoxic rats (Rabinovitch M et
al, 1988). Interestingly prior exposure to chronic hypoxia appears to sensitise the
pulmonary vasculature to the acute pulmonary pressor effects of ANG II in rats
(Caldwell RW et al, 1981). Studies in humans are rare although a recent study has
shown that although ANG II is a potent pulmonary pressor agent when given
systemically to normal man and the pulmonary pressor effect of angiotensin II is
blunted in the presence of hypoxaemia (Cargill RI et al, 1994). This may simply
represent a geometric phenomenon due to large differences in pulmonary vascular
tone during normoxaemia and acute hypoxaemia rather than representing a specific
interaction between these two pressor stimuli. It may potentially be important in
situations where hypoxaemia and elevated levels of ANG II co-exist such as cor
pulmonale. Where alleviating reversibly HPV with oxygen therapy could allow
endogenous ANG II to elicit proportionately greater pulmonary vasoconstriction and
hence limit the potential benefits of oxygen therapy.
ACE inhibitors and ANG II antagonists have given us some insight into the role of
ANG II during hypoxaemia. The competitive ANG II antagonist, saralasin when
administered to dogs had no significant effects on HPV (Hales CA et al, 1977)
although in conditions where ANG II levels are not elevated saralasin behaves as a
partial agonist (Fagard R et al, 1980). Studies performed with ACE inhibitors in the
cat (Prewitt RL et al, 1981) have shown that although they were unable to attenuate
the acute HPV response they did attenuate the development of pulmonary
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hypertension and vascular remodelling in chronically hypoxic rats (Zakheim RM et al,
1975) possibly an effect secondary to inhibition of the well known mitogenic
properties of ANGII.
Interestingly patients with hypoxaemic cor pulmonale have activation of the RAS.
Although treatments such as diuretics (Burnier M et al, 1992) cause activation of the
RAS, even in the absence of diuretic therapy, Mannix et al demonstrated activation of
the RAS in cor pulmonale (Mannix ET et al, 1990). The stimulus for RAS activation
in this patient group remains unclear although observations suggest that hypercapnia
may play a central role. In the absence of hypercapnia, RAS activation in hypoxaemic
patients is rare (Farber MO et al, 1982) and indeed hypoxaemia has not been shown to
increase circulating ANG II levels in normal man although these may not represent
accurately ANG II levels at a tissue level. This would suggest an aetiological role for
combined effects of hypercapnia with hypoxia and may relate to the following
observations. Firstly, hypercapnia is a potent systemic vasodilator and during
exacerbations of COPD this is associated with a reduction in systemic vascular
resistance (Anand IS et al, 1992). Thus, although these patients have normal or
increased cardiac output (Anand IS et al, 1992, Reihmann DH et al, 1985) they
appear to have severely reduced renal blood flow and glomerular filtration rate
(Farber MO et al, 1982, Anand IS et al, 1992). It is therefore an attractive hypothesis
to suggest that in the presence of increased right ventricular afterload, a consequence
of pulmonary hypertension, that the heart is unable to compensate for falling systemic
vascular resistance by further increments in cardiac output. This pattern has been
observed during exercise where patients with cor pulmonale had a proportionately
smaller cardiac output response to exercise compared with COPD patients without
pulmonary hypertension (Khaja F et al, 1971). This may lead to further reductions in
renal blood flow and direct stimulation of the RAS. ANG II may then sustain this
vicious circle by causing further pulmonary vasoconstriction (Segel N et al, 1960),
50
and perhaps interact adversely with HPV. In terms of the haemodynamic effects of
blood gas abnormalities, it may also be relevant that hypercapnia, as well as causing
systemic vasodilatation may also induce some degree of pulmonary vasoconstriction
(Kilburn KH et al, 1969) whilst hypoxia which causes marked pulmonary
vasoconstriction, may also contribute to systemic vasodilatation in patients with
COPD (Anand IS et al, 1992).
Hypercapnia and hypoxia have also been studied in relation to direct effects on renal
function. Kilburn et al studied the effects of hypoxia and hypercapnia on renal function
in patients with COPD recovering from episodes of respiratory failure (Kilburn KH et
al, 1971). In this study, decreasing arterial oxygen tension led to an initial increase in
renal plasma flow and glomerular filtration rate (GFR), presumably a result of intra-
renal autoregulation, but with further decreases in oxygenation, a decline in renal
function was observed. Severe hypercapnia also caused renal blood flow and GFR to
decrease. It would appear therefore in cor pulmonale that although hypoxaemia and
hypercapnia can individually influence the RAS, both may need to be present in
synergistic fashion to produce clinically detectable RAS activation and consequent
fluid retention.
In view of evidence suggesting that angiotensin II may have detrimental pulmonary
pressor effects in hypoxaemic cor pulmonale a number of small acute dosing studies
have been performed (Boschetti E et al, 1985, Takade K et al, 1986, Bertoli L et al,
1986, Zielinski J et al, 1986, Patakas D et al, 1988, Peacock AJ et al, 1992, Burke
CM et al, 1985, Pison CM et al, 1991). These have been limited by small patient
numbers and inconsistent inclusion criteria which may explain their variable effect on
pulmonary haemodynamics. The use of vasodilators in this condition is also
controversial due to concern over worsening of ventilation perfusion mismatching
although this may be offset by improvements in cardiac output and oxygen delivery to
the tissues.
The exciting advent of new more specific ANGII receptor antagonists will allow us to
more selectively and specifically block the effects of angiotensin II and help us to









The work encompassed in this thesis includes both studies in normal man as well as
patient studies. In view of ethical considerations and repeated interventions in our
study population our measurements were made using non-invasive methodology. This
has given us insight into hitherto unknown cardiovascular effects and neurohormonal
interactions in normal man. This methodology, however, has associated limitations
which will be alluded to in the text.
This chapter includes a review of different methods available for measuring systemic
and pulmonary haemodynamics and cardiac function with particular reference to the
methods employed during the conduct of the studies included in this thesis.
2.2 SYSTEMIC HAEMODYNAMICS
2.2.1 Measurement of heart rate and blood pressure
Heart rate, systolic arterial blood pressure, mean arterial blood pressure and diastolic
arterial blood pressure were measured using a semiautomatic sphygmomanometer
(Vital Signs Monitor, Critikon, Tampa, FL, USA). The mean of three consistent
readings was taken at each time point. Where electrocardiographic measurements
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were made heart rate was calculated form the electrocardiogram from the mean of at
least five R-R intervals.
2.2.2 Cardiac output
Cardiac output (CO) can be assessed using a variety of different direct and indirect
methods. The commonest used direct methods include the Fick method,
thermodilution and dye dilution techniques. The Fick method is regarded by many as
the gold standard. This technique measures the amount of oxygen taken up by the
volume of blood passing through the lungs in one minute as a measure of CO. This
technique however, requires a number of invasive procedures including right heart
catheterisation to measure mixed venous oxygen concentration, arterial puncture to
measure the oxygen content of arterial blood and analysis of inspired and expired
gases. In addition the Fick equation cannot be accurately applied whilst oxygen
uptake is changing and as such calculations using this method may not be valid in this
situation (Fishman AP et al, 1952, Zierler KL et al, 1991). Dye dilution also requires
right heart catheterisation and insertion of an arterial line but is limited by the number
of measurements that can be made due to accumulation of the dye injection.
Thermodilution techniques although requiring right heart catheterisation do not
require insertion of an arterial line and allow repeated measures to be taken.
In addition to these direct methods a number of non-invasive indirect methods have
been used and validated against these invasive measures. These include the use of
Doppler echocardiography (Coats AJS, 1990) the indirect Fick method using carbon
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dioxide as the indicator (Defares JG, 1968, Clausen JP et al, 1970) and impedance
cardiography (Appel PJ et al, 1986, Northridge DB et al, 1990). Impedance
cardiography measures the electrical impedance between electrodes located in the
neck and thorax. A current is passed between electrodes around the neck and thorax
and as blood leaves the thorax during the cardiac cycle the impedance of the system
changes allowing calculation of CO. The indirect Fick method uses CO as the
indicator and although allowing repeated measurements to be made it makes
assumptions regarding steady state conditions regarding gaseous exchange.
We have, however, chosen Doppler echocardiography to calculate CO. It has been
shown to be a valid measure when compared with invasive measures, is reproducible,
can be applied during states of changing gaseous exchange and is non-invasive,
allowing repeated measurements to be made and the response to a variety of different
interventions assessed without the associated risks of invasive monitoring.
Mathematical considerations
Voulumetric flow rate (Q) may be calculated as Q (t) = V (t) x CSA where v is the
spatial mean blood velocity, CSA is cross sectional area of the vessel and t is time.
Therefore to calculated stroke volume (SV) from ascending aortic blood flow SV =
spatial mean aortic blood flow x ejection time x CSA of aorta. Inherent in this
approach are certain assumptions that the total forward flow during systole equals the
net stroke volume and that the cross sectional size of the aorta equals the cross
sectional area of flow. For the purpose of our studies patients with aortic
regurgitation and or stenosis were excluded. The spatial mean aortic velocity can then
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be obtained from the mean Doppler shift if the artery is uniformly insonated. The
narrow ultrasound beam, however, only insonates part of the cross sectional area of
the aorta. For a flat velocity profile the spatial mean velocity will be close to the
spatial maximum of the velocity in the centre of the lumen. The maximum velocity
measured by the narrow Doppler beam, therefore approximates the spatial mean
velocity assuming that the velocity profile in the aorta is fairly flat. Studies in animals
have shown that the velocity profile in the aorta is fairly flat (Seed WA et al, 1971)
and thus we can assume that the Doppler measured maximum velocity approximates
the spatial mean velocity. Allowing for the above assumptions and an angle of less
than 25°, the traversed distance of blood may be obtained by integrating the velocity
measured over systole.
Doppler technique
The Doppler recordings were made using a Vingmed SD50 (Vingmed Sound, Horten,
Norway) in either pulsed or continuous wave mode. When used in pulsed mode the
sample volume of the cylinder is approximately 5 mm in depth and 5mm in length.
The received signals are processed by frequency estimators and converted into
analogue voltages proportional to mean and maximal frequency shifts. These
estimators have been shown to determine the mean and maximal velocities accurately
in experimental studies and also in the human aorta (Angelsen BAJ et al, 1976,
Brubakk AO et al, 1977). The integrator accurately calculates the velocity integral.
For the purposes of analysis we integrated the maximal velocity curve as this has been
shown to influenced less by aiming errors than mean velocity (Brubakk AO et al,
1982).
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The Doppler probe was placed in the suprasternal notch and the angle was adjusted
until flow signals were obtained in the ascending aorta using continuous mode. The
pulsed wave was then used and the depth and angle adjusted to achieve maximal
velocity and clearly defined flow velocity envelopes. All normal volunteers and
patients were screened prior to inclusion in the studies to ensure good
echocardiographic windows and Doppler flow profiles. The criteria for acceptance of
an adequate signal were the presence of a high frequency whistling sound when
listening to the audible signal and a smooth velocity envelope characterised by a rapid
increase to peak velocity (Hatle L et al, 1982) . The maximal velocity was integrated
automatically through each systole and calculations were based on at least 10
consecutive beats measured whilst an adequate signal was obtained. The aortic
systolic velocity integral was obtained as described above and on-line calculations of
stroke volume (SV = SVI x CSA) and CO as the product of SV and HR were also
made. Cross sectional area of the aorta was measured at the level of the aortic root
using M-mode echocardiography.
Validation and reproducibility of Doppler measures of cardiac output.
Several studies have been performed in patients and normal volunteers and show a
good correlation between both pulsed wave and continuous wave Doppler measures
of CO and those measured invasively during right heart catheterisation using either the
Fick principle or thermodilution methods. We have used pulsed wave to measure
maximal aortic velocity. We found as have others that a clear envelope is more easily
obtained using pulsed wave echocardiography than continuous mode (Ihlen H et al,
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1984). In addition we find the pulsed wave technique more preferential since
continuous mode sends velocity information from all along the Doppler beam and the
velocities measured may not be from the aortic root. These Doppler measures have
also been shown to be reproducible in patients and in normal healthy subjects with
coefficients of variability of consistently less than less than 10% (Coats AJS, 1990)
which concur with our own published coefficients of variability (Lipworth BJ et al,
1994, Kiely DG et al 1997a, Kiely DG et al, 1997b). The largest source of error in
Doppler estimation of CO is generally accepted as measurement of cross sectional
aortic area (Ihlen H et al, 1984). Although the accurate determination of diameter is
not imperative to study relative changes in stroke volume and CO as was the case in
our series of studies it is very important for an absolute measure. In this respect the
aortic diameter of our study patients was kept as a constant during placebo and active
treatments days. It is known that cross sectional area is a function of pressure and
studies in man indicate that it can change ±3% to ±12% during the normal cardiac
cycle (Greenfield JC et al, 1962, Merillon JP et al, 1978). We measured the aortic
root diameter during early systole using M-mode echocardiography. Studies have
shown this measurement to be reproducible and CO calculated from it to have a good
correlation with catheter measures (Loeppky JA et al, 1984) and to be significantly
better than predictions of diameter based on body surface area (Francis GS et al,
1973). Indeed, Goldberg and workers showed that aortic diameter measurements by
echocardiography are not apparently different from those measured during
angiography (Goldberg SJ et al, 1982) During serial visits in both our normal
volunteer and patient studies the pulsed wave Doppler measurements were made at
the same depth and although this is likely to improve the reproducibility of results
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studies have shown that the sampling site for blood velocities is of significantly less
importance than the level at which the cross sectional area is measured in terms of
influencing the measured CO (Fischer DC et al, 1983). Indeed Ihlen and colleagues
found that although measurements of cross sectional area differed at different
sampling sites the maximal obtained velocities were no different at the aortic orifice,
proximal and distal aortic root (Ihlen H et al, 1984). Table 2.1 includes a
representative sample of studies comparing Doppler measures of CO with those
measured using the Fick method and thermodilution techniques and evaluating the
reproducibility of these measures. In addition to a good correlation between Doppler
measures and invasive measures of CO these studies have also shown that Doppler
echocardiography is capable of detecting changes in CO after vasodilator therapy.
Rose et al (Rose JS et al, 1984) studied the effect of a number of different
vasodilators on CO and found a good correlation between baseline measures of CO
using continuous wave Doppler echocardiography and thermodilution techniques at
baseline (r=0.92) and also after intervention (r=0.88) and a similar percentage change
from control to intervention; Doppler 32±11% versus thermodilution 28±9%. In
addition except for one patient the directional changes in CO by the two techniques
were identical.
As previously alluded to there are a number of potential errors when using the
Doppler technique and in particular although vasodilators may theoretically affect the
diameter of the aorta Rose et al found little difference between his correlation
coefficients found before and after intervention assuming the diameter of the aorta
remained unchanged during vasodilator therapy. This suggests that the assumption
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that the diameter of the aorta would remain constant during vasodilator therapy is
unlikely to introduce a significant error into estimation of CO using Doppler
echocardiography. Studies have demonstrated that adequate Doppler signals can be
acquired in 85-90 % of unselected patients (Huntsman et al, 1983, Ihlen et al, 1984).
This table also includes the published results of our own reproducibility using this
technique in both patient and normal volunteer studies.
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Table 2.1. Validation and reproducibility of Doppler echocardiographic
measures of cardiac output
















































Kiely DG et al
1997a
pulsed mode n/a n=10
m=60
CV=9.3% normals
Kiely DG et al
1997b
pulsed mode n/a n=8
m=24
CV=9.6% COPD
A summary of technique employed and patient group studied is given r=correlation
coefficient, n=number of patients studied, n=number of measurements made, CV= co¬
efficient of variation, COPD=chronic obstructive pulmonary disease).
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2.2.3 Systemic vascular resistance
For the calculation of systemic vascular resistance an assumption was made that the
mean right atrial pressure was zero. Systemic vascular resistance was expressed in
dyne.s.cm-5; systemic vascular resistance = (mean arterial blood pressure/cardiac
output) x 80.
2.3 PULMONARY HAEMODYNAMICS
2.3.1 Non invasive measures of pulmonary artery pressure
The reluctance to repeatedly catheterise patients to establish the degree of pulmonary
hypertension and to follow its course has resulted in the development of a variety of
different techniques to estimate systolic (SPAP) and mean pulmonary artery pressure
(MPAP) using non-invasive means. Initially M-mode and 2D-echocardiography were
developed but have these have now been superseded by the development of Doppler
echocardiography which is the most direct and accurate echocardiographic technique
for assessing blood flow. Broadly speaking there are two different Doppler methods
for estimating pulmonary artery pressure. Firstly, assessment of trans tricuspid
gradient by continuous mode Doppler echocardiography can be used to measure
systolic pulmonary artery pressure, is a direct measure and has a good correlation with
catheter measures. We have however, used right systolic time intervals in particular
pulmonary acceleration time to estimate MPAP in our series of studies. Although this
estimation is based on correlation rather by being a direct measure it has a good
correlation with catheter measures of MPAP and has the advantage that pulmonary
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flow is demonstrable in a significantly larger number of subjects than tricuspid
regurgitation lending itself to the study of pulmonary haemodynamic changes in
normals (Chan KL et al, 1987, Tramarin R et al, 1991). We will therefore confine
ourselves to primarily describing the use of this technique and its limitations with
some reference to the measurement of pulmonary artery pressure based on trans
tricuspid gradients
Technical considerations
The normal pattern of pulmonary artery flow is a gradually accelerating then
decelerating laminar flow peaking in mid systole. This profile extends for several
centimetres distal to the valve. Inappropriate positioning of the sample volume
particularly medial to this stream can result in alterations in this profile, in particular
significant shortening of the pulmonary acceleration time (PAT), an increase in peak
velocity and wide frequency dispersion with a profile similar to that seen in pulmonary
hypertension (Pandis IP et al, 1986). This can be avoided by accurate positioning of
the sample volume. It has been demonstrated that a reduction in pulmonary
acceleration time and an increase in peak velocity occurs as the probe moves distally
from the right ventricular outflow tract to the centre of the pulmonary artery (Pandis
IP et al, 1986). Although some investigators have sampled form the right ventricular
outflow tract (Tramarin R et al, 1991), because pulmonary artery flow varies with
sample location our practice is to sample distal to the pulmonary valve allowing the
optimal signal to be recorded more easily with an angle of incidence always less than
15° so minimising sampling errors (Gardin JM et al, 1984)
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In patients with pulmonary hypertension the flow velocity pattern can be recorded in
greater than 85% of patients (Chan KL et al, 1987, Kitabatake A et al, 1983). It is
changed with a more rapid increase in velocity after valve opening, an earlier peak
velocity and an earlier decrease in velocity although the peak velocity does not differ
appreciably from normal. In addition a systolic notch is present in approximately 40-
50% of patients and appears to be associated with more severe disease. In pulmonary
hypertension shortening of the PAT has been shown to be the most consistent finding
in these patients. Dabestani (Dabestani A et al, 1987) showed that a PAT of 100ms
or less resulted in a 78% sensitivity and a 100% specificity for the detection of
elevated pulmonary artery pressure which was corroborated by the work of Handshoe
(Handshoe R et al, 1985) who showed that a PAT of less than 106ms had a sensitivity
of 79% and specificity of 100% for an abnormal pulmonary artery pressure although
other investigators have found predictive accuracy only when the PAT is less than
80ms which in itself has been shown to be a good predictor of three year mortality in
cor pulmonale (Stevenson JG et al, 1989).
Doppler technique
Our measurements were made using a Vingmed SD50 which we have previously
described. In addition a Vingmed SD 200 was used to screen all patients for
underlying valvular disease and in addition to establish the position of the valves and
outflow tracts to aid in positioning of the stand alone Doppler probe on the SD 50.
Study subjects were selected because of technically optimal Doppler studies and a
clearly defined spectral display of the pulmonary artery flow. The PAT was defined as
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the interval from the onset of pulmonary flow to peak velocity. Normal volunteers
were studied in a supine position rolled slightly on their left side. After initial
interrogation of the echocardiographic/Doppler windows the 2.0 Mhz Doppler probe
was angled and the sample depth adjusted until a clear envelope was obtained. Fine
adjustments were then made to the sample depth to attain maximal pulmonary artery
velocity whilst maintaining a clear Doppler signal. Measurements were then made on¬
line with a display speed of lOOmm/s. Three complexes were then measured and
averaged and this value was recorded as the measured PAT. The criteria for
acceptance of an adequate signal were the presence of a whistling sound of lower
frequency than for aortic flow when listening to the audible signal and a smooth
velocity envelope. Repeated interrogation of the Doppler flow was then made from
the same position at the same depth and angulation, as suggested by Dabestani
(Dabestani A et al, 1983) when evaluating the effects of vasodilators, allowing for fine
adjustments to be made in order to obtain the optimal signal. In normal volunteer
studies the pulmonary artery flow measurements were made from 2/3/4 intercostal
spaces parasternally and in patients with cor pulmonale the pulmonary valve was
interrogated subcostally. MPAP was then calculated from the PAT using Dabestani's
regression MPAP =73-(0.42 x PAT) for normal volunteer studies and MPAP =73-
(0.42 x PAT) for our patient studies, all of whom had PAT's of less than 110ms
(Dabestani A et al, 1987).
67
Validation and reproducibility of Doppler measures of pulmonary artery
pressure
Good correlations have been found between PAT and catheter measures of MPAP
(Dabestani A et al, 1987, Beard JT et al, 1991, Chan KL et al, 1987, Jiang L et al,
1984, Matsuda M et al, 1986, Kitabatake A et al, 193, Kiely DG et al 1997a).
Dabestani found a significant negative correlation between PAT and MPAP in a group
of 39 patients (16 of whom did not have elevated pulmonary artery pressures)
undergoing diagnostic cardiac catheterisation. The regression equation relating these
parameters over the range of pulmonary artery pressures MPAP =73-(0.42 x PAT)
had a correlation coefficient of r= -0.84; p<0.001. In patients with a PAT of less than
120ms the regression equation linking these parameters MPAP=90-(0.62 x PAT) had
a correlation coefficient r= -0.87. Similar correlations have been done by other
investigators and indeed the work of our own group showed a good correlation
between these PAT and MPAP over a range of pulmonary artery pressures with an
correlation coefficient r= -0.88 (Kiely DG et al, 1997a).
To try and improve the correlation and reduce variation a number of ratios have been
used including the ratio of PAT/right ventricular ejection time (RVET), the ratio of
right ventricular pre-ejection period (RVPEP)/PAT and RVPEP/RVET. Although
some studies have shown correlations similar to those using PAT (Dabestani A et al,
1987, Kitabatake A et al, 1983) several studies have shown that this ratio compares
less favourably (Chan KL et al, 1987, Beard JT et al, 1991, Kosturakis D et al, 1984)
and as a consequence we have used Dabestani's regression equations for the
calculation of MPAP in our study. Our experience and certainly that of others is that
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it is sometimes difficult to measure precisely termination of systolic flow and in
addition at high pulmonary artery pressures , admittedly significantly higher than the
great majority of our subjects, flow may terminate early, inappropriately shifting the
ratio towards normal. Although some investigators have suggested that the
correlation between PAT and MPAP can be improved by comparing PAT to
logioMPAP (Kitabatake A et al, 1983) this has not been generally accepted (Chan KL
et al, 1987, Chow LC et al, 1988).
It has been suggested that heart rate may affect PAT but this does not appear to be a
problem unless heart rates exceed 120 bpm (Weyman AE, 1993). This was not
anticipated to be the case in any of our studies no corrections for heart rate were
made.
Although a good correlation has been obtained between PAT and catheter measured
MPAP and studies have been performed using non-invasive methodology that concur
with results of invasive studies Chow (Chow LC et al, 1988) examined the changes in
MPAP and PAT in patients before and after pulmonary thromboendarterectomy and
although statistically significant the correlation between changes in PAT and catheter
measures of MPAP was weak (r=-0.41). Beard (Beard JT et al 1991) showed a good
correlation between changes in the ratio of PAT/Right ventricular ejection time and
changes in catheter MPAP (r=-0.73 in 11 subjects made hypoxic) and although the
correlation was weaker for changes in PAT (r=-0.55) he found a significantly better
correlation between absolute PAT and absolute MPAP than absolute PAT/Right
ventricular ejection time and absolute MPAP (r=-0.84 vs r=-0.35). We have used
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changes in PAT to asses the response of the pulmonary vascular bed to a variety of
different vasodilators. The validity of our work is dependent on a change in
pulmonary acceleration time being proportional to changes in MPAP. Although the
correlation between absolute values is good and changes observed using this non¬
invasive methodology concur well with studies using invasive methodology more
work is required to validate changes in Doppler echocardiographically measured PAT
as a measure of response to vasodilators.
It is generally accepted that continuous wave Doppler echocardiography, which is
capable of measuring high flow velocities provides the best method of diagnosis of
pulmonary hypertension in a patient population (Tramarin R et al, 1991, Burghuber
OC, 1996). It is a direct method whereas measures using pulmonary flow are based
on correlation. The usefulness of this technique however, depends on the presence of
tricuspid regurgitation and the ability to obtain accurate transducer measurements as
well as the ability to accurately estimate right atrial pressure. Recent work has
suggested that the accuracy of the latter can be improved using 2D echocardiographic
measurements of atrial size in addition to colour Doppler flow measurements
(Burghuber OC, 1996). This aside a good correlation has been obtained with systolic
pulmonary artery pressure using this methodology with coefficients of variation
ranging form 0.68 to 0.98 (Tramarin R et al, 1991, Himelman RB et al, 1989). A
European multicentre study compared a variety of different techniques and concluded
that a Doppler measure of pulmonary artery pressure could be obtained in 98% of
patients with COPD (Tramarin R et al, 1991). In this study Doppler recordings of
tricuspid regurgitation adequate for velocity measurements could only be obtained in
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30% of patients overall and in only 11% of patients with normal pulmonary artery
pressures compared to an analysable pulmonary flow velocity profile in 98% of cases
and right ventricular isovolumic relaxation time in 61% of patients. All measures
were found to be reproducible but the best correlation was found between pulmonary
artery pressure measured by transtricuspid regurgitation (r=0.73) compared to PAT
(r=0.65) and right ventricular isovolumic relaxation time (r=0.61). These correlation
coefficients are generally lower than that reported in other studies and in this study
may relate to a number of factors such as the large number of patients with normal
pulmonary artery pressures (37%). It has been shown that the relationship between
pulmonary flow velocities and catheter measures of MPAP is not linear over a wide
rang of pressures and that the correlation can be significantly improved by performing
regression analysis on patients with for example PAT of less than 120ms (Dabestani A
et al, 1987). The multicentre nature of this study is likely to have increased scattering
around the lines of regression and importantly the regression equations were not based
on simultaneously made measurements. This is important in view of the fact that
spontaneous variability at rest in COPD patients can exhibit a coefficient of variability
of approximately 10%.
Although other investigators have found that transtricuspid regurgitation can be
measured in most patients with COPD and in large numbers of normal volunteers
using colour flow mapping and techniques such as saline enhancement we have used
pulmonary artery flow measurements in our series of studies because of the good
correlation that has been found between PAT and MPAP by ourselves and others, the
reproducibility of this measure and the ability to obtain good Doppler profiles in
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significant numbers of both our patients and normal volunteers. Table 2.2 summaries
the relationship between Doppler and catheter measures of pulmonary artery pressure
including our own published data.
Key to Table 2.2
The correlation coefficient (r) for the linear regression equation linking the variables in
column 2 is given along with the patient group in which the study was performed.
Where referred to as "mixed patients" the data may include patients with a wide
variety of cardiopulmonary conditions including primary pulmonary hypertension,
ischaemic heart disease, valvular heart disease, congenital heart disease,
cardiomyopathies and does not necessarily imply the presence of pulmonary
hypertension. Indeed the majority of these studies recruited patients undergoing
diagnostic cardiac catheterisation at which time Doppler echcardiography was
performed. Where the patients are indicated as having COPD, the patient group
contains exclusively these patients. PAT=pulmonary acceleration time; RVET=right
ventricular ejection time, PEP=right ventricular pre-ejection period; TR=peak velocity
of transtricuspid regurgitant jet; PSAP=pulmonary systolic arterial pressure;
RVAT=right ventricular acceleration time; RVIVRT=right ventricular isovolumic
relaxation time.
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Table 2.2. Relationship between Doppler and catheter measures of pulmonary artery
pressure
Dabestani et al PAT vs MPAP r= -0.84 n=39 mixed patients
PAT vs log 10 MPAP r= -0.84 n=39 mixed patients
PAT/RVET vs MPAP r= -0.80 n=39 mixed patients
PAT/RVET vs log 10 MPAP r= -0.82 n=39 mixed patients
PATvs MPAP r= -0.87 n=27 patients,PAT< 120ms
Beard et al PAT vs MPAP r= -0.84 n=21 patients and normals
PAT/RVET vs MPAP r=-0.35 n=21 patients and normals
Chan et al TR vs PSAP r= -0.87 n=36 mixed patients
PAT vs MPAP r=-0.85 n=44 mixed patients
Jiang et al PAT vs MPAP r= -0.86 n=34 mixed patients
PAT/RVET vs MPAP r= -0.86 n=34 mixed patients
PEP/PAT vs MPAP r= -0.94 n=34 mixed patients
PEP/RVET vs MPAP r= -0.68 n=34 mixed patients
Matsuda et al PAT vs MPAP r= -0.75 n=67 mixed patients
Himelman et al TR vs PSAP r= 0.98 n=10 COPD
Kitbatake et al PAT vs MPAP r= -0.82 n=33 mixed patients
PAT vs log 10 MPAP r= -0.88 n=33 mixed patients
Tramarin et al RVAT vs MPAP r= -0.65 n=97 COPD
TR vs PASP r=0.68 n=30 COPD
RVIVRT vs MPAP r=0.61 n=61 COPD
Kiely et al PAT vs MPAP r= -0.88 n=17 mixed patients
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Our group has published reproducibility data in both normal man and also in patients
with cor pulmonale that concurs well with that obtained in other studies. Our
published coefficients of variability of MPAP calculated from PAT are quoted in the
relevant chapters but range between 4-6% in normal healthy subjects and in patients
with hypoxaemic cor pulmonale.
2.3.2 Total pulmonary vascular resistance
This was expressed in dyne.s.cm-5 as total pulmonary vascular resistance (TPR) =
MPAP/CO x 80. When interpreting changes in TPR as a reflection of changes in
pulmonary vascular tone a limitation of this methodology is that TPR neglects the
downstream pressure of the pulmonary circulation, namely left atrial pressure, as
conventionally assessed by pulmonary capillary wedge pressure (PCWP). Although
studies have shown that stimuli such as hypoxia and hypercapnia have no significant
effects on PCWP this can obviously be affected by changes in ventricular function and
this has been alluded to in the relevant parts of the discussion.
2.4 MEASURES OF SYSTOLIC AND DIASTOLIC FUNCTION
2.4.1 Systolic function
The non-invasive assessment of systolic ventricular function has become increasingly
important with the advent of effective therapies for systolic heart failure. Although
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assessments of systolic function can be made during cardiac catheterisation treatment
in clinical practice is usually based on the results of an ejection fraction obtained form
a multiple upgated acquisition scan or more commonly on the basis of a two
dimensional echocardiogram. In this thesis we undertook to asses the cardiovascular
effects of acute hypoxaemia and hypercapnia in normal man. To detect changes of
systolic cardiovascular performance the methodology must be sensitive, reproducible
and valid. A number of non-invasive measures of cardiovascular performance have
been developed over recent years and used in clinical pharmacology as well as in
clinical practice and include, two dimensional echocardiography, Doppler aortic blood
flow measurements , systolic time intervals and transthoracic impedance cardiography.
We have chosen systolic time intervals and Doppler aortic blood flow measurements
because of their reproducibility and sensitivity in the assessment of changes in systolic
function.
Technical considerations, validity and reproducibility of systolic time intervals
Systolic time intervals have been measured since the early 1920's and have been used
extensively in a variety of different physiological studies allowing their limitations and
strengths to be evaluated (Li Q et al, 1993). Investigators have focused their
attentions primarily on three time intervals: total electromechanical systole (QS2)
measured from the onset of the QRS complex to aortic valve closure, the pre-ejection
period (PEP) measured form the onset of ventricular depolarisation to the beginning
of left ventricular ejection and representing isovolaemic contraction and finally let
ventricular ejection time representing isotonic contraction and lasting from the onset
to cessation of systolic aortic blood flow. Standardised conditions have been shown
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to be important and if the studies are carried out under these controlled conditions
excellent reproducibility has been demonstrated with Scott (Scott MJ et al, 1989)
showing coefficients of variation for the same subjects on different study days ranging
between 1.2 to 7.0 %, which is similar to the work of our own group with coefficients
of variation for QS2I 3.5% (Kiely DG et al, 1997b), LVET 1.6% (Lipworth BJ et al,
1994). STI's are dependent as are other measures of left ventricular function on heart
rate and loading conditions. Although there appears to be some non-linearity between
heart rate and STI's reflected by the linearity of STI's and beat to beat intervals (Wolf
GK et al, 1978) these deviations are small and unlikely to affect results unless extreme
extrapolations are used. We have therefore corrected our intervals according to
standard criteria (Weissler AM et al, 1970). Recent studies have shown however that
although the expected relationships existed between QS2 and LVET and heart rate
(Kelman AW et al, 1981) that there did not appear to be such a convincing
relationship for PEP and heart rate (Spoddick DH et al, 1984). There is some debate
therefore whether corrections should be used for this measure. We have therefore
presented both corrected and uncorrected data where appropriate. Information
regarding the effects of loading conditions on systolic time intervals is based on in
vitro studies using isolated cardiac tissues where loading conditions can be closely
controlled (Nakamura Y et al, 1983) and in vivo where one haemodynamic change
can alter a number of haemodynamic variables. Positive inotropism shortens QS2,
PEP and LVET whereas negative inotropism prolongs these intervals (Li Q et al,
1993). Although changes in preload and afterload in vivo and using in vitro models
affect both PEP and LVET the effects on QS2 are less marked and this index is
thought to reflect primarily inotropic effects with loading conditions having
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significantly less effect (Nakamura Y et al, 1983, Lewis RP et al, 1977, Stern HC et
al, 1984). These effects apart the STI have been shown to be sensitive measures of
comparing drug induced changes in systolic function and in this respect de Mey and
colleagues showed that in a dose ranging study using isoprotenerol that STI's were
capable of detecting changes at the lowest dose whereas a 2 fold increase in this dose
required to produce significant changes in aortic blood flow measured using Doppler
echocardiogaphy and impedance echocardiography whereas a fourfold increase in
dose was required to produce significant changes as measured using two dimensional
echocardiography (de Mey C et al, 1992)
Technical considerations, validity and reproducibility of Doppler measures of
aortic blood flow
As alluded to above Doppler measures of aortic blood flow can be used to measure
changes in systolic performance. Studies have been performed in both normal
subjects and in patients with a variety of cardiac conditions using both pulsed wave
and continuous wave Doppler echocardiography to asses left ventricular function at
rest and after a number of different haemodynamic and pharmacological interventions.
Noble (Noble MIM et al, 1966) has shown in a number of animal experiments that
maximal aortic acceleration is a sensitive indicator of inotropic state and relatively
insensitive to the loading conditions of the heart. Subsequent work has shown that
blood acceleration was intrinsic to the rate of change in power developed by the left
ventricle (Stein PD et al, 1976a) and a study in patients during cardiac catheterisation
using catheter tip velocity sensors demonstrated that peak acceleration was capable of
differentiating patients with normal from abnormal ventricular performance (Stein PD
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et al, 1976b). The advent of Doppler echocardiography has allowed us to measure
these indices non-invasively. Sabbah and colleagues (Sabbah NH et al, 1986)
measured both peak aortic velocity and acceleration in 36 patients undergoing
diagnostic cardiac catheterisation they found that both aortic peak acceleration
(r=0.90) and peak aortic velocity (r=0.77) had good correlations with ejection fraction
and that these indices were capable of distinguishing patients with low ejection
fractions from those with normal left ventricular systolic function. It is known
however that loading conditions can affect these indices (Bennet ED et al, 1984
Bedotto JB et al, 1989) and changes in response to haemodynamic stimuli must be
interpreted with these potentially confounding effects taken into account.
The reproducibility intra and interobserver variation of Doppler aortic blood flow
measurements were assessed by Gardin (Gardin JM et al, 1984) in 10 normal subjects
over two visits. The intraobserver variability ranged from 1.9±1.8% for ejection time
to 3.2±2.9% for peak aortic velocity to 7.9%±6.6% for acceleration time.
Interobserver variability ranged form 3.5±2.2% for ejection time to 5.4±3.4% for peak
aortic velocity to 17±9% for acceleration time. Day to day variability was 3.6±3.9%
for ejection time, 5.2±4% for peak aortic velocity and 7.0±5.2% for acceleration time.
They concluded that changes in aortic peak flow velocity, ejection time or flow
velocity integral of greater than 13% or a change of aortic acceleration time of greater
than 17% on serial recordings performed by the same technician would represent a
true haemodynamic change. Hatle and colleagues (Hatle L et al, 1982) also reported
reproducibility data in 5 normal subjects for 10 measurements made over a period of
days to months and found a mean coefficient of variation of 6.4% for maximal
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velocity and 8.6% for peak acceleration. The mean coefficient of variability for 5
measurements made in 16 subjects within minutes was 5.9% for peak velocity and
15.1% for peak acceleration which are similar to the results of our published work in
10 normal volunteers in whom 6 measurements were made over a period of 150
minutes; mean coefficients of variability 12.5% for mean acceleration and 18.7% for
peak acceleration (Kiely DG et al, 1997b).
Doppler technique
Simultaneous lead II ECG, phonocardiogram (Siemens AG, Munich, Germany) and
pulsed-wave Doppler ascending aortic blood flow (Vingmed SD50) were recorded.
Doppler flow profiles were recorded with a non-imaging 2.0 MHz transducer with
depth adjusted to give maximal velocity. All measurements were made with display
sweep speed at 100 mm/sec and analysed in triplicate. From these recordings, the
following variables were measured: Left ventricular ejection time (LVET) was
measured as the time in ms from onset to end of systolic aortic flow,
electromechanical systole (QS2) was measured from the onset of the ECG Q wave to
the second heart sound on the phonocardiogram and the pre-ejection period (PEP) as
time in ms from ECG Q wave to onset of systolic aortic flow. QS2, ET and PEP were
also corrected for changes in HR according to standard criteria (Weissler AM et al,
1970), and are denoted QS2C (or QS2I), ETc and PEPc. Aortic peak acceleration
(Accpgak), aortic mean acceleration (Accmean), and aortic acceleration time (AT) as




Diastole is a complex sequence of interrelated events involving myocardial relaxation,
ventricular filling, atrial contraction, the viscoelastic properties of the myocardium,
diastolic suction, pericardial constraint, ventricular interaction and the hydraulic effect
of the coronary arteries (Clarkson PBM et al, 1994). Diastole encompasses the time
period between aortic and mitral valve closure and can be divided into four intervals.
The period of isovolumic relaxation (IVRT) during which time ventricular pressure
rapidly declines without ventricular filling and extends from aortic valve closure to
mitral valve opening. This phase is thought to be primarily attributable to active
myocardial relaxation. It is followed by early filling due to the pressure gradient
between the atria and ventricles which accounts for approximately 75% of filling at
rest. The atrial and ventricular pressures then equalise and this phase accounting for
approximately 5% of filling is a primarily passive process followed by atrial systole
which contributes approximately 20% to filling in healthy young individuals.
Technical considerations and validation of Doppler echocardiography in the
assessment of diastolic function
Assessment of diastolic function can be made by a number of different means.
Presently much time is being spent trying to devise and validate a number of non¬
invasive measures, however the complexities of left ventricular filling mean that none
of these are absolutely satisfactory. Invasive techniques allow measurement of
continuous volume-time curves and pressure time curves allowing calculation of
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indices of chamber rigidity and compliance and Tau-the time constant of relaxation
(Weisfeldt M et al, 1974). Although radionuclide ventriculography has been shown to
correlate well with invasive measures of diastolic function and is non-invasive (Seals
A et al, 1986) its use is limited by its lack of precision and exposure to radiation.
Echocardiography is now most frequently used in the assessment of ventricular
diastolic function and several studies have been performed validating the use of
Doppler measured transmitral flow profiles. Rokey and colleagues (Rokey R et al,
1985) compared Doppler transmitral flow profiles with cineangiography. They found
a significant correlation between Doppler and angiographic peak filling rate (r=0.87),
Doppler and normalised peak filling rate (r=0.83) and Doppler early peak diastolic
velocity and angiographic peak filling rate (r=0.64). In addition there was a good
correlation between early and late diastolic filling when Doppler and radionuclide
angiography were compared (Spirito P et al, 1986). Studies have been performed
comparing filling rates of transmitral Doppler recordings with indexes of diastolic
function using invasive techniques such as measuring pressures using high fidelity
micromanometers and volumes derived from cineangiography. Drinkovic and
workers (Drinkovic N et al, 1986) did not find good correlations between Doppler
measures and invasive indexes. Therefore although studies have shown that
transmitral recordings provide a good representation of left ventricular filling rates
they cannot be equated with filling rates calculated using conventional invasive
indexes of diastolic function. Although not so well described Doppler measures of
trans tricuspid filling also been used to evaluate right ventricular diastolic function
(Marangoni S et al, 1992) where it has been shown to be useful in the diagnosis of this
condition in chronic obstructive pulmonary disease.
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We have experience with techniques for evaluating both right and left ventricular
diastolic function using Doppler measured transmitral and transtricuspid filling rates
and isovolumic relaxation times for both left and right ventricles. Our coefficients of
variability for these measurements show that this methodology is reproducible.
Published values (Cargill RI et al, 1995): mitral e-wave deceleration time (mitral
EDT)=2.4%; tricuspid EDT=4.8%; right ventricular IVRT=12.2%; left ventricular
IVRT=1.1%. Kiely (Kiely DG et al, 1997b) mitral E wave peak velocity
Evmax=12.2%; mitral A wave peak velocity Avmax=17.2%; transmitral E/A ratio
=12.4%; left ventricular IVRT 13.8%; tricuspid Evmaz=8.8%; tricuspid
Avmax=14.2%;right ventricular IVRT=29.1%; transtricuspid E/A ratio=14.8%.
Doppler technique
From the apical window, pulsed-wave Doppler analysis of mitral and tricuspid
diastolic flow (Vingmed SD50) was combined with simultaneous phonocardiogram
recording with the microphone (Siemens AG; Munich, Germany) positioned over the
2nd left intercostal space. Measurements were all made on-line during expiration and
in triplicate, with a display sweep speed of lOOmm/sec. Transmitral and transtricuspid
flow was analysed after adjusting sample volume depth to yield maximal E-wave
velocities with clearly defined flow velocity envelopes. Aortic and pulmonary
components of the second heart sound were identified on the phonocardiogram trace
by noting closure artefacts from superimposition of aortic and pulmonary Doppler
flow profiles. From diastolic transmitral and transtricuspid flow, maximal velocities of
the early (Evmax) and atrial (Avmax) components of flow were measured, and the
E/A ratio was calculated. In addition, the E wave deceleration time (EDT) was
calculated as the time in milliseconds from peak velocity to the end of the E wave.
The isovolumic relaxation time (IVRT) was calculated for the left ventricle as the time
82
in milliseconds from the aortic component of the phonocardiogram second heart
sound to the onset of diastolic transmitral flow, and for the right ventricle, the time
from the pulmonary component of the phonocardiogram second heart sound to the
onset of diastolic transtricuspid flow. Both time intervals (EDT and IVRT) were also
corrected for changes in heart rate induced by hypoxaemia by dividing by the square
root of the simultaneous ECG R-R interval; EDTc = EDT/VRR, IVRTc = IVRT/VrR,
2.5 ELECTROPHYSIOLOGICAL INDICES
2.5.1 QT interval and QT dispersion
The surface electrocardiogram has been investigated for its ability to identify those
patients at risk of arrhythmias and as such represents a cheap, non-invasive and
simple method. Traditionally the single measurement of QTc interval has been used to
measure the recovery of ventricular excitability, widely recognised to be the most
important factor in arrhythmogenesis.
QT prolongation has been shown to be a predictor of sudden death in alcoholic
cirrhosis (Day CP et al, 1993), sudden cardiovascular mortality in apparently healthy
individuals (Schouten EG et al, 1991), as well as sudden death in patients with
ischaemic heart disease (Puddu PE et al, 1986). Recently however, QTc dispersion
(interlead variability in QTc interval) has been suggested as a more sensitive and
specific marker as it measures differences in regional repolarisation and has been
shown to be increased in patients with hypertrophic obstructive cardiomyopathy at
risk from ventricular arrhythmias (Buja G et al, 1993) and in patients with long QT
intervals it distinguished between those with ventricular arrhythmias and those without
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(Day CP et al, 1990). Recently it has been found to be a more sensitive and specific
marker of sudden death in heart failure than QTc interval alone (Barr CS et al, 1994).
To measure QT dispersion we used a computer linked digitising tablet which has been
shown by other investigators to be a reliable and accurate measure of QTc dispersion
(Bhullar HK et al, 1993). Probably the most important aspect concerning
methodology is the protocol to define the end of the T wave. We have thus used the
most commonly used protocol (Higham PD et al, 1994) and one which has been
shown to correlate with arrhythmia risk and sudden death. We also measured the
QTc interval in the majority of leads in each individual although occasionally leads
were omitted due to difficulty defining the end of the T-wave. We used routine
ECG's to measure QTc dispersion since we felt this would have most clinical
relevance and indeed no substantial evidence suggests that simultaneous ECG
recording has any benefits.
2.5.2 QT Interval and QT dispersion measurement
The ECG's from the study days were analysed in random order after completion of
the study, by an investigator who was blinded with respect to which was the pre-post
intervention ECG. QT interval if feasible was measured in all leads of a surface 12
lead ECG (paper speed = 25mm/s). Three consecutive cycles were measured in each
lead where possible and the mean value was taken as representing the QT interval in
that lead. QT interval was calculated according to standard criteria (Higham PD et al,
1994) from the onset of the QRS complex to the end of the T wave ie a return to the
T/P baseline. In the presence of U waves the QT interval was measured to the nadir
of the curve between the T and the U waves. QT intervals were then corrected for
rate using Bazett's formula (Bazett HC, 1920) (QTc = QT/VrR).
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QT dispersion was defined as the difference between the maximum and minimum QT
interval measured during analysis of all leads of the surface ECG whereas QTc
dispersion was defined as the difference between the maximum and minimum QTc
interval (Higham PD et al, 1994). The measurements were made using a computer
linked digitising tablet (Bhullar HK et al, 1993). To compare the standard measure of
QTc interval with QTc dispersion we calculated the average of three QT intervals in
lead II and corrected for heart rate using Bazett's formula (QTc = QT/a/RR).
2.6 NEUROENDOCRINE VARIABLES
2.6.1 Sampling
Blood samples for measurement of resting neurohormonal hormones and plasma
electrolytes and serum creatinine was made after the subject or patient had rested in
the supine position for at least 30 minutes to achieve baseline haemodynamic
parameters. Blood was sampled from an intravenous cannula inserted into the
antecubital fossa which was flushed with saline to keep it patent. After removal of
5ml of dead space blood from the cannula which was discarded blood was then taken
for analysis. Further samples were then taken in accordance with the study protocol.
The only exception to the above was in the study entitled "A management role for
natriuretic peptides in the diagnosis of pulmonary thromboembolism?" where venous
blood samples were taken from patients in the supine position at the time of the
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perfusion scan, prior to injection of Tc labelled macroaggregated albumin. Patients
were required to have rested supine for at least 15 minutes.
2.6.2 Endothelin-1
Samples were collected into chilled EDTA tubes and then centrifuged at 2000 rpm at
4°C for 15 minutes and stored at -70°C until assayed in a batch on completion of the
study. Assay was carried out in duplicate using a commercially available
radioimmunoassay (RIA) kit (Nicholls Institute Diagnostics, San Juan Capistrano,
CA, USA) after solid phase extraction on CI8 silica columns. The specificity of the
Nichols Institute Diagnostics Endothelin RIA was determined by cross reactivity of
several compounds. The anti-endothelin antibody used had cross-reactivity of 100%
with endothelin-1, 96% with endothelin-3 and 7% with proendothelin. Cross
reactivity with ANP, angiotensin II and ACTH was less than 0.1%. The lower limit of
detection was 0.4 pmol/1 and the intra-assay co-efficient of variation was 4.5% and the
interassay coefficient of variation 6.8%.
2.6.3 Natriuretic peptide system
Samples were collected into chilled EDTA tubes containing 4,000 klU of aprotonin.
Plasma was separated by centrifiigation at 3,000 rpm for 15 minutes at 4C and stored
at -70C until measurement of ANP-like, BNP-like and N-ANP-like immunoreactivity
in one batch at the end of the study. After solid phase extraction from plasma, assays
were performed in duplicate using commercially available radioimmunoassay kits
(Penninsula Laboratories, St Helens, United Kingdom). The coefficients of variability
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for each assay were: ANP intra-assay = 12.6%, interassay = 11.8%; BNP intra-assay
= 9.9%, interassay = 14.8%; N-ANP intra-assay = 7.7%, interassay = 11.7%.
2.6.4 Renin angiotensin aldosterone system
Samples for measurement of plasma renin activity (PRA) were collected into chilled
EDTA tubes and samples for plasma aldosterone were collected in chilled lithium-
heparin tubes. They were centrifuged at 4°C immediately and separated plasma was
stored at -20°C until assayed in one batch in duplicate at the end of the study. PRA
and plasma aldosterone were assayed using commercially available RIA kits (Sorin
Biomedica, Saluggia, Italy) . PRA was assayed by measurement of amount of
angiotensin I generated per hour. Samples for ANG II assay were collected into
chilled glass tubes containing 0.5 ml of a cocktail comprising 0.05mmol/l, 0-
phenanthrolene, 0.2g neomycin, 0.125 mmol/1 EDTA and 2% (v/v) ethanol before
centrifugation and separated plasma was stored at -70°C. ANG II assay was
performed following separation from plasma proteins by ethanol extraction using a
specific commercially available RIA kit (Nichols Institute Diagnostics, Juan
Capistrano, CA, USA). The intra-assay coefficients of variability for each assay were:
PRA = 6.50% and plasma aldosterone = 8.77%.
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2.6.5 Catecholamines
Samples for adrenaline and noradrenaline were collected in chilled lithium-heparin
tubes and were centrifiiged at 4°C immediately. Separated plasma was stored at -70°
C and assayed in one batch at the end of the study using the double isotope
radioenzymatic method (Brown MJ et al, 1980).
2.7 SERUM ELECTROLYTES
Samples for serum electrolytes were collected in chilled lithium-heparin tubes and
were centrifiiged at 4°C immediately and separated plasma was stored at -20°C until
measured in duplicate in one batch at the end of the study using an internal caesium
standard flame photometer (Instrumentation Laboratory, Milan, Italy).
2.8 MEASUREMENT OF OXYGEN SATURATION AND END-TIDAL
CARBON DIOXIDE CONCENTRATION
2.8.1 Oxygenation
Arterial blood oxygen saturation was continuously monitored by transcutaneous
oximetry with the probe placed on the index finger (CSI 503, Criticare Systems Inc,
Waukesha, WI, USA). When required for the purpose of analysis recordings were
averaged at steady state over a period of 5 minutes at each time point.
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2.8.2 End-tidal carbon dioxide concentration
This was measured continuously with the tip of the gas sampling tube adjacent to the
mouth of the subject, using a transportable ET C02 monitor (POET TE, Criticare
Systems Inc, Waukesha, WI, USA). End-tidal C02 is known to closely mirror the
concentration of carbon dioxide in the blood. The ET C02 is approximately 0.5 Kpa
lower than that measured in arterial blood. This difference is due to blood leaving the
ventilated alveoli mixing with blood from both parenchymal lung tissue and with blood
passing through non-ventilated alveoli so creating a venous admixture. It is this
venous admixture that accounts for the normal alveolar-arterial carbon dioxide tension
difference. When required for the purpose of analysis recordings were averaged at












Although some of the cardiovascular responses to hypoxaemia are well described,
effects on myocardial contractility have not been defined. Such effects are readily
assessed by non-invasive techniques and we have therefore evaluated Doppler-
phonocardiographic parameters of systolic left ventricular contractility in normal
humans rendered hypoxaemic.
Eight healthy male volunteers were studied. Parameters were measured after resting
to achieve baseline haemodynamics, after 20 minutes moderate hypoxaemia (Sa02 85-
90%) and after a further 20 minutes of severe hypoxaemia (Sa02 75-80%).
Hypoxaemia was induced by breathing a variable N2/02 mixture.
Pulsed-wave Doppler analysis of ascending aortic blood flow was combined with
phonocardiography to measure indices of systolic left ventricular function at baseline
and at the end of each period of hypoxaemia.
There was a significant, dose related increase in cardiac output in response to
hypoxaemia, from 5.5+0.26 1/min at baseline to 6.1+0.08 1/min during moderate
hypoxaemia and to 7.0+0.23 1/min during severe hypoxaemia. Likewise, heart rate
increased significantly in dose related fashion although stroke volume was not affected
by either level of hypoxaemia. Hypoxaemia had no significant effects on systolic or
diastolic blood pressures, but caused a significant reduction in systemic vascular
resistance. Aortic peak and mean acceleration and acceleration time were not affected
by moderate or severe hypoxaemia. Although the systolic time intervals measured
shortened significantly during severe hypoxaemia these were no longer significant
when appropriate corrections were made for heart rate.
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Although cardiac output increases during hypoxaemia, this is due to increases in heart
rate but not to any effect on stroke volume. Parameters of left ventricular systolic
function and myocardial inotropic state were also not affected by severe hypoxaemia.
Systolic left ventricular function and myocardial contractility is therefore well
preserved in normal humans during hypoxaemia.
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3.2 INTRODUCTION
Acute hypoxaemia commonly occurs in humans as a result of cardiorespiratory
disease or adverse environmental conditions. The cardiovascular responses to the
stress of hypoxaemia have therefore been of great interest. It is clear that acute
hypoxaemia induces pulmonary hypertension due to hypoxic pulmonary
vasoconstriction (Cutai M et al, 1990), increases heart rate and cardiac output
(Phillips BA et al, 1988) without affecting systemic blood pressure (Cutai M et al,
1990, Vonmoos S et al, 1990). There is however no information available regarding
the effects of hypoxaemia on intrinsic myocardial contractility during systole. Such
effects may well be important in the assessment of cardiovascular performance in
subjects with fluctuating levels of oxygenation.
The non-invasive assessment of systolic ventricular function has become particularly
important with the advent of effective therapies for systolic heart failure (Consensus
Trial Study Group, 1987). Although quantification of ejection fraction appears a
suitable measure of systolic function, this is subject to other haemodynamic influences
(Ross J Jr et al, 1979) and does not directly assess intrinsic myocardial contractility.
This latter component can however be assessed by a number of other non-invasive
methods including echocardiography and phonocardiography. Echo-Doppler
assessment of aortic flow acceleration parameters have been used to study changes in
overall ventricular performance and compares favourably with invasive measurements
(Sabbah HN et al, 1986). Other systolic time intervals, derived in conjunction with
phonocardiography have also been proposed to reflect the inotropic state of the left
ventricle (Li Q et al, 1993) and have been used extensively to monitor drug induced
changes in myocardial contractility (Belz GG et al, 1992, Belz GG et al, 1978).
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We have therefore combined these two methods to assess for the first time the effects





Eight normal male volunteers, age (mean±SEM) 29.3±2.9 years were evaluated after
giving informed written consent to the study protocol, previously approved by the
Tayside Committee for Medical Research Ethics. All subjects had normal clinical
history and examination, biochemical and haemotological screening and 12 lead
electrocardiogram.
Study design
All subjects attended the clinical laboratory at the same time of day and remained in a
supine position throughout the study. Once stable resting haemodynamic parameters
were obtained, subjects were rendered hypoxaemic by breathing a variable mixture of
oxygen and nitrogen to achieve moderate hypoxaemia with Sa02 between 85 and 90%
for 20 minutes followed by 20 minutes of severe hypoxaemia with Sa02 between 75
and 80%. Parameters were recorded at baseline and at the end of each 20 minute
period of hypoxaemia.
Measurements
Systemic haemodynamic variables and systolic flow parameters were measured as
previously described
Data analysis
Comparisons were made by multifactorial analysis of variance and where this was
significant, Duncan's multiple-range testing was used to determine where significant





Moderate hypoxaemia significantly increased CO by 0.7 1/min (95% confidence
interval 0.1, 1.3) and HR by 4.5 beats/min (95% CI -0.7, 9.7) from baseline. Severe
hypoxaemia caused further increases in CO; 1.5 1/min (95% CI 0.9, 2.1) and HR; 10.5
beats/min (95% CI 5.3, 15.7) (Table 1). SV however, was not affected by
hypoxaemia, whilst SBP and DBP were unchanged during moderate or severe
hypoxaemia (Table 3.1). SVR decreased significantly during moderate hypoxaemia (-
138 dyne.s.cm"^ from baseline; 95% CI -2, -274) and during mild hypoxaemia (-245
dyne.s.cm"^ from baseline; 95% CI -109, -381) (Table 3.1).
Systolic flow parameters.
Accpeak was similar at baseline (23 8±1.5 ms"l) and after moderate (22.1 ±1.0 ms"*)
and severe hypoxaemia (21.4±2.5 ms~l). Similarly, Accmean did not change from
baseline (10.9±1.0 ms~l) during either moderate (10.4+1.0 ms"l) or severe
hypoxaemia (12.0+1.8 ms~l). AT was also unchanged from baseline (76+6.7 ms)
during either moderate (75+6.5 ms) or severe hypoxaemia (73+6.7 ms).
Although similar at baseline (411+8 ms) and during moderate hypoxaemia (410+8
ms), QS2 was significantly shortened during severe hypoxaemia (385+11 ms).
Likewise ET was similar at baseline (293+9 ms) and during moderate hypoxaemia
(289+10 ms) but shortened significantly during severe hypoxaemia (277+10 ms). PEP
was also significantly shorter during severe hypoxaemia (109+8 ms) than at baseline
(118+9 ms) or during moderate hypoxaemia (121+8 ms). However, following
correction of these parameters for HR changes, neither QS2C, ETc or PEPc were
significantly affected by either level of hypoxaemia (Figure 3.1).
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TABLES





HR(beats/min) 60±2.7 65+2.8* 71+4.3*t
SV(ml) 102+7.5 102+4.7 104+4.9
CO(L/min) 5.5+0.26 6.1+0.08* 7.0±0.23*t
SBP(mmHg) 120+7.5 125+6.8 125+6.9
DBP(mmHg) 65+3.8 70+3.7 67+4.0
SVR(dyne.s.cm~5) 1224+80 1085+36* 979+59*
Absolute values (mean±SEM) of heart rate (HR), stroke volume (SV), cardiac output
(CO), systolic blood pressure (SBP), diastolic blood pressure (DBP) and systemic
vascular resistance (SVR) at baseline and during moderate and severe hypoxaemia.
* significantly different from baseline
t significantly different from moderate hypoxaemia
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FIGURE LEGEND
Figure 3.1. Effects of acute hypoxaemia on systolic flow indices and
electromechanical systole in normal man.
Systolic time intervals, uncorrected corrected for changes in heart rate (c), showing
QS2, left ventricular ejection time (ET) and pre-ejection period (PEP) at baseline and




We have shown that whilst causing significant changes in haemodynamic status,
hypoxaemia does not impair left ventricular myocardial contractility in normal
humans. It is therefore appropriate to consider these haemodynamic effects separately
from indices of myocardial contractility.
These observations are in agreement with the work of other investigators (Phillips BA
et al, 1988) who also noted using similar methodology, that increases in CO during
hypoxaemia were the result of positive chronotropic effects rather than any effect on
SV. The pulsed-wave Doppler techniques we have employed are however more
accurate and reproducible (Coats AJS, 1990), comparing favourably with invasive
measurement of CO (Labovitz AJ et al, 1985, Schuster AH et al, 1984). Unlike the
work of Phillips et al (Phillips BA et al, 1988) we did not control PaC02 in our
subjects. However, in view of the concordant findings it is unlikely that this has a
bearing on CO over the Sa02 range studied.
We also calculated SVR which fell significantly during hypoxaemia. The consequent
decrease in left ventricular afterload by itself might therefore be expected to cause an
increase in SV. Since SV did not change during hypoxaemia, this may have been
limited by the increased right ventricular afterload secondary to hypoxic pulmonary
vasoconstriction. The constant SV we observed would therefore make it less likely
that mechanical factors in accordance with Starling's law (i.e. left ventricular
distension) could have affected systolic left ventricular contractility during
hypoxaemia.
Of the Doppler aortic acceleration indices, both mean and peak acceleration have been
used as markers of left ventricular contractility (Bedotto JB et al, 1989) although
Accpeak appears to be relatively less influenced by changes in loading conditions
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(Bennett ED et al, 1984). Furthermore, although Accpeak declines with increasing
HR during pacing (Harrison MR et al, 1989), the effects across the HR range of our
study are small and consistent with the non-significant decrease observed. Thus,
hypoxaemia has no significant effects on left ventricular contractility as measured by
either peak or mean aortic acceleration.
The systolic time intervals are easily measured and repeatable markers of the inotropic
state of the left ventricle (Li Q et al, 1993), which are in some cases more sensitive
than echo-Doppler parameters (de Mey et al, 1992). Their changes with heart rate are
well established and corrections appropriate to the study population are easily applied
(Warrington SJ et al, 1988). As measures of the inotropic state of the myocardium,
the systolic time intervals are prolonged if contractility is impaired with the QS2
interval being relatively unaffected by changes in loading conditions (Li Q et al, 1993).
We found that hypoxaemia did not affect heart rate corrected QS2, as has been found
previously(Bremner P et al, 1992), or any of the other systolic time intervals
measured. We can therefore be confident that hypoxaemia did not significantly alter
left ventricular myocardial contractility.
It would appear therefore that systolic contractility of normal human myocardium is
relatively resistant to the effects of hypoxaemia. This is in contrast to the effects of
myocardial ischaemia where in addition to myocyte hypoxia, limitation of blood flow
might also allow accumulation of anaerobic metabolites which impair contractility
(Kilhara Y et al, 1989). These findings may well be important in determining the
relevance of hypoxaemia as a cause of abnormal cardiovascular performance in





ADVERSE EFFECTS OF HYPOXAEMIA
ON DIASTOLIC FILLING
IN NORMAL MAN
Clinical Science 1995;89; 165-169.
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4.1 SUMMARY
Abnormalities of myocardial relaxation may occur as a consequence of myocyte
hypoxia. We have therefore examined the effects of hypoxaemia on right and left
ventricular diastolic function in 10 healthy male volunteers.
After resting to reach baseline haemodynamics, subjects were rendered hypoxaemic by
breathing a variable nitrogen/oxygen mixture. Oxygen saturation (Sa02) was
maintained at 85-90% for 20 minutes and then 75%-80% for a further 20 minutes.
Haemodynamic and diastolic filling parameters were measured noninvasively at
baseline and at the end of each period of hypoxaemia.
Diastolic filling of both ventricles was significantly impaired by hypoxaemia. In
comparison with baseline, left ventricular isovolumic relaxation time and transmitral
E-wave deceleration time corrected for heart rate (IVRTc and EDTc) , were
significantly prolonged at Sa02 75-80%, IVRTc mean difference 9.8ms (95%
confidence interval 1 - 19), EDTc mean difference 34ms (95% CI 11 - 56). Similarly,
right ventricular IVRTc and transtricuspid EDTc were significantly prolonged at
SaC>2 of 75-80% compared with baseline; IVRTc mean difference 20.3 ms (95% CI 3
- 38), EDTc mean difference 33 ms (95% CI 11 - 55) During hypoxaemia there were
dose related increases in heart rate, cardiac output and mean pulmonary artery
pressure, but no effects on mean arterial pressure.
Hypoxaemia significantly impairs relaxation of left and right ventricles in normal man.
These changes may reflect impairment of intracellular calcium transport secondary to
the effects of myocyte hypoxia.
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4.2 INTRODUCTION
Ventricular diastolic function has emerged as an important determinant of overall
cardiovascular performance (Clarkson PBM et al, 1994) and is a particularly sensitive
marker of cardiac dysfunction. Abnormal diastolic function precedes systolic function
abnormalities in a number of disease states, including ischaemic heart disease (Wind
BE et al, 1987), hypertrophic cardiomyopathy (Pearson AC et al, 1987) and
hypertensive left ventricular hypertrophy (Hatle L, 1993), and may contribute to the
morbidity of these conditions.
Although most human studies of diastolic function have evaluated filling patterns of
the left ventricle, the role of ventricular interaction during diastole (Janicki JS et al,
1980, Stojnic et al, 1992) might indicate the need to consider abnormalities of right
and left ventricular filling together. In this respect, right as well as left ventricular
filling is impaired in patients with ischaemic heart disease (Fujii J et al, 1985) and
restrictive cardiomyopathy (Appleton CP et al, 1988) whilst patients with pulmonary
hypertension have paradoxical impairment of left ventricular filling (Stojnic BB et al,
1992).
In many of the above conditions, it is difficult to differentiate between structural
cardiac changes (e.g. ventricular remodelling) and functional abnormalities related to
changes in myocyte metabolism. Cellular hypoxia and the consequent abnormalities of
intracellular calcium transport (Kihara Y et al, 1989) may impair myocyte relaxation
and hence may worsen overall diastolic function. These cellular events may be of
relevance during myocardial ischaemia which leads to local hypoxia, or if hypoxaemia
accompanies cardiopulmonary disease as in cor pulmonale where at least right
ventricular diastolic function is impaired (Marangoni S et al, 1992).
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To elucidate further the role of these functional abnormalities during diastole, we have
studied the effects of hypoxaemia in normal humans. In this setting structural
abnormalities can be excluded, allowing us to study in vivo the functional effects of




Ten normal male volunteers, age (mean±SEM) 28.0±1.9 years were evaluated. All
subjects had no abnormality on clinical history and examination, biochemical and
haemotological screening or 12 lead electrocardiogram. In addition,
echocardiographic study was required to be normal with high quality transmitral and
transtricuspid Doppler flow profiles. Informed written consent to the study protocol,
previously approved by the Tayside Committee for Medical Research Ethics, was
obtained.
Study design
Subjects attended the clinical laboratory between 2 and 4 hours after lunch and
remained in a supine position, rolled slightly on to the left side. After resting to obtain
stable resting haemodynamic parameters, subjects were rendered hypoxaemic by
breathing a variable mixture of nitrogen and oxygen to achieve an SaC>2 between 85
and 90% for 20 minutes followed by 20 minutes with SaC>2 between 75 and 80%.
Haemodynamic variables and diastolic filling parameters were recorded at baseline and
at the end of each period of hypoxaemia at steady state.
Measurements
Haemodynamic and diastolic filling indices were measured as previously described. In
our hands the short term co-efficients of variation were as follows: mitral EDT 2.4%;
tricuspid EDT 4.8%; left ventricular IVRT 1.1% and right ventricular IVRT 12.2%.
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Data analysis
Comparisons were made by multifactorial analysis of variance and where this was
significant, Duncan's multiple-range testing was used to determine where significant
differences lay. A probability value of p<0.05 (two-tailed) was considered to be
statistically significant. Data are presented in the text and figures as means and
standard error of the mean, and where a difference between means is quoted, the 95%




Hypoxaemia caused significant dose related increases in both HR and CO (Table 4.1).
Hypoxic pulmonary vasoconstriction resulted in an increase in MPAP at both levels of
hypoxaemia whilst no significant effects on systemic MAP were observed (Table 4.1)
Diastolic filling parameters.
Transmitral E/A ratio decreased progressively in response to increasing levels of
hypoxaemia (Figure 4.1), due to significant increases in A wave velocity whereas E
wave velocity was unchanged (Table 4.2). A similar pattern was observed for
transtricuspid flow where reductions in the E/A ratio in response to hypoxaemia
(Figure 4.2) were due to increases in Avmax rather than changes in Evmax (Table
4.3).
Absolute levels of left ventricular IVRT were not significantly affected by hypoxaemia
(Table 4.2) although after correction for changes in HR, IVRTc was significantly
prolonged from baseline when SaC>2 was 85-90% (mean difference 8.9ms; 95% CI 1-
16) and when SaC>2 was 75-80% (mean difference 9.8ms; 95% CI 1-19) (Figure 4.1).
In the right ventricle, IVRT was prolonged when SaC>2 was reduced to 75-80% but
not at 85-90% (Table 3). In comparison with baseline, right ventricular IVRTc was
prolonged by hypoxaemia at SaC>2 75-80% (mean difference 20.3ms; 95% CI 3-38)
but not at SaC>2 85-90% (Figure 4.2).
Mitral EDT was only prolonged at SaC>2 75-80% (Table 4.2). After correction for
HR, EDTc was also significantly prolonged from baseline at SaC>2 75-80% (mean
difference 34ms; 95% CI 11-57) (Figure 4.1). Tricuspid EDT was similarly prolonged
by hypoxaemia (Table 4.3) and tricuspid EDTc was significantly prolonged from
baseline only at SaC>2 75-80% (mean difference 33ms; 95% CI 11-55) (Figure 4.2).
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Comparison of changes between left and right ventricles showed that as a percentage
of baseline IVRTc, at SaC>2 85-90% right ventricular IVRTc increased by 51%
compared with an increase in left ventricular IVRTc of 13% (mean difference 38%,
95% CI -11-100. p=ns). At the higher level of hypoxaemia where SaC>2 was reduced
to 75-80%, right ventricular IVRTc increased by 72% compared with an increase in
left ventricular IVRTc of 14% (mean difference 58%; 95% CI 6-109. P<0.05).
Ill




HR(beats/min) 62.1+2.9 67.9+3.5* 74.5±4.5*t
CO(L/min) 5.59 + 0.28 6.41+0.41* 7.22+ 0.42*1"
MAP(mmHg) 85.0+3.4 87.2+3.3 88.1+3.6
MPAP(mmHg) 9.3+0.4 17.8+0.8* 27.6+1.0*1"
Absolute values (mean±SEM) of heart rate (HR), cardiac output (CO), mean arterial
pressure (MAP) and mean pulmonary artery pressure (MPAP) at each level of
oxygenation.
* significantly different from >95%
t significantly different from 85-90%
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Table 4.2. Effects of acute hypoxaemia on left ventricular diastolic filling




Evmax(m/s) 0.70±0.02 0.69+0.02 0.71+0.04
Avmax(m/s) 0.44±0.01 0.48+0.02* 0.57+0.03*
E/A 1.53+0.03 1.44+0.06* 1.24+0.02*t
IVRT(ms) 70.7±6.0 74.8+6.5 72.5+7.1
EDT(ms) 146+5.6 150+8.3 168+14.4*
Absolute values (mean±SEM) of maximal transmitral early (Evmax) and atrial
(Avmax) wave velocity, E/A ratio, left ventricular isovolumic relaxation time (IVRT)
and E wave deceleration time (EDT) at each level of oxygenation.
* significantly different from >95%
t significantly different from 85-90%
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Evmax(m/s) 0.57±0.02 0.61+0.03 0.61+0.05
Avmax(m/s) 0.36±0.01 0.44+0.03* 0.50+0.04*
E/A 1.57+0.06 1.41+0.08* 1.22±0.07*t
IVRT(ms) 40.1±4.3 50.0+7.6 52.9+8.9*
EDT(ms) 150+6.1 151+7.0 170+8.3*
Absolute values (mean±SEM) of maximal transtricuspid early (Evmax) and atrial
(Avmax) wave velocity, E/A ratio, right ventricular isovolumic relaxation time
(IVRT) and E wave deceleration time (EDT) at each level of oxygenation.
* significantly different from >95%
t significantly different from 85-90%
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FIGURE LEGEND
Figure 4.1a, b and c.
Parameters of left ventricular diastolic function showing a) E/A velocity ratio, b) heart
rate corrected isovolumic relaxation time (IVRTc) and c) heart rate corrected E-wave
deceleration time (EDTc). Values are means and SEM.
* denotes significant difference from baseline (SaC>2 >95%)





Figure 4.2a, b and c.
Parameters of right ventricular diastolic function showing a) E/A velocity ratio, b)
heart rate corrected isovolumic relaxation time (IVRTc) and c) heart rate corrected E-
wave deceleration time (EDTc). Values are means and SEM.
* denotes significant difference from baseline (SaC>2 >95%)




































The present study has demonstrated abnormalities of left and right ventricular filling
during hypoxaemia in normal humans. Whilst the pattern of changes in E/A ratios
might conceivably be explained solely by changes in HR, the prolongation of IVRT
and EDT on both sides of the heart indicate abnormal diastolic function, particularly
evident when these parameters are corrected for heart rate. These haemodynamic
changes are in agreement with previous work showing that chronotropic rather than
inotropic effects of hypoxaemia are responsible for the increment in CO (Phillips BA
et al, 1988).
IVRT is widely accepted as a measure of active myocardial relaxation and its
prolongation indicates impaired diastolic function (Nishimura RA et al, 1989).
Conversely, EDT represents a measure of myocardial compliance, and is shortened
when compliance is decreased (Nishimura RA et al, 1989). However it is important
to realise that impairment of relaxation has confounding effects on EDT. In this
situation, active ventricular relaxation continues while passive filling takes place. This
paradoxically increases apparent ventricular compliance with consequent lengthening
of the EDT (Thomas JD et al, 1991). Thus the pattern of abnormality described in the
present study is one of impaired myocardial relaxation.
These findings in humans are therefore confirmatory to previously described
abnormalities of myocardial relaxation observed during hypoxia in laboratory animal
systems. Studies using isolated ventricular papillary muscle have demonstrated marked
impairment of relaxation during hypoxia (Frist WH et al, 1978, Nakamura Y et al
1986) whilst in isolated intact heart preparations, hypoxia was associated with an
increase in ventricular chamber stiffness (Serizawa T et al 1980) as well as impairment
of relaxation during diastole (Kihara Y et al 1989, Serizawa T et al 1980). The
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mechanisms whereby hypoxaemia might produce these effects has been extensively
studied and two possible theories are briefly considered.
Firstly, the effects of hypoxia on intracellular calcium transport may be important.
Cellular hypoxia has been shown to increase intracellular calcium concentrations
during diastole (Kihara Y et al 1989), due to decreased calcium uptake by the
sarcoplasmic reticulum (Nayler WG et al, 1979) and perhaps other ion channel
mediated effects (Rodman DM, 1992). Myocardial relaxation depends critically on
rapid removal of free intracellular calcium ions to quickly reverse the calcium
facilitated actin-myosin interaction which would otherwise sustain contraction
(Nishimura RA et al, 1989). It is likely that hypoxia delays this process so allowing
contractile elements within the cell to remain cross-linked into diastole and impairing
relaxation.
The second possibility is a mechanical one, related to the concept of ventricular
interaction across the interventricular septum (Stojnic BB et al, 1992). Hypoxaemia,
by inducing pulmonary hypertension (Cutai M et al, 1990), increases right ventricular
afterload which might cause dynamic changes in septal motion. This pattern has been
observed in other forms of pulmonary hypertension (Jessup M et al, 1987, Tanak H et
al, 1980) but has only been studied at much higher pulmonary artery pressures than
we achieved. Although we did not study this phenomenon directly in the present
study, it is conceivable that abnormal septal motion, which is associated with
impairment of left ventricular filling (Stojnic BB et al, 1992), might explain some of
the abnormalities observed.
Interestingly, the effects of pulmonary hypertension alone on right ventricular diastolic
function have not been studied, although this is impaired in cor pulmonale (Marangoni
S et al, 1992) where either pulmonary hypertension or hypoxaemia might play a role.
In the present study, we have shown that whilst both right and left ventricular
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relaxation is impaired by hypoxaemia, prolongation of IVRTc as a percentage of
baseline is more marked in the right ventricle than in the left. Obviously baseline
IVRTc was shorter in the right ventricle (with values in the present study similar to
those previously published although recorded by a different method (Marangoni S et
al, 1992)) but increases in pulmonary artery pressure would be expected to prolong
systolic pulmonary artery flow. This would delay pulmonary valve closure and in fact
shorten right ventricular IVRT. This effect would however need to be balanced by the
possibility that increased pulmonary artery pressure would alter myocyte loading
conditions in the right ventricle, which may directly impair relaxation as has been
shown to occur in the left ventricle (Raff GL et al, 1981). In view of the finding that
right ventricular IVRTc was prolonged proportionately more than left ventricular
IVRTc, this may indicate that right ventricular relaxation is more sensitive to the
adverse effects of hypoxaemia.
It would appear therefore that as is the case in vitro, hypoxaemia significantly impairs
myocardial relaxation in humans and that these abnormalities are of similar magnitude
to the diastolic filling abnormalities observed in some disease states. IVRTc in the
right ventricle was prolonged by 20.3 ms which approaches the level of abnormality
detected in patients with hypoxaemic COPD and pulmonary hypertension (Marangoni
S et al, 1992). In the left ventricle, the observed lengthening of IVRTc (by 9.8 ms)
during hypoxaemia is more difficult to place in a clinical context although is similar in
magnitude to the adverse effects of very high dose infusions of angiotensin II
(Clarkson PBM et al, 1994). The haemodynamic significance of these effects is
therefore speculative at present as clinical studies are lacking. Whether treating
hypoxaemic patients with oxygen would actually improve diastolic function has not
been studied, but it is conceivable that this is one way in which oxygen therapy is of










Prolongation of the QTc interval has been associated with cardiac dysrhythmias and
sudden death. Recently QTc dispersion (inter-lead variability in QTc interval) has
been proposed as being a more sensitive marker of repolarisation abnormalities and
shown to be a more specific index of arrhythmia risk. Although hypoxaemia and
fenoterol have previously been shown to prolong QTc interval this does not reflect
regional myocardial repolarisation abnormalities.
Electrophysiological effects were measured at baseline and after 30 mins steady state
hypoxaemia at an SaC>2 75-80 % (study 1) and at baseline then 30 mins after inhaled
fenoterol 2.4mg (study 2). From the ECG, lead II corrected QT interval (QTc) and
overall corrected QT dispersion were measured using a computer linked digitising
tablet according to standard criteria.
QTc dispersion was increased during hypoxia compared to baseline mean (SE) at
69(6) ms vs 50(5) ms and after fenoterol compared to baseline at 79(13) vs 46(4) ms
respectively. There was also an increase in QTc interval and heart rate after fenoterol
at 493(23) vs 420(6) ms and 98(3) vs 71(6) bpm respectively. There was an increase
in heart rate during hypoxaemia compared to baseline at 78(3) vs 64(2) bpm, but no
change in QTc interval.
Thus, both hypoxaemia and fenoterol cause myocardial repolarisation abnormalities
in humans in terms of increased QTc dispersion, whereas only fenoterol increased
QTc interval. This may be relevant in the aetiology of arrhythmias in patients with
acute severe asthma where (3-agonist therapy and hypoxaemia co-exist.
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5.2 INTRODUCTION
The surface electrocardiogram has been investigated for its ability to identify those
patients at risk of arrhythmias and as such represents a cheap, non-invasive and
simple method. Traditionally the single measurement of QTc interval has been used to
measure the recovery of ventricular excitability, widely recognised to be the most
important factor in arrhythmogenesis.
QT prolongation has been shown to be a predictor of sudden death in alcoholic
cirrhosis (Day CP et al, 1993), sudden cardiovascular mortality in apparently healthy
individuals (Schouten EG et al, 1991), as well as sudden death in patients with
ischaemic heart disease (Puddu PE et al, 1986). Recently however, QTc dispersion
(interlead variability in QTc interval) has been suggested as a more sensitive and
specific marker as it measures differences in regional repolarisation and has been
shown to be increased in patients with HOCM at risk from ventricular arrhythmias
(Buja G et al, 1993) and in patients with long QT intervals it distinguished between
those with ventricular arrhythmias and those without (Day CP et al, 1990). Recently
it has been found to be a more sensitive and specific marker of sudden death in heart
failure than QTc interval alone (Barr CS et al, 1994).
Cardiac arrhythmias are a very common finding in patients with respiratory failure and
COPD (Terlapur VG et al, 1982, Holford FD et al, 1973, Kleiger RE et al, 1974). It
has been shown that depressed left ventricular diastolic performance is a predictive
factor for ventricular arrhythmias during respiratory failure from COPD although the
poor definition of the statistical model suggests that other factors contribute to the
genesis of these arrhythmias (Raffaele Al et al, 1990). In this respect Stewart et al
(Stewart AG et al, 1995) have recently shown that QTc prolongation is a better
predictor of death in patients with COPD than hypoxaemia, hypercapnia or
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spirometry. Interest has also surrounded the use of (3-agonists which have inotropic,
chronotropic and electophysiological effects. In particular the epidemiological
observation that fenoterol was associated with an increased risk of death in patients
with severe asthma (Crane F et al, 1989, Grainger J et al, 1991) has suggested that
this drug may predispose these individuals to arrhythmias. Interestingly the use of
high dosed nebulised P-agonist has been associated with an increased risk of cardiac
arrhythmias in patients with COPD (Higgins RM et al, 1987) and a further study
revealed that normoxaemic COPD patients had a higher frequency of ventricular
ectopy during treatment with high dose in comparison to low dose terbutaline
although 24 hour Holter recordings did not reveal an increase in significant
arrhythmias (Lipworth BJ et al, 1990).
We have therefore, for the first time looked at the effects of two separate stimuli
which have been suggested as important factors in arrhythmogenesis in respiratory





Sixteen healthy male volunteers aged 21-37 years were studied. There was no
abnormality present on clinical history, clinical examination, 12 lead ECG, biochemical
or haematological screening. Patients abstained from alcohol and caffeine for a 24 hr
period prior to the study. Informed written consent to the study protocol, previously
approved by the Tayside Committee for Medical Research Ethics was obtained.
Study design
Study 1.
Eight subjects were studied. An intravenous cannula was inserted into the left
forearm for blood sampling. They then rested supine for at least 30 mins to obtain
stable resting haemodynamics (To). They were then rendered hypoxaemic, as
previously described, for 30 minutes by breathing a variable mixture of oxygen and
nitrogen which rendered their arterial oxygen saturation between 75-80% (Ti). The
hypoxic gas mixture was produced from separate cylinders of nitrogen and oxygen
fitted with variable flow valves. A 12 lead ECG and venous blood samples for
catecholamine and serum potassium assays, were taken at To and Tj.
Study 2: Eight subjects were studied. An intravenous cannula was inserted into
the left forearm for blood sampling. Subjects then rested supine for at least 30 mins to
obtain stable resting haemodynamics (To). Patients were then given fenoterol 2.4 mg
from a metered dose inhaler (MDI) via a spacer device (12 x 0.2mg actuations with
three inhalations per actuation). A 12 lead ECG and venous blood samples for serum
potassium, were taken at To and 30 minutes post inhalation of fenoterol (T]).
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MEASUREMENTS
QT interval and QT dispersion were measured as previously described and heart rate
was calculated from five consecutive R to R intervals in lead II. Serum potassium and
catecholamines were measured as previously described.
Data analysis
Comparison of values were made by multifactorial analysis of variance (Brown RA et
al, 1990). A probability value of p<0.05 (two-tailed) was considered to be statistically




Treatment with fenoterol significantly [p<0.01] increased QTc interval compared to
baseline at 493(23) vs 420(6) ms respectively (Figure 5.1 A). Hypoxaemia, however
had no significant effect (Figure 5. IB).
QTc dispersion.
Fenoterol significantly [p<0.05] increased QTc dispersion compared to baseline at
79(13) vs 46(4) ms respectively (Figure 5.1C). Similarly hypoxaemia significantly
[p<0.05] increased QTc dispersion compared to baseline at 69(6) vs 50(5) ms
respectively (Figure 5. ID).
Heart Rate.
Both fenoterol [p<0.01]: 98(3) vs 71(6) ms and hypoxaemia [p<0.05]: 78(3) vs 64(2)
ms significantly increased heart rate compared to baseline (Figure 5.2A).
Serum potassium.
Treatment with fenoterol resulted in a significant [p<0.0001] reduction in serum
potassium compared to baseline at 2.93(0.12) vs 3.86(0.07) mmol/1 respectively.
Hypoxaemia however, had no significant effect (Figure 5.2B).
Catecholamines.
Hypoxaemia had no significant effect on either noradrenaline: 4.75(0.65) vs




Figure 5.1. Effects of hypoxaemia and fenoterol on QTc interval and QTc
dispersion in normal man.
A Absolute QTc interval measured at baseline and after fenoterol. * represents a
significant (p<0.01) difference between fenoterol treatment compared to baseline.
B Absolute QTc interval measured at baseline and during hypoxaemia.
C Absolute QTc dispersion measured at baseline and after fenoterol. * represents
a significant (p<0.05) difference between fenoterol treatment compared to baseline.
D Absolute QTc dispersion measured at baseline and during hypoxaemia. *
represents a significant (p<0.05) difference between fenoterol treatment compared to
baseline.
In the above figure values for the same patient are connected and the mean and




Figure 5.2. Effects of hypoxaemia and fenoterol on heart rate and serum
potassium in normal man.
A Left: absolute heart rate measured at baseline (clear bars) and during
hypoxaemia (hatched bars). Right: absolute heart rate measured at baseline (clear
bars) and after fenoterol (hatched bars). * represents a significant (p<0.05) difference
between hypoxaemia and baseline whilst + represents a significant (p<0.01) difference
between fenoterol and baseline.
B Left: serum potassium measured at baseline (clear bars) and during
hypoxaemia (hatched bars). Right: serum potassium measured at baseline (clear bars)
and after fenoterol (hatched bars). * represents a significant (p<0.0001) difference








Our results show that both hypoxaemia and fenoterol significantly increase QTc
dispersion in healthy volunteers suggesting that these two stimuli cause abnormalities
in myocardial repolarisation. However, only fenoterol significantly increased QTc
interval and significantly decreased the serum potassium concentration compared to
baseline; changes which have previously documented in normal and asthmatic subjects
(Bremner P et al, 1992, Newnham DM et al, 1993).
It is thought that QTc dispersion reflects regional variation in ventricular
repolarisation and existing evidence suggests that it is a powerful index of the
propensity for developing life threatening arrhythmias (Buja G et al, 1993, Day CP et
al, 1990, Barr CS et al, 1994). The underlying mechanism responsible for an increase
in QTc dispersion is not known although it has been suggested that fibrosis may be
important (Barr CS et al, 1994). However, as our results suggest dynamic
physiological abnormalities must play a part as both stimuli are acute and self limiting
in nature. Indeed our results are not the first to implicate dynamic variables as having
an important role to play in altering QTc dispersion; Moreno et al (Moreno FL et al,
1994) have shown that QTc dispersion is decreased following successful thrombolysis
after myocardial infarction demonstrating that localised ischaemia affects regional
repolarisation. In the context of congestive cardiac failure no correlation was noted
between increased QTc dispersion and catecholamine levels (Barr CS et al, 1994).
We were unable to show any increase in circulating catecholamines during acute
hypoxia although this was a small study and as such has an inherently large type 2
error. It is known that large oral doses of (3-agonists do not affect catecholamine
levels (Barnes PJ et al, 1982) and they were not measured in this study although
Scheinin et al have shown that noradrenaline was dose dependently increased by
fenoterol treatment (Scheinin M et al, 1987). It may be that hypoxia and (3-agonists
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have their effects on QTc dispersion by altering autonomic tone although it is likely
that local metabolic and electrical disturbances may play a role. In this respect,
hypokalaemia affects the electrical stability of cell membranes and is known to
predispose individuals to arrhythmias and may explain, at least in part why fenoterol
increases QTc dispersion.
Although hypoxia did not significantly increase QTc interval in this study, this
phenomenon has previously been documented (Bremner P et al, 1992). However, it
may be that QTc dispersion is a more sensitive marker of abnormal myocardial
repolarisation than QTc interval alone.
With respect to our methodology there are undoubtedly limitations in all studies
measuring QTc dispersion. We used a computer linked digitising tablet which has
been shown by other investigators to be a reliable and accurate measure of QTc
dispersion (Bhullar HK et al, 1993). Probably the most important aspect concerning
methodology is the protocol to define the end of the T wave. We have thus used the
most commonly used protocol (Higham PD et al, 1994) and one which has been
shown to correlate with arrhythmia risk and sudden death. We also measured the
QTc interval in the majority of leads in each individual although occasionally leads
were omitted due to difficulty defining the end of the T-wave. We used routine
ECG's to measure QTc dispersion since we felt this would have most clinical
relevance and indeed no substantial evidence suggests that simultaneous ECG
recording has any benefits.
What is the clinical relevance of QTc dispersion and what if any are its merits
compared to our traditional measure of ventricular repolarisation, QTc interval?
Firstly, much time and effort has been expended to find markers of mortality in
hypoxic chronic lung disease and to find high risk patients who may benefit from
further investigation or treatment. It would certainly be of interest if QTc dispersion
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correlates with risk of sudden death in patients with cor pulmonale. Use of fenoterol,
has been associated with an increased incidence of asthma deaths, could it be possible
that this observation is due to arrhythmias occurring in the presence of abnormal
myocardial repolarisation? It has been suggested that certain individuals may be more
susceptible to the effects of P-agonists. In this respect it is interesting to note the
large increase in QTc dispersion that occurred in two individuals in response to
inhaled fenoterol (Figure 1C). Although we exceeded the standard dose of fenoterol
suggested by the manufacturer, in an asthmatic attack very high doses of P-agonists
may have to be taken (Windom H et al, 1990) and indeed the British Thoracic Society
guidelines recommend up to 50 puffs of a P-agonist from a metered dose inhaler
during a severe attack(British Thoracic Society Guidelines for management of asthma
in adults, 1990). We have also shown that acute hypoxaemia increases QTc
dispersion suggesting that this may have a role to play in arrhythmogenesis in acute
asthma although we can infer little concerning chronic hypoxia. Compared with QTc
interval, QTc dispersion, which measures ventricular repolarisation in several leads,
may be a better indicator of arrhythmia risk Indeed, it has been shown to be both a
more sensitive and specific marker of sudden death than QTc interval alone (Barr CS
et al, 1994). Amiodarone which is known to prolong QTc interval is used in the
treatment of ventricular tachycardia. It is perhaps no coincidence that this drug also
reduces QTc dispersion (Dristas A et al, 1992).
Thus, we have shown for the first time that two stimuli thought to be associated with
arrhythmogenesis in respiratory disease increase QTc dispersion, namely hypoxia and
P-agonists. It seems likely that this index of abnormal myocardial repolarisation will
have important implications in terms of risk stratification of patients and in the




EFFECTS OF HYPERCAPNIA ON HAEMODYNAMIC,
INOTROPIC, LUSITROPIC AND ELECTROPHYSIOLOGICAL




The inotropic, lusitropic and electrophysiologcal effects of acute hypercapnia in man
are not known. Although the effects of hypercapnia on the systemic circulation have
been well documented there is still some debate as to whether hypercapnia causes true
pulmonary vasoconstriction in vivo. We have therefore evaluated the effects of acute
hypercapnia on these cardiac indices as well as the interaction of hypercapnia with the
systemic and pulmonary vascular beds in man.
Eight healthy male volunteers were studied using Doppler echocardiography. After
resting for at least 30 mins to achieve baseline haemodynamic parameters (T0), they
were rendered hypercapnic to achieve an end-tidal C02 of 7 KPa for 30 mins by
breathing a variable mixture of C02/air (Ti). They were restudied after 30 mins
recovery breathing air (T2). Haemodynamic, diastolic and systolic flow parameters,
QT dispersion (maximum-minimum QT interval measured in a 12 lead ECG) and
venous blood samples for plasma renin activity (PRA), angiotensin II (ANG II) and
aldosterone (ALDO) were measured at each time point.
Hypercapnia compared to placebo significantly increased mean pulmonary artery
pressure 14±1 vs 9±1 mmHg and total pulmonary vascular resistance 171±17 vs
129±17 dyne. s.cm"5, respectively. Heart rate, stroke volume, cardiac output and mean
arterial blood pressure were increased by hypercapnia. Indices of systolic function
namely peak aortic velocity and aortic mean and peak acceleration were unaffected by
hypercapnia. Similarly, hypercapnia had no effect on lusitropic indices reflected by its
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lack of effect on the isovolumic relaxation time, mitral E wave deceleration time and
mitral E/A wave ratio. Hypercapnia was found to significantly increase both QTc
interval and QT dispersion: 428±8 vs 411±3 ms and 48±2 vs 33±4 ms respectively.
There was no significant effect of hypercapnia on PRA, ANG II or ALDO.
Thus, acute hypercapnia appears to have no adverse inotropic or lusitropic effects on
cardiac function although repolarisation abnormalities, reflected by an increase in QT




Hypercapnia is a well recognised consequence of a variety of disease states. It is
frequently encountered in the context of chronic obstructive airways disease and more
unusually in disorders of the nervous and musculoskeletal systems. In recent years
there has been much interest in the effects of hypercapnia in anaesthetic practice after
the finding that mechanical ventilation may contribute to increased morbidity and
mortality as a consequence of barotrauma (Hickling KG, 1990, Lachan B et al, 1982,
Hamilton PP et al, 1983). This has resulted in a volume and pressure limited
ventilation strategy and elevated levels of carbon dioxide, so called permissive
hypercapnia (Hickling KG et al, 1990, Pesant A, 1990).
The effects of hypercapnia on the systemic circulation have been well documented
(Price HL, 1960, Cullen DJ et al, 1974) although there is still some debate as to
whether carbon dioxide causes true pulmonary vasoconstriction in vivo (Kilburn KH
et al, Fishman AP et al, 1960, Rosketh R, 1966, Twining RH et al, 1968, Durand J et
al , 1970, Harris P et al, 1986). Many of these studies were performed over twenty
years ago and findings were sometimes based purely on changes in mean pulmonary
artery pressure and where pulmonary vascular resistance was measured, it was derived
from cardiac outputs calculated using the Fick principle, with errors a consequence of
a changing state of respiratory gas exchange (Kierler KL, 1961, Phillips BA et al,
1988).
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The advent of newer non-invasive methodology such as Doppler echocardiography
has permitted a more detailed examination not only of haemodynamic effects but also
of inotropic (Bennet ED et al, 1984, Cargill et al, 1995a) and lusitropic (Rokey R et
al, 1985, Cargill et al, 1995b) activity. A novel marker of abnormal myocardial
repolarisation, QT dispersion (Higham PD et al 1994, Kiely DG et al, 1995) has also
provided us with information regarding the electrophysiological effects of different
stimuli.
We have therefore evaluated for the first time the effects of acute hypercapnia on
inotropic, lusitropic and repolarisation indices as well as re-examining the interaction





Eight healthy male volunteers, mean age 24 years (range 21-34 years) were studied.
There was no abnormality present on clinical history, examination, 12 lead ECG,
echocardiography, biochemical or haematological screening. Informed written
consent to the study protocol, previously approved by the Tayside Committee for
Medical Research Ethics, was obtained.
Study design
Subjects attended the clinical laboratory and were studied in a supine position, rolled
slightly on the left side. An intravenous cannula was inserted into the left forearm for
blood sampling. Subjects then rested to obtain stable resting haemodynamics (T0).
They were then rendered hypercapnic by breathing a variable mixture of carbon
dioxide and medical air to attain an end-tidal C02 (ET C02) of 7 KPa for thirty
minutes (T,) and then breathed room air for a further thirty minutes (T2). The
hypercapnic gas mixture was produced from separate cylinders of carbon dioxide and
medical air fitted with variable flow valves.. Measurements of pulmonary and
systemic haemodynamic variables, inotropic, lusitropic and electrophysiological
indices and venous blood samples for plasma renin activity (PRA), angiotensin II
(ANG II) and aldosterone (ALDO) were taken at T0, Tl5 and T2.
Measurements
Systemic and pulmonary haemodynamics, systolic and diastolic filling parameters, QT
interval and QT dispersion and oxygenation and end tidal carbon dioxide
concentrations were measured as previously described.
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Data analysis
Comparisons between serial time points on the same study day were made using
multifactorial analysis of variance followed by Duncan's multiple range test. A
probability value of p<0.05 (two-tailed) was considered to be statistically significant.
Data are presented in the text, tables and figures as means and SEM.
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6.4 RESULTS
Oxygenation and ET C02.
Breathing the C02/air mixture compared to air significantly increased respiratory rate
21±1 vs 13±1 breaths/min, ET C02 7.0±0.2 vs 5.0±0.3 KPa and oxygen saturation
98±0.2 vs 97±0.2%, respectively. There was no significant difference between T2
(thirty minutes post hypercapnia) and baseline.
Pulmonary Haemodynamics.
Hypercapnia (Ti) was associated with a significant (p<0.05) increase in both MPAP
and TPR compared to baseline (T0). There was no significant difference between T2
(thirty minutes post hypercapnia) and baseline (Figure 6.1).
Systemic Haemodynamics.
Hypercapnia (Ti) was associated with a significant (p<0.05) increase in SBP, DBP,
MAP, HR and CO compared to baseline (T0). However, hypercapnia had no
significant effect on SVR compared to baseline: 1102±38 vs 1162±78 dyne.s.cm-5.
There was no significant difference between T2 and To for any of the systemic
haemodynamic parameters (Figure 6.2).
Systolic flow parameters.
Hypercapnia compared to baseline had no significant effect on Avpeaic, Accpeak or
Accmean. (Table 6.1)
Diastolic flow parameters.
Similarly hypercapnia compared to baseline had no significant effect on Evmax, Avmax,
E/A ratio, EDT, EDTc, IVRT or IVRTc (Table 6.1).
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QT dispersion.
Hypercapnia compared to baseline had no significant effect on QT interval although
QTc was significantly increased after hypercapnia. Hypercapnia also significantly
increased QT dispersion compared to baseline and this was also significantly elevated
after 30 minutes rebreathing air compared to baseline (Figure 6.3).
RAS activity.
Hypercapnia had no significant effect on All, PRA or ALDO although PRA was
significantly lower at T2 compared to baseline (Table 6.2).
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Table 6.1: Hypercapnia and its effects on systolic and diastolic parameters in
normal man.
TO Tl T2
AVpeak (mS ) 1.20±0.08 1.26±0.10 1.15±0.05
AcCmean (niS~ ) 11.9±1.4 10.8±1.2 10.8±1.1
Accpeak (ms-J) 26.8±4.0 24.8±3.6 28.1±3.6
Evmax (rns-1) 77±5 75±6 71±5
Avmax (ms-1) 42±2 41±3 41±3
E/A ratio 1.86±0.17 1.90±0.21 1.81±0.19
EDT (ms) 121±5 123±7 114±9
EDTc (ms) 121±9 137±9 124±5
IVRT (ms) 66±5 65±4 68±3
IVRTc (ms) 74±5 70±3 72±4
There were no significant differences between T0 (baseline), Ti (ET CO2 =7 KPa) and
T2 (after rebreathing air for thirty minutes) for each of the above variables.
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Table 6.2. Hypercapnia and its effects on the RAS in normal man.
TO Tl T2
PRA (pmol/h/ml) 1.21±0.31 1.00±0.21 0.57±0.15 *
ANG H (pmol/1) 15.8±2 19.0±4.7 13.2±1.4
ALDO (pmol/1) 86.2±14.7 74.49±11.6 72.3±16.3
* represents a significant difference in PRA at T2 (thirty minutes after rebreathing air)
compared to T0 (baseline). There were no significant differences between Ti (ET
C02=7 KPa) and the other time points for any of the above variables.
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FIGURE LEGEND
Figure 6.1. Effects of hypercapnia on pulmonary haemodynamics and
electrophysiological parameters in normal man.
Top left : absolute mean pulmonary artery pressure (MPAP) measured during
normoxaemia (baseline), after 30 mins hypercapnia and 30 mins after rebreathing air,
respectively.
Bottom left: absolute total pulmonary vascular resistance (TPR) measured during
normoxaemia (baseline), after 30 mins hypercapnia and 30 mins after rebreathing air,
respectively.
Top right: absolute QTc interval measured during normoxaemia (baseline), after 30
mins hypercapnia and 30 mins after rebreathing air, respectively.
Bottom right: absolute QT dispersion measured during normoxaemia (baseline), after
30 mins hypercapnia and 30 mins after rebreathing air, respectively.
* represents a significant (p<0.05) difference between baseline and hypercapnia or
































Figure 6.2. Effects of hypercapnia on systemic haemodynamic parameters.
Top Left: absolute cardiac output (CO) measured during normoxaemia (baseline),
after 30 mins hypercapnia and 30 mins after rebreathing air, respectively.
Bottom Left: absolute heart rate (HR) measured during normoxaemia (baseline),
after 30 mins hypercapnia and 30 mins after rebreathing air, respectively.
Top Right: absolute stroke volume (SV) measured during normoxaemia (baseline),
after 30 mins hypercapnia and 30 mins after rebreathing air, respectively.
Bottom Right: absolute systolic blood pressure (clear squares), mean arterial blood
pressure (bold circles) and diastolic blood pressure (clear circles) measured during
normoxaemia (baseline), after 30 mins hypercapnia and 30 mins after rebreathing air,
respectively.















We have shown that acute hypercapnia causes true pulmonary vasoconstriction in
vivo in normal volunteers as reflected by a significant increase in both MPAP and
PVR. Although acute hypercapnia had no significant inotropic or lusitropic effects it
significantly increased QT dispersion suggesting that hypercapnia may cause
abnormalities in myocardial repolarisation.
The effect of carbon dioxide on the pulmonary circulation in man remains
controversial although the evidence appears to suggest a vasoconstrictor effect
(Kilburn KH et al, Fishman AP et al, 1960, Rosketh R, 1966, Twining RH et al, 1968,
Durand J et al, 1970, Harris P et al, 1986). We aimed to achieve ET C02 similar to
that encountered in patients with exacerbations of COPD and also that found in
permissive hypercapnia. Our mean ET C02 of 7 KPa equates with an arterial pC02
of approximately 7.5 KPa, and ET C02 is known to closely mirror the concentration
of carbon dioxide in arterial blood (O'Flaherty D, 1994). Blood leaving the ventilated
alveoli usually mixes with blood from both parenchymal lung tissue and with blood
passing through non-ventilated alveoli, creating a venous admixture. It is this venous
admixture that accounts for the normal alveolar-arterial C02 tension difference. The
early work of Fishman (Fishman AP et al, 1960) looked at the effect of 3-5% C02 on
the pulmonary vasculature in normal volunteers and in patients with COPD and
concluded that breathing air rich in carbon dioxide had no effect on pulmonary
vasoconstriction. This was in sharp contrast to work performed in animals and this
apparent dichotomy was explained by Kilburn (Kilburn et al, 1969) who demonstrated
pulmonary vasoconstriction in patients with COPD exposed to more severe
hypercapnia. These findings have been corroborated in other studies in patients with
elevated and normal mean pulmonary artery pressures (Rosketh R, 1966, Paul G et al,
1964). This study in normal man provides further support for the evidence in patient
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studies that hypercapnia is a relatively weak pulmonary vasoconstricitor and that
pulmonary vessels may be the exception to the rule that acidosis causes vasodilatation
(Bergofsky EH et al, 1962). Thus, hypercapnia may function in man as an intrinsic
mechanism diverting blood from underventilated areas of the lung in an effort to
maintain ventilation perfusion matching. In contrast to previous studies we have used
Doppler-echocardiography to measure haemodynamic changes in the pulmonary
circulation. These non-invasive techniques have been shown to be highly reproducible
(Lipworth BJ et al, 1994a) and the close correlation between Doppler PAT and
MPAP as measured by right heart catheter, is well established (Dabestani A et al,
1987, Graettinger WF et al, 1987, Kitbatake A et al, 1983). We looked at two
measures of pulmonary vasoconstriction; changes in MPAP and TPR. The use of total
pulmonary vascular resistance does not account for any changes in the post-capillary
vascular bed, as conventionally assessed by pulmonary capillary wedge pressure
(PCWP). In this respect we feel it is unethical to insert Swan-Ganz catheters into
normal volunteers for research purposes and the extra information this would give us
is not essential. It has previously been shown that hypercapnia has no significant
effects on PCWP either in patients with normal pulmonary artery pressures or those
with elevated pressures occurring as a consequence of hypoxic lung disease and so
effects on total pulmonary vascular resistance are reflective of changes in true PVR in
pre-capillary arterioles during hypercapnia (Rosketh R, 1966). We believe therefore,
that the observed changes in total pulmonary vascular resistance are a true reflection
of changes in pulmonary vascular tone.
The systemic effects of hypercapnia are complex and reflect a balance between the
direct effects of carbon dioxide and the secondary effects of carbon dioxide mediated
via the central and autonomic nervous systems. In this study we have demonstrated
significant increases in HR, SV, CO, SBP, MAP and DBP and a non-significant
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reduction in SVR, changes which have previously been documented in patients with
similar degrees of hypercapnia (Price HL, 1960, Cullen DJ et al, 1974).
Interestingly, although hypercapnia has been shown to be a direct myocardial
depressant in the isolated heart (Price HL et al, 1955, Williams El, 1955), we have
shown no significant effects of hypercapnia on either inotropic or lusitropic indices of
cardiac function measured using Doppler echocardiography. Mean and peak aortic
acceleration as well as peak aortic velocity have been shown to be sensitive markers
of left ventricular contractility (Bennet ED et al, 1984, Wallmeyer K et al, 1986,
Bedotto JB et al, 1989, Sabbah HN et al, 1986) Although Accpeak and Avpeak decline
with increasing heart rate (Harrison MR et al, 1989) during pacing, the effects across
our HR range are small and consistent with the non-significant changes observed.
This suggests that the systolic contractility of the normal human myocardium is
relatively resistant to the effects of acute hypercapnia. Similarly we have shown no
effect on ventricular diastolic function which is an important determinant of overall
cardiovascular performance and a sensitive marker of cardiac dysfunction, as reflected
by the lack of effect of hypercapnia on all of the measured indices. This suggests that
the secondary effects of hypercapnia on the central and autonomic nervous systems in
the integrated physiological system of man are capable of antagonising the direct
myocardial depressant effects of hypercapnia (Cross BA et al, 1962, Downing SE et
al, 1963).
Although acute hypercapnia appears to have no significant effects on myocardial
contractility, the observation that hypercapnia increases both QTc interval and QT
dispersion suggests that it has significant effects on myocardial repolarisation. The
finding that hypercapnia increases QT dispersion is probably of more significance
since this represents differences in regional myocardial repolarisation and as such
represents a putative substrate for arrhythmias. In contrast QTc interval provides no
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information regarding regional repolarisation abnormalities. Evidence suggests that
QT dispersion is a sensitive index of the propensity for developing life threatening
arrhythmias and as such may lower the arrhythmogenic threshold in conditions where
hypercapnia exists. The mechanism whereby hypercapnia causes these abnormalities
in myocardial repolaristion may be related to its effects on autonomic function or
elevated levels of catecholamines which have been previously demonstrated during
acute hypercapnia (Sechzer PH et al, 1960). QT dispersion is a useful , easily
applicable non-invasive technique. We used a computer linked digitising tablet which
has been shown by other investigators to be a reliable and accurate measure of QT
dispersion (Buja G et al, 1993). Probably the most important aspect concerning
methodology is the protocol to define the end of the T wave. We have thus used the
most commonly used protocol (Higham PD et al, 1994) and one which has been
shown to correlate with arrhythmia risk and sudden death in patient studies (Barr CS
et al, 1994, Farber MO et al, 1977). We used routine ECG's to measure QT
dispersion since we felt this would have most clinical relevance and indeed no
substantial evidence suggests that simultaneous ECG recording has any benefits.
We have also investigated the effect of acute hypercapnia on the RAS. In the absence
of hypercapnia RAS activation in hypoxaemic patients is rare (Colice GL et al, 1985)
suggesting a possible role for hypercapnia possibly occurring as a consequence of
renal vasoconstriction or as a result of a direct cellular effect. In this study, however,
we were unable to demonstrate any significant effect of hypercapnia on either PRA,
ANG II or ALDO. This may be related to the brevity of our stimulus, although
similar periods of hypoxia suppressed ALDO levels (Cohen EL et al, 1967). It is also
possible that hypoxia and hypercapnia may need to be present in synergistic fashion to
produce clinically detectable RAS activation. The significant fall in PRA thirty
minutes after cessation of hypercapnia compared to baseline is consistent with the
known effects of resting in the supine position, where values of PRA increase with
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upright body posture and fall with time when the supine position is assumed (Tuck
MLetal, 1975).
To conclude, acute hypercapnia appears to have no effects on myocardial contractility
or relaxation in the integrated physiological system of man although repolarisation
abnormalities reflected by an increase in QT dispersion may provide an environment
for arrhythmogenesis. We have also shown that hypercapnia causes true pulmonary
vasoconstriction in man. This agrees with findings in patient studies but also suggests





ANGIOTENSIN II RECEPTOR BLOCKADE AND EFFECTS ON
PULMONARY HAEMODYNAMICS AND HYPOXIC
PULMONARY VASOCONSTRICTION IN MAN
Chest 1996;110:698-703.
(Editorial. The renin angiotensin system and the "lesser circulation".
A role in cor pulmonale? Chest 1996;110:584-585.)
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7.1 SUMMARY
We examined the hypothesis that angiotensin II (ANG II) is a modulator of pulmonary
vascular tone by examining the effects of ANG II blockade on pulmonary
haemodynamics during normoxaemia and hypoxaemia in normal volunteers with an
activated renin angiotensin system (RAS).
Eight normal volunteers, pre-treated with furosemide, were studied on two separate
occasions and received either an infusion of saralasin 5 pg/kg/min or placebo. After
20 mins they were rendered hypoxaemic, by breathing N2/O2 mixture for 20 mins to
achieve SaC>2 85-90% adjusted for a further 20 mins to achieve SaC>2 75-80%.
Doppler echocardiography was used to measure mean pulmonary artery pressure
(MPAP), cardiac output and hence total pulmonary vascular resistance (TPR).
Saralasin compared to placebo resulted in a significant (p<0.05) reduction in MPAP
during normoxaemia: 6.70±1.0 vs 11.7±1.3 mmHg, at SaC>2 85-90%: 14.7±1.4 vs
20.5±1.0 mmHg and at SaC>2 75-80%: 18.1±1.9 vs 27.8±1.9 mmHg respectively.
Likewise saralasin compared to placebo resulted in a significant reduction in TPR
during normoxaemia: 104±14 vs 180±20 dyne.s.cm""', at SaC>2 85-90%: 222±24 vs
295±21 dyne.s.cm""' and at SaC>2 75-80%: 238±21 vs 362±11 dyne.s.cm""'
respectively. The AMPAP response to hypoxaemia was likewise significantly (p<0.01)
attenuated by saralasin infusion compared with placebo: mean difference 5.0 mmHg,
95% CI 1.9-8.08 and there was a trend towards attenuation of the ATPR response to
hypoxaemia (0.05<p<0.10): mean difference 47 dyne.s.cm""', 95% CI -10-105.
In addition to causing pulmonary vasodilatation in the presence of an activated renin
angiotensin system, our results suggest that angiotensin II receptor blockade
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attenuates acute hypoxic pulmonary vasoconstriction and that angiotensin II may play
a role in modulating this response in normal man.
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7.2 INTRODUCTION
In man hypoxaemia usually arises as a result of pulmonary disease or adverse
environmental conditions such as altitude. The effects of hypoxaemia on the
pulmonary vasculature have been extensively studied since Von Euler (Von Euler US
et al, 1946) first described the phenomenon of hypoxic pulmonary vasoconstriction
(HPV). Although HPV has beneficial effects the stimulus of chronic hypoxia results in
an elevation of pulmonary artery pressure leading to the development of cor
pulmonale (Fishman AP et al, 1976, Klinger JR et al, 1991).
These patients have activation of the RAS (Lang CC et al, 1992, Farber MO et al,
1977, Farber MO et al, 1982), with elevated levels of angiotensin II (ANG II). ANG
II and hypoxia have both been shown to be potent pulmonary vasoconstrictors in man
(Cargill RI et al, 1994). In vitro studies have shown that ANG II facilitates HPV in
the rat and potentiates this response in dogs (Berkov S, 1974, Alexander JM et al,
1976). Furthermore, the use of ACE-inhibitors in chronically hypoxic rats has been
shown to attenuate the development of pulmonary hypertension (Zakheim RM et al,
1975).
Studies in humans are rare, although recent data has shown that pre-treatment with
the long acting ACE-inhibitor Lisinopril blunts acute HPV in normal volunteers
compared to placebo (Cargill RI et al, 1996). The effect of ACE-inhibition could in
theory be due to lowering levels of ANG II (a vasoconstrictor) or augmenting levels
of bradykinin (a vasodilator) by suppressing the activity of kininase II which normally
contributes to the degradation of kinins (Kramer HJ et al, 1990).
The purpose of this study was to determine the role of ANG II in the pulmonary
circulation during both normoxaemia and hypoxaemia by competitive inhibition of
ANG II with its analogue, saralasin (l-sar-5-val-8-ala-ANG II), which has been
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shown to be a competitive antagonist of ANG II in the presence of an activated RAS,




Eight healthy male volunteers, age (mean±SEM) 29±3 years were studied on two
separate occasions. There was no abnormality present on clinical history,
examination, 12 lead ECG, echocardiography, biochemical or haematological
screening. No medications were permitted during and for one month prior to the
study. Informed written consent to the study protocol, previously approved by the
Tayside Committee for Medical Research Ethics, was obtained.
Study design
Subjects attended the laboratory at the same time of the day on two separate
occasions, at least one week apart. Subjects were pre-treated with 4 daily doses of
furosemide 40mg to activate the RAS such that saralsin would function as a pure
antagonist of ANG II devoid of partial agonist activity. An indwelling intravenous
cannula was inserted into each antecubital fossa, one for infusion of saralasin or
placebo and the other for blood sampling. Subjects then rested supine for 30 mins to
obtain stable resting haemodynamics (To). They then received either an infusion of
5% dextrose or saralasin 5 pg/kg/min (Sigma Chemical Company, St Louis, USA).
They were restudied after 20 minutes (Ti), and were then rendered hypoxaemic by
breathing a variable mixture of oxygen and nitrogen sufficient to render arterial
oxygen saturation between 85-90% (T2) for twenty minutes adjusted for a further
twenty minutes to achieve an arterial oxygen saturation of 75-80% (T3).
Measurements of pulmonary and systemic haemodynamic variables and venous blood
samples for plasma renin activity (PRA) were taken at To, T], T2 and T3. Serum
electrolytes were measured at To.
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Measurements
Systemic and pulmonary haemodynamic indices and plasma sodium, potassium and
plasma renin activity were measured as previously described
Data analysis
Comparison of values between study days or between serial time points on the same
study day were made by multifactorial analysis of variance. A probability value of
p<0.05 (two-tailed) was considered to be statistically significant. Data are presented
in the text, tables and figures as means and SEM, and where a difference between




There was no significant difference in PAT, MPAP or TPR at baseline (To) between
study days. Infusion of saralasin compared to the placebo resulted in a significant
(p<0.05) reduction in MPAP during normoxaemia (Ti): mean difference 4.6 mmHg
(95% CI 1.25-8.0), at an SaC>2 of 85-90% (T2): mean difference 6.1 mmHg (95% CI
1.4-10.8) and a significant (p<0.0005) difference at an Sa02 of 75-80% (T3): mean
difference 9.6 mmHg (95% CI 6.0-13.2), respectively (Figure 7.1 A). Likewise
saralasin infusion compared to placebo resulted in a significant (p<0.05) reduction in
TPR at T]: mean difference 76 dyne.s.cm""' (95% CI 29-123), at T2: mean
difference 72 dyne.s.cm""' (95% CI 8-136) and a significant (p<0.0005) reduction at
T3: mean difference 123 dyne.s.cm""' (95% CI 82-165), respectively (Figure 7.IB).
Hypoxaemia caused a significant (p<0.05) increase in MPAP and TPR at T2 and T3
compared to baseline on both study days. Saralasin compared to placebo significantly
reduced PAT during both normoxaemia, moderate and severe hypoxaemia (Table
7.1).
In terms of change in MPAP (AMPAP) from baseline (To) to severe hypoxaemia
(T3), the AMPAP response was significantly (p<0.005) attenuated by saralasin
infusion compared with placebo: mean difference 7.3 mmHg, 95% CI 3.9-10.7.
Likewise the ATPR response from To to T3 was significantly (p<0.05) attenuated by
saralasin infusion compared with placebo: mean difference 89 dyne.s.cm""', 95% CI
26-152. Because there was a significant fall in MPAP and TPR at T] compared with
baseline (To) after saralasin infusion compared to placebo we also assessed the A
MPAP and ATPR response from Ti to T3 The AMPAP response was likewise
significantly (p<0.01) attenuated by saralasin infusion compared with placebo: mean
difference 5.0 mmHg, 95% CI 1.9-8.08 and there was a trend towards attenuation of
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the ATPR response from T] to T3 (0.05<p<0.10): mean difference 47 dyne.s.cm"^,
95% CI-10-105.
Systemic Haemodynamics.
Although, saralasin infusion compared to placebo did not significantly alter systemic
haemodynamic parameters either at baseline or during hypoxia, saralasin infusion had
significant effects on systemic haemodynamics compared with baseline measurements
(Table 7.1). Compared to baseline (To), a significant (p<0.05) increase in CO in
response to hypoxaemia (T3) was noted on both study days. A fall in SVR in
response to hypoxaemia (T3) was also noted on both study days although this reached
statistical significance (p<0.05) only during saralasin infusion. HR and MAP were
unaffected by hypoxaemia on the placebo day although saralsin infusion resulted in a
significant (p<0.05) decrease in MAP at T3 and T1 compared to baseline (To).
Electrolytes.
There was no significant difference in serum sodium or potassium at baseline (To),
between the study days when patients received placebo (P) or saralasin (S). Serum
sodium: 137.4±0.8 (P) vs 138.9±0.8 (S) mmol/1 and serum potassium: 3.97±0.10 (P)
vs 3.89±0.08 (S) mmol/1.
RAS activity.
Saralasin infusion resulted in a significant (p<0.05) increase in PRA at T2 and T3
compared to baseline (To): 5.25±1.36 and 5.60±1.31 vs 3.99±0.55 ng/ml/hr
respectively. Hypoxia alone was not associated with a significant change in PRA at
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T2 and T3 compared to baseline (To): 3.48±0.65 and 3.29±0.58 vs 3.84±0.77
ng/ml/hr respectively. There was no significant difference in PRA at any of the time
points between the two study days.
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Table 7.1 Effects of ANG II receptor blockade on systemic haemodynamics and
pulmonary acceleration time during hypoxaemia in normal man.
pre-infusion infusion:
Sa02 >95% (T0) >95% (Ti) 85-90% (T2) 75-80% (T3)
HR(bpm) P 71.0±4.8 68.6+4.2 73.1+4.3 73.8+5.6
S 67.2+3.8 64.1±3.5 68.5+4.5 71.8+5.1
MAP(mmHg) P 84.8±4.5 81.9+3.5 82.4+3.8 86.5+3.1
s 83.4+3.0 76.9+1.9 * 79.4+3.3 77.4+4.2 *
CO(l/min) p 5.45±0.48 5.20+0.25 5.69+0.38 6.18+0.24 *
s 5.36+0.34 5.06+0.17 5.42+0.36 6.10+0.39 *
SVR(dyne.s.cm~^) p 1306±132 1262+72 1192+98 1128+48
s 1332+80 1251+54 1260+69 1082+73 *
PAT(ms) p 146±2 146+3 125+2 * 108+2 *
s 152±2 158+2 *+ 139+3 *+ 130+5 *+
Absolute values (mean±SEM) of heart rate (HR), mean arterial pressure (MAP),
cardiac output (CO), systemic vascular resistance (SVR) and pulmonary acceleration
time (PAT) at each level of oxygen after pre-treatment with placebo (P) or saralasin
(S).
* significantly (p<0.05) different from baseline (To).




Figure 7.1: Pulmonary haemodynamic response to ANG II receptor blockade
during hypoxaemia in normal man.
A Absolute Doppler mean pulmonary artery pressure (MPAP) measured at a)
baseline before infusion with normoxaemia, b) during infusion of placebo or saralasin
with normoxaemia, c) during infusion with hypoxaemia (Sa O2 85-90%) and d)
during infusion with hypoxaemia (Sa O2 75-80%). * represents a significant (p<0.05)
difference between placebo and saralasin at each time point.
B Absolute total pulmonary vascular resistance (TPR) measured at a) baseline
before infusion with normoxaemia, b) during infusion of placebo or saralasin with
normoxaemia, c) during infusion with hypoxaemia (Sa O2 85-90%) and d) during
infusion with hypoxaemia (Sa O2 75-80%). * represents a significant (p<0.05)










































Our results demonstrate that the ANG II antagonist saralasin causes pulmonary
vasodilatation in the presence of an activated RAS. In this respect we have shown that
absolute MPAP and TPR were significantly lower during hypoxaemia after saralasin
compared to placebo and similarly that the AMPAP and ATPR responses from
baseline to each level of hypoxaemia were also significantly attenuated by saralsin.
There is also evidence to suggest that angiotensin II blockade may attenuate acute
hypoxic pulmonary vasoconstriction reflected by a significant reduction in the AMPAP
and a trend towards a reduction of the ATPR response from Ti to severe hypoxaemia
(T3).
Saralasin is a highly soluble and stable ANG II analogue which was developed as an
ANG II antagonist (Holenberg NK et al, 1976). However, saralasin also possesses
partial agonist type activity. It has been demonstrated that saralasin functions as an
agonist in the presence of low renin states (Case DB et al, 1976, Streeten DHP et al,
1976), whereas elevated levels of PRA and ANG II are associated with antagonism
(Pettinger WA et al, 1976, Anderson GH et al, 1977). Consequently, we pre-treated
our study patients with diuretics to reduce total body sodium concentration and
extracellular volume to achieve elevated levels PRA. We found PRA to be the same
after furosemide pre-treatment on both study days suggesting comparable degrees of
RAS activation. PRA was elevated at baseline in all patients on both days, compared
with our own normal reference range (0.2-2.8 ng/ml/hr), allowing saralasin to function
as an ANG II antagonist rather than agonist. This antagonistic activity is supported
by the findings of a significant reduction in MAP at Ti and T3 compared to baseline
(To) when patients received saralsin. We also observed a significant increase in PRA
at T2 and T3 compared to baseline (To), supportive of the antagonistic activity of
saralsin where blockade of ANG II receptors on renin secreting cells would be
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expected to result in an increase in renin secretion due to inhibition of ANG II
mediated negative feedback, occurring at the level of the juxtaglomerular apparatus.
Our results agree with animal studies suggesting a possible role for ANG II in
modulating HPV. Berkov suggested that ANG II was required to facilitate HPV in
the saline perfused rat lung and studies in dogs suggest that ANG II infusion augments
HPV (Berkov S, 1974, Alexander JM et al, 1976). Recently studies in man have
shown that ANG II infusion augments HPV although not in a synergistic manner
(Cargill RI et al, 1994). The finding that lisinopril pre-treatment significantly
attenuated acute HPV in normal volunteers suggested that ANG II plays an important
role in modulating HPV in normal man (Cargill RI et al, 1996). Although this could
theoretically have been due to increased levels of bradykinin, this agent has not been
shown to produce pulmonary vasodilatation in normal humans (Bonner G et al, 1990).
Saralasin and lisinopril alleviate HPV to similar extents provides further evidence for a
role of ANG II in modulating HPV. Although ANG II undoubtedly has important
pressor effects in the pulmonary circulation studies have suggested that it is not the
sole mediator of HPV. McMurty has shown that ANG II is not required for HPV in
vitro (McMurty IF, 1984) and studies in man have shown that acute hypoxaemia does
not increase ANG II levels although this may not necessarily reflect tissue angiotensin
II activity in the lung (Lawrence DL et al, 1990). In this study acute hypoxaemia had
no effect on PRA and ANG II blockade with saralsin only attenuated and did not
abolish HPV. This supports the theory that ANG II has a role to play in modulating
HPV rather than being the sole mediator of HPV.
How ANG II and hypoxia interact remains unclear although much interest has
surrounded in vitro studies showing that pulmonary but not mesenteric arterial
myocytes close potassium channels in response to hypoxia (Yuan XJ et al, 1993).
This results in membrane depolarisation and inward calcium flux through voltage
dependant calcium channels. ANG II is known to increase intracellular calcium
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through the inositol triphosphate pathway and it has recently been suggested that it
may act directly on calcium channels through its receptor (Nabika T et al, 1985,
Cohen CJ et al, 1988). It may be that one subtype of potassium channel acts as a
hypoxia sensor in the pulmonary vasculature and ANG II may modulate acute HPV
via its effects on calcium flux or on this potassium channel via membrane voltage
changes. Such that in the presence of angiotensin II blockade the hypoxic signal, with
respect to pulmonary vasoconstriction, is reduced.
We have used Doppler-echocardiography to measure haemodynamic changes in the
pulmonary circulation. These non-invasive techniques have been shown to be
reproducible (Lipworh BJ et al, 1994) and a good correlation between Doppler PAT
and MPAP as measured by right heart catheter, is well established (Dabestani A et al,
1987, Matsuda M et al, 1986, Kitbatake A et al, 1983, Graettinger WF et al, 1987).
We looked at two measures of pulmonary vasoconstriction; changes in MPAP and
TPR. A possible limitation of this methodology is that the use of TPR does not
account for any changes in the post-capillary vascular bed, as assessed by pulmonary
capillary wedge pressure (PCWP). In this respect we feel it is unethical to insert
Swan-Ganz catheters into normal volunteers for research purposes. However, we
believe this extra information is not essential. It is known from previous work that
hypoxaemia has no significant effects on PCWP suggesting that changes in TPR are
reflective of changes in true pulmonary vascular resistance in pre-capillary arterioles
during hypoxia (Beard JT et al, 1991). There is no information available regarding
chronic dosing with diuretics in normal volunteers, the only study available looked at
the acute haemodynamic consequences of iv ethacrynic acid which showed a
reduction in PCWP (Samet P et al, 1968). It would, however, be difficult to
extrapolate these findings to chronic dosing and although chronic diuretic therapy may
affect PCWP in normal volunteers, it is important to note that patients were exposed
to both hypoxia and pre-treatment with furosemide on both study days suggesting that
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these stimuli are unlikely to be responsible for the changes observed between study
days. With respect to saralasin, its infusion has not been shown to affect PCWP
(Mookerjee S et al, 1978). We believe therefore, that the observed changes in TPR
are a true reflection of changes in pulmonary vascular tone.
We have shown for the first time in man that ANG II blockade with a specific
competitive ANG II antagonist causes pulmonary vasodilatation and alleviates acute
HPV in patients with an activated RAS. This suggests the possibility that ANG II is a
modulator of acute HPV in normal man. Although one must be careful when
extrapolating results from normal volunteer studies, the ability to cause pulmonary
vasodilatation and attenuate acute HPV and therefore the stimulus for pulmonary
hypertension in cor pulmonale, suggests that angiotensin II antagonists may have a
role to play in chronic hypoxic lung disease either to prevent or treat the
cardiopulmonary consequences of chronic hypoxaemia. The availability of orally
active ANG II antagonists such as losartan may therefore provide a novel therapeutic
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We examined the hypothesis that angiotensin II (ANG II) is a modulator of acute
hypoxic pulmonary vasoconstriction (HPV) by looking at the effect of losartan a
selective type 1 ANG II receptor antagonist on acute HPV in man.
Ten normal volunteers were studied on two separate days. They either received pre-
treatment with losartan 25, 50, 100, lOOmg respectively on four consecutive days or
placebo. They were then rendered hypoxaemic, by breathing an N2/O2 mixture for 20
mins to achieve an SaC>2 of 85-90% adjusted for a further 20 mins to achieve an SaC>2
of 75-80%. Pulsed wave Doppler echocardiography was used to measure mean
pulmonary artery pressure (MPAP), cardiac output and hence total pulmonary
vascular resistance (TPR).
Baseline MPAP and TPR (during normoxaemia) were unaffected by losartan pre-
treatment compared with placebo. However, losartan significantly reduced MPAP at
both levels of hypoxaemia compared to placebo: 14.7±0.7 vs 19.0±0.7 mmHg at an
Sa02 85-90% [p<0.01] and 20.0±0.7 vs 25.7±0.8 mmHg at an Sa02 75-80%
[p<0.05], respectively. Similarly losartan significantly reduced TPR compared to
placebo: 191±9 vs 246±10 dyne.s.cm" ^ at an Sa02 85-90% [p<0.005] and 233±12
vs 293±18 dyne.s.cm ^ at an SaC>2 75-80% [p<0.05], respectively. Pre-treatment
with losartan, however, had no significant effect on systemic vascular resistance
although losartan compared to placebo resulted in a significant [p<0.05] reduction in
mean arterial pressure at an SaC>2 75-80%: 78±2 vs 87±2 mmHg.
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Losartan had no effect on baseline pulmonary haemodynamics but significantly
attenuated acute hypoxic pulmonary vasoconstriction, suggesting that angiotensin II




Hypoxic pulmonary vasoconstriction (HPV) is an important homeostatic mechanism
allowing blood to be diverted from areas of alveolar hypoxia. Although this
undoubtedly has beneficial effects chronic hypoxia results in a continued stimulus to
pulmonary vasoconstriction with consequent vascular remodelling and over time the
development of cor pulmonale (Fishman et al, 1976, Magee F et al, 1988, Klinger JR
et al, 1991). Interestingly patients with cor pulmonale have activation of the renin
angiotensin system (RAS) (Lang CC et al, 1992, Farber MO et al, 1977, Lipworth BJ
et al, 1994), with elevated levels of angiotensin II (ANG II), itself a potent direct
pulmonary vasoconstrictor. Whilst in vivo studies have shown ANG II to be a pressor
agent in the pulmonary circulation (Lipworth BJ et al, 1994) there is conflicting
evidence as to whether ANG II is involved in a facilitatory capacity in modulating
HPV (Berkov S, 1974, McMurty IF, 1984).
There has been much research into pharmacological manipulation of the hypoxic
pulmonary vasoconstrictor response although concern surrounds worsening of
hypoxaemia by the use of vasodilators which could theoretically have detrimental
effects on ventilation perfusion matching. Interestingly the ANG II antagonist
saralasin improved systemic oxygenation presumably by redistributing pulmonary
blood flow and improving ventilation perfusion matching (Mookerjee S et al, 1983).
ACE-inhibitors have been shown to attenuate the development of pulmonary
hypertension in chronically hypoxic rats (Zakheim RM et al, 1975). A recent study in
humans has shown that ACE inhibition attenuated acute HPV (Cargill RI et al, 1994).
However, this cannot solely be attributed to a reduction in ANG II levels as ACE
inhibitors affect many other systems in particular the kinins and prostanoids.
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The purpose of this study, therefore, was to elucidate the role of ANG II and in
particular the type 1 ANG II (ATi) receptor in modulating acute HPV by competitive
inhibition with losartan-potassium (DuP 753) a selective orally active specific ATi
receptor antagonist which shows no affinity for other hormonal receptors and at a
functional level, excepting ANG II, does not alter the contractile response to a variety
of pressor stimuli (Timmermans PBMWM et al, 1993). Although Jaiswal et al
(Jaiswal et al, 1991) reported that in vitro losartan stimulates prostacyclin release this





Ten healthy male volunteers, age (mean±SEM) 26±5 years were studied on two
separate occasions. There was no abnormality present on clinical history,
examination, 12 lead ECG, echocardiography, biochemical or haematological
screening. Informed written consent to the study protocol, previously approved by
the Tayside Committee for Medical Research Ethics, was obtained.
Study design
Subjects attended the laboratory at the same time of the day on two separate
occasions, at least one week apart. Subjects were pre-treated with 4 daily doses of
losartan (25mg on day 1, 50mg on day 2, lOOmg on day 3,4) or placebo. They
attended the laboratory 3 hours after receiving their final dose such that the drug
would be studied at maximal effect. An intravenous cannula was inserted into the left
forearm for blood sampling. Subjects then rested supine for at least 30 mins to obtain
stable resting haemodynamics (To). They were then rendered hypoxaemic by
breathing a variable mixture of oxygen and nitrogen which rendered arterial oxygen
saturation between 85-90% (Ti) for twenty minutes then adjusted for a further twenty
minutes to achieve an arterial oxygen saturation of 75-80% (T2). Measurements of
pulmonary and systemic haemodynamic variables, and venous blood samples for
plasma renin activity (PRA) and electrolyte assays, were taken at To, T], and T2
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Measurements
Systemic and pulmonary haemodynamic indices and plasma sodium, potassium and
plasma renin activity were measured as previously described. The intra-assay
coefficient of variation for analysis of PRA was 7.6%.
Data analysis
Comparison of values between study days was made by multifactorial analysis of
variance. Comparisons between serial time points on the same study day were made
using Duncan's multiple range test. A probability value of p<0.05 (two-tailed) was
considered to be statistically significant. Data are presented in the text, tables and




There was no significant difference in absolute values of MPAP or TPR at baseline
during normoxaemia (To). Losartan compared to placebo resulted in a significant
[p<0.01] reduction in MPAP at an SaC>2 of 85-90% (Ti): mean difference 4.3 mmHg
(95% CI 1.6-7.0) and a significant (p<0.05) difference at an SaC>2 of 75-80% (T2):
mean difference 5.6 mmHg (95% CI 2.8-8.5), respectively (Figure 8.1 A). Likewise
losartan compared to placebo resulted in a significant (p<0.005) reduction in TPR at
T]: mean difference 55 dyne.s.cm"5 (95% CI 24-86) and a significant (p<0.05)
reduction at T2: mean difference 60 dyne.s.cm""' (95% CI 9-110), respectively
(Figure 8. IB). Hypoxaemia was associated with a significant (p<0.001) increase in
MPAP and TPR at T1 and T2 compared to baseline (To) on both study days.
In terms of change in MPAP (AMPAP) from To to Ti and To to T2, the AMPAP
response induced by hypoxaemia was significantly (p<0.01) attenuated by losartan
compared with placebo (Figure 8.2A): mean difference 5.2 mmHg (95% CI 2.0-8.4)
and 6.6 mmHg (95%CI 3.3-9.9) respectively. Likewise the ATPR response induced
by hypoxaemia from To to Ti and To to T2 was significantly (p<0.01) attenuated by
losartan compared with placebo (Figure 8.2B): mean difference 70 dyne.s.cm""' (95%
CI 26-152) and 78 dyne.s.cm"5 (95% CI 29-127).
Systemic Haemodynamics.
There was no significant difference between HR, CO and SVR at each time point
between the two study days although severe hypoxaemia (at T2) resulted in a
significant (p<0.01) increase in CO and HR and a significant decrease in SVR on both
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study days. There was no significant difference between study days with respect to
MAP at baseline (To) or T]; although in the presence of severe hypoxaemia (T2),
MAP was significantly (p<0.05) lower following pre-treatment with losartan
compared with placebo: mean difference 9 mmHg (95%CI 2-16). Hypoxaemia had
no significant effects on MAP on either study day (Table 8.1).
Electrolytes.
There was no significant difference in serum sodium or potassium following treatment
with losartan or placebo at any time point. Similarly, hypoxia had no significant
effects on serum sodium or potassium in comparison with baseline (T0) on either study
day (Table 8.2).
RAS activity.
Pre-treatment with losartan resulted in a significant (p<0.01) increase in PRA
compared to placebo at baseline (T0) at an SaC>2 of 85-90% (Ti) and at an SaC>2 of
75-80% (T2). Hypoxia did not significantly affect PRA on either study day in
comparison with baseline (Table 8.2).
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Table 8.1. Systemic Haemodynamic effects of type 1 ANG II receptor blockade







HR (bpm) P: 58±2 64±2 70±3*
L: 61±2 67±3 73±3*
MAP (inni 11 g) P: 85±3 85±2 87±2
L: 80±2 80±2 78±2+
CO (1/min) P: 5.52±0.17 6.17±0.11 7.18±0.37*
L: 5.39±0.24 6.22±0.33 6.96±0.36*
SVR (dyne.s.cm-^) P: 1232±42 1098±33 994±65*
L: 1209±39 1060±62 909±43 *
* significantly (p<0.05) different from SaC>2 >95%.
+ significantly (p<0.05) different from placebo at the same time point
Values are shown as means ± standard error of the mean after prior treatment with
losartan or placebo at each level of oxygenation.
HR = heart rate; MAP = mean arterial pressure; CO = cardiac output; SVR = systemic
vascular resistance.
P = placebo; L = losartan.
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Table 8.2. Effects of type 1 ANGII receptor blockade on serum electrolytes and







Na+ (mmol/1) P: 139.1+0.4 139.3+0. 139.3±0.4
L: 139.2±0.4 139.7+0.3 139.3±0.3
K (mmol/1) P: 4.08±0.09 4.09±0.12 4.01±0.10
L: 4.15±0.06 4.11±0.06 4.05±0.07
PRA (pmol/l/hr) P 1.00±0.14 1.08±0.19 0.84±0.12
L 7.48±1.42+ 6.62+1.18+ 6.46+1.02+
+ significantly (p<0.01) different from placebo at the same time point
Values are shown as means ± standard error of the mean after prior treatment with
losartan or placebo at each level of oxygenation.
Na+ = serum sodium; K+ = serum potassium; PRA = plasma renin activity.
P = placebo; L = losartan
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FIGURE LEGEND
Figure 8.1. Effects of type 1 ANG II receptor blockade on MPAP and TPR during
hypoxaemia in normal man.
A Absolute Doppler mean pulmonary artery pressure (MPAP) measured at a)
baseline during normoxaemia, b) at an SaC>2 85-90% and c) at an SaC>2 75-80%.
Asterix represents a significant (p<0.05) difference between placebo and losartan at
each time point.
B Absolute total pulmonary vascular resistance (TPR) measured at a) baseline
during normoxaemia b) at an SaC>2 85-90% and c) at an SaC>2 75-80%). Asterix
























Figure 8.2. Effects of type 1 ANGII receptor blockade on AMPAP and ATPR
during hypoxaemia in normal man.
A Change in mean pulmonary artery pressure (AMPAP) from baseline induced
by hypoxaemia a) at an SaC>2 of 85-90% (ie T0 to Ti) and b) at an SaC>2 of 75-80%
(ie Ti to T2). The AMPAP represents the mean of the individual changes. Asterix
denotes that the hypoxic pulmonary vasoconstrictor response was significantly
(p<0.01) attenuated by losartan (hatched bars) compared with placebo (clear bars) at
an SaC>2 of 85-90% and at an SaC>2 of 75-80%.
B Change in total pulmonary vascular resistance (ATPR) induced by hypoxaemia
a) at an SaC>2 of 85-90% and b) at an SaC>2 of 75-80%, compared to baseline. The
APVR represents the mean of the individual changes. Asterix denotes that the
hypoxic pulmonary vasoconstrictor response in man was significantly (p<0.01)
attenuated by losartan (hatched bars) compared with placebo (clear bars) at an SaC>2






We have demonstrated that the selective type 1 ANG II blocker losartan attenuates
acute hypoxic pulmonary vasoconstriction in man. In this respect both absolute
MPAP and absolute PVR were significantly lower during hypoxia in those pre-treated
with losartan compared to placebo. In addition, to correct for any possible
confounding baseline effects, we have also shown that the delta-MPAP and delta-PVR
responses to each level of hypoxia were significantly attenuated by losartan. This
supports the hypothesis that ANG II may modulate the acute HPV response in man
via its effects on the ATI receptor.
Losartan is a potent, orally active drug which selectively blocks the ATI receptor
(Timmermans PBMWM et al, 1993) and as such provides us with a specific tool for
elucidating the role of ANG II in HPV. It has been shown to produce concentration-
dependent inhibition of angiotensin II induced vasoconstriction in vitro and in vivo
(Christen Y et al, 1991, Rhaleb NE et al, 1991). Studies using radioligand membrane
binding and autoradiography techniques have shown heterogenicity of ANG II
receptors in a variety of different tissues (Timmermans PBMWM et al, 1993),
however, the relative importance of the ATI and AT2 receptor subtypes with respect
to pulmonary pressor effects has not been previously documented in man. Our results
support the hypothesis that ANG II has its effect primarily via the ATI receptor since
blockade of the ATI receptor significantly attenuated this response. We also
observed a significant increase in PRA after treatment with losartan during both
normoxaemia and hypoxaemia. This is consistent with blockade of ANG II receptors
in the juxtaglomerular apparatus resulting in renin secretion due to inhibition of ANG
II mediated negative feedback. Indeed juxtaglomerular cell hypertrophy and
hyperplasia has been shown to occur as a consequence of losartan therapy in rhesus
monkeys (Owen RA et al, 1994). In contrast, if the AT2 receptor was as important in
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mediating the acute HPV response then one would have expected a nullification or a
paradoxical increase in response after treatment with losartan compared to placebo
occurring as a result of elevated ANGII levels. Although the pulmonary and systemic
vascular beds may respond differently to the same stimulus these results agree with
findings in the systemic circulation which have shown that none of the established
cardiovascular effects of ANG II can be attributed to the AT2 receptor (Timmermans
PBMWMetal, 1993).
Our findings are consistent with those in animal studies suggesting an important role
for ANG II in modulating HPV. Berkov suggested that ANG II was required to
facilitate HPV in the saline perfused rat lung (Berkov S, 1974) and ANG II infusion
has been shown to augment HPV in dogs (Alexander JM et al, 1976). Studies in man
have shown that ANG II infusion augments HPV although not synergistically (Cargill
RI et al, 1994). Interestingly the finding that pre-treatment with lisinopril attenuated
acute HPV in normal volunteers suggested an important role for ANG II in
modulating HPV in normal man (Christen Y et al, 1991). This could theoretically
have been due to increased bradykinin levels although bradykinin infusion did not
produce pulmonary vasodilatation in normal volunteers (Bonner G et al, 1990). In
this study we have shown that losartan attenuates HPV to a similar degree as lisinopril
further implicating ANG II as having an important role in modulating HPV. Although
ANG II undoubtedly has important pressor effects in the pulmonary circulation it is
unlikely to be the sole mediator of HPV. McMurty has shown that ANG II is not
required to produce HPV in vitro (McMurty IF, 1984) and studies in man have shown
that acute hypoxaemia does not increase ANG II levels (Lawrence DL et al, 1990).
This is consistent with the present study where we have shown that acute hypoxaemia
had no significant effect on PRA and that ANG II blockade with losartan only
attenuated rather than abolished HPV. This suggests that rather than being the sole
mediator of HPV that ANG II has an important role in modulating this response.
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The mechanism whereby ANG II and hypoxaemia interact remains unclear although
interestingly in vitro studies have shown that pulmonary but not mesenteric vascular
smooth muscle cells react to hypoxia by closing potassium channels (Yuan XJ et al,
1992). The resultant membrane depolarisation results in an increase in intracellular
calcium as a result of calcium influx through voltage dependent calcium channels and
consequently smooth muscle contraction. ANG II is known to increase intracellular
calcium due to increased inositol triphosphate production (Nabika T et al, 1985) and it
has recently been suggested that it may act directly on calcium channels (Cohen CJ et
al, 1988). It may be that one subtype of potassium channel acts as a hypoxia sensor in
the pulmonary vasculature and that ANG II may modulate acute HPV via its effect on
calcium flux or this potassium channel via membrane voltage changes. Such that in
the absence of ANG II the hypoxic signal, with respect to pulmonary
vasoconstriction, is reduced.
With respect to methodology, we have used Doppler-echocardiography to measure
haemodynamic changes in the pulmonary circulation. These non-invasive techniques
have been shown to be highly reproducible (Lipworth BJ, 1994) and the close
correlation between Doppler PAT and MPAP as measured by right heart catheter, is
well established (Dabestani A et al, 1987, Kitbake A et al, 1983, Graettinger WF et al,
1987). We looked at two measures of pulmonary vasoconstriction; changes in MPAP
and TPR. A possible limitation of this methodology is that the use of TPR does not
account for any changes in the post-capillary vascular bed, as conventionally assessed
by pulmonary capillary wedge pressure (PCWP). In this respect we feel it is unethical
to insert Swan-Ganz catheters into normal volunteers for research purposes
particularly as volunteers would have to be restudied on different days. The extra
information this would give us is however, not essential. Both groups were exposed
to hypoxia and it is known from previous work that hypoxaemia does not affect
PCWP and so effects on TPR are reflective of changes in true pulmonary vascular
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resistance in pre-capillary arterioles during hypoxia (Beard JT et al, 1991). With
respect to ANG II blockade, an acute dosing study looking at the haemodynamic
effects of losartan has shown that it does not affect PCWP (Gottileb SS et al, 1993).
We believe therefore, that the observed changes in TPR are a true reflection of
changes in pulmonary vascular tone.
Thus, we have shown for the first time in man that ANG II blockade with a type 1
ANG II antagonist attenuates acute HPV. This suggests that ANG II acts as an
important modulator of acute HPV in healthy humans via its effects on the ATI
receptor. One must be cautious when extrapolating from normal volunteer studies to
the clinical situation. However, the ability of losartan to attenuate HPV, the initial
stimulus for pulmonary vascular remodelling, suggests that it may delay or prevent
progression from chronic hypoxic lung disease to cor pulmonale. Losartan may also
have a role to play in the treatment of cor pulmonale where vasoreactivity is still
present. This benefit may not only result from the interaction between ANG II and
hypoxia with respect to the pulmonary vascular bed, but also as a consequence of
blockade of the direct pulmonary pressor effects of ANG II, particularly in patients on
oxygen therapy, where ANG II would be predicted to exhibit proportionately greater




HAEMODYNAMIC AND ENDOCRINE EFFECTS OF TYPE 1
ANGIOTENSIN II RECEPTOR BLOCKADE IN PATIENTS




Angiotensin II (ANG II) is known to be a potent vasoconstrictor agent in the
pulmonary circulation. Furthermore type 1 ANG II receptor blockade with losartan
attenuates acute hypoxic pulmonary vasoconstriction in normal subjects. The aim of
this study was therefore to evaluate the haemodynamic and endocrine sequelae of type
1 ANG II receptor blockade in patients with hypoxaemic cor pulmonale.
Nine patients with chronic obstructive pulmonary disease (COPD) age 67±3 years
with pulmonary hypertension and normal left ventricular systolic function were
studied on two separate occasions in a double blind, placebo controlled, crossover
study. They were randomised to receive either 50 mg of oral losartan or matched
placebo. Pulsed wave Doppler echocardiography was used to measure cardiac output
(CO), mean pulmonary artery pressure (MPAP) and hence systemic vascular
resistance (SVR) and total pulmonary vascular resistance (TPR). Haemodynamic
measurements and venous blood samples were taken at baseline and after 2 and 4
hours.
Maximal effects were observed at 4 hours where losartan compared to placebo
resulted in a significant reduction in both MPAP: 28.6±2.0 vs 32.4±1.5 mmHg and
TPR: 428±40 vs 510±40 dyne.s.cm"'', respectively. Similarly losartan compared to
placebo resulted in a significant reduction in MAP: 87±4.5 vs 93±3.2 mmHg and
SVR: 1293±94 vs 1462±112 dyne.s.cm"'', and significantly increased CO 5.58±0.43
vs 5.31±0.42 L/min. In addition plasma aldosterone was significantly lower after
treatment with losartan compared to placebo: 76±23 vs 164±43 pg/ml respectively.
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Thus, selective type 1 angiotensin II receptor blockade appears to have beneficial
pulmonary and endocrine effects, suggesting a possible therapeutic role in the
management of hypoxaemic cor pulmonale.
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9.2 INTRODUCTION
Acute hypoxic pulmonary vasoconstriction (HPV) is an important phenomenon
present in a wide variety of different animal species allowing blood to be diverted
from areas of alveolar hypoxia so maintaining ventilation perfusion matching.
Although this undoubtedly has beneficial effects it can also have deleterious effects.
In particular, in chronic hypoxic lung disease, hypoxaemia provides a sustained
stimulus to pulmonary vasoconstriction resulting in an elevation of mean pulmonary
artery pressure (Fishman AP et al, 1976), vascular remodelling (Magee F et al, 1988)
and over time the development of cor pulmonale and consequently a poor prognosis
(Report of the Medical Research Council working party, 1981, Timms RM et al,
1985).
The benefits of treating pulmonary hypertension in the context of chronic hypoxic
lung disease are unknown. Oxygen therapy has been shown to reduce mean
pulmonary artery pressure acutely (MacNee W et al, 1988), and reduce mortality in
patients with hypoxaemic cor pulmonale (Report of the Medical Research Council
working party, 1981, Timms RM et al, 1985). Whether this is primarily due to
improved systemic oxygenation or a reduction in right ventricular afterload is not
known. Nevertheless therapy that could either prevent or treat pulmonary
hypertension in these patients could conceivably reduce both mortality and morbidity
and have additional benefits to oxygen therapy.
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In the context of pulmonary hypertension, the role of vasoactive peptides has been
extensively investigated (Cargill RI et al, 1995). It is known that angiotensin II (ANG
II) is a potent pulmonary vasoconstrictor in man (Segel N et al, 1960, Lipworth BJ et
al, 1994) and that patients with hypoxaemic cor pulmonale have activation of the renin
angiotensin aldosterone system (RAAS) (Farber MO et al, 1977, Farber MO et al,
1982). Indeed ANG II has been shown to promote a growth response in vascular
smooth muscle cells (Berk BC et al, 1989) suggesting the possibility that in addition
to acting as pressor agent, ANG II could also contribute directly to vascular
remodelling. Interestingly angiotensin II converting enzyme inhibitors (ACE-
inhibitors) have been shown to attenuate the development of pulmonary hypertension
in chronically hypoxic rats (Zakheim RM et al, 1975), although there is conflicting
evidence from in vitro studies as to whether ANG II plays a facilitatory role in
modulating HPV (Berkov S, 1974, McMurty IF, 1984). In normal humans however,
ACE-inhibition with lisinopril (Cargill RI et al, 1996) and type 1 ANG II receptor
blockade with losartan (Kiely DG et al, 1995) have been shown to attenuate acute
HPV. Subsequent studies in patients with hypoxaemic cor pulmonale using ACE-
inhibitors have shown variable pulmonary and systemic haemodynamic benefit
(Boschetti E et al, 1985, Takada K et al, 1986, Bertoli L et al, 1986, Zielinski J et al,
1986). Whether the beneficial haemodynamic effects are a consequence of reducing
ANG II levels is unknown since ACE inhibitors also increase levels of bradykinin, a
vasodilator.
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We have therefore evaluated for the first time the effects of selective type 1





Nine patients (6 male, 3 female), with clinically stable cor pulmonale secondary to
hypoxaemic cor pulmonale (mean age±standard error of the mean 67±3 years), were
included in the study after attending a screening visit to assess inclusion criteria and
characterise the study population. All had spirometric evidence of obstructive airways
disease (FEVi/FVC<70%) and arterial hypoxaemia whilst breathing air (Pa02<8 5
KPa) and had or gave a history of having peripheral oedema. On echocardiography
subjects were required to be in sinus rhythm, have normal left ventricular function, no
evidence of valvular heart disease and a resting mean pulmonary artery pressure,
whilst breathing room air, of at least 25 mmHg. In addition, all subjects had evidence
of reversible, dynamic pulmonary vasoconstriction as assessed by > 10% fall in MPAP
on breathing 60% oxygen for 30 minutes. All subjects were taking inhaled
bronchodilators (beta-agonist n=9; anticholinergic n=6) and inhaled steroids, five
patients were taking oral loop diuretics and 6 patients used domiciliary oxygen for at
least 15 hours per day. Medications were unchanged throughout the study period.
The summary demographic data for this patient group are given in Table 1. All
subjects gave informed written consent to the study protocol previously approved by
the Tayside Committee for Medical Research Ethics and conforming with the
principles outlined in the Declaration of Helsinki.
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Study design
Subjects were studied at the same time of the day on two separate occasions at least
one week apart in a randomised, double blind placebo controlled, cross-over design.
Patients taking regular diuretics were asked to omit their morning dose of diuretic on
each visit. On each study day, an intravenous cannula was sited in the right forearm
for venous blood sampling. Subjects then remained semi-recumbent throughout and
were studied whilst breathing room air. Patients then received either 50mg of oral
losartan potassium (Merck Sharp and Dohme Ltd, Hertfordshire, UK) or placebo.
Haemodynamic parameters were measured and blood samples were taken at baseline
after subjects had rested for at least 30 minutes to obtain stable resting hamodynamics
(T0), 2 hours (Ti) and 4 hours (T2) after administration of either losartan or placebo.
Measurements
Systemic and pulmonary haemodynamic parameters, indices of plasma renin activity
and plasma creatinine were measured as previously described. The short term co¬
efficient of variability for MAP was 8.2%, CO was 9.6%, SVR was 5.3%, PAT was
3 .2%, MPAP was 5 .8% and TPR was 12.4%. The intra-assay coefficient of variation
for analysis of PRA was 6.50% and plasma aldosterone was 8.77%.
Data analysis
Comparison of values between study days was made by multifactorial analysis of
variance and where there was a significant difference the mean difference and 95%
confidence intervals for the mean difference are given (95% CI). Comparisons
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between serial time points on the same study day were made using Duncan's multiple
range test. A probability value of p<0.05 (two-tailed) was considered to be




There were no significant differences in absolute values of HR, SV, CO, MAP or SVR
at baseline between study days. Although there was no significant difference in either
MAP or SVR after treatment with losartan or placebo at 2 hours, both MAP
(p<0.05): mean difference 5.7 mmHg (95% CI 0.4-10.9) and SVR (p<0.01): mean
difference 169 dyne. s.cm"5 (95% CI 71-267) were significantly lower 4 hours after
treatment with losartan compared to placebo (Figure 9.2). Although losartan
compared to placebo had no significant effects on SV, CO was significantly (p<0.05)
higher 4 hours after losartan compared to placebo: mean difference 0.27 1/min (95%
CI 0.04-0.50), (Table 9.2). Figure 9.3 shows the changes in SVR 4 hours after
administration of losartan compared to placebo for individual patients. Whilst there
was no significant difference in HR between study days at 4 hours, HR was
significantly higher 4 hours after treatment with losartan compared to baseline (Table
9.2).
Pulmonary Haemodynamics
There was no significant difference in absolute values of MPAP or TPR at baseline
(T0) between study days. Losartan compared to placebo resulted in a significant
(p<0.01) reduction in MPAP at 2 hours (Ti): mean difference 3.1 mmHg (95% CI
1.6-4.6) and a significant (p<0.05) reduction at 4 hours (T2): mean difference 3.8
mmHg (95% CI 0.3-7.3), respectively. Although there was no significant difference
in TPR between treatment with losartan and placebo at 2 hours, TPR was significantly
(p<0.05) lower 4 hours after treatment with losartan compared to placebo: mean
difference 82 dyne.s.cm"5 (95% CI 15-150). In addition both MPAP and TPR were
significantly (p<0.05) lower 4 hours after treatment with losartan compared to
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baseline (Figure 9.4). Figure 8.3 shows the changes in TPR 4 hours after
administration of losartan compared to baseline for individual patients.
RAAS Activity and serum creatinine
There were no significant differences in absolute values of PRA, plasma aldosterone
or serum creatinine at baseline between study days. Although there were no
significant differences between study days for PRA either at baseline or 2 and 4 hours
after administration of losartan or placebo, PRA was significantly increased 4 hours
after administration of losartan compared to baseline. There were significant (p<0.05)
falls in plasma aldosterone with time on both study but in addition losartan compared
to placebo resulted in a significant (p<0.05) reduction in plasma aldosterone at 4
hours (T2): mean difference 89 pg/ml (95% CI 19-159). There were no significant
differences in plasma creatinine at baseline (T0), Ti or T2 between study days or with
time on either study day (Table 9.3).
Oxygen saturation
There were no significant differences in oxygen saturation between days on which
patients received placebo or losartan at baseline (T0): 91.4±1.2 vs 91.1 ±1.1 %, at Ti:
90.7±1.1 vs 90.7±1.1 %, or at T2: 90.7±1.2 vs 90.8±1.1 % respectively, or with time
on either study day.
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Table 9.1. Baseline characteristics of patients with COPD.
FEVi (L) 0.78±0.09
FEVi % predicted (%) 30±2
FEVi/FVC 43±3
Pa 02 (KPa) on air 7.01±0.24
Pa C02 (KPa) on air 6.84±0.28
MPAP (mmHg) 32±2
The above values are expressed as means± standard error of the mean for respiratory
function and pulmonary haemodynamics in the patient group studied.
FEVi= forced expiratory volume in one second; FEVi/FVC = ration ofFEVi to
forced vital capacity; MPAP = mean pulmonary artery pressure.
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Table 9.2 Systemic haemodynamic effects of type 1 ANGII receptor blockade
in patients with cor pulmonale complicating COPD.
To t, t2
CO (1/min) P 5.47±0.42 5.56±0.49 5.31±0.42
L 5.26±0.32 5.37±0.46 5.58±0.43 *
SV (ml) P 79±7 79±7 75±7
L 76±6 78±6 76±6
HR (bpm) P 73±2 73±2 75±2
L 75±3 73±3 81±4 +
Values are given as mean±statndard error of the mean.
* significantly (p<0.05) different from placebo at the same time point.
+
significantly (p<0.05) different from T0.
CO = cardiac output; SV = stroke volume; HR = heart rate.
P = placebo; L = losartan.
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Table 9.3. Effects of type 1 ANGII receptor blockade on RAAS activity and
serum creatinine levels in patients with cor pulmonale complicating
COPD.
To ti t2
PRA (ng/ml/hr) P 4.21±1.50 4.97±1.92 4.40±1.38
l 4.54±1.62 5.66±1.97 9.46±2.56 +
Aldosterone (pg/ml) P 238±50 187±45+ 164±43+
l 179±43 142±45 76±23 *+
Creatinine (p.mol/1) P 106±11 102±11 101±9
l 101±10 99±11 99±9
Values are given as mean±standard error of the mean.
* significantly (p<0.05) different from placebo at the same time point.
+
significantly (p<0.05) different from To.
PRA = plasma renin activity.
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FIGURE LEGEND
Figure 9.1. Validation of Doppler-derived measures of MPAP.
Upper: Data comparing pulmonary acceleration time (PAT) and
simultaneously measured mean pulmonary artery pressure (MPAP)
during right heart catheterisation in patients with suspected pulmonary
hypertension.
Lower: Bland and Altman plot comparing mean pulmonary artery pressure
measured during right heart catheterisation (MPAPcatheter) and that
estimated using pulmonary acceleration time (MPAPpat). Mean
difference 0.88 mmHg, SD of the difference 2.69 mmHg.





Figure 9.2. Systemic haemodynamic effects of type 1 ANGII receptor blockade
in patients with cor pulmonale complicating COPD.
Upper: Mean arterial blood pressure (MAP) measured at baseline, after 2
hours and after 4 hours.
Lower: Systemic vascular resistance (SVR) measured at baseline, after 2 hours
and after 4 hours.
Treatment with losartan is represented by the bold triangles whereas treatment with
placebo is represented by the open circles. Values are given as mean±standard error of
the mean. * represents a significant (p<0.05) difference between placebo and losartan
at that time point whereas a + represents a significant (p<0.05) difference between that



























Figure 9.3. Effects of type 1 ANG II receptor blockade on changes in vascular
resistance in patients with cor pulmonale complicating COPD.
Upper: Total pulmonary vascular resistance (TPR), measured at baseline and 4
hours after acute administration of losartan 50 mg in 9 patients with
hypoxaemic cor pulmonale.
Lower: Systemic vascular resistance (SVR), measured at baseline and 4 hours
after acute administration of losartan 50 mg in 9 patients with
hypoxaemic cor pulmonale.
Values are given as mean±standard error of the mean. * = significant (p<0.05)









Figure 9.4. Pulmonary Haemodynamic effects of type 1 ANG II receptor
blockade in patients with cor pulmonale complication COPD.
Upper: Doppler mean pulmonary artery pressure (MPAP) measured at
baseline, after 2 hours and after 4 hours.
Lower: Total pulmonary vascular resistance (TPR) measured at baseline, after
2 hours and after 4 hours.
Treatment with losartan is represented by the bold triangles whereas treatment with
placebo is represented by the open circles. Values are given as mean±standard error of
the mean. * represents a significant (p<0.05) difference between placebo and losartan
at that time point whereas a + represents a significant (p<0.05)] difference between









We have demonstrated for the first time that the selective type 1 ANG II receptor
blocker losartan has beneficial pulmonary haemodynamic effects in hypoxaemic cor
pulmonale without altering oxygen saturation. In this respect both MPAP and TPR
were significantly lower after treatment with losartan compared to placebo, although
this effect was of small magnitude and of uncertain clinical relevance. In addition type
1 ANG II receptor blockade appears to have beneficial endocrine effects reflected by
significantly lower levels of plasma aldosterone after treatment with losartan
compared to placebo. We also noted a significant reduction in both MAP and SVR as
well as a small but significant increase in cardiac output after treatment with losartan.
This suggests that angiotensin II blockade may have a therapeutic role in the
management of hypoxaemic cor pulmonale.
Losartan a potent, orally active type 1 angiotensin II receptor blocker (AT]) has
provided us with a tool for elucidating the role of ANG II in the pulmonary circulation
in man. It is a selective orally active selective AT i receptor antagonist which shows
no affinity for other hormonal receptors and at a functional level excepting ANG II it
does not alter contractile response to a variety of different stimuli (Timmermans
PBMWM et al, 1993) and has been shown to produce concentration-dependent
inhibition of angiotensin II induced vasoconstriction in vitro and in vivo (Christen Y et
al, 1991, Rhaleb NE et al, 1991). Losartan undergoes an important first pass effect
and is extensively transformed to its active metabolite EXP 3174 reaching peak
concentrations between 2 and 4 hours after oral administration of losartan (Munafo A
et al, 1992). Early studies in normal volunteers have confirmed antagonism of pressor
responses to exogenous administration of angiotensin I and ANG II with
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approximately 60-70 % inhibition of control responses at maximum effect (3 hours)
(Christen Y et al, 1991, Christen Y et al, 1991). Although the interaction of losartan
with the eicosanoid system has been observed in animals with high concentrations of
the drug by some workers (Jaiswal N et al, 1991, Bertolino F et al, 1994) it seems
unlikely that this accounts for the observed effects to a significant degree. Indeed
conflicting results surround evidence suggesting that losartan stimulates prostacyclin
synthesis (Jaiswal N et al, 1991, Leung KH et al, 1991, Trachte GJ et al, 1990).
We examined the acute haemodynamic effects of a single dose of oral losartan. Our
patients had activation of the RAAS system reflected by elevated levels of PRA at
baseline compared with our own normal reference range (0.2-2.8 ng/ml/hr). We also
observed a significant increase in PRA 4 hours after administration of losartan
compared to baseline consistent with blockade of the type 1 ANG II receptor in the
juxtaglomerular apparatus resulting in renin secretion due to inhibition of ANG II
mediated negative feedback.
In terms of both systemic and pulmonary haemodynamic changes we observed
maximal effect at 4 hours. Whether the peak effect may have occurred after 4 hours
or if larger doses of losartan would achieve greater pulmonary heamodynamic benefit
or whether this would be limited by systemic haemodynamic effects is not answered
by this study. Interestingly acute dosing studies in patients with congestive cardiac
failure have shown no greater systemic haemodynamic effects with doses of losartan
of greater than 25 mg of losartan and noted falls in MAP and SVR after 2 hours with
peak effect observed between 4 and 12 hours and an effect still seen at 24 hours
(Gottileb SS et al, 1993). This study does however, suggest that angiotensin II
contributes to the maintenance of both pulmonary and systemic vascular tone in
patients with hypoxaemic cor pulmonale. Although ANG II has been shown to have
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pressor effects in man (Segel N et al, 1960, Lipworth BJ, 1994), studies using ACE
inhibitors in patients with hypoxaemic cor pulmonale have not consistently shown a
pulmonary haemodynamic benefit possibly as a consequence of inclusion criteria
(Boschetti E et al, 1985, Takada K et al, 1986, Bertoli L et al, 1986, Zielinski J et al,
1986). We have, however, specifically excluded patients who did not have
demonstrable pulmonary vascular reactivity as assessed by the absence of a significant
fall in mean pulmonary artery pressure in response to acute oxygen administration. In
this respect we feel it is important that patients who are included in vasodilator trials
have at least some dynamic component to their pulmonary hypertension, a situation
analogous to studying bronchodilator therapy, where the degree of airway reversibility
is established before evaluating the impact of therapy.
We observed a small but significant increase in cardiac output after treatment with
losartan compared to placebo and although HR was not significantly different between
study days, losartan significantly increased HR compared to baseline. Although no
significant increase in heart rate has been observed in acute dosing studies with
losartan in patients with congestive cardiac failure, it is interesting that an increase in
HR was noted in studies performed in normal volunteers pre-treated with oral
frusemide (Doig JK et al, 1995). This could possibly represent a reflex vagal
withdrawal response to an acute reduction in afterload or a direct effect of losartan on
the autonomic nervous system.
In terms of the methodology employed to measure pulmonary haemodynamic
changes, we have used the pulmonary acceleration time as a measure of mean
pulmonary artery pressure which we have shown to be reproducible in both normal
volunteer (Lipworth BJ et al, 1994) and patient studies (Cargill RI et al, 1996) and
has been shown to have a good correlation with catheter derived measures in both our
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own hands and those of other workers (Dabestani A et al, 1987, Matsuda M et al,
1986) although it is generally accepted that the pulmonary acceleration time cannot be
used to precisely measure MPAP in a patient population (Dabestani A et al, 1987).
We have previously employed these methods to study the pulmonary vascular effects
of vasoconstrictors (Lipworth BJ et al, 1994) and vasodilators (Cargill RI et al, 1995)
giving results which concur well with invasive studies of the same agents (Segel N et
al, 1960, Cody RJ et al, 1986) although some studies have shown a poor correlation
between changes in pulmonary acceleration time and catheter measured MPAP (Beard
JT et al, 1991, Chow LC et al, 1988). Doppler echocardiography is also a well
validated and reproducible measure of cardiac output (Huntsman LL et al, 1983). We
do not think that that the observed changes in TPR are likely to be confounded by
alterations in wedge pressure since in cor pulmonale the increase in resistance is
confined to the precapillary vasculature.
In addition to beneficial pulmonary haemodynamic changes, the inclusion of a placebo
limb has allowed us to examine the effects of ANG II receptor blockade on plasma
aldosterone levels. Plasma aldosterone is known to increase following the assumption
of the upright posture and decrease following resumption of the supine posture (Tuck
ML et al, 1975, Williams GH et al, 1972), an effect thought to be due to changes in
both aldosterone secretion and clearance Bougas J et al, 1964). As expected with
supine rest plasma aldosterone levels fell on both study days with falls on the placebo
day similar to those seen in normal volunteers (Tuck ML et al, 1975). In addition
however, treatment with losartan appears to have additional beneficial effects with
plasma aldosterone significantly lower 4 hours after dosing. This reduction in plasma
aldosterone is likely to reflect a reduction in ANG II mediated aldosterone
biosynthesis and secretion and although ACE-inhibitors have been shown to have a
similar effect, ANG II blockers may theoretically produce greater aldosterone
suppression since bradykinin may indirectly potentiate aldosterone release
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(Rosolowsky LJ et al, 1992). By lowering plasma aldosterone, ANG II receptor
blockade may act to prevent excessive salt and water retention, which maybe an
important precipitating factor in acute exacerbations of cor pulmonale (Anand IS et al,
1992). The RAAS also has significant trophic effects on vascular and cardiac muscle
(Pratt RE et al, 1993), whether lowering aldosterone levels and inhibiting the trophic
effects of ANG II is sufficient to inhibit these mitogenic effects is unknown but may
be important in arresting the cardiopulmonary remodelling characterising this
condition.
So to conclude, in addition to previous work demonstrating that angiotensin II
receptor blockade can attenuate the acute hypoxic pulmonary vasoconstrictor
response, we have now shown that the acute administration of losartan has beneficial
pulmonary haemodynamic and endocrine effects without worsening systemic
oxygenation. Whether manipulating the renin angiotensin aldosterone system with
angiotensin converting enzyme inhibitors or angiotensin II blockade may be of
therapeutic value in hypoxaemic cor pulmonale by inhibiting cardiopulmonary
remodelling or reducing right ventricular afterload can only be answered by









Secretion of the vasoconstrictor peptide endothelin-1 from vascular endothelium is
increased by a variety of stimuli. Whether hypoxaemia affects plasma levels of
endothelin-1 in humans is unknown but this may well be important in the
haemodynamic response to hypoxaemia. We have therefore measured plasma
endothelin-1 concentrations in hypoxaemic humans.
Plasma endothelin-1 was measured by specific radioimmunoassay in 10 control
subjects at rest and following 30 minutes acute hypoxaemia (Sa02 75-80%) induced
by breathing a nitrogen/oxygen mixture, and in 10 patients with hypoxaemic cor
pulmonale.
Plasma endothelin-1 concentration in control subjects was increased from (mean ±
standard error) 0.90+0.11 pmol/1 at baseline to 2.34+0.34 pmol/1 during hypoxaemia.
In patients with cor pulmonale, plasma endothelin-1 concentration was 2.96+0.34
pmol/1, elevated in comparison with control subjects at rest but similar to levels in
controls during hypoxaemia.
Plasma levels of endothelin-1 were therefore increased by hypoxaemia in humans. The
elevated levels observed in patients with cor pulmonale may be largely attributable to
the effects of hypoxaemia, although the pathophysiological significance of these
observations remains to be established.
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10.2 INTRODUCTION
The endothelins are a group of structurally similar peptides synthesised by vascular
endothelium. These peptides act via two specific receptors. Stimulation of the type A
endothelin receptor (ETA), the main subtype found on vascular smooth muscle cells
(Davenport AP et al, 1995), results in profound and long-lasting vasoconstriction
whilst stimulation of the type B receptor (ETB), causes release of vasodilator
metabolites and transient vasodilatation (Bigaud M et al, 1992). Interestingly
however, in rat pulmonary resistance vessels in vitro, ETB activation may be important
in mediating endothelin-1 induced vasoconstriction (MacLean MR et al, 1994). In
humans, endothelin-1 is the most potent vasoconstrictor substance known through its
relatively selective activation of the ETA receptor (Arai H et al, 1990). A role in the
maintenance of vascular tone is suspected but this remains speculative at present.
Synthesis of this peptide is increased by a number of humoral and physical stimuli,
including hypoxia, which may be pathophysiologically relevant (Haynes WG et al,
1993). In vitro studies have shown that acute hypoxia increases endothelin-1
production by human endothelial cells (Kourembanas S et al, 1991) whilst in
experimental animals in vivo, hypoxia increases plasma concentrations of endothelin-1
(Shirakami G et al, 1991). The effect of hypoxaemia on endothelin-1 in humans is
unknown but may be relevant in the cardiovascular adaptations to hypoxaemia and the
circulatory abnormalities seen in conditions like cor pulmonale.
We have therefore studied the effects of hypoxaemia on plasma endothelin-1 levels in




Normal controls: Ten young male volunteers, age (mean ± standard error) 28.1±2.2
years were studied. None were taking prescribed medication and all had normal
clinical history and examination, 12-lead electrocardiogram, echocardiogram and
haematological and biochemical screen and forced expiratory volume in 1 second
(FEVi) >90% predicted.
Cor pulmonale patients: Ten (6 male, 4 female) patients age 73.4±1.7 years with
clinically stable cor pulmonale secondary to chronic obstructive pulmonary disease
were studied. All had obstructive pattern spirometry (FEVj/ forced vital capacity
(FVC) <70%), arterial hypoxaemia while breathing air (PaO2<8.0 KPa), and had or
gave a history of having peripheral oedema despite normal left ventricular function (on
echocardiogram or radionuclide ventriculography), normal renal function (serum
creatinine<120mmol/L) and normal serum albumin (>35g/l). Patients with other
significant cardiovascular disease were excluded.
In this group, FEVj in litres was 0.75±0.06 (range 0.36-1.11), FEVj as % of
predicted 33.8±5.2 (range 19-61), Pa02 on air 6.30±0.34 KPa (range 4.35-7.80) and
PaCC>2 on air 6.17+0.50 KPa (range 3.84-8.80).
Study design
Informed consent was obtained to the protocol previously approved by the Tayside
Committee for Medical Research Ethics. Baseline venous blood samples were after 30
minutes supine rest while breathing air. Control subjects only were then rendered
hypoxaemic (steady state SaC>2 75-80% measured by pulse oximetry) for 30 minutes
by breathing a variable nitrogen/oxygen mixture before taking a further blood sample.
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Measurements
Levels of endothelin-1 were measured as previously described. The lower limit of
detection was 0.4 pmol/1 and the intra-assay co-efficient of variation was 4.5%. The
anti-endothelin antibody used was 100% specific for endothelin-1 and had cross-
reactivity of 96% with endothelin-3 and 7% with proendothelin.
Data Analysis
After testing for normality of distribution, between group comparisons were made by
analysis of variance followed by Duncan's multiple range testing with p<0.05
considered significant [8], Results are expressed as mean ± standard error with 95%
confidence intervals (CI) for significant differences.
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10.4 RESULTS
Plasma endothelin-1 concentration in normoxaemic controls was 0.90+0.11 pmol/1.
After 30 minutes hypoxaemia, plasma endothelin-1 increased significantly to 2.34±
0.34pmol/l (95% CI for mean difference 0.41, 2.48). In patients with cor pulmonale,
plasma endothelin-1 was 2.96±0.34 pmol/1, significantly greater than control subjects
when normoxaemic (95% CI for mean difference 1.02, 3.09) but not when
hypoxaemic.
Plasma endothelin-1 therefore increased 2.6 fold in response to hypoxaemia in
controls and was elevated 3.3 fold in patients with cor pulmonale compared with
normoxaemic controls. Results from individual subjects with sample means are
depicted in Figure 10.1.
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FIGURE LEGEND
Figure 10.1. Hypoxaemia and release of endothelin-1.
Levels of endothelin-1 in n = 10 controls when normoxaemic (®)and following 30
minutes hypoxaemia (O), and in = 10 patients with cor pulmonale (A). Boxes indicate
sample means with standard error bars and asterisks (*) indicate values significantly
(p<0.05) different from normoxaemic controls.
231
0 J
normoxaemic hypoxaemic cor pulmonale
controls
10.5 DISCUSSION
These findings indicate that hypoxaemia increases plasma levels of endothelin-1 in
humans. In patients with cor pulmonale, endothelin-1 was increased to levels
comparable to those in normal subjects rendered acutely hypoxaemic. It is interesting
to note that baseline levels in controls were similar to those observed in other series
(Stewart DJ et al, 1991) and that the increase following hypoxaemia and in patients
with cor pulmonale is comparable to the rise seen in normal subjects at high altitude
(Goerre S et al, 1995).
These observations in humans are largely confirmatory of in vitro and animal studies
which have shown hypoxia to be a potent stimulus for endothelin-1 synthesis and gene
expression (Kouremabanas S et al, 1991, Shirikami G et al, 1991). In normal humans,
Therkelson et al found that 15 minutes of hypoxaemia caused only a small increase in
plasma endothelin-1 which was not statistically significant, perhaps due to the shorter
duration of the stimulus (Therkelson K et al, 1994). Abnormally high levels of
endothelin-1 have been described in a series of patients with pulmonary hypertension
of varying aetiology, not all of whom were hypoxaemic (Stewart DJ et al, 1991) and
thus other stimuli may also be implicated. In the present series, by excluding subjects
with other significant cardiovascular diseases (e.g. hypertension, congestive heart
failure) we feel hypoxaemia is the most significant stimulus responsible for increased
endothelin-1 levels in cor pulmonale. The in vitro evidence would suggest that the
elevated endothelin-1 levels observed were due to increased synthesis although as
endothelin-1 clearance mechanisms in humans have not been fully characterised
(Haynes WG et al, 1993), the possibility of decreased removal cannot be discounted.
The potent vasoactive properties of endothelin-1 may also be responsible for some of
the circulatory abnormalities seen during hypoxaemia although plasma levels may not
accurately reflect local concentrations and hence vasoconstrictor activity. Whether
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endothelin-1 acts as a mediator of acute hypoxic pulmonary vasoconstriction is
unknown. Support for this hypothesis might be drawn from studies using endothelin
receptor blockers which can in rats attenuate acute hypoxic pulmonary
vasoconstriction (Oparil S et al, 1995) and prevent development of pulmonary
hypertension following chronic hypoxia (Eddahibi S et al, 1995). These drugs now
need to be tested in humans where it is likely that endothelin-1 plays a significant role
in the cardiovascular response to hypoxaemia. Manipulation of the endothelin system
may therefore be a useful measure in patients with hypoxaemic lung disease, either to









Endothelin-1 levels are elevated in a number of conditions characterised by impaired
cardiovascular performance and abnormal vasoconstriction such as congestive cardiac
failure and primary and secondary pulmonary hypertension. The aim of the present
study was to assess the effects of the vasoconstrictor peptide endothelin-1 on
pulmonary and systemic haemodynamics and cardiovascular performance in normal
man.
Ten healthy male volunteers were studied on two occasions in a randomised, double-
blind, placebo controlled, cross-over study and received systemic infusions of either
endothelin-1 (0.75, 1.5 and 3 pmol.kg'Vmin"1 for 30 mins each) or saline placebo.
Systemic and pulmonary haemodynamic parameters were monitored non-invasively by
pulsed-wave Doppler, as were parameters of left and right ventricular diastolic filling
and inotropic state. Effects on renin-angiotensin and natriuretic peptide system activity
were also measured.
Endothelin-1 infusion produced dose-related falls in heart rate, stroke volume and
cardiac output. Systemic vascular resistance (SVR) increased from 1156±57 to 1738±
115 dynes.s.cm-5, and total pulmonary vascular resistance (TPR) increased from 142±
12 to 329±22 dynes.s.cm"5. Endothelin-1 caused significant impairment of left and
right ventricular diastolic filling, even at a low dose which had no pulmonary or
systemic pressor effects. Electromechanical and Doppler acceleration indices of
inotropic state were also significantly impaired. Activity of the renin-angiotensin
system was suppressed by endothelin-1 whilst plasma levels of atrial natriuretic
peptide (ANP) were unchanged.
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Thus, in addition to systemic and pulmonary pressor effects our results suggest that
endothelin-1 impairs overall cardiovascular performance by causing diastolic
dysfunction and acting as a negatively inotropic agent. These effects were associated
with compensatory changes in the renin-angiotensin system.
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11.2 INTRODUCTION
Endothelial function is an important regulator of vascular tone although the
physiological roles of the endothelium-derived relaxing and constricting factors and
their functional antagonism remain the subject of much ongoing research effort. In
terms of vasoconstriction, the family of peptides known as the endothelins have
emerged as being of major importance. These are a group of structurally similar
peptides synthesised by vascular endothelium which act via two specific receptors.
Stimulation of the type A endothelin receptor (ETA) results in a gradual onset but
long-lasting vasoconstriction whilst stimulation of the type B receptor (ETB), causes
release of vasodilator metabolites and transient vasodilatation but may also be
involved in the vasoconstrictor response (Haynes WG et al, 1993). ETA receptors are
the main subtype found on vascular smooth muscle cells (Davenport AP et al, 1995)
and have also been localised to the heart and adrenal gland (Davenport AP et al,
1989). In vitro, endothelin-1 is the most potent vasoconstrictor substance known
through its relatively selective activation of the G-protein-linked ETA receptor
(Yangisawa M et al, 1988) as well as being the most abundant endothelin isoform in
human plasma (Suzuki N et al, 1989).
Release of endothelin-1 from endothelial cells is stimulated by a variety of physical
and chemical stimuli in vitro (Haynes WG et al, 1993) whilst in humans in vivo,
hypoxia and angiotensin II increase plasma concentrations of endothelin-1 (Cargill RI
et al, 1995, Good JM et al, 1994). Abnormalities of circulating endothelin-1
concentrations have also been observed in a number of conditions characterised by
abnormal vasoconstriction such as hypertension (Kohno M et al, 1990), congestive
heart failure (CHF) (Cody RJ et al, 1992), primary pulmonary hypertension (PPH)
(Stewart DJ et al, 1991), and hypoxaemic cor pulmonale (Cargill RI et al, 1995),
raising the possibility that endothelin-1 may play a pathogenic role in both
cardiovascular and cardiopulmonary disease. As the physiological effects of
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endothelin-1 in man have not been fully studied, a precise understanding of this role
remains elusive.
Although in previous in vivo studies in man, endothelin-1 increased systemic blood
pressure (Vierhapper H et al, 1990) and caused renal vasoconstriction (Rabelink TJ et
al, 1994) the effects of endothelin-1 on the pulmonary vasculature and cardiovascular
performance are not known. Furthermore, the design of some studies (Vierhapper H
et al, 1990) has not allowed for the prolonged action of endothelin-1 and as such, may
have produced misleading information.
We have therefore evaluated the effects of systemic endothelin-1 administration in
healthy volunteers. This study documents effects on systemic and pulmonary





Ten healthy, non-obese, male volunteers, age (mean ± SEM) 26.1+1.4 years were
studied. All had normal clinical history and examination, 12-lead electrocardiogram,
echocardiogram and haematological and biochemical screen. Subjects refrained from
alcohol, tobacco and caffeine for at least 12 hours and had taken no medications for at
least one month before the study. Informed consent was obtained to the study
protocol previously approved by the Tayside Committee for Medical Research Ethics
and this investigation conforms with the principles outlined in the Declaration of
Helsinki.
Study design
Subjects were studied at the same time of day on two occasions at least one week
apart in a randomised, double blind, cross-over design. Subjects were randomised
prior to commencement of the study with both subject and echocardiographer (DGK)
blinded with respect to the infusate. After completion of the final study day and of all
measurements and calculations the active and placebo days were revealed to allow
statistical analysis to be performed. On arrival at the clinical laboratory, intravenous
cannulae were sited in both forearms for infusion (left) and blood sampling (right).
Subjects then remained supine, turned slightly on the left side throughout the study.
After allowing at least 30 minutes rest to achieve baseline haemodynamic parameters,
infusion of either pharmaceutical grade human endothelin-1 (Clinalfa AG;
Laufelfingen, Switzerland) or identical volume placebo (0.9% saline) was commenced
in random order. Endothelin-1 was infused at 0.75 pmol.kg'Vmin"1 for 30 minutes,
then increased to 1.5 pmol.kg'Vmin"1 for 30 minutes and then to 3.0 pmol.kg'Vmin"1
for a further 30 minutes. Infusions were then discontinued and subjects monitored for
a further 60 minutes. Measurements were made at baseline, at the end of each infusion
dose period and 30 and 60 minutes after stopping the infusion.
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Measurements
Pulmonary and systemic haemodynamic parameters and inotropic and diastolic indices
were measured as previously described The short term coefficients of variability (CV)
for the Doppler measurements in this study were; SV 4.9%, CO 9.3%, MPAP 4.5%,
mitral Evmax 12.2%, mitral Avmax 17.2%, transmitral E/A ratio 12.4%, left ventricular
IVRT 13.8%, tricuspid Evmax 8.8%, tricuspid Avmax 14.2%, transtricuspid E/A ratio
14.8%, right ventricular IVRT 29.1%, Accpeak 18.7%, Accmean 12.5% and QS2I 3.5%.
Venous blood samples for measurement of serum electrolytes, PRA, aldosterone and
atrial natriuretic peptide were collected and analysed as previously described. The
intra-assay CV for these assays were; PRA 7.6%, aldosterone 8.3%, ANP 8.0%.
Data Analysis
Comparisons were made between active and placebo treatments for each treatment by
repeated measures analysis of variance (ANOVA). Where the overall ANOVA was
significant, Duncan's multiple range testing was used to determine differences at
individual time points . A p value of less than 0.05 was considered significant and
results are expressed as means ± SEM.
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11.4 RESULTS
There were no significant adverse effects during the study although one subject felt
transiently nauseous and sweaty during maximal rate infusion of endothelin-1.
Haemodynamic effects
Baseline conditions on each study day were similar for all haemodynamic parameters
measured. Endothelin-1 had significant systemic pressor effects compared with
placebo, where MAP was elevated following medium and high dose endothelin-1
infusion and remained significantly greater than placebo for 30 minutes after stopping
the infusion (Figure 11.1a). Data for SBP and DBP are given in table 1 where the
pattern of changes was similar. HR decreased during medium and high dose
endothelin-1 infusion compared with placebo and remained significantly lower than
placebo for 30 minutes after stopping infusions (Figure 11.1b) whilst SV was only
significantly reduced during high dose endothelin-1 infusion (Table 11.1). CO also
decreased during medium and high dose endothelin infusion but was not significantly
different from placebo during the recovery period (Figure 11.1c). Endothelin-1
significantly increased SVR during medium and high dose infusion and remained
greater than placebo after 30 minutes recovery (Figure 11.Id). In the pulmonary
circulation, both MPAP and TPR were increased by medium and high dose infusion,
remaining higher than placebo after 30 minutes recovery (Figures 11. le and 11. If).
Inotropic effects
Aortic Accmean and Accpeak were similar at baseline on each study day. Both
parameters decreased during endothelin-1 infusion to levels significantly lower than
placebo during medium and high dose infusion for Accpeak (Figure 11.2a) and at high
dose only for Accmean (Figure 11.2b). Compared with placebo, QS2I was significantly
prolonged only during high dose endothelin-1 infusion (Figure 11.2c).
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Lusitropic effects
All lusitropic parameters were similar at baseline on each study day. Mitral and
tricuspid E/A ratio decreased during endothelin-1 infusion and were significantly
different from placebo during high dose infusion only (Figure 11.3a and 11 3b). These
changes were due to falls in Evmax rather than increases in Avmax (Table 11.2). IVRT
was a more sensitive marker of impaired ventricular filling where in the left ventricle
IVRT was prolonged by endothelin-1 even at the lowest infusion rate compared with
placebo (Figure 11.3 c) whilst in the right ventricle, IVRT during endothelin-1 infusion
was not significantly different from placebo but was prolonged from baseline during
medium and high dose infusion (Figure 11.3d).
Endocrine effects
Plasma sodium and potassium were similar at baseline on both study days and did not
change significantly during either placebo or endothelin-1 infusion (Table 11.3). PRA
was similar at baseline on both days and fell significantly from baseline after 90
minutes of placebo infusion (Figure 11.4a). The fall during endothelin-1 infusion was
however more rapid and levels were significantly lower than baseline after low dose
infusion and continued to fall up to 60 minutes after stopping infusion. Levels were
significantly lower than placebo during medium and high dose endothelin-1 infusion
and throughout the recovery period (Figure 11.4a). There was no difference in plasma
aldosterone either at baseline or following endothelin-1 infusion compared with
placebo. Levels fell significantly from baseline after 60 minutes of placebo infusion
and then began to plateau (Figure 11.4b). Levels also fell following endothelin-1
infusion, reaching a significant nadir at the medium dose (Figure 11.4b). No effect on
plasma ANP levels was observed during either placebo or endothelin-1 infusion (Table
11.3).
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Table 11.1. Systemic haemodynamic effects of ET-1 infusion in normal man.
Time (minutes)
0 30 60 90 120 150
SBP Placebo 112±2.9 107±2.9 106+2.5 108+3.5 110+2.8 110+3.6
(mmHg) Active 108±2.5 107±2.2 109+2.1 114+3.5** 113+1.9 112+1.9
DBP Placebo 61±2.5 58±2.5 57±2.5 60+2.2 60+1.7 61+2.2
(mmHg) Active 57±2.0 57+1.8 62+2. ln 67+3.2^ 64+1.8n 64±2.4t
SV Placebo 90±4.0 89±4.2 88+3.6 86+3.2 87+4.7 89+4.4
(ml) Active 90±3.8 88±4.4 85+4.6 81+5.0^ 90+4.6 90+4.3
Absolute values (mean±SEM) of systolic and diastolic blood pressure (SBP, DBP)
and stroke volume (SV) during placebo and endothelin-1 infusion.
Asterisk (*) indicates significant difference from placebo at the same time point.
Cross (f) indicates significant difference from baseline during endothelin-1 infusion.
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Table 11.2. Left and right ventricular filling parameters in response to endothelin-1
infusion in normal man.
Time (minutes)
All units (m.s1) 0 30 60 90 120 150
Mitral Placebo 70±4.1 69±4.3 71±4.0 68±3.4 70±3.2 68±4.0
E Vmax Active 71 ±3.9 71±4.2 62±3.3n 59+3.4n 63±3.0f 71±4.4
Mitral Placebo 42±1.9 42±1.7 43+1.6 41±1.7 41+1.6 41+1.8
A Vmax Active 41±1.7 43+2.0 40+1.8 40±2.4 38+1.8 42±2.7
Tricuspid Placebo 47+1.7 45±1.2 47+1.3 46±1.3 46±1.4 46±1.2
E Vmax Active 46±2.1 46±2.1 45+1.8 43+1.7 42±0.7n 43±1.0t
Tricuspid Placebo 31±1.0 30±1.1 31+1.2 30±0.9 32+1.1 31±0.8
A Vmax Active 30±0.9 32±1.4 31+1.0 31+1.5 29±0.9 29±1.3
Absolute values (mean±SEM) of transmitral and transtricuspid E and A wave maximal
velocity during placebo and endothelin-1 infusion.
Asterisk (*) indicates significant difference from placebo at the same time point.
Cross (f) indicates significant difference from baseline during endothelin-1 infusion.
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Table 11.3. Serum electrolytes and ANP in response to ET-1 infusion in normal
man.
Time (minutes)
0 30 60 90 120 150
Na Placebo 138±0.7 13810.6 13810.8 13810.6 13610.8 13811.0
(mmol.r1) Active 137±0.7 13810.7 13710.9 13710.8 13710.6 13810.6
K Placebo 4.010.08 4.110.04 4.110.06 4.110.05 4.010.06 4.110.08
(mmol.l1) Active 4.110.07 4.210.11 4.110.08 4.210.06 4.210.08 4.210.09
ANP Placebo 4.8211.53 4.6110.59 4.3610.43 4.0510.49
(pmol.r1) Active 5.5710.68 5.9710.43 5.7110.79 6.0010.71
Absolute values (mean±SEM) of serum sodium (Na), potassium (K) and atrial
natriuretic peptide (ANP) during placebo and endothelin-1 infusion. There were no
significant differences between endothelin-1 and placebo treatments or with time.
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FIGURE LEGEND
Figure 11.1a, b, c, d, e and f. Systemic and pulmonary haemodynamic changes in
response to ET-1 (■) and placebo (O) infusions in normal man.
The doses of endothelin-1 infused are shown in diagramatic form on the x-axis.
Endothelin-1 was infused at 0.75 pmol.kg'Vmin"1 for 30 minutes, then increased to 1.5
pmol.kg" .min"1 for 30 minutes and then to 3.0 pmol.kg"'.min"1 for a further 30
minutes.
Asterisk (*) indicates significant difference from placebo at the same time point.






























































Figure 11.2a, b and c. Changes in inotropic indices in response to endothelin-1 (■)
and placebo (O) infusions in normal man.
The doses of endothelin-1 infused are shown in diagramatic form on the x-axis.
Endothelin-1 was infused at 0.75 pmol.kg^.min"1 for 30 minutes, then increased to 1.5
pmol.kg'Vmin"1 for 30 minutes and then to 3.0 pmol.kg'Vmin"1 for a further 30
minutes.
Asterisk (*) indicates significant difference from placebo at the same time point.






























Figure 11.3a, b, c and d. Echo-Doppler parameters of left (LV) and right
(RV) ventricular filling in response to endothelin-1
(■) and placebo (O) infusions in normal man.
The doses of endothelin-1 infused are shown in diagramatic form on the x-axis.
Endothelin-1 was infused at 0.75 pmol.kg'Vmin"1 for 30 minutes, then increased to 1.5
pmol.kg"1.min'1 for 30 minutes and then to 3.0 pmol.kg"1.min"1 for a further 30
minutes.
Asterisk (*) indicates significant difference from placebo at the same time point.













































Figure 11.4a and b. Changes in renin-angiotensin system activity in response to
endothelin-1 (■) and placebo (O) infusions in normal
man.
The doses of endothelin-1 infused are shown in diagramatic form on the x-axis.
Endothelin-1 was infused at 0.75 pmol.kg'Vmin"1 for 30 minutes, then increased to 1.5
pmol.kg'Vmin'1 for 30 minutes and then to 3.0 pmol.kg'Vmin'1 for a further 30
minutes.
Asterisk (*) indicates significant difference from placebo at the same time point.





























Although endothelin-1 was initially characterised as a vasoconstrictor, it is clear from
the present study that in addition to pressor effects, endothelin-1 may also have direct
effects on myocardial function in man. In comparison with animal studies (Goetz KL
et al, 1988), these effects were observed using relatively low doses of endothelin-1,
although just exceeding the previously highest reported dose in humans (Vierhapper H
et al, 1990). We have administered endothelin-1 exogenously in a range of doses, with
the lowest dose achieving levels of endothelin-1 found in pathophysiological states
whilst the higher doses will have achieved so called "pharmacological" concentrations.
Unlike previous studies we have not measured plasma endothelin-1 levels as this
appears highly variable between individuals during infusions of endothelin-1
(Vierhapper H et al, 1990) and as endothelin-1 has paracrine rather than endocrine
actions, plasma levels may not be comparable with levels measured in pathological
states. In these conditions plasma levels are likely to represent "spillover" with much
higher levels of endothelin-1 found abluminally. It is for these reasons that our dose
range included infusions that were known to achieve pathophysiological
concentrations of endothelin-1 and greater. The relatively longer infusion times in the
present investigation have also allowed a clearer definition of the dose related effects
of endothelin-1 than would be obtained with shorter dose increments.
The parameters in this study were measured non-invasively due to ethical
considerations and as such have associated limitations. Although our indices of
inotropicity and lusitropicity have previously been validated (Sabbah HN et al, 1986,
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Ahmed SS et al, 1972, Rokey R et al, 1985) these measures can be affected to greater
or lesser degrees by loading conditions and we have alluded to this in the text.
Doppler echocardiography was used to measure haemodynamic changes in the
pulmonary circulation. Pulmonary acceleration time, which we have shown to be
reproducible in our own hands, was used to estimate mean pulmonary artery pressure
which has been shown to have a good correlation with catheter derived measures,
although in a patient population it cannot be accurately used to precisely estimate
pulmonary artery pressure (Dabestani A et al, 1987, Matsuda M et al, 1986).
Although estimation of changes in pulmonary artery pressure over time may be
accurate, some caution should be used when taking these values for further
calculations. We looked at two measures of pulmonary vasoconstriction changes in
MPAP and TPR. A limitation of this methodology is that TPR neglects the
downstream pressure of the pulmonary circulation, namely left atrial pressure, as
conventionally assessed by pulmonary capillary wedge pressure (PCWP). Although
this may be increased if left ventricular function is impaired, as was the case in this
study, the magnitude of the changes observed in the pulmonary vascular bed suggest
an effect on the pre-capillary vasculature. With respect to Doppler measures of
cardiac output, these are accepted as a relatively accurate measure which can be made
in most patients (Huntsman LL et al, 1983), the major source of error is generally
accepted as measurement of the annular diameter and this would be mitigated by the
cross-over design of the study. In addition it remains difficult to separate primary
from secondary effects of endothelin-1 on cardiopulmonary performance using this
protocol although some of the data does support direct effects on the heart.
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The haemodynamic effects of endothelin-1 in man are not well characterised although
our haemodynamic data agree with findings from animal studies (Goetz KL et al,
1988). Our study confirms that endothelin-1 is a potent in vivo systemic
vasoconstrictor and it is interesting to note that MAP and SVR were elevated
compared to baseline for at least 30 minutes after stopping the infusion indicating
prolonged vasoconstriction. This is in keeping with in vitro data (Kiowski W et al,
1991) and with the observation that although plasma levels fall rapidly after stopping
endothelin-1 infusion, the increase in blood pressure is maintained (Vierhapper H et al,
1990). The relative bradycardia and fall in CO during endothelin infusion may have
been due to a vagal reflex response to systemic vasoconstriction, myocardial
ischaemia or due to a direct effect on the conducting system of the heart.
Most previous studies have neglected the action of endothelin-1 on pulmonary
haemodynamics. We have tried to characterise these using non-invasive techniques
which we have previously employed to study the pulmonary vascular effects of
vasoconstrictors (Lipworth BJ et al, 1994) and vasodilators (Cargill RI et al, 1995),
giving results which concur well with invasive studies of the same agents (Segel N et
al, 1960, Cody RJ et al, 1986). We have measured TPR and not pulmonary vascular
resistance (PVR) and as such have neglected the downstream pressure of the
pulmonary circulation. Our results suggest that endothelin-1 impairs diastolic function
and acts as a negatively inotropic agent, and as such have reasons to believe that left
atrial pressure did increase in these subjects. Although we cannot conclude that PVR
was increased in our subjects the magnitude of the changes in the pulmonary vascular
bed is consistent with a vasoconstrictor effect for endothelin-1, an effect that would
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be predicted from in vitro and animal studies (Goetz KL et al, 1988, Crawley D et al,
1989). At a receptor level, although still attributable to enothelin-1, some debate
exists about the role activation of the ETB receptor plays in producing pulmonary
vasoconstriction (MacLean MR et al, 1994).
Our findings also support the hypothesis that endothelin-1 has negative inotropic
effects and impairs ventricular filling in humans and is similar to the findings of
previous animal studies (Ohno M et al, 1994). We have used echo-Doppler
parameters and systolic time intervals to assess left ventricular contractility as both
QS2I and AcCpeak are thought to be relatively independent of loading conditions. In
this respect in vitro and in vivo work have shown that changes in QS2I reflect
inotropic influences and load conditions only have a proportionately small effect on
this interval (Li Q et al, 1993) although conflicting data exists regarding Doppler
derived parameters of ascending aortic flow (Bennet ED et al, 1984, Bedotto JB et al,
1989). Studies examining effect of afterload on transmitral flow patterns have been
hampered by difficulties involving sympathetic and neurohormonal activation,
however, the general consensus is that afterload decreases early filling velocity and
E/A ratio (Zile MR et al, 1993). The IVRT also varies with changes in afterload and
prolongation of the IVRT is directly related to the natural logarithm of aortic closing
pressure (Thomas JD et al, 1992). Although the changes in IVRT and our Doppler
indices of left and right ventricular function can be explained in part by increases in
afterload it is important to note that changes in left ventricular IVRT were observed at
low dose endothelin-1 infusion which had no significant pressor effects. This suggests
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that endothelin-1 may impair ventricular filling via a direct effect on the myocardium
as well as by increasing afterload.
Thus in addition to a reflex response to vasoconstriction the observed fall in CO and
SV may also be due a direct effect of endothelin-1 on the myocardium possibly
mediated through the ETA receptor which is found on cardiac muscle (Davenport AP
et al, 1989) although a secondary effect from myocardial ischaemia remains a
possibility, despite the absence of clinical or ECG evidence of ischaemia in these
subjects. Alternatively, endothelin-1 by directly affecting myocyte calcium handling
could lead to inefficient excitation-contraction coupling, an effect observed in vitro
(Kohmoto O et al, 1993). The changes in IVRT observed were of similar magnitude
to abnormalities associated with pulmonary heart disease (Marangono S et al, 1992)
and hypertensive heart disease (Grossman W, 1991). Whether endothelin-1
contributes to the ill-defined syndrome of diastolic heart failure is also unknown.
In terms of effects on the renin-angiotensin system (RAS), endothelin-1 has been
variously reported to have stimulatory and inhibitory actions (Haynes WG et al,
1993). In vitro studies would indicate that endothelin-1 inhibits renin release (Takagi
M et al, 1988) and stimulates aldosterone release in cell culture (Cozza EN et al,
1989) although in humans in vivo, this effect may be offset by renal vasoconstriction
(Rabelink TJ et al, 1994) increasing renin release and hence aldosterone , as no effect
on these parameters has been reported (Vierhapper H et al, 1990, Rabelink TJ et al,
1994). The findings of the present study are therefore of interest where the inclusion
of a placebo limb allows the prolonged, time dependent fall in parameters of RAS
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activity to be considered. We observed PRA to fall in comparison with placebo after
medium dose infusion, an effect which continued throughout the remainder of the
study even when haemodynamic parameters had normalised. This therefore provides
indirect evidence for a direct effect on renin production rather than a phenomenon
secondary to renal vasoconstriction. The pattern with regard to aldosterone was
different where although not significantly different from placebo, there was a biphasic
response during endothelin-1 infusion. This apparent dissociation of components of
the RAS may be related to increases in ACTH-mediated effects on aldosterone
secretion. In addition despite the increase in cardiac afterload, no change in plasma
ANP concentration was observed.
Contrary to a previous study in humans (Vierhapper H et al, 1990), we found no
significant effects on plasma electrolytes, a finding in agreement with animal studies
(Goetz KL et al, 1988). The possibility that mild haemolysis was responsible for this
finding has been raised (Vierhapper H et al, 1990) and thus different peptide or
infusion preparation practices may have been responsible.
We have shown that endothelin-1, in addition to potent pressor effects has adverse
effects on both inotropic and lusitropic parameters. These new findings may be
important in considering the pathophysiological role of endothelin-1 in both
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12.1 SUMMARY
The aim of his study was to examine whether nitric oxide (NO) has an important role
in maintaining basal vascular tone in normal man by examining the effects of nitric
oxide inhibition using NG-monomethyl-L-arginine (L-NMMA) on systemic and
pulmonary haemodynamics.
10 normal male volunteers 26±1.6 years were studied on two separate occasions in a
double blind, placebo controlled crossover study. They were randomised to receive
either a continuous infusion of L-NMMA (4mg/kg/hr) with a front loaded bolus
(4mg/kg) or volume matched placebo. Pulsed wave Doppler echocardiography was
used to measure cardiac output (CO), mean pulmonary artery pressure (MPAP) and
hence systemic vascular resistance (SVR) and total pulmonary vascular resistance
(TPR). Measurements were made prior to infusion (T0) and after 4, 8, and 12 minutes
(Ti, T2 and T3).
Infusion of L-NMMA significantly increased mean arterial blood pressure (MAP),
SVR and TPR and significantly reduced heart rate (HR), stroke volume (SV) and CO
compared to placebo. These effects were observed at Ti and persisted during the
entire infusion period.
These results are consistent with a role for basal nitric oxide generation in the
maintenance of basal systemic and pulmonary vascular tone in normal man.
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12.2 INTRODUCTION
Endothelial function is known to be an important determinant of vascular tone
although the physiological roles of the endothelium-derived relaxing and constricting
factors and their functional antagonism remain the subject of much ongoing research
effort. Much interest surrounds a potent short acting vasodilator, nitric oxide, which
is generated by the vascular endothelium through the action of nitric oxide synthase
(Palmer RMJ et al, 1987). Studies in animals using systemic infusions of nitric oxide
synthase inhibitors such as NG-monomethyl-L-arginine (L-NMMA) have
demonstrated an increase in mean arterial pressure and systemic vascular resistance
(Rees DD et al, 1989, Loeb AL et al, 1992). Evidence in humans suggesting an
important role for nitric oxide generation in the maintenance of systemic vascular
tone comes from studies demonstrating that infusion of L-NMMA into the brachial
artery results in vasoconstriction (Vallance P et al, 1989) and systemic infusions of L-
NMMA increase systemic vascular resistance (Haynes WG et al, 1993).
There is however, some debate as to the role of nitric oxide generation in the
maintenance of the low pressure pulmonary circulation where conflicting results exist
suggesting the possibility of species specificity (Stamler JS et al, 1994, Fineman JR et
al, 1992, McMahon TJ et al, 1991, Hasunuma K et al, 1991, Nishiwaki K et al, 1992).
Interestingly, studies in animals and humans have suggested that impaired endothelial
relaxing activity may contribute to the pathogenesis of pulmonary hypertension
(Adnot S et al, 1991, Dinh-Xuan AT et al, 1991). To date only Stamler and his
colleagues have examined the effects of nitric oxide inhibition on pulmonary vascular
tone in normal man in a dose ranging study (Stamler JS et al, 1994). This study
examines for the first time in a placebo controlled manner the effects of nitric oxide





Ten healthy, non-obese, male volunteers, age (mean±SEM) 26±1.6 years were
studied. All had normal clinical history and examination, 12-lead electrocardiogram,
echocardiogram and haematological and biochemical screen. Subjects refrained from
alcohol, tobacco and caffeine for at least 12 hours and had taken no medications for at
least one month before the study. Informed consent was obtained to the study
protocol previously approved by the Tayside Committee for Medical Research Ethics
and this investigation conforms with the principles outlined in the Declaration of
Helsinki.
Protocol
Subjects were studied at the same time of day on two occasions in a randomised,
double blind, cross-over design. Subjects then remained supine, turned slightly on the
left side throughout the study. After allowing at least 30 minutes rest to achieve
baseline haemodynamic parameters they received either a continuous infusion of L-
NMMA (4mg/kg/hr) with a front loaded bolus (4mg/kg) given over two minutes or
volume matched placebo (0.9% N. saline). Measurements were made prior to infusion
(T0) and after 4, 8, and 12 minutes (Ti, T2 and T3).
Measurements
Systemic and pulmonary haemodynamic indices were measured as previously
described. The coefficients of variability (CV) for these measurements in this study
were HR: 12.8%; SV: 18.7%; CO: 14.0%; PAT 2.8%; and MAP: 7.1%.
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Data Analysis
Comparisons were made between active and placebo treatments by repeated measures
analysis of variance (ANOVA). Where the overall ANOVA was significant, Duncan's
multiple range testing was used to determine differences at individual time points . A p
value of less than 0.05 was considered significant and results are expressed as means ±
SEM and where a difference between means is quoted, the 95% confidence (CI) for
this difference is given.
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12.4 RESULTS
Acute administration ofL-NMMA was not associated with any adverse effects during
the study. Baseline conditions on each study day were similar for all haemodynamic
parameters measured. L-NMMA had significant pressor effects compared with
placebo, where both SVR (p=0.02); mean difference 479 dyne.s.cm"5 (95% CI 87-
872) and TPR (p=0.02); 63 dyne.s.cm"5 (95% CI 15-110) were elevated at Ti and
these effects persisted throughout the entire infusion period (Figure 12.1). Although
MAP was significantly increased during infusion of L-NMMA compared to placebo at
Ti (p=0.03); mean difference 5mmHg (95% CI 1-10) an effect that persisted
throughout the entire infusion period, MPAP was unchanged. In addition HR
(p=0.003); mean difference 9 bpm (95% CI 5-13) and CO (p=0.02); mean difference
1.74 L/min (95% CI 0.33-3.15) were significantly lower during infusion with L-
NMMA compared to placebo at Ti an effect that persisted throughout the infusion
period (Table 12.1).
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Table 12.1 Haemodynamic effects ofL-NMMA and placebo infusions in normal
man.
TO T1 T2 T3
HR P 71±2 69 ±3 70±4 67±3
(bpm) L 68±4 60±4 *+ 59±3 *+ 57±3 *+
SV P 102±5 104±6 101±4 111±6
(ml) L 100±6 95±6 + 91±5 + 90±7 *+
CO P 6.92±0.47 6.91±0.48 6.66±0.44 7.21±0.56
(L/min) L 6.34±0.52 5.17±0.5 *+ 5.10±0.41
*+
5.27±0.52 *+
MAP P 87±3 89±3 89±3 87±3
(mmHg) L 90±3 94±3 *+ 95±3 + 94±2 *+
MPAP P 11±1 11±1 12±1 11±1
(mmHg) L 10±1 12±1 12±2 12±1
Absolute values (mean±SEM).
Asterisk (*) indicates significant difference between infusion with L-NMMA (L) and
placebo (P) at that time point.
Cross (+) indicates significant difference from baseline during L-NMMA infusion.
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FIGURE LEGEND
Figure 12.1. Systemic and pulmonary pressor effects ofL-NMMA and placebo
infusions in normal man.
Asterisk (*) indicates significant difference between infusion with L-NMMA and
placebo at that time point.




Our results suggest that basal generation of NO is important in the regulation of both
systemic and normoxic pulmonary vascular tone in normal man reflected by an
increase in both SVR and TPR during inhibition of nitric oxide synthesis.
The systemic effects of NO inhibition in man are well documented. Our results
however suggest that in addition that resting normoxic pulmonary vascular tone is
dependent on the continuous generation of nitric oxide. In this respect infusion of L-
NMMA resulted in a significant increase in TPR which was sustained throughout the
entire infusion period. The lack of effect on MPAP is likely to reflect the coexistent
reduction in cardiac output Although this phenomenon has been shown in some lower
mammals (Fineman JR et al, 1992, McMahon TJ et al, 1991) it has not been
demonstrated in either rat (Hasunuma K et al, 1991) or dog models (Nishiwaki K et
al, 1992). The results of this study support the findings of Stamler et al (Stamler JS et
al, 1994) who demonstrated a similar effect during a dose ranging study in normal
man. In addition, our results suggest that these changes persist throughout a more
prolonged infusion period.
We chose to use a dose of L-NMMA based on findings from previous in vivo studies
conducted in man to insure a good profile of nitric oxide inhibition over the whole
time course of the study and found comparable systemic haemodynamic effects.
Previous work by Haynes et al (Haynes WG et al, 1993) examined the maximal
haemodynamic responses to increments in doses of L-NMMA. He examined on
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separate days doses of L-NMMA in ascending order (0.03, 0.1, 0.3, 1.0, 3.0 mg/kg)
infused over 60 minutes and then 3 mg/kg L-NMMA infused over 20 minutes then the
same dose infused over 5 minutes via a peripheral cannula. Although, at doses
>1 mg/kg there was an apparent decrease in heart rate, cardiac index and an increase in
peripheral vascular resistance no effect on blood pressure was observed until a dose of
3 mg/kg was given over 20 minutes when there were isolated increases in both systolic
and diastolic blood pressure but these did not occur consistently at similar time points.
He and co-workers performed the definitive study using 3 mg/kg over 4 minutes and
found maximal increases in mean arterial blood pressure 10 minutes after the start of
the infusion. In a dose ranging study by Stamler et al (Stamler JS et al, 1994) the
haemodynamic responses to dosages of 0.01, 0.03, 0.1, 0.3 and l.Omg/kg/min each
for 3 minutes via a central venous catheter sheath were examined. Although an
increase in mean arterial blood pressure was observed at 0. lmg/kg/min infused over 3
minutes no effects were observed on the pulmonary vascular bed until the maximal
rate of infusion l.Omg/kg/min given over 3 minutes. The discrepancy between effects
on the systemic and pulmonary vascular beds may be explained by in vitro studies
suggesting that L-NMMA is a relatively ineffective inhibitor of NO synthase in
pulmonary blood vessels (Archer SL et al, 1992).
We used a front loaded infusion ie a combination of bolus with a continuous infusion
to give a good overall profile of NO inhibition over the whole time course of the
study. We infused an initial 4mg/kg bolus over 2 minutes (ie 2mg/kg/min for 2
minutes) with a continuous infusion of 4mg/kg/hr to ensure that we would achieve
maximal NO inhibition during the period under investigation . The maximal
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haemodynamic changes in this study were noted at 4 minutes and persisted
throughout the entire infusion period. We cannot comment whether haemodynamic
changes occurred earlier than 4 minutes since the time scale of measurements was
influenced partly by the time required for signal acquisition and measurements to be
made in triplicate.
In addition for safety considerations we did not feel that a dose escalation above the
infusion rate used in this study would be safe because of worries over limiting
systemic hypertension and worries over precipitating coronary vascular spasm. The
evidence from studies suggests that L-NMMA is a relatively ineffective inhibitor of
NO synthase in pulmonary blood vessels (Archer SL et al, 1992) and therefore to
construct a dose response curve based on the results of previous studies would have
meant doubling and quadrupling our dose of L-NMMA and exposing our patients to
unwanted risks.
With respect to methodology, we have used non-invasive Doppler-echocardiography
to measure haemodynamic changes in the pulmonary circulation. These non-invasive
techniques have been shown to be reproducible (Lipworth BJ et al, 1994) and the
close correlation between Doppler PAT and MPAP as measured by right heart
catheter, is well established both in our own hands and those of other workers (Kiely
DG et al, 1997, Dabestani A et al, 1987, Kitbatake A et al, 1983, Graettinger WF et
al, 1987). Less, however, is known of the correlation between changes in MPAP and
PAT. Using regression equations incorporating PAT, Chow et al (Chow LC et al,
1988) examined patients before and after pulmonary thromboendarterectomy and
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although statistically significant the correlation between changes in PAT and catheter
measures of MPAP was weak (r=-0.41). Beard et al (Beard JT et al, 1991), however,
showed a good correlation in 11 normal subjects made hypoxic r=-0.73. In addition
studies performed in normal man using this non-invasive methodology concur with
results of invasive studies and we therefore feel that the available evidence supports
our view that PAT can be used to assess changes in the pulmonary vascular bed,
particularly in normal volunteers where repeated cardiac catheterisation is viewed by
some including ourselves as unethical. Doppler derived measures of cardiac output
have been shown to be reproducible and correlate well with invasive measures
(Huntsman LL et al, 1983). The major source of error is generally accepted as
measurement of the annular diameter and this would be mitigated by the cross-over
design of this study.
There is a growing body of evidence suggesting that endothelial dysfunction is
important in the development of hypoxic pulmonary hypertension. Endothelium
dependent relaxation is reduced in chronically hypoxic rats (Adnot S et al, 1991) and
in man in end stage chronic hypoxic lung disease endothelium dependent pulmonary
artery relaxation is impaired and in addition the contractile responses to pressor
stimuli increased (Dinh-Xuan AT et al, 1991). These patients are known to have
elevated levels of pressor substances such as endothelin-1 (Cargill RI et al, 1995),
which has been shown to be potent pressor agent in man in vivo (Kiely DG et al,
1997), and may have significantly greater pressor effects in the context of a
dysfunctional endothelium.
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In addition to pressor effects we also noted a reduction in HR, CO and SV. This may
have been mediated via a baroreceptor reflex and increase in left ventricular afterload
although a role for nitric oxide generation in the maintenance of cardiac output
remains a possibility.
To conclude, we have shown that basal nitric oxide generation is important in
maintaining basal vascular tone. In disease states an imbalance of constricting and
relaxing factors may contribute to both systemic and pulmonary vasoconstriction.
The development of therapies which are able to deliver relaxing factors such as nitric
oxide to the site of endothelial dysfunction hold exciting prospects, particularly in
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13.1 SUMMARY
We hypothesised that levels of natriuretic peptides would be increased in patients with
pulmonary thormboembolism (PTE) as a consequence of the cardiopulmonary
sequelae and that measuring levels of these peptides might be of value in the
management of this condition.
Venous blood samples were obtained from an unselected group of 114 patients with
suspected PTE referred for ventilation-perfusion scintigraphy. B-type natriuretic
peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal pro-ANP (N-ANP)
were measured by radioimmunoassay using commercially available kits. The scans
were classified into three groups according to standard criteria (PIOPED); normal
scan (N) (n=20), low/intermediate probability (L/I) of PTE (n=77) and high
probability (H) of PTE (n=17). Comparisons were also made between patients with
high probability scans who died (n=3) and those who survived (n=14). Values are
quoted for the median and interquartile ranges. There were statistically significant
differences between groups for levels of a) BNP (p<0.001): N=6.7pmol/l (5.6-11.9),
L/I=12.5pmol/l (6.7-28.2) and H=18.5pmol/l (12.6-74.6); b) ANP (p<0.005):
N=12.6pmol/l (7.1-16.0), L/I=19.51pmol/l (12.5-28.2) and H=19.1pmol/l (15.7-31.7)
and c) N-ANP (p<0.05): N=177 pmol/1 (119-200), L/I=302 pmol/1 (152-576) and
H=322 pmol/1 (223-563). Levels of BNP and ANP were significantly (p<0.05) higher
in patients with high probability scans who died than in those who survived; BNP:
91.6 pmol/1 (77.5-336.2) vs 14.4 pmol/1 (11.9-27.4) and ANP 32.5 pmol/1 (21.7-
105.5) vs 17.6 pmol/1 (15.2-19.3), respectively. Levels of ANP and BNP were
elevated in patients with PTE.
Measuring these peptides may help to evaluate the cardiopulmonary effects of
pulmonary thromboembolism as well as identifying a high risk group who may benefit
from more intensive therapy such as thrombolysis.
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13.2 INTRODUCTION
The clinical diagnosis of pulmonary thromboembolism (PTE) is notoriously difficult
and as a consequence much emphasis has been placed on both direct and indirect
imaging of the pulmonary vascular bed. The present gold standard is pulmonary
angiography but this is not widely available and the diagnosis is usually made on a
combination of clinical impression and the results of a ventilation perfusion scan.
Interest has recently surrounded the emergence of helical computerised tomogram
scanning of the thorax as a diagnostic tool in pulmonary embolism (Remy -Jardin M et
al, 1992, Teigen CL et al, 1995, Hansell DM et al, 1997) and the results of an ongoing
multicentre European Trial are currently awaited. The British Thoracic Society has
recently published guidelines on the diagnosis and management of PTE (BTS
Standards of Care Committee, 1997). However, in addition to diagnostic difficulty
there is still debate regarding the role of thrombolysis in the immediate management of
large PTE (Gulba DC et al, 1994, Millar GAH et al, 1971, Goldhaber SZ et al, 1993).
In an ideal situation the clinician would like to be aided by a series of tests that not
only aid in the diagnosis but also help in risk stratification such that an informed
decision concerning the risk/benefit ratio of a number of treatments can be made.
Recently there has been much interest in a family of peptides known as that natriuretic
peptides and their potential diagnostic value in conditions such as heart failure
(McDonagh TA et al, 1998, Davidson NC et al, 1996). Atrial natriuretic peptide
(ANP) and B-type natriuretic peptide (BNP) are secreted predominantly form the
atrial and ventricular myocardium respectively in responses to changes in wall tension
(Yasue H et al, 1994) and plasma levels of these peptides have been shown to be
sensitive markers of left ventricular systolic dysfunction (McDonagh TA et al, 1998,
Davidson NC et al, 1996). Acute pulmonary thromboembolism results in a variety of
derangements of pulmonary function and a significant number patients are known to
have increased right atrial and ventricular pressures and arterial hypoxaemia (Mclntyre
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KM et al, 1971, Szucs MM et al, 1971) all of which are known to stimulate natriuretic
peptide secretion. In addition patients who die acutely of pulmonary
thromboembolism are thought to have died as a consequence of right ventricular
failure and a recent study has shown that right ventricular afterload stress is a major
determinant of short term prognosis in patients with PTE (Kasper W et al, 1997).
We have hypothesised, therefore, that levels of natriuretic peptides may be elevated in
patients with pulmonary thromboembolism as a consequence of the cardiopulmonary
sequelae and that measuring levels of these peptides may help us identify high risk




114 unselected patients age range 20-91 years were recruited into this prospective
study, approved by the Tayside Committee for Medical Research Ethics, over a 3
month period. All patients were referred by their own physician according to their
clinical suspicion of pulmonary thromboembolism and each patient gave informed
written consent to blood sampling. There were no exclusions from the study on the
basis of underlying medical problems. Patient characteristics are shown in Table 13.1
These include those known to have medical conditions associated with elevated levels
of natriuretic peptides.
Radionuclide scans
Ventilation and perfusion scintigraphy was normally performed on the same day with
the ventilation scan 3-4 hours before the perfusion scan. However, occasionally the
perfusion scan was the first investigation to be performed. If this was abnormal the
ventilation scan was performed the following day. Ventilation and perfusion
scintigraphy was performed using a Gamma Camera (General Electric) fitted with a
general purpose collimator. Images were acquired using a 20% energy window
positioned over the 140 keV energy peak and a 128 matrix. The six standard views
obtained were right posterior oblique, posterior, left posterior oblique, right anterior
oblique, anterior and left anterior oblique. For the ventilation scan., patients breathed
in 40 Mbq 99m Tc labelled diethylenenetriamine pentacetic acid (DTPA) in an aerosol
form produced using a CIS Ventics 11 kit. The six standard views were acquired for
400kcps or 360 s, whichever was attained first. For the perfusion scan, patients in the
prone position were given an intravenous injection of 80 Mbq 99mTc labelled
macroaggregated albumin (MAA). The six standard views were acquired for 500kcps
or 360s, whichever was attained first.
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On completion of the study the radionuclide scans were classified into three groups
(normal, high probability of pulmonary thromboembolism, and a third group including
patients with a low or intermediate probability of pulmonary thromboembolism) by a
consultant radiologist, blinded to the values of natriuretic peptides, based on the
findings of the PIOPED study (The PIOPED Investigators, 1990, Gottschalk A et al,
1993).
Natriuretic peptide assays
Venous blood was taken from patients in the prone position at the time of the
perfusion scan, prior to injection of Tc labelled MAA. Samples were collected and
assayed as previously described. The coefficients of variability for each assay were:
ANP interassay = 11.8%, intra-assay = 12.6%; BNP interassay = 14.8%, intra-assay =
9.9%; N-ANP interassay = 11.7%, intra-assay = 7.7%. Extraction efficiency for each
assay was: ANP = 80%, BNP = 86% and N-ANP = 78%.
Data analysis
The individual data points for levels of natriuretic peptides in patients with normal,
high probability and low/intermediate probability scans are represented in dot plots.
Comparisons between these groups was made using the non-parametric Kruskal-
Wallis test. Comparisons between levels of natriuretic peptides in patients with high
probability scans who were alive on discharge or died during their hospital admission
were made using the non-parametric Mann Witney test. A probability value of p<0.05




The study group consisted of 114 patients. Of the 114 ventilation perfusion scans
performed 20 were reported as normal, 77 as representing low or intermediate
probability of pulmonary embolism and 17 representing a high probability of
pulmonary thromboembolism. Of the patients with a high probability of pulmonary
thromboembolism 3 died of PTE and 14 were discharged home. On review of the
clinical case notes all 17 patients with high probability scans were anticoagulated and
had a clinical diagnosis of PTE made on the basis of clinical features and other
investigations, including the result of the VQ scan. In contrast none of the patients
with a normal VQ scan had a final clinical diagnosis of PTE.
Values are quoted for the median and interquartile ranges. There were statistically
significant differences between groups for levels of a) BNP (p<0.001): N=6.7pmol/l
(5.6-11.9), L/I=12.5pmol/l (6.7-28.2) and H=18.5pmol/l (12.6-74.6); b) ANP
(p<0.005): N=T2.6pmol/l (7.1-16.0), L/I=19.51pmol/l (12.5-28.2) and H=19.1pmol/l
(15.7-31.7) and c) N-ANP (p<0.05): N-177 pmol/1 (119-200), L/I=302 pmol/1 (152-
576) and H-322 pmol/1 (223-563), (Figure 13.1). In addition levels of BNP and ANP
were significantly (p<0.05) higher in patients with high probability scans who died of
PTE than in those who survived; BNP: 91.6 pmol/1 (77.5-336.2) vs 14.4 pmol/1 (11.9-
27.4) and ANP:32.5 pmol/1 (21.7-105.5) vs 17.6 pmol/1 (15.2-19.3), and there was a
non-significant trend towards a difference in levels of N-ANP (p=0.07) between these
two groups (Figure 13.2).
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TABLES
Table 13.1 Baseline characteristics of 114 participants with suspected PTE
undergoing V/Q scanning.
Probability of PE as defined by V/Q scan result
Characteristic Normal Low/Intermediate High
Number 20 77 17
Age (years) 46±18 64±15 69±11
Male (%) 25 39 65
Impaired LV function 1 6 3
PPH 0 2 1
Creatinine>120 mmol/1 2 14 4
COPD 0 18 1
Age is expressed as mean±standard deviation. PPH=primary pulmonary hypertension;
COPD=chronic obstructive pulmonary disease.
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FIGURE LEGEND
Figure 13.1 Levels of natriuretic peptides in patients with suspected PTE.
The individual data points for levels of natriuretic peptides atrial natriuretic peptide
(ANP), B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide
(N-ANP) in patients with normal (N), high probability (H) and low/intermediate

































































































Outcome of V/Q scan
FIGURE LEGEND
Figure 13.2 Levels of natriuretic peptides in patients surviving or dying of PTE.
Comparisons between levels of natriuretic peptides atrial natriuretic peptide (ANP),
B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide (N-
ANP) in patients with high probability scans who were alive on discharge or died



















































Outcome of high probability scans
13.5 DISCUSSION
This study is the first to report elevated levels of natriuretic peptides in patients with
PTE. In addition although our numbers were small, patients with high probability
scans who died had significantly elevated levels of natriuretic peptides compared to
survivors. Perhaps suggesting that measuring levels of natriuretic peptides may have a
role in identifying patients with PTE at high risk of sudden death.
Natriuretic peptides are thought to be released as a consequence of a stretch coupling
mechanism and are elevated in a number of conditions characterised by elevations in
left and right atrial and ventricular pressures such as left ventricular failure
(McDonagh TA et al, 1998, Davidson NC et al, 1996), hypoxaemic cor pulmonale
(Lang CC et al, 1992) and primary pulmonary hypertension (Morice AH et al, 1990).
It is also known that acute hypoxia is a potent stimulus to ANP but not BNP (Cargill
RI et al, 1996) secretion and the hypoxaemia seen in patients with pulmonary
embolism may have contributed to elevated levels. We have also shown that levels of
the inactive N-terminal portion of the 126 amino acid prohormone of ANP , N-ANP
which is thought to reflect cardiac pressures over a more prolonged time period than
ANP and BNP is elevated (Buckley MG et al, 1990). The natriuretic peptides have
been shown to exert beneficial haemodynamic and endocrine effects by causing
vasodilatation and natriuresis as well as antagonising the effects of the renin
angiotensin system (Richards AM et al, 1988, Cargill RI et al, 1995). In pulmonary
thromboembolism elevated levels of ANP and BNP are likely to reflect the
cardiopulmonary consequences of PTE and may exert beneficial effects by causing
pulmonary vasodilatation and reducing right ventricular afterload (Cargil RI et al,
1995). Elevated levels of natriuretic peptides, which are known to promote a
natriuresis, offer an alternative explanation for the observation that patients with PTE
may present with collapse in the lavatory. It is possible that rather than the art of
290
defaecation dislodging a clot (Kollef MH et al, 1991) that elevated levels of natriuretic
peptides promote an intense desire to micturate.
A further interesting finding of this study was the significant difference in levels of
natriuretic peptides in patients who had high probability scans who died and those
who survived. Indeed levels of BNP were 15-100 times greater in patients with high
probability scans who died than our laboratory's upper limit of normal (Davidson NC
et al, 1996), suggesting a huge increase in right ventricular afterload. Perhaps
measurement of levels of these peptides in conjunction with a specific diagnostic test
may help to identify a group of patients at high risk who may benefit from more
intensive early intervention.
What are the possible clinical applications of our results? The advent of new
technology means that samples can be measured individually if required using a simple
rapid assay (Murdoch D et al, 1997). As an adjunct to diagnosis BNP levels could
easily be measured with rapid results providing information on the cardiopulmonary
sequelae of pulmonary embolism without the need for invasive monitoring or
specialised echocardiographic skills. In combination with either VQ scanning or
helical computerised tomogram scanning of the thorax it may be possible to receive
information regarding diagnosis and the degree of haemodynamic compromise. This in
turn may help to select a group of patients at "high risk" who could then be managed
in a high dependency unit or entered into trials to evaluate the role of thrombolysis in
a more systematic manner than has been done previously. Measuring natriuretic
peptide levels would also help us to identify patients with other conditions such as left
ventricular failure (McDonagh TA et al, 1998, Davidson NC et al, 1996) and cor
pulmonale (Lang CC et al, 1992) who have an increased mortality as a consequence
of PTE (Carson JL et al, 1992), where elevated levels reflect the cardiopulmonary
sequelae of both pulmonary embolism and the underlying disease process. Levels of
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these peptides could also be used to follow up patients diagnosed as having had a
pulmonary embolism as an indicator of clot resolution.
This paper reports for the first time elevated levels of natriuretic peptides in patients
with PTE. Further work is required to evaluate more fully the potential diagnostic
role of this peptide family, and in particular, whether measuring levels of natriuretic
peptides may prove to be useful in risk stratification and identification of patients with





The work of this thesis has encompassed a series of studies in both normal man and
patients with secondary pulmonary hypertension. The findings of these studies,
including the limitations of both methodology and the pitfalls of extrapolation are
discussed in Chapters 3 to 13. To avoid repetition the following synopsis refers to the
core findings of these studies with particular reference to potential further research.
The first aim was to elucidate more fully the response of the cardiopulmonary system
in normal man to hypoxaemia and hypercapnia. To help understand the importance of
these physiological stimuli in health and thus give us clues to the cardiopulmonary
sequelae of disease states characterised by these abnormalities of gaseous exchange.
In particular we have examined the acute hypoxic vasoconstrictor response in normal
man and the effects of hormonal manipulations of this response in health and disease.
The unassisted ascent of Mount Everest is testament to human endurance as well as a
reflection of the ability of the heart to resist the effects of hypoxaemia. In Chapter 3
we demonstrated, using pulsed wave Doppler echocardiography and
phonocardiography, that left ventricular systolic function and inotropic state are not
affected by severe hypoxaemia. This is in contrast to the effects of myocardial
ischaemia, such as occurs in myocardial infarction, and is consistent with the
experimental findings that it is the accumulation of anaerobic metabolites that impairs
myocardial contractility (Kihara Y et al, 1989). Acute hypoxaemia has been reported
as increasing, decreasing or having no effect on cardiac output in humans. Our
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findings of a dose dependent increase in cardiac output during hypoxaemia due to
chronotropic effects rather than increases in stroke volume are consistent with the
work of Phillips et al (Phillips et al, 1988). Indeed this physiological response to
hypoxaemia makes adaptive sense by compensating for decreased oxygen saturation
by increasing oxygen delivery. The apparent resistance of the inotropic function of the
human myocardium to hypoxaemia is reflected in the well preserved systolic function
of patients with cor pulmonale complicating COPD.
More recently diastolic function has emerged as an important determinant of overall
cardiovascular performance (Clarkson PBM et al, 1994). Impaired relaxation of the
myocardium occurs in a number of disease states including cor pulmonale secondary
to COPD where at least right ventricular function is impaired.(Marangoni S et al,
1992). We examined whether functional abnormalities such as acute hypoxaemia
could impair diastolic filling, in light of in vitro findings that acute hypoxaemia results
in abnormalities of intracellular calcium transport. Using pulsed-wave Doppler
echocardiography and phonocardiorgraphy we were able to demonstrate abnormalities
of both left and right ventricular diastolic filling. Although the abnormalities of right
ventricular diastolic function were of a similar magnitude to those seen in cor
pulmonale complicating COPD (Marangoni S et al, 1992) the effects on left
ventricular filling were less marked and more difficult to place in a clinical context.
These findings are consistent with in vitro work and suggest that hypoxaemia may be
an important aetiological factor in the development of diastolic filling abnormalities in
COPD
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In Chapter 4 we have demonstrated for the first time in normal man that hypercapnia
is capable of causing pulmonary vasoconstriction. We have shown that it is a weak
pulmonary vasoconstrictor when compared with hypoxaemia. In humans hypercapnia
may function as an intrinsic mechanism diverting blood from under ventilated areas of
the lung in an effort to maintain ventilation perfusion matching in much the same way
as hypoxaemia.
We have also examined the effects of a number of stimuli that have been suggested as
important factors in arrhythmogenesis in respiratory disease using a novel marker of
myocardial repolarisation, QT dispersion. This marker has been shown to be a
powerful index for the propensity to develop life threatening arrhythmias (Barr CS et
al, 1994). We have shown that both abnormalities of gaseous exchange and high
doses of the potent B-agonist fenoterol increase QTc dispersion. This may be
important in the aetiology of arrhythmias in acute severe asthma where B-agonists and
abnormalities of gaseous exchange co-exist. Further work needs to be performed to
see if this index predicts arrhythmia risk in patients with COPD.
The effects of hypoxaemia on the pulmonary vasculature have been studied
extensively since Von Euler and Liljestrand described the phenomenon of hypoxic
pulmonary vasoconstriction in the cat in 1946. Since then there have been great
strides in understanding some of the mechanisms of this response although the site of
the "oxygen sensor" and the exact way in which hypoxia results in pulmonary
vasoconstriction is unknown (NF Voelkel, 1996). We have examined the role of
ANG II in modulating this response in man in health and disease based on a series of
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observations suggesting that ANG II may play an important role. Firstly ANG II is a
potent pulmonary pressor in man (Segel N et al, 1960), levels of this peptide are
elevated in patients with hypoxaemic cor pulmonale (Peacock AJ et al, 1992) and
ACE inhibitors have been shown to attenuate the development of pulmonary
hypertension in chronically hypoxic rats (Zakheim RM et al, 1975). There is,
however, some concern that certain animal models may not be a good model for
pulmonary hypertension in man, where for example the reaction of the pulmonary
vasculature of the rat is very different to that of the human lung. (D Heath et al,
1996). Our studies were therefore limited to man and have been aided by the advent
of non-invasive methodology which has removed the ethical constraints of performing
some of these studies. In a series of studies in normal man we have demonstrated that
ANG II is capable of modulating the acute HPV response using infusions of the
angiotensin II receptor blocker saralasin and the orally active type 1 ANG II blocker
losartan. This work was then extended to patients with hypoxaemic cor pulmonale
where we demonstrated both modest beneficial pulmonary haemodynamic changes at
rest in addition to beneficial endocrine changes. A number of small acute dosing
studies have also been performed by other investigators studying pulmonary
haemodynamic changes in patients treated with ACE inhibitors. These have been
limited by small patient numbers and inconsistent inclusion criteria which may explain
their variable effect on pulmonary haemodynamics. In our small study which shows
only a modest pulmonary haemodynamic benefit we selected patients who had
vasoreactive pulmonary circulations (based on changes in their MPAP in response to
inspired oxygen in an analogous manner to asthmatics who are selected for
bronchoreactivity prior to studying the effects of new bronchodilators). The clinical
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significance of these results is unknown but the benefits from a pulmonary
haemodynamic point of view in end stage disease, when put in the context of other
studies, are likely to be modest and our current clinical practice is not to routinely use
these drugs in the treatment of pulmonary hypertension complicating COPD.
Undoubtedly, if we are to try and definitively answer the question as to whether
vasodilators have a role to play in managing secondary pulmonary hypertension
complicating COPD we must ask ourselves whether it is likely to have benefits.
Indeed there is some debate as to the importance of pulmonary hypertension in terms
of influencing morbidity and mortality in COPD. Our feeling is that it is important.
This is reflected in part by the finding that the level of MPAP is a good indicator of
prognosis in COPD. This has been shown in large studies by (Weitzenblum E et al,
1981) and Bishop et al (Bishop JM et al, 1984) who found that the level of
pulmonary hypertension was a predictor of mortality. Although the increases in
MPAP at rest are modest when compared with primary pulmonary hypertension it is
well recognised that these pressures can increase 20-30 mmHg during exercise, sleep
and respiratory failure resulting in increased right ventricular afterload and right heart
failure. Indeed activities such as climbing stairs or walking can result in significant
increases in pulmonary artery pressure which are perceived by the patient as
breathlessness suggesting that treatment that can attenuate this increase in pressure
may improve morbidity. It is recognised that oxygen therapy as well as improving
mortality can reverse or attenuate the development of pulmonary hypertension
(Weitzenblum E et al, 1985, Report of the Medical Research Council, 1981) and that
there is an association between a fall in MPAP and survival. It seems logical,
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therefore, not only to treat the underlying lung disease but also its pathophysiological
sequelae. To achieve this end we need to conduct large long term follow up studies
with concrete end points. In addition to using a vasodilator, that we feel is likely to
have beneficial effects on for example, haemodynamics and vascular remodelling. In
our eyes the "jury remains out" until such studies are conducted.
The development of pulmonary hypertension in hypoxic lung disease in the setting of
COPD is complex and reflects an interplay between acute hypoxic pulmonary
vasoconstriction, pulmonary vascular remodelling, ablation of the pulmonary vascular
bed and more recently the recognition that abnormalities of endothelial function are
likely to play an important role. Pulmonary vasoconstriction may result from
endothelial dysfunction with an imbalance of vasodilators such as nitric oxide and
prostacyclin and vasoconstrictors such as ANG II and ET-1. Indeed endothelium
dependant relaxation is reduced in chronically hypoxic rats and in man in end stage
chronic hypoxic lung disease endothelium dependant relaxation mediated via nitric
oxide is impaired (Dinh-Xuan AT et al, 1991). In man evidence suggests that basal
NO production is important in maintaining systemic vascular tone (Vallance P et al,
1989, Haynes WG et al, 1993) however, there is some debate as to the role of NO in
maintaining the low pressure pulmonary circulation in man where conflicting results
exist suggesting the possibility of species specificity. In chapter 12 we have shown for
the first time in a placebo controlled manner that basal nitric oxide generation plays an
important role in maintaining both systemic and pulmonary vascular tone as well as
cardiac output in normal man. These results concur with the findings of Dinx-Yuan et
al suggesting that compromise of the normal constitutive mechanisms of NO
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production may have direct pathophysiological consequences. The delivery of NO to
the lung in the treatment of hypoxic lung disease complicating COPD holds exciting
prospects.
Following identification of endothelial derived relaxing factors attention was again
turned to identifying potent vasoconstrictors. In 1988 ET-1 was isolated as the most
potent vasoconstrictor substance known to man. Growing evidence suggests that ET-
1 plays an important role in modulating the vascular response to hypoxaemia.
Although levels of this peptide were known to be elevated in primary pulmonary
hypertension (Stewart DJ et al, 1991) the effects of hypoxaemia on ET-1 release at
sea level and the effects of ET-1 on the pulmonary vascular bed in normal man were
not known. We have demonstrated for the first time that acute hypoxaemia results in
ET-1 release in normal man , that levels of this peptide are elevated in cor pulmonale
complicating COPD and that infusions of this peptide are capable of causing
pulmonary vasoconstriction in a dose dependant manner in the integrated
physiological system of man. It is possible that the potent vasoactive properties of
ET-1 may be responsible for some of the circulatory abnormalities seen during
hypoxaemia. In cor pulmonale the elevated levels of ET-1 may have adverse effects
by causing pulmonary vasoconstriction as well as affecting pulmonary vascular
remodelling. Additionally, we have also shown that ET-1 has adverse dose-dependant
effects on both systolic and diastolic left and right ventricular function. These novel
findings may be important in considering the pathophysiological role of ET-1 in both
cardiovascular and cardiopulmonary disease. Whether ET-1 acts as a mediator of
acute HPV is unknown. Support or otherwise for this hypothesis may be drawn from
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studies using endothelin receptor blockers which have been shown to attenuate
hypoxic pulmonary vasoconstriction (Oparil S et al, 1995) and prevent pulmonary
hypertension following chronic hypoxia in the rat (Eddahibi S et al, 1995). Work
needs to be performed using a human model to see if ET-1 receptor blockade
attenuates acute EDPV and in patients with hypoxaemic lung disease to see if ET-1
receptor blockade is of value in the treatment and or prevention of the
cardiopulmonary consequences of chronic hypoxaemia.
In the final chapter of this thesis we have examined the effects of pulmonary
thromboembolism on the natriuretic peptide system. In recent times there has been
much interest in the diagnostic potential of these peptides in left ventricular failure
where they have been shown to be sensitive markers of left ventricular systolic
dysfunction. This study is the first to our knowledge to report elevated levels of
natriuretic peptides in PTE in a group of 114 patients in whom the diagnosis was
suspected. Although we have no data from this study to support our observations we
believe that elevated levels of ANP, BNP and N-ANP are likely to reflect the well
documented cardiopulmonary consequences of PTE. Although the numbers were
small an interesting finding of this study was the significant difference in levels of
natriuretic peptides in patients who died of PTE compared to survivors. Indeed for
BNP, levels were 15-100 times greater in patients who died of PTE compared to our
laboratories upper limit of normal suggesting a huge increase in right ventricular
overload. The advent of new technology allows individual measurement of samples
with rapid results (Murdoch D et al, 1997) providing us with the potential to stratify
patients (who have also had a diagnostic test) into those at low and high risk of death
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without the need for invasive monitoring or specialised echocardiographic skills. This
in turn may help us to select patients at "high risk" who could be managed in a high
dependency unit or considered for thrombolysis.
To confirm the findings of this pilot study we are in the process of organising a 2
stage trial using spiral CT scanning as a diagnostic tool in addition to performing
echocardiography and measuring levels of natriuretic peptides of PTE in all patients
with suspected PTE. In addition we will perform right heart catheterisation to
measure pulmonary haemodynamic changes and indices of right ventricular
performance in a cohort of this group. If the findings of the first part of his study
confirm the findings of our pilot study we then plan to use natriuretic peptides as an
indicator of "high risk" in the acute situation and randomise high risk patients to
receive thrombolysis or heparin.
In conclusion. The pulmonary vascular bed is more than just a passive conduit for the
transport of blood from the right to the left side of the heart. The appreciation of the
role of vasoactive mediators, endothelial function and vascular remodelling hold the
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Left Ventricular Systolic Performance
During Acute Hypoxemia*
Robert I. Cargill, MB; David G. Kiely, MB; and Brian J. Lipworth MD
Study objective: Although some of the cardiovascular
responses to hypoxemia are well described, effects on
myocardial contractility have not been defined. Such
effects are readily assessed by noninvasive techniques
and we have therefore evaluated Doppler-phonoear-
diographic parameters of systolic left ventricular con¬
tractility in normal humans rendered hypoxemic.
Design: Eight healthy male volunteers were studied.
Parameters were measured after resting to achieve
baseline haemodynamics, after 20 min moderate hy¬
poxemia (Sa02 85 to 90%), and after a further 20 min
ofsevere hypoxemia (Sa02 75 to S0%). Hypoxemia was
induced by breathing a variable No/O-i mixture.
Measurements: Pulscd-wave Doppler analysis of as¬
cending aortic blood flow was combined with phono¬
cardiography to measure indices of systolic left ven¬
tricular function at baseline and at the end of each
period of hypoxemia.
Results: There was a significant, dose-related increase
in cardiac output in response to hypoxemia, from
5.5±0.26 L/min at baseline to 6.1±0.08 L/min during
moderate hypoxemia and to 7.0±0.23 L/min during
severe hypoxemia. Likewise, heart rate increased sig¬
nificantly in dose-related fashion although stroke vol¬
ume was not affected by either level of hypoxemia.
Hypoxemia had no significant effects on systolic or di¬
astolic blood pressures, but caused a significant re¬
duction in systemic vascular resistance. Aortic peak
and mean acceleration and acceleration time were not
affected by moderate or severe hypoxemia. Although
the systolic time intervals measured shortened signif¬
icantly during severe hypoxemia, these were 110 longer
significant when appropriate corrections were made
for heart rate.
Conclusions: Although cardiac output increases during
hypoxemia, this is due to increases in heart rate but not
to any effect on stroke volume. Parameters of left
ventricular systolic function and myocardial inotropic
state were also not affected by severe hypoxemia. Sys¬
tolic left ventricular function and myocardial contrac¬
tility are thus well preserved in normal humans during
hypoxemia. (CHEST 1995; 108:899-902)
Acc„lcan=mean aortic acceleration; Acc.,, ^-[>cak aortic
acceleration; AT=aortic acceleration time;CI-confidence
interval; CO=cardiac output; CSA=aortic cross-sectional
area; ET=Ieft ventricular ejection time; HR=heart rate;
MAP=inean arterial pressure; PEP=pre-ejection period;
QS2=lime interval from ECG Q wave to plionocardiogram
aortic closure sound; Sat C-owgen saturation; SV-st roke
volume; SVI=aortic systolic velocity integral; SVR=system-
ic vascular resistance
Key words: Doppler; hemodynamics; hypoxemia; systolic
function
Vute hypoxemia commonly occurs in humans as a
^ result of cardiorespiratory disease or adverse en¬
vironmental conditions. The cardiovascular responses
to the stress ofhypoxemia have therefore been of great
For editorial comment see page 889
interest. It is clear that acute hypoxemia induces pul¬
monary hypertension due to hypoxic pulmonary vaso¬
constriction,1 and increases heart rate (HR) and car¬
diac output (CO)2 without affecting systemic blood
pressure.2'3 To our knowledge, there is no information
*Froin the Department of Clinical Pharmacology, Ninewells Hos¬
pital and Medical School, University of Dundee, Scotland.
Manuscript received January 26,1995; revision accepted March 24.
available regarding the effects of hypoxemia on intrin¬
sic myocardial contractility during systole. Such effects
may well be important in the assessment of cardiovas¬
cular performance in subjects with fluctuating levels of
oxygenation.
The noninvasive assessment of systolic ventricular
function has become particularly important with the
advent of effective therapies for systolic heart failure.4
Although quantification of ejection fraction appears a
suitable measure of systolic function, this is subject to
other haemodynamic influences and does not directly
assess intrinsic myocardial contractility. This latter
component, however, can be assessed by a number of
other noninvasive methods, including echocardiogra¬
phy and phonocardiography. Echo-Doppler assess-
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IIR, (beats/min) 60±2.7 65±2.8' 71 ±4.3'!
SV, mL 102 ±7.5 102±4.7 104±4.9
CO, L/min 5.5±0.26 6.1 ±0.08* 7.0±0.23'1
Systolic BP, mm Hg 120 ±7.5 125±6.S 125±6.9
Diastolic BP, mm Hg 65±3.S 70±3.7 67±4.0
SVR, dyne's-cm"5 1,224±80 1,0!55 ±36' 979±59'
*Absolute values (mean±SEM) of heart rate (1 IK), stroke volume (SV),
cardiac output (CO), systolic blood pressure, diastolic blood pressure,
and systemic vascular resistance (SVR) at baseline and during moder¬
ate and severe hypoxemia.
'Significantly different from baseline.
'Significantly different from moderate hypoxemia.
ment of aortic flow acceleration parameters has been
used to study changes in overall ventricular perfor¬
mance and compares favorably with invasive measure¬
ments.6 Other systolic time intervals, derived in con¬
junction with phonocardiography, have also been pro¬
posed to reflect the inotropic state of the left ventricle'
and have been used extensively to monitor drug-
induced changes in myocardial contractility.8,9
We have therefore combined these two methods to
assess for the first time the effects ol moderate and
severe acute hypoxemia on parameters of systolic my¬
ocardial performance in humans.
Methods
Study Design
Eight normal male volunteers, age (mean±SKM) 29.3±2.9
years, were evaluated after giving informed written consent to the
study protocol, previously approved by the Tayside Committee lor
Medical Research Ethics. All subjects bad normal clinical history
and examination results, biochemical and hemotologic screening,
and 12-lead electrocardiogram.
All subjects attended the clinical laboratory at the same time of
day and remained in a supine position throughout the study. Once
stable resting hemodynamic parameters were obtained, subjects
were rendered hypoxemic by breathing a variable nitrogen/oxygen
mixture. Gases were mixed in a 25-L Douglas bag from separate
cylinders fitted with variable flow valves. Subjects breathed from
this reservoir through a mouthpiece connected by a series of one¬
way valves, while wearing an occlusive nose clip. Relative gas con¬
centrations were adjusted to achieve moderate hypoxemia with
pulse oximeter (CSI 503; Criticare Systems Inc; Waukesha, Wis)
monitoring of oxygen saturation (SaOo) between 85 and 90% for 20
mill followed by 20 min of severe hypoxemia with SaOs between 75
and 80%. Parameters were recorded at baseline and at the end of
each 20-min period of hypoxemia.
Measurements
Systemic Hemodynamic Variables: Heart rate was recorded by
electrocardiograph and rate was averaged over 60 s. Blood pressure
was monitored by semiautomatic sphygmomanometer (Vital Signs
Monitor; Critikon; Tampa, Fla). To measure CO, aortic cross-sec¬
tional area (CSA) was first measured by M-niode echocardiography
(Vingmed SD50; Vingmed Sound, Horten, Norway) from the left
parasternal Hew at the level of the aortic root. The aortic systolic
flow velocity integral (SVI) was then measured by computer-
assisted determination from the pulsed-wave Doppler profile of
aortic blood flow from the suprasternal notch allowing stroke vol¬
ume (SV=SVtxaortic cross-sectional area [CSA]) and CO to be
calculated on line. Systemic vascular resistance (SVR) was calcu¬
lated as (mean arterial pressure/CO)x80 dyne • s • cm"5.
Systolic Flow Parameters: Simultaneous lead II ECG, phono-
cardiogram (Siemens AC; Munich, Germany), and pulsed-wave
Doppler ascending aortic blood flow (Vingmed SD50) were
recorded. Doppler flow profiles were recorded with a nonimaging
2.0-MHz transducer with depth adjusted to give maximal velocity.
All measurements were recorded onto videotape with display sweep
speed at 100 mm/s and analyzed in triplicate at the end of the study.
From these recordings, the following variables were measured:
Aortic peak acceleration (Ac'tpM. aortic mean acceleration
(Accnrean), aortic acceleration time (AT) as time in milliseconds from
onset to peak aortic flow, left ventricular ejection time (ET) as time
in milliseconds from onset to end of systolic aortic flow, interval
from ECG Q wave to second heart sound on phonocardiogram
(QSj) and pre-ejection period (PEP) as time in milliseconds from
ECG Q wave to onset ofsystolic aortic flow. QSs, ET, and PEP were
also corrected for changes in HR according to standard criteria,10
and are denoted QSoc, ETc, and PEPc. We have previously shown
the coefficients of variability for measurement by these methods of
SVI to be 1.2%, Act-mean to be 12.5%, AT to be 6.4%, and ET to be
1.6%.11
Data Analysis
Comparisons were made by multifactorial analysis of variance
and where this was significant, Duncan's multiple-range testing was
used to determine where significant differences lay.12 A probabil¬




Moderate hypoxemia significantly increased CO by
0.7 L/min (95% confidence interval [CI], 0.1 to 1.3,1
and 111! by 4.5 beats/min (95% CI, 0.7 to 9.7) from
baseline. Severe hypoxemia caused further increases in
CO, 1.5 L/min (95% CI, 0.9 to 2.1), and HR, 10.5
beats/min (95% CI, 5.3 to 15.7) (Table 1). The SV,
however, was not affected by hypoxemia, while systolic
and diastolic blood pressure were unchanged during
moderate or severe hypoxemia (Table 1). SVR de¬
creased signi ficantly during moderate hypoxemia (-138
dyne-s-cirr5 from baseline; 95% CI, 2 to -274) and
during mild hypoxemia (-245 dyne-s-cirT5 from base¬
line; 95% CI, 109 to 381) (Table 1).
Systolic Flow Parameters
AcCpeap was similar at baseline (23.8±1.5 ms"!) and
after moderate (22.1± 1.0 ins"') and severe hypoxemia
(21.4±2.5 ms"1). Similarly, Accinean did not change
from baseline (10.9± 1.0 ms"1) during either moderate
(10.4± 1.0 ms"1) or severe hypoxemia (12.0± 1.8 ms"1).
AT was also unchanged from baseline (76±6.7 ms)
during either moderate (75±6.5 ms) or severe hypox¬
emia (73±6.7 ms).
Although similar at baseline (411 ±8 ms) and during
moderate hypoxemia (410±8 ms), QS2 was signifi-
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antly shortened during severe hypoxemia (3S5±11
ns). Likewise ET was similar at baseline (293 ±9 ms)
nd during moderate hypoxemia (289±10 ms) but
hortened significantly during severe hypoxemia
277± 10 ms). PEP was also significantly shorter dur-
ig severe hypoxemia (109±8 ms) than at baseline
11S±9 ms) or during moderate hypoxemia (121±8
as). However, following correction of these parame-
ers for HR changes, QSoc, ETc, or PEPc were not
ignificantly affected by either level of hypoxemia (Fig
)•
Discussion
We have shown that while causing significant
hanges in haemodynamic status, hypoxemia does not
npair left ventricular myocardial contractility in nor-
nal humans. It is therefore appropriate to consider
hese hemodynamic effects separately from indices of
ayocardial contractility.
These observations are in agreement with the work
fPhillips et al~ who also noted using similar methods,
hat increases in CO during hypoxemia were the result
f positive chronotropic effects rather than any effect
n SV. The pulsed-wave Doppler techniques we have
mployed, however, are more accurate and reproduc-
fle,13 comparing favorably with invasive measurement
f CO.141 Unlike Phillips et al,2 we did not control
'aCCL in our subjects. However, in view of the con-
ordant findings, it is unlikely that this has a bearing on
X) over the Sa02 range studied.
We also calculated SVR which fell significantly
uring hypoxemia. The consequent decrease in left
entricular afterload by itself might therefore be
xpected to cause an increase in SV. Since SV did not
hange during hypoxemia, this may have been limited
y the increased right ventricular afterload secondary
3 hypoxic pulmonary vasoconstriction. The constant
V we observed would therefore make it less likely that
lechanical factors in accordance with Starling's law
e, left ventricular distention) could have affected
/stolic left ventricular contractility during hypoxemia.
Of the Doppler aortic acceleration indices, both
lean and peak acceleration have been used as mark-
is of left ventricular contractility,16 although Accpeak
apears to be relatively less influenced by changes in
lading conditions.1. Furthermore, although Accyx.a^
eclines with increasing HR during pacing,18 the
[fects across the HR range of our study are small and
insistent with the nonsignificant decrease observed,
hus, hypoxemia has no significant effects on left
entricular contractility as measured by either peak or
lean aortic acceleration.
The systolic time intervals are easily measured and
peatable markers of the inotropic state of the left
mtricle,' which are in some cases more sensitive than




















Figure 1. Systolic time intervals, corrected for changes in heart
rate, showing QSsC, left ventricular ejection time (ETc), and pre-
ejection period (PEPc) at baseline and during moderate and severe
hypoxemia.
rate are well established and corrections appropriate to
the study population are easily applied.10 As measures
of the inotropic state of the myocardium, the systolic
time intervals are prolonged ifcontractility is impaired
with the QSo interval being relatively unaffected by
changes in loading conditions.' We found that hypox¬
emia did not affect heart rate corrected QSo, as has
been found previously by Bremner et al,20 or any of the
other systolic time intervals measured. We can there¬
fore be confident that hypoxemia did not significantly
alter left ventricular myocardial contractility.
It would appear therefore that systolic contractility
of normal human myocardium is relatively resistant to
the effects of hypoxemia. This is in contrast to the ef¬
fects of myocardial ischemia in which, in addition to
myocyte hypoxia, limitation of blood flow might also
allow accumulation of anaerobic metabolites that im¬
pair contractility.21 These findings may well be impor¬
tant in determining the relevance of hypoxemia as a
cause of abnormal cardiovascular performance in hy¬
poxemic patients as well as in assessing hemodynamic
responses to changes in oxygenation status.
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Adverse effects of hypoxaemia on diastolic filling
in humans
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1. Abnormalities of myocardial relaxation may occur
as a consequence of myocyte hypoxia. We have
therefore examined the effects of hypoxaemia on
right and left ventricular diastolic function in 10
healthy male subjects.
2. After resting to reach baseline haemodynamics,
subjects were rendered hypoxaemic by breathing a
variable nitrogen/oxygen mixture. Oxygen saturation
(Sa02) was maintained at 85-90% for 20min and
then at 75-80% for a further 20min. Haemodynamic
and diastolic filling parameters were measured non-
invasiveiy at baseline and at the end of each period of
hypoxaemia.
3. Diastolic filling of both ventricles was significantly
impaired by hypoxaemia. In comparison with base¬
line, left ventricular isovolumic relaxation time and
transmitral E-wave deceleration time corrected for
heart rate were significantly prolonged at Sa02
75-80%: mean difference in corrected relaxation
time, 9.8 ms (95% confidence interval 1-19); mean
difference in corrected deceleration time, 34 ms (95%
confidence interval 11-56). Similarly, right ventricular
isovolumic relaxation time and transtricuspid E-wave
deceleration time were significantly prolonged at
SaOj values of 75-80% compared with baseline:
mean difference in relaxation time, 20.3 ms (95%
confidence interval 3-38); mean difference in decele¬
ration time, 33 ms (95% confidence interval 11-55).
4. During hypoxaemia there were dose-related
increases in heart rate, cardiac output and mean
pulmonary artery pressure, but no effects on mean
arterial pressure.
5. Hypoxaemia significantly impairs relaxation of
left and right ventricles in normal humans. These
changes may reflect impairment of intracellular
calcium transport secondary to the effects of myocyte
hypoxia.
INTRODUCTION
Ventricular diastolic function has emerged as an
important determinant of overall cardiovascular
performance [1] and is a particularly sensitive
marker of cardiac dysfunction. Abnormal diastolic
function precedes systolic function abnormalities in
a number of disease states, including ischaemic
heart disease [2], hypertrophic cardiomyopathy [3]
and hypertensive left ventricular hypertrophy [4],
and may contribute to the morbidity of these
conditions.
Although most human studies of diastolic func¬
tion have evaluated filling patterns of the left
ventricle, the role of ventricular interaction during
diastole [5, 6] might indicate the need to consider
abnormalities of right and left ventricular filling
together. In this respect, right as well as left ventri¬
cular filling is impaired in patients with ischaemic
heart disease [7] and restrictive cardiomyopathy
[8], while patients with pulmonary hypertension
have paradoxical impairment of left ventricular fill¬
ing [6],
In many of the above conditions, it is difficult to
differentiate between structural cardiac changes (e.g.
ventricular remodelling) and functional abnor¬
malities related to changes in myocyte "metabolism.
Cellular hypoxia and the consequent abnormalities
of intracellular calcium transport [9] may impair
myocyte relaxation and hence may worsen overall
diastolic function. These cellular events may be of
relevance during myocardial ischaemia which leads
to local hypoxia, or if hypoxaemia accompanies
cardiopulmonary disease, as in cor pulmonale, in
which at least right ventricular diastolic function is
impaired [10].
To elucidate further the role of these functional
abnormalities during diastole, we have studied the
effects of hypoxaemia in normal humans. In this
setting structural abnormalities can be excluded,
allowing us to study in vivo the functional effects of




Ten normal male subjects, age (mean + SEM)
28.0+1.9 years, were evaluated. All subjects had no
Key words: diastolic function, Doppler analysis, hypoxaemia.
Abbreviations: CO, cardiac output; CSA, cross-sectional area; EDT, E-wave deceleration time; HR, heart rate; IVRT, isovolumic relaxation time; MAP, mean arterial pressure;
MPAP, mean pulmonary arterial pressure; PAT, pulmonary flow acderation time; SV, stroke volume; SVI, systolic flow velocity integral.
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abnormality on clinical history and examination,
biochemical and haematological screening or 12-
lead electrocardiogram. In addition, echocardio-
graphic study was required to be normal with high-
quality transmitral and transtricuspid Doppler flow
profiles. Informed written consent to the study
protocol, previously approved by the Tayside Com¬
mittee for Medical Research Ethics, was obtained
from each subject.
Study protocol
Subjects attended the clinical laboratory between
2 and 4h after lunch and remained in a supine
position, rolled slightly on to the left side. After
resting for at least 40min to obtain stable resting
haemodynamic parameters, subjects were rendered
hypoxaemic by breathing a variable mixture of
nitrogen and oxygen. The hypoxic gas mixture was
produced from separate cylinders of nitrogen and
oxygen fitted with variable flow valves, mixed in a
25-1 Douglas bag, from which subjects breathed
through a mouth-piece connected by a series of one¬
way valves, while wearing an occlusive nose clip.
Precise concentrations of each gas were adjusted to
achieve an oxygen saturation (Sa02) between 85%
and 90% for 20min followed by 20min with Sa02
between 75% and 80%. Haemodynamic variables
and diastolic filling parameters were recorded
at baseline and at the end of each period of
hypoxaemia at steady state.
Measurements
Oxygen saturation. Arterial blood oxygen satu¬
ration was continuously monitored by trans¬
cutaneous pulse oximetry (CSI 503; Criticare
Systems, Waukesha, WI, U.S.A.).
Haemodynamic variables. Heart rate (HR) was
recorded on an electrocardiograph trace and an
average rate over 1 min was obtained. To measure
cardiac output (CO), aortic cross-sectional area
(CSA) was first measured by M-mode echocardio¬
graphy (Vingmed SD50; Vingmed Sound, Horten,
Norway) from the left parasternal view at the level
of the aortic root. The aortic systolic flow velocity
integral (SVI) was then measured by on-line
computer-assisted determination from the pulsed-
wave Doppler profile of aortic blood flow from the
suprasternal notch. On-line determination of stroke
volume (SV = SVI x CSA) and hence CO, as the
product of SV and HR, was calculated.
Mean arterial pressure (MAP) was measured by
semiautomatic sphygmomanometer (Vital Signs
Monitor; Critikon, Tampa, FL, U.S.A.). Mean
pulmonary artery pressure (MPAP) was calculated
from measurement of pulmonary flow acceleration
time (PAT) by pulsed-wave Doppler echo¬
cardiography (Vingmed SD50) from the left third/
fourth intercostal space as previously described [11]
using the regression equation MPAP = 73— (0.42 x
PAT) [12]. The mean of three consistent waveforms
at each time point was used for the purpose of
analysis for each Doppler-derived parameter. We
have previously shown the short term coefficients of
variation for measurement of PAT and SVI to be
1.7% and 1.2% respectively [11],
Diastolic filling parameters. From the apical
window, pulsed-wave Doppler analysis of mitral and
tricuspid diastolic flow (Vingmed SD50) was com¬
bined with simultaneous phonocardiogram record¬
ing with the microphone (Siemens, Munich,
Germany) positioned over the second left intercostal
space. Measurements were all made on-line during
expiration and in triplicate, with a display sweep
speed of lOOmm/s. Transmitral and transtricuspid
flow was analysed after adjusting sample volume
depth to yield maximal E-wave velocities with
clearly defined flow velocity envelopes. Measure¬
ment of diastolic flow parameters from these signals
has previously been shown to be highly reproduc¬
ible and easily applicable in our own laboratory
[11] and also by other workers [13], Aortic and
pulmonary components of the second heart sound
were identified on the phonocardiogram trace by
noting closure artefacts from superimposition of
aortic and pulmonary Doppler flow profiles.
From diastolic transmitral and transtricuspid
flow, maximal velocities of the early (Eymsx) and
atrial (Aumai) components of flow were measured,
and the E/A ratio was calculated. In addition, the
E-wave deceleration time (EDT) was calculated as
the time in milliseconds from peak velocity to the
end of the E-wave. The isovolumic relaxation time
(IVRT) was calculated for the left ventricle as the
time in milliseconds from the aortic component of
the phonocardiogram second heart sound to the
onset of diastolic transmitral flow, and for the right
ventricle as the time from the pulmonary compo¬
nent of the phonocardiogram second heart sound to
the onset of diastolic transtricuspid flow. In our
hands, the short-term coefficients of variation for
these measurements were as follows: mitral EDT,
2.4%; tricuspid EDT, 4.8%; left ventricular IVRT,
1.1%; and right ventricular IVRT, 12.2%. Both time
intervals (EDT and IVRT) were also corrected for
changes in heart rate induced by hypoxaemia by
dividing by the square root of the simultaneous
ECG R-R interval; EDTc = EDT%/RR; IVRTc =
ivrt/^/rr.
Data analysis
Comparisons were made by multifactorial analy¬
sis of variance and, where this was significant,
Duncan's multiple-range testing was used to deter¬
mine where significant differences lay [14], A prob¬
ability value of f <0.05 (two-tailed) was considered
to be statistically significant. Data are presented in
the text and figures as means and SEM, and where
a difference between means is quoted the 95%
confidence interval for this difference is also given.
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Table I. Haemodynamic changes. Absolute values (means ± SEM) of
heart rate (HR). cardiac output (CO), mean arterial pressure (MAP) and
mean pulmonary artery pressure (MPAP) at each level of oxygenation.
"Significantly different from > 95%. tSignificantly different from 85-90%.
Sao,
>95% 85-90% 75-80%
HR (beats/min) 611 +19 67.9 + 3.5* 74.5 ± 4.5*t
CO (l/min) 5.59+0.28 6.41+0.41* 7.22 ± 0.42*t
MAP (mmHg) 85.0 + 3.4 87.2 ±3.3 88.1 ±3.6
MPAP (mmHg) 9.3 ±0.4 17.8 ±0.8* 27.6 ± 1.0*+
RESULTS
Haemodynamic changes
Hypoxaemia caused significant dose-related
increases in both HR and CO (Table 1). Hypoxic
pulmonary vasoconstriction resulted in an increase
in MPAP at both levels of hypoxaemia, while no
significant effects on systemic MAP were observed
(Table 1).
Diastolic function parameters
Transmitral E/A ratio decreased progressively in
response to increasing levels of hypoxaemia (Fig. la)
as a result of significant increases in A-wave
velocity, whereas E-wave velocity was unchanged
(Table 2). A similar pattern was observed for trans-
tricuspid flow, reductions in the E/A ratio in
response to hypoxaemia (Fig. la) being due to
increases in Aumax rather than changes in Eumax
(Table 3).
Absolute levels of left ventricular IVRT were not
significantly affected by hypoxaemia (Table 2)
although, after correction for changes in HR, IVRTc
was signficantly prolonged from baseline when Sa02
was 85-90% (mean difference 8.9 ms; 95% confidence
interval 1-16) and when Sao2 was 75-80% (mean
difference 9.8 ms; 95% confidence interval 1-19) (Fig.
1 b). In the right ventricle, IVRT was prolonged
when Sa02 was reduced to 75-80% but not at
85-90% (Table 3). In comparison with baseline,
right ventricular IVRTc was prolonged by hypox¬
aemia at Sa02 75-80% (mean difference 20.3 ms;
95% confidence interval 3-38) but not at Sa02
85-90% (Fig. 1 b).
Mitral EDT was only prolonged at SaOz 75-80%
(Table 2). After correction for HR, EDTc was also
significantly prolonged from baseline at Sa02 75-
80% (mean difference 34 ms; 95% confidence interval
11-57) (Fig. lc). Tricuspid EDT was similarly pro¬
longed by hypoxaemia (Table 3), and tricuspid
EDTc was significantly prolonged from baseline
only at Sao2 75-80% (mean difference 33 ms; 95%
confidence interval 11-55) (Fig. lc).
Comparison of changes between left and right
ventricles showed that, as a percentage of baseline
Fig. I. Parameters of left (□) and right (g3) ventricular diastolic
function showing (a) E/A velocity ratio, (b) heart rate-corrected
isovolumic relaxation time (IVRTc) and (c) heart rate-corrected
E-wave deceleration time (EDTc). Values are means and SEM. "Signifi¬
cant difference from baseline (Sao, > 95%). tSignificant difference from Sao,
85-90%.
IVRTc, at Sa02 85-90% right ventricular IVRTc
increased by 51% compared with an increase in left
ventricular IVRTc of 13% (mean difference 38%;
95% confidence interval —11 to 100; not signifi¬
cant). At the higher level of hypoxaemia where Sa02
was reduced to 75-80%, right ventricular IVRTc
increased by 72% compared with an increase in left
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Table 2. Left ventricular diastolic filling parameters. Absolute values
(means+ SEM) of maximal transmitral early (Ew) and atrial (Aw) wave
velocity, E/A ratio, left ventricular isovolumic relaxation time (IVRT) and
E-wave deceleration time (EDT) at each level of oxygenation. "Significantly
different from > 95%. ^Significantly different from 85-90%.
Sao,
>95% 85-90% 75-80%
Ew (m/s) 0.70 + 0.02 0.69 ±0.02 0.71+0.04
Aw (m/s) 0.48 + 0.01 0.48 + 0.02* 0.57 + 0.03*
E/A 1.53 ±0.03 1.44 ±0.06' l.24 + 0.02*f
IVRT (ms) 70.7 + 6.0 74.8 + 6.5 715 + 7.1
EDT (ms) 146 ±5.6 150 + 8.3 168 ±14.4*
Table 3. Right ventricular diastolic filling parameters. Absolute values
(means+ SEM) of maximal transtricuspid early (Ew;) and atrial (Aw)
wave velocity, E/A ratio, right ventricular isovolumic relaxation time (IVRT)
and E-wave deceleration time (EDT] at each level of oxygenation. "Signifi¬
cantly different from > 95%. tSignificantly different from 85-90%.
Sao,
>95% 85-90% 75-80%
Evmax (m/s) 0.57 ±0.02 0.61 +0.03 0.61 ±0.05
Avmix (m/s) 0.36 ±0.01 0.44 + 0.03* 0.50 + 0.04*
E/A 1.57 ±0.06 1.41+0.08* 1.22 ±0.07*1
IVRT (ms) 40.1+4.3 50.0 + 7.6 52.9 + 8.9*
EDT (ms) 150 ± 6.1 151 ±7.0 170 ±8.3*
ventricular IVRTc of 14% (mean difference 58%;
95% confidence interval 6-109; P<0.05).
DISCUSSION
The present study has demonstrated abnorma¬
lities of left and right ventricular filling during
hypoxaemia in normal humans. While the pattern of
changes in E/A ratios might conceivably be
explained solely by changes in HR, the prolongation
of IVRT and EDT on both sides of the heart
indicate abnormal diastolic function, particularly
evident when these parameters are corrected for
heart rate. These haemodynamic changes are in
agreement with previous work showing that chrono¬
tropic rather than inotropic effects of hypoxaemia
are responsible for the increment in CO [15].
IVRT is widely accepted as a measure of active
myocardial relaxation, and its prolongation indi¬
cates impaired diastolic function [16]. Conversely,
EDT represents a measure of myocardial com¬
pliance and is shortened when compliance is de¬
creased [16]. However, it is important to realize
that impairment of relaxation has confounding
effects on EDT. In this situation, active ventricular
relaxation continues while passive filling takes place.
This paradoxically increases apparent ventricular
compliance with consequent lengthening of the EDT
[17]. Thus, the pattern of abnormality described in
the present study is one of impaired myocardial
relaxation.
These findings in humans therefore confirm pre¬
viously described abnormalities of myocardial relax¬
ation observed during hypoxia in laboratory animal
systems. Studies using isolated ventricular papillary
muscle have demonstrated marked impairment of
relaxation during hypoxia [18, 19], while in isolated
intact heart preparations hypoxia is associated with
an increase in ventricular chamber stiffness [20] as
well as impairment of relaxation during diastole
[9, 20]. The mechanisms whereby hypoxaemia
might produce these effects have been extensively
studied, and two possible theories are briefly
considered.
Firstly, the effects of hypoxia on intracellular
calcium transport may be important. Cellular
hypoxia has been shown to increase intracellular
calcium concentrations during diastole [9] as a
result of decreased calcium uptake by the sarco¬
plasmic reticulum [21] and perhaps other ion
channel-mediated effects [22]. Myocardial relaxa¬
tion depends critically on rapid removal of free
intracellular calcium ions to reverse quickly the
calcium-facilitated actin-myosin interaction which
would otherwise sustain contraction [23], It is likely
that hypoxia delays this process, so allowing con¬
tractile elements within the cell to remain cross-
linked into diastole and impairing relaxation.
The second possibility is a mechanical one,
related to the concept of ventricular interaction
across the interventricular septum [6], Hypoxaemia,
by inducing pulmonary hypertension [24], increases
right ventricular afterload, which might cause
dynamic changes in septal motion. This pattern has
been observed in other forms of pulmonary hyper¬
tension [25, 26] but has only been studied at much
higher pulmonary artery pressures than we
achieved. Although we did not study this phenom¬
enon directly in the present study, it is conceivable
that abnormal septal motion, which is associated
with impairment of left ventricular filling [6], might
explain some of the abnormalities observed.
Interestingly, the effects of pulmonary hyper¬
tension alone on right ventricular diastolic function
have not been studied, although this is impaired in
cor pulmonale [10], in which either pulmonary
hypertension or hypoxaemia might play a role. In
the present study, we have shown that, while both
right and left ventricular relaxation is impaired by
hypoxaemia, prolongation of IVRTc as a percentage
of baseline is more marked in the right ventricle
than in the left. Obviously, baseline IVRTc was
shorter in the right ventricle (with values in the
present study similar to those previously published
although recorded by a different method [10]), but
increases in pulmonary artery pressure would be
expected to prolong systolic pulmonary artery flow.
This would delay pulmonary valve closure and in
fact shorten right ventricular IVRT. This effect
would, however, need to be balanced by the possibi¬
lity that increased pulmonary artery pressure would
alter myocyte loading conditions in the right
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ventricle, which may directly impair relaxation, as
has been shown to occur in the left ventricle [27],
The finding that right ventricular IVRTc was pro¬
longed proportionately more than left ventricular
IVRTc may indicate that right ventricular relaxation
is more sensitive to the adverse affects of
hypoxaemia.
It would appear therefore that, as is the case in
vitro, hypoxaemia signficantly impairs myocardial
relaxation in humans and that these abnormalities
are of similar magnitude to the diastolic filling
abnormalities observed in some disease states.
IVRTc in the right ventricle was prolonged by
20.3 ms, which approaches the level of abnormality
detected in patients with hypoxaemic chronic
obstructive pulmonary disease and pulmonary
hypertension [10]. In the left ventricle, the observed
lengthening of IVRTc (by 9.8 ms) during hypox¬
aemia is more difficult to place in a clinical context,
although is similar in magnitude to the adverse
effects of very high-dose infusions of angiotensin II
[28], The haemodynamic significance of these effects
is therefore speculative at present as clinical studies
are lacking. Whether treating hypoxaemic patients
with oxygen would actually improve diastolic func¬
tion has not been studied, but it is conceivable that
this is one way in which oxygen therapy is of benefit
to such patients.
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Abnormal myocardial repolarisation in response
to hypoxaemia and fenoterol
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Background - Prolongation of the QTc
interval has been associated with cardiac
dysrhythmias and sudden death. QTc
dispersion (interlead variability in QTc
interval) has recently been proposed as
being a more sensitive marker of re-
polarisation abnormalities and shown to
be a more specific index of arrhythmia
risk. Although hypoxaemia and fenoterol
have previously been shown to prolong
the QTc interval, this does not reflect
regional myocardial repolarisation ab¬
normalities.
Methods - Electrophysiological effects
were measured at baseline and after 30
minutes steady state hypoxaemia at an
arterial oxygen saturation (Sa02) of 75—
80% (study 1) and at baseline then 30 min¬
utes after inhaled fenoterol 2-4 mg (study
2). From the ECG, lead II corrected QT
interval (QTc) and overall corrected QT
dispersion were measured using a com¬
puter linked digitising tablet according to
standard criteria.
Results — QTc dispersion was increased
during hypoxia compared with baseline
values (mean (SE) 69 (6) ms v 50 (5) ms)
and after fenoterol compared with baseline
(79 (13) v 46 (4) ms), respectively. There
was also an increase in QTc interval and
heart rate after fenoterol (493 (23) v 420
(6) ms and 98 (3) v 71 (6) bpm, re¬
spectively). The heart rate was increased
during hypoxaemia compared with base¬
line (78 (3) v 64 (2) bpm), but no change
occurred in the QTc interval.
Conclusions - Both hypoxaemia and fen¬
oterol cause myocardial repolarisation ab¬
normalities in man in terms of increased
QTc dispersion, but only fenoterol in¬
creased the QTc interval. This may be
relevant in the aetiology of arrhythmias in
patients with acute severe asthma where
|! agonist therapy and hypoxaemia coexist.
(Thorax 1995;50:1062-1066)
Keywords: hypoxaemia, (i agonist, QT dispersion.
The surface electrocardiogram has been in¬
vestigated for its ability to identify those
patients at risk of arrhythmias and as such
represents a cheap, non-invasive and simple
method. Traditionally the single measurement
of QTc interval has been used to measure
the recovery of ventricular excitability, widely
recognised to be the most important factor in
arrhythmogenesis.
Prolongation of the QT interval has been
shown to be a predictor of sudden death in
alcoholic cirrhosis,' sudden cardiovascular
mortality in apparently healthy individuals,2 as
well as sudden death in patients with ischaemic
heart disease.3 Recently, however, QTc dis¬
persion (interlcad variability in QTc interval)
has been suggested as a more sensitive and
specific marker as it measures differences in
regional repolarisation and has been shown
to be increased in patients with hypertrophic
obstructive cardiomyography (HOCM) at risk
from ventricular arrhythmias,4 and in patients
with long QT intervals it distinguished between
those with ventricular arrhythmias and those
without.5 It has also been found to be a more
sensitive and specific marker of sudden death
in heart failure than QTc interval alone.6
Cardiac arrhythmias are a very common
linding in patients with respiratory failure
and chronic obstructive pulmonary disease
(COPD).7'' It has been shown that depressed
left ventricular diastolic performance is a pre¬
dictive factor for ventricular arrhythmias during
respiratoiy failure from COPD, although the
poor definition of the statistical model suggests
that other factors contribute to the genesis of
these arrhythmias.10 In this respect Stewart ct
aln have recently shown diat QTc prolongation
is a better predictor of death in patients with
COPD than hypoxaemia, hypercapnia, or
spirometric measurements. Interest has also
surrounded the use of (I agonists which have
inotropic, chronotropic, and electrophysio¬
logical effects. In particular, the epidemio¬
logical observation that fenoterol was as¬
sociated with an increased risk of death in
patients with severe asthma'2" has suggested
that this drug may predispose these individuals
to arrhythmias. Interestingly, the use of high
dose nebulised [5 agonists has been associated
with an increased risk of cardiac arrhythmias
in patients with COPD,'4 and a further study
revealed that normoxaemic patients with
COPD had a higher frequency of ventricular
ectopy during treatment with high dose than
with low dose terbutaline, although 24 hour
Holter recordings did not reveal an increase in
significant arrhythmias.15
We have therefore, for the first time, looked
at the effects of two separate stimuli which
have been suggested as important factors in
arrhythmogenesis in respiratory disease —
myocardial ncpolarisation 1063
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Sixteen healthy male volunteers aged 21-37
years were studied. There was no abnormality
present on clinical history, clinical examination,
12 lead ECG, biochemical, or haematological
screening. Patients abstained from alcohol and
caffeine for a 24 hour period prior to the study.
Informed written consent to the study protocol,
previously approved by the Tayside committee
for medical research ethics, was obtained.
STUDY PROTOCOL
Study 1
Eight subjects were studied. An intravenous
cannula was inserted into the left forearm for
blood sampling after which they rested supine
for at least 30 minutes to obtain stable resting
haemodynamics (T0). They were then rendered
hypoxaemic for 30 minutes by breathing a
variable mixture of oxygen and nitrogen which
rendered their arterial oxygen saturation be¬
tween 75% and 80% (T,). The hypoxic gas
mixture was produced from separate cylinders
of nitrogen and oxygen fitted with variable flow
valves. Gases were mixed in a 25 litre Douglas
bag, from which the subjects breathed through
a mouthpiece connected by a series of one way
valves while wearing an occlusive nose clip. A
12 lead ECG and venous blood samples for
catecholamine and serum potassium assays
were taken at T0 and T,.
Study 2
Eight subjects were studied. An intravenous
cannula was inserted into the left forearm for
blood sampling after which they rested supine
for at least 30 minutes to obtain stable resting
haemodyamics (T0)- Patients were then given
fenoterol 2-4 mg from a metered dose inhaler
(MDI) via a spacer device (12x0-2mg ac¬
tuations widt three inhalations per actuation).
A 12 lead ECG and venous blood samples for
serum potassium were taken at T0 and 30
minutes after inhalation of fenoterol (T,).
MEASUREMENTS
QT interval
The ECGs from both study days were analysed
in random order after completion of the study
by an investigator who was not involved during
either of the study days and who was blinded
with respect to the stimulus the volunteers
had received. If feasible, the QT interval was
measured in all leads of a surface 12 lead ECG
(paper speed = 25 mm/s). Three consecutive
cycles were measured in each lead where pos¬
sible and die mean value was taken as rep¬
resenting the QT interval in diat lead. The QT














Figure 1 Effects of hypoxaemia and fenoterol on QTc interval and QTc dispersion. (A) Absolute QTc interval
measured at baseline and after fenoterol; *p<0-01 fcnoterol treatment versus baseline. (B) Absolute QTc interval
measured at baseline and during hypoxaemia. (C) Absolute QTc dispersion measured at baseline and after fcnoterol;
*p<0-05 fenoterol treatment versus baseline. (D) Absolute QTc dispersion measured at baseline and during hypoxaemia;
*p<() 05 fcnoterol treatment versus baseline. Values for the same patient arc connected and the mean and standard error
of the mean arc represented as clear circles and error bars, respectively.
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criteria16 from the onset of the QRS complex
to the end of the T wave - that is, a return to
the T/P baseline. In the presence of U waves
the QT interval was measured to the nadir of
the curve between the T and the U waves. QT
intervals were then corrected for rate using
Bazett's formula (QTc = QT/y RR).17
QTc dispersion was defined as the difference
between the maximum and minimum QTc
interval measured during analysis of all leads
of the surface ECG.16 The measurements were
made using a computer linked digitising tab¬
let.18 To compare the standard measure of QTc
interval widi QTc dispersion we calculated the
average of three QT intervals in lead II and
corrected for heart rate using Bazett's formula
(QTc = QT//RR).
Heart rate
This was calculated from five consecutive R to
R intervals in lead II.
Oxygenation
Arterial blood oxygen was continuously mon¬
itored by transcutaneous oximetry (CSI 503,


























Samples for serum potassium were collected in
chilled lithium-heparin tubes and centrifuged
at 4°C immediately. The separated plasma was
stored at — 20°C until measured in one batch
at the end of the study using an internal caesium
standard flame photometer (Instrumentation
Laboratory, Milan, Italy).
Figure 2 Effects of hypoxacmia atid fcnoterol on heart
rate and serum potassium. (A) Left: absolute heart rate
measured at baseline (TP and during hypoxaemia (M).
Right: absolute heart rate measured at baseline (Tl) and
after fenoterol (ffl). *p<0-05 difference between
hypoxacmia and baseline; fp<0 ()l difference between
fenoterol and baseline. (B) Left: serum potassium
measured at baseline (Q) and during hypoxaemia (W).
Right: scrum potassium measured at baseline fT~U and
after fenolcrol (ffl). *p<0-0001 difference between
fenoterol and baseline.
Catecholamines
Samples for adrenaline and noradrenaline were
collected in chilled lithium-heparin tubes and
centrifuged immediately at 4°C. Separated
plasma was stored at — 70°C and assayed in
one batch at the end of the study using the
double isotope radiocnzymatic method.19
DATA ANALYSIS
Comparison of values between points was
made by multifactorial analysis of variance
(MANOVA).20 A probability value of p<0-05
(two tailed) was considered to be statistically
significant. Data are presented as means and
the standard error of the mean (SB).
Results
QTc interval
Treatment with fenoterol significantly (p<0-01)
increased QTc interval compared with baseline
(493 (23) v 420 (6) ms; fig 1A). Hypoxaemia,
however, had no significant effect (fig. IB).
QTc dispersion
Fenoterol significantly (p<0 05) increased QTc
dispersion compared with baseline (79(13) v
46(4) ms; fig 1C). Similarly, hypoxaemia sig¬
nificantly (p<0-05) increased QTc dispersion
compared with baseline (69 (6) v 50 (5) ms;
fig ID).
Heart rate
The heart rate was significantly increased by
both fenoterol (98 (3) v 71 (6) bpm; p<0-01)
and hypoxaemia (78 (3) v 64 (2) bpm; p<0-05)
compared with baseline values (fig 2A).
Scrum potassium
Treatment with fenoterol resulted in a sig¬
nificant (p<0-0001) reduction in serum potas¬
sium compared with baseline values
(2-93 (0-12) v 3-86 (0-07) mmol/1). Hypox¬
aemia, however, had no significant effect (fig
2B).
Catecholamines
Hypoxaemia had no significant effect on either
noradrenaline (4-75 (0-65) v3-97 (0-36) nmol/1)
or adrenaline (0-22 (0 02) v 0-16 (0 02) nniol/
1) compared with baseline values.
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Discussion
Our results show that both hypoxaemia and
fenoterol significantly increase QTc dispersion
in healthy volunteers, suggesting that these two
stimuli cause abnormalities in myocardial re-
polarisation. However, only fenoterol sig¬
nificantly increased QTc interval and
significantly decreased the serum potassium
concentration compared with baseline -
changes which have previously been docu¬
mented in normal and asthmatic subjects.2122
It is thought that QTc dispersion reflects
regional variation in ventricular repolarisation
and existing evidence suggests that it is a power¬
ful index of the propensity for developing life
threatening arrhythmias,4 6 The underlying
mechanism responsible for an increase in QTc
dispersion is not known, although it has been
suggested that fibrosis may be important.6 How¬
ever, as our results suggest, dynamic physio¬
logical abnormalities must play a part as both
stimuli arc acute and self limiting in nature. In¬
deed, our results are not the first to implicate
dynamic variables as having an important role
in altering QTc dispersion; Moreno ct al2'' have
shown that QTc dispersion is decreased fol¬
lowing successful thrombolysis after myocardial
infarction, demonstrating (hat localised isch-
aemia affects regional repolarisation. In the con¬
text of congestive cardiac failure no correlation
was noted between increased QTc dispersion
and catecholamine levels.6 We were unable to
show any increase in circulating catecholamines
during acute hypoxia, although this was a small
study and as such has an inherently large type 2
error. It is known that large oral doses of (I agon¬
ists do not affect catecholamine levels;2'1 they
were not measured in this study although
Scheinin ct al have shown that noradrenaline
was Ilose dependently increased by fenoterol
treatment.25 It may be that hypoxia and (3 agon¬
ists have their effects on QTc dispersion by al¬
tering autonomic tone, although it is likely that
local metabolic and electrical disturbances may
play a pan. In this respect, hypokalemia affects
the electrical stability of cell membranes and is
known to predispose individuals to arrhythmias
and may explain, at least in part, why fenoterol
increases QTc dispersion.
Aldtough hypoxia did not significantly in¬
crease QTc interval in this study, this phe¬
nomenon has previously been documented.21
However, it may be that QTc dispersion is a
more sensitive marker of abnormal myocardial
repolarisation than QTc interval alone.
With respect to our methodology there are
undoubtedly limitations in all studies meas¬
uring QTc dispersion. We used a computer
linked digitising tablet which has been shown by
other investigators to be a reliable and accurate
measure of QTc dispersion.18 Probably the
most important aspect concerning method¬
ology is the protocol to define the end of the
T wave. We have thus used the most commonly
used protocol16 and one which has been shown
to correlate with risk of arrhythmia and sudden
death. We also measured the QTc interval in the
majority of leads in each individual, although
occasionally leads were omitted due to difficulty
defining the end of the T wave. We used routine
ECGs to measure QTc dispersion since we felt
this would have most clinical relevance and,
indeed, no substantial evidence suggests that
simultaneous EGG recording has any benefits.
What is the clinical relevance of QTc dis¬
persion and what, if any, are its merits com¬
pared with our traditional measure of
ventricular repolarisation, QTc interval? Firstly,
much time and effort has been expended to
find markers of mortality in hypoxic chronic
lung disease and to find high risk patients
who may benefit from further investigation or
treatment. It would certainly be of interest if
QTc dispersion correlates with risk of sudden
death in patients with cor pulmonale. The
use of fenoterol has been associated with an
increased incidence of asthma deaths. Could
it be possible that this observation is due to
arrhythmias occurring in the presence of ab¬
normal myocardial repolarisation? It has been
suggested that certain individuals may be more
susceptible to the effects of [3 agonists. In this
respect it is interesting to note the large increase
in QTc dispersion that occurred in two in¬
dividuals in response to inhaled fenoterol (fig
1C). Although we exceeded the standard dose
of fenoterol suggested by the manufacturer, in
an asthmatic attack very high doses of (3 agonists
may have to be taken26 and, indeed, the British
Thoracic Society guidelines recommend up to
50 puffs of a [3 agonist from a metered dose
inhaler during a severe attack.27 We have also
shown that acute hypoxaemia increases QTc
dispersion suggesting that this may have a part
to play in arrhythmogenesis in acute asthma,
although we can infer little concerning chronic
hypoxia. Compared with the QTc interval, QTc
dispersion, which measures ventricular re¬
polarisation in several leads, may be a better
indicator of arrhythmia risk. Indeed, it has been
shown to be both a more sensitive and specific
marker of sudden death than QTc interval
alone.6 Amiodarone which is known to prolong
QTc interval is used in the treatment of vent¬
ricular tachycardia. It is perhaps no coincidence
that this drug also reduces QTc dispersion.28
Thus, we have shown for the first time that
two stimuli thought to be associated with
arrhythmogenesis in respiratory disease in¬
crease QTc dispersion - namely, hypoxia and
P agonists. It seems likely that this index of
abnormal myocardial repolarisation will have
important implications in terms of risk strat¬
ification of patients and in the development of
new drugs and the investigation of current
drugs in respiratory medicine.
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ffects of Hypercapnia on
lemodynamic, Inotropic, Lusitropic, and
ilectrophysiologic Indices in Humans*
jvid G. Kiclt/, MB; Robert 1. Cargill, MB; and Brian f. Lipworth, MD
Study objective: The inotropic, lusitropic, and electrophysiologic elTects of acute hypercapnia in hu¬
mans are not known. Although the effects of hypercapnia on the systemic circulation have been well
documented, there is still some debate as to whether hypercapnia causes true pulmonary vasocon¬
striction in vivo. We have therefore evaluated the effects of acute hypercapnia on these cardiac in¬
dices and the interaction of hypercapnia with the systemic anil pulmonary vascular beds in humans.
Participants and interventions: Eight healthy male volunteers were studied using Doppler echocar¬
diography. After resting for at least 30 min to achieve baseline hemodynamic parameters (To), they
were rendered hypercapnic to aclieive an end-tidal carbon dioxide (C X ).,) ol 7 kPa for 30 min by
breathing a variable mixture of COo/air (T|). They were restudieil after 30 min recovery breathing
air (T2). Hemodynamic, diastolic, and systolic flow parameters, QT dispersion (maximum-minimum
QT interval measured in a 12-lead ECG), and venous blood samples for plasma renin activity (l'KA),
angiotensin II (ANG II), anil aldosterone (ALDO) were measured at each lime point.
Results: Hypercapnia compared with placebo significantly increased mean pulmonary artery pres¬
sure 14±1 vs 9±I mm Hg and pulmonary vascular resistance 17I±17 vs 129±17 dync-s-cm , re¬
spectively. Heart rate, stroke volume, cardiac output, and mean arterial 151' were increased by hy¬
percapnia. Indexes of systolic function, namely peak aortic velocity and aortic mean and peak
acceleration, were unaffected by hypercapnia. Similarly, hypercapnia hail no effect 011 lusitropic
indexes reflected by its lack ofeffect 011 isovolumic relaxation time, mitral E-yvave deceleration time,
and mitral E/A yvave ratio. Hypereapnia yvas found to significantly increase both QTe interval and
QT dispersion: 428±8 vs 411 ±3 111s and 48±2 vs 33±4 ms, respectively. There yvas no significant
effect of hypercapnia 011 PI5A, ANG II, or ALDO.
Conclusion: Thus, acute hypercapnia appears to have 110 adverse inotropic or lusitropic effects 011
cardiac function, although repolarization abnormalities, reflected by an increase in QT dispersion,
and its effects on pulmonary vasoconstriction may have important sequelae in man.
(CUEST 1.996'- 109:1215-21)
Key words: electrophysiologic; hvpercapnia; inotropic; lusitropic; pulmonary circulation
Abbreviations: Accmean=aortic mean acceleration; Acc,y.a^-aortic peak acceleration; ALDO=aldosterone; ANG
II=angiotensin II; Avmax=maximal velocity of atrial transmitral flow; Av^d—aortic peak velocity; CO=cardiac output;
CCb=carbon dioxide; DBI'=diastolic arterial BP; EDT=early transmitral flow deceleration time; EDTc=early transmitral
flow deceleration time adjusted for heart rate; ETc02=end-tidal carbon dioxide; Ev,nax=maximal velocity of early transmi¬
tral flow; HR=heart rate; IYKT- isovolumic relaxation time; IVRTc=isovoIumic relaxation time adjusted for heart rate;
MAP=mean arterial BP; MPAP=mean pulmonary aiteiy pressure; PAT=pulmonaty acceleration time; PRA=plasma renin
activity; PVR=pulmonary vascular resistance; RAS=renin angiotensin system; RIA= radioimmunoassay; SBP=systoIic arte¬
rial BP; SV=stroke volume; SVI=aortic systolic velocit)' integral; SVR=systemic vascular resistance
ypercapnia is a well-recognized consequence of a
variety ol disease states. It is frequently encoun-
red in the context of chronic obstructive airways
:sease and more unusually in disorders of the nervous
id musculoskeletal systems. In recent years, there lias
sen much interest in the effects of hypercapnia in
leslhetic practice after the finding that mechanical
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ital and Medical School, University ol Dundee, Dundee, Scot-
md, United Kingdom.
anuscript receixed August 15, 1995; rexision accepted Noxem-
ir 21.
ventilation may contribute to increased morbidity and
mortality as a consequence of barotrauma.1"3 This has
resulted in a volume- and pressure-limited ventilation
strategy and elevated levels of carbon dioxide (CCL),
so-called permissive hypercapnia.4'0
The effects of hypercapnia on the systemic circula¬
tion have been well documented,6,' although there is
still some debate as to whether COo causes true pul¬
monary vasoconstriction in vivo. Many of these
studies were performed more than 20 years ago and
findings were sometimes based purely on changes in
mean pulmonary artery pressure (MPAP) and where
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pulmonary'vascular resistance (PVR) was measured, it
was derived from cardiac outputs (COs) calculated
using the Fick principle, with errors a consequence ol
a changing state o( respiratory gas exchange.14,15
The advent of newer noninvasive methods such as
Doppler echocardiography lias permitted a more de¬
tailed examination not only of hemodynamic effects
but also of inotropic16,1' and lusitropic1S19 activity. A
novel marker of abnormal myocardial repolarization,
QT dispersion, ,21 has also provided us with informa¬
tion regarding the electrophysiologic effects of differ¬
ent stimuli.
We have therefore evaluated for the first time (to our
knowledge) the effects of acute hypercapnia on ino¬
tropic, lusitropic, and repolarization indexes and reex¬
amined the interaction between hypercapnia and the




Eight 1 lealthy male volunteers, mean age 24 years (range, 21 to
34 years), were studied. There was no abnormality present on clin¬
ical history, examination, 12-lead ECG, echocardiography, bio¬
chemical screening, or hematologic screening. Informed written
consent to the study protocol, previously approved by the Tayside
Committee for Medical Research Ethics, was obtained.
Study Protocol
Subjects attended the clinical laboratory and were studied in a
supine position, rolled slightly on the left side. An IV cannula was
inserted into the left forearm for blood sampling. Subjects then
rested supine for at least 30 min to obtain stable resting hemody¬
namics (To). They were then rendered hypercapnic by breathing a
variable mixture of CO2 and medical air to attain an end-tidal CO2
(ETcOa) of 7 kPa lor 30 min (Ti) and then they breathed room air
for a further 30 min (T2). The hypercapnic gas mixture was
produced from separate cylinders ofCCb and medical air fitted with
variable flow valves. Gases were mixed in a 25-L Douglas bag
(Collins Inc; Braintree, Mass) from which the subjects breathed
through a mouthpiece connected by a series of one-way valves,
while wearing an occlusive nose clip. Measurements of pulmonary
and systemic hemodynamic variables, inotropic, lusitropic, and
electrophysiologic indexes, and venous blood samples for plasma
renin activity (PRA), angiotensin II (ANG II), and aldosterone
(AJLDO) were taken at To, Ti, and T2.
Measurements
Oxygenation: Arterial blood oxygen saturation was continuously
monitored by transcutaneous oximetry (CSI 503; Criticare Systems
Inc; Waukesha, Wis). Recordings were averaged at steady state over
a period of 5 min at each time point for die purpose of analysis.
End-tidal COo: This was measured continuously with the tip of
the gas sampling tube adjacent to the mouth of the subject, using
a transportable ETccn monitor (POET TE; Criticare Systems
Inc; Waukesha, Wis). Recordings at steady state were averaged
over a period of 5 min and this value was used for the purpose of
analysis.
Hemodynamics: Systolic arterial BP (SBP), mean arterial BP
(MAP) and diastolic arterial BP (DBP) were measured using a
semiautomatic sphygmomanometer (Vital Signs Monitor; Critikon;
1216
Tampa, Fla). The mean of three consistent readings was taken at
each time point. Heart rate (IIR) was recorded on an ECG trace
and an average rate over 6 R-R intervals was calculated. Pulmonary
acceleration time (PAT) in milliseconds was measured as previously
described22 23 from pulmonary arterial flow by pulsed-wave Dop¬
pler echocardiography (Vingmed SD50; Vingmed Sound; Horten,
Norway) from die left third/fourth intercostal space. The mean of
diree consistent waveforms at each time point was used for the
purpose of analysis. MPAP in mm Hg was calculated as MPAP=73-
(0.42xPAT).2-1 Aortic cross-sectional area was measured by M-mode
echocardiography (Vingmed SD50). The aortic systolic velocity in¬
tegral (SVI) was measured by on-line computer-assisted determi¬
nation using pulsed-wave Doppler echocardiography of ascending
aortic blood flow from die suprasternal notch. On-line calculations
of stroke volume (SV=SVIxcross-sectional area) and CO as the
product of SV and HR were also made. Total PVR was calculated
as: PVR=MPAP/COx80 dyne s-cm 0. We have previously shown
the short term coefficients for measurement of PAT and SVI to be
1.7% and 1.2%, respectively.22
Systolic Flow Parameters: Doppler ascending aortic blood flow
(Vingmed SD50) was recorded with a 2.0-MHz pulsed-wave
transducer with depth adjusted to give maximal velocity and die
following variables were measured: aortic peak acceleration
(AcCpeajc), aortic mean acceleration (Accmean), and aortic peak
velocity (AvpgajJ. We have previously shown the coefficient of vari¬
ability for the measurement of Accmean and Avpeak by this mediod
to be 12.5% and 4.4%, respectively.22
Diastolic Filling Parameters: From the apical window, pulsed-
wave Doppler analysis of mitral and diastolic flow was combined
with simultaneous plionocardiogram recording with the micro¬
phone (Siemens AG; Munich, Germany). Measurements were all
made on-line during expiration and in triplicate, with a display
sweep speed of 100 mm/s. Transmural flow was analyzed after ad¬
justing sample volume depth to yield maximal E-wave velocities
with clearly defined flow velocity envelopes. Measurement of dias¬
tolic flow parameters from these signals has previously been shown
to be highly reproducible and easily applicable in our own labora¬
tory19 and also by other workers.35 The aortic component of the
second heart sound was identified on the phonocardiogram trace bv
noting closure artifacts from superimposition ofaortic Doppler flow
profiles. From diastolic transmitral flow, maximal velocities of the
early (Evma:I) and atrial (Avmax) components of flow were measured,
and the ratio of Evmax and Avmax (E/A ratio) was calculated. In ad¬
dition, the E-wave deceleration time (EDT) was calculated as the
time in milliseconds from peak velocity to the end of the E wave.
The isovolumic relaxation time (IVRT) was calculated for the left
ventricle as the time in milliseconds from the aortic component of
the phonocardiogram second heart sound to the onset of diastolic
transmitral flow. Both EDT and IVRT were corrected for changes
in J1K induced by hypoxemia by dividing by the square root of the
simultaneous ECG R-R interval; EDTc=IVRT/\/RR, lVRTc=
ivrt/Vrr.
QT Interval Measurement: The ECGs from both study days were
analyzed in random order after completion of the study, by an in¬
vestigator who was blinded with respect to the stimulus the volun¬
teers had received. QT interval if feasible was measured in all leads
of a surface 12-lead ECG (paper speed=25 mm/s). Three consec¬
utive cycles were measured in each lead where possible and the
mean value was taken as representing the QT interval in that lead.
QT interval was calculated according to standard criteria20 from the
onset of the QRS complex to the end of the T wave ie, a return to
llie T/P baseline. In the presence of U waves, the QT interval was
measured to the nadir of the curve between the T and the U waves.
QT dispersion was defined as the difference between the max-
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Figure I. Effects of hypercapnia on pulmonary hemodynamics and electrophysiologic parameters. Top
left: absolute MPAP measured during normoxemia (baseline), after 30 min hypercapnia, and 30 min after
rebreatliing air, respectively. Bottom left: absolute PVR measured during normoxemia (baseline), after 30
min hypercapnia, and 30 min after rebreathing air, respectively. Top right: absolute QTc interval measured
during normoxemia {baseline), after 30 min hypercapnia, and 30 min after rebreathing air, respectively.
Bottom right.: absolute QT dispersion measured during normoxemia (baseline), after 30 min hypercapnia,
and 30 min after rebreathing air, respectively. Asterisk a significant (p<0.05) difference between baseline
and hypercapnia or between baseline and after 30 min rebreathing air.
imum and minimum QT interval measured during analysis of all
leads of the surface ECG.20 The measurements were made using
a computer-linked digitizing tablet.26 To compare the standard
measure of QT interval with QT dispersion, we calculated tire av¬
erage ofsix QT intervals in lead II. QT intervals were then corrected
for rate using the formula of Bazett2' (QTc=QT/\/RR)-
BAS Activity: Venous blood samples for plasma ALDO were
collected into lithium heparin tubes, and for measurement of
plasma renin activity (PRA) into edetic acid tubes, before being
cenlifuged; plasma was stored at -20"C until assayed. PRA was
assayed using commercially available radioimmunoassay (RIA) kits
(Sorin Biomedica; Saluggia, Italy) that assayed PRA by measure¬
ment of amount ol angiotensin I generated per hour. ALDO
was measured using a similar RIA assay kit (Sorin Biomedica).
Samples for ANG II assay were collected into chilled glass
tubes containing 0.5 mL of a cocktail comprising 0.05 mmol/L
O-phenanthrolene, 0.2 g neomycin, 0.125 mmol/L edetic acid, and
2% (vol/vol) alcohol before centrifugation, and separated plasma
was stored at -70°C. ANG II assay was performed following sep¬
aration from plasma proteins by alcohol extraction using a specific
commercially available RIA kit (Nichols Institute Diagnostics; San
Juan Capistrano, Calif). We have previously shown the coefficients
ofsatiation for analysis were as follows: ANG II 11.2%; PRA, 7.6%;
and ALDO, S.3%.26
Data Analysis
Comparisons between serial time points on the same study day
were made using multifactorial analysis of variance followed by
Duncan's multiple range test. A probability value of p<0.05 (two-
tailed) was considered to be statistically significant. Data are
presented in the text, tables, and figures as means and SEM.
Results
Oxygenation and ETcoo
Breathing the CCD/air mixture compared to air sig¬
nificantly increased respiratory rate 21 ±1 vs 13±1
breaths/min, ETcov 7.0±0.2 vs 5.0±0.3 kPa, and ox¬
ygen saturation 98±0.2 vs 97±0.2%, respectively.
There was no significant difference between T2 (30
min posthvpercapnia) and baseline.
Pulmonary Hemodynamics
Hypercapnia (Tj) was associated with a significant
(p<0.05) increase in both MPAP and PVR compared












normocapnia hypercapnia normocapnia normocapnia hypercapnia normocapnia
Figure 2. Effects of hypercapnia on systemic hemodynamic parameters. Top left: absolute CO measured
during normoxemia (baseline), after 30 min hypercapnia, and 30 nun after rebreathing air, respectively.
Bottom left: absolute lilt measured during normoxemia (baseline), after 30 min hypercapnia, and 30 min
after rebreathing air, respectively. Top right: absolute SV measured during normoxemia (baseline), after
30 min hypercapnia, and 30 min after rebreathing air, respectively. Bottom right: absolute SBP (open
squares), MAP (solid circles), and DBP (open triangles) measured during normoxemia (baseline), after 30
min hypercapnia, and 30 min rebreathing air. respectively. Asterisk a significant (p<0.05) difference be¬
tween baseline and hypercapnia.
with baseline (To) (Fig 1). There was no significant
difference between To (30 min posthypercapnia) and
baseline.
Systemic Hemodynamics
Hypercapnia (Ty) was associated with a significant
(p<0.05) increase in SBP, DBP, MAP, IiR, and CO
compared with baseline (Ty) (Fig 2). However, hyper¬
capnia had no significant effect on systemic vascular
resistance (SVR) compared with baseline: 1,102±38 vs
l,162±78 dyne-s-cm F There was no significant dif¬
ference between T2 and Ty for any of the systemic
1 temodynamic parameters.
Systolic Flow Parameters
Hypercapnia compared with baseline had no signif¬
icant effect on Av^ap, AcCpeai(, or Accmeaj, (Table 1).
Table 1—Hypercapnia and Its Effects on Systolic and Diastolic Parameters*
To ti t2
AVpeak, HIS 1 1.20±0.0s 1.26±0.10 1.15±0.05
AcCmean, ms 11.9±1.4 10.8±1.2 10.8± 1.1
AcCpg^, ms 26.8±4.0 24.8±3.6 28.1 ±3.6
Evmax, ms"1 77±5 75±6 71±5
Avmax, ms" 42±2 41±3 41±3
E/A ratio 1.86±0.17 1.90±0.21 1.s1±0.19
EDT, ms 121±5 123±7 114±9
EDTc, ms 121 ±9 137±9 124±5
IVRT, ms 66 ± 5 65 ± 4 68 ± 3
IVRTc, ms 74±5 70±3 72±4
♦There were no significant differences between Tq (baseline), Tj (ETcOo^T kPa), and To (alter rebreatliing air for 30 min) for each of the above vari¬
ables.
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Table 2—Hypercapnia and Its Effects on the HAS
To Ti T-z
PRA, pmol/li/mL 1.21+0.31 1.00±0.21 0.57±0.15°
ANG II, pmoI/L 15.8+2 19.0±4.7 13.2±1.4
ALDO, pmol/L 86.2±14.7 74.49±11.6 72.3±16.3
*A significant difference in PRA at T» (30 rnin after rebreathing air) compared with To (baseline). There were no significant differences between T]
(ETcoj=7 kPa) and the other time points for any of the above variables.
Diastolic Flow Parameters
Similarly hypercapnia compared with baseline had
no significant effect on Evmax, Avmax, E/A ratio, EDT,
EDTc, IVRT, or IVRTc (Table 1).
QT Dispersion
Hypercapnia compared with baseline had no signif¬
icant effect on QT interval, although QTc was signif¬
icantly increased after hypercapnia (Fig ] ). Hypercap¬
nia also significantly increased QT dispersion compared
with baseline and this was also significantly elevated
after 30 min rebreathing air compared with baseline.
Renin Angiotensin System (RAS) Activity
Hypercapnia had no significant effect on ANG II,
PRA, or ALDO, although PRA was significantly lower
at Tz with baseline (Table 2).
Discussion
We have shown that acute hypercapnia causes true
pulmonary vasoconstriction in vivo in normal volun¬
teers as reflected by a significant increase in botli
MPAP and PVR. Although acute hypercapnia had no
significant inotropic or lusitropic effects, it significantly
increased QT dispersion, suggesting that hypercapnia
may cause abnormalities in myocardial repolarization.
The effect of COo on the pulmonary circulation in
man remains controversial, although the evidence ap¬
pears to suggest a vasoconstrictor effect.8*13 We aimed
to achieve ETCO2 similar to that encountered in
patients with exacerbations of COPD and ;ilso that
found in permissive hypercapnia. Our mean ETcoo of
7 kPa equates with an arterial PCO2 of approximately
7.5 kPa, and ETCO2 is known to closely mirror the
concentration of COo in arterial blood.29 Blood leaving
the ventilated alveoli usually mixes with blood from
both parenchymal lung tissue and with blood passing
through nonventilated alveoli, creating a venous ad¬
mixture. It is this venous admixture that accounts for
the normal alveolar-arterial CO2 tension difference.
The early work of Fish ma n et al9 looked at the effect
of 3 to 5% COo on the pulmonary vasculature in nor¬
mal volunteers and in patients with COPD and
concluded that breathing air rich in COo had no effect
on pulmonary vasoconstriction. This was in shaip
contrast to work performed in animals and this ap¬
parent dichotomy was explained by Kilbum et als
who demonstrated pulmonary vasoconstriction in pa¬
tients with COPD exposed to more severe hyper¬
capnia. These findings have been corroborated in other
studies in patients with elevated and normal
MPAPs.10'30 This study in normal humans provides
further support for the evidence in patient studies that
hypercapnia is a relatively weak pulmonary vasocon¬
strictor and that pulmonary vessels may be the excep¬
tion to the rule that acidosis causes vasodilatation.31
Thus, hypercapnia may function in humans as an
intrinsic mechanism diverting blood from underventi-
lated areas of the lung in an effort to maintain venti¬
lation perfusion matching. In contrast to previous
studies, we have used floppier echocardiography to
measure hemodynamic changes in the pulmonary cir¬
culation. These noninvasive techniques have been
shown to Ire highly reproducible22 and the close cor¬
relation between Doppler PAT and MPAP as mea¬
sured by right heart catheter is well established.24'32 '3
We looked at two measures of pulmonary vasocon¬
striction: changes in MPAP and PVR. The use of total
PVR does not account for any changes in the postcap¬
illary vascular bed, as conventionally assessed by pul¬
monary capillary wedge pressure. In this respect we
believe that it is unethical to insert Swan-Ganz cathe¬
ters into normal volunteers for research purposes and
the extra information this would give us is not essen¬
tial. It has previously been shown that hypercapnia has
no significant effects on pulmonary capillary wedge
pressure either in patients with normal pulmonary ar¬
tery pressures or those with elevated pressures occur¬
ring as a consequence of hypoxic lung disease and so
effects on total PVR are reflective of changes in true
PVR in precapillary arterioles during hypercapnia.10
We believe, therefore, that the observed changes in
total PVR are a line reflection of changes in pulmonary
vascular tone.
The systeinic effects of hypercapnia are complex and
reflect a balance between the direct effects of CO2 and
(he secondary effects of CO2 mediated via the central
and autonomic nervous systems. In this study, we have
demonstrated significant increases in FIR, SV, CO,
SBP, MAP, and DBP and a nonsignificant reduction in
SVR, changes that have previously been documented
in patients with similar degrees of hypercapnia.0''
Interestingly, although hypercapnia has been shown
to be a direct myocardial depressant in the isolated
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heart,3'1' we have shown no significant effects of hv-
percapnia on either inotropic or lusitropic indexes of
cardiac function measured using Doppler echocardi¬
ography. Mean and peak aortic acceleration as well as
peak aortic velocity have been shown to be sensitive
markers of left ventricular contractility.16'36"38 Al¬
though Accpeak and Avpeak decline with increasing
I1R',!) during pacing, the effects across our 1111 range
are small and consistent with the nonsignificant changes
observed. This suggests that the systolic contractility of
the normal human myocardium is relatively resistant to
the effects of acute hypercapnia. Similarly we have
shown no effect on ventricular diastolic function, which
is an important determinant of overall cardiovascular
performance and a sensitive marker of cardiac dys¬
function, as reflected by tire lack of effect of hyper¬
capnia on all of the measured indexes. This suggests
that the secondary effects of hypercapnia on the cen¬
tral and autonomic nervous systems in the integrated
physiologic system of humans are capable of antago¬
nizing the direct myocardial depressant effects of hy¬
percapnia.''0'11
Although acute hypercapnia appears to have no
significant effects on myocardial contractility, the ob¬
servation that hypercapnia increases both QTc interval
and QT dispersion suggests that it has significant
effects on myocardial repolarization. The finding that
hypercapnia increases QT dispersion is probably of
more significance since this represents differences in
regional myocardial repolarization and as such repre¬
sents a putative substrate for arrhythmias. In contrast,
QTc interval provides no information regarding re¬
gional repolarization abnormalities. Evidence suggests
that QT dispersion is a sensitive index of the propen¬
sity for developing life-threatening arrhythmias and ;is
such may lower the arrhythmogenic threshold in con¬
ditions in which hypercapnia exists. The mechanism
whereby hypercapnia causes these abnormalities in
myocardial repolarization may be related to its effects
on autonomic function or elevated levels of catechola¬
mines that have been previously demonstrated during
acute hypercapnia.12 QT dispersion is a useful, easily
applicable noninvasive technique. We used a comput¬
er-linked digitizing tablet that has been shown by other
investigators to be a reliable and accurate measure of
QT dispersion.26 Probably the most important aspect
concerning methods is the protocol to define the end
of the T wave. We have thus used the most commonly
used protocol20 and one that has been shown to
correlate with arrhythmia risk and sudden death in
patient studies.43,44 We used routine ECGs to measure
QT dispersion because we believed that this would
have the most clinical relevance, and indeed no
substantial evidence suggests that simultaneous ECG
recording has any benefits.
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We have also investigated the effect of acute hy¬
percapnia on the RAS. In the absence of hypercapnia,
HAS activation in hypoxemic patients is rare,43 sug
gesting a possible role for hypercapnia possibly occur¬
ring as a consequence of renal vasoconstriction or as a
result of a direct cellular effect. In this study, however,
we were unable to demonstrate any significant effect
of hypercapnia on PRA, ANG II, or ALDO. This may
be related to the brevity of our stimulus, although
similar periods of hypoxia suppressed ALDO levels.46
It is also possible that hypoxia and hypercapnia may-
need to be present in synergistic fashion to produce
clinically detectable RAS activation. The significant fall
in PRA 30 min after cessation of hypercapnia com¬
pared with baseline is consistent with the known effects
ofresting in die supine position, in which values of PRA
increase with upright body posture and fall with time
when the supine position is assumed.4'1
To conclude, acute hypercapnia appears to have no
effects on myocardial contractility or relaxation in the
integrated physiologic system of humans, although re¬
polarization abnormalities reflected by an increase in
QT dispersion may provide an environment for ar-
rhythmogenesis. We have also shown that hypercapnia
causes true pulmonary vasoconstriction in humans.
This agrees with findings in patient studies but also
suggests that in vivo, hypercapnia has a role to play in
modulating pulmonary blood flow in healthy humans.
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Angiotensin II Receptor Blockade and
Effects on Pulmonary Hemodynamics
and Hypoxic Pulmonary
Vasoconstriction in Humans*
David G. Kiely, MB; Robert I. Cargill, MB; and Brian J. Lipworth, MD
Study objective: We examined the hypothesis that angiotensin II (ANG II) is a modulator of pulmo¬
nary vascular tone bv examining the effects of ANG II blockade on pulmonary hemodynamics dur¬
ing normoxemia and hypoxemia in normal volunteers with an activated renin angiotensin system
(RAS).
Participants atul interventions: Eight normal volunteers, pretreated with furosemide, were stutlied
on two separate occasions and received either an infusion of saralasin, 5 pg/kg/inin, or placebo. Af¬
ter 20 min, they were rendered hypoxemic, by breathing Nj/Os mixture for 20 min to achieve ar¬
terial oxygen saturation (SaCE) of 85 to 90% adjusted lor a lurther 20 min to achieve SaOo of 75 to
80%. Doppler echocardiography was used to measure mean pulmonary artery pressure (MPAP),
cardiac output, and hence total pulmonary vascular resistance (TPR).
Results: Saralasin compared with placebo resulted in a significant (p<0.05) reduction in MPAP dur¬
ing normoxemia, 6.70± 1.0 vs 1I.7±1.3 mm Ilg; at SaOs of 85 to 90%, 14.7± 1.4 vs 20.5± 1.0 mm Hg;
and at SaOs of 75 to 80%, 18.1 ± 1.9 vs 27.8±1.9 mm Hg, respectively. Likewise saralasin compared
with placebo resulted in a significant reduction in TPR during normoxemia, 104±14 vs 180±20
dvne-s-cm"5; at SaOo of 85 to 90%, 222±24 vs 295±21 dyne-scm 5; and at Sa02 of 75 to 80%, 238±21
vs 362±11 dvne-s-cm , respectively. The AM PAP response to hypoxemia was likewise significantly
(p<0.01) attenuated bv saralasin infusion compared with placebo: mean difference 5.0 mm Hg, 95%
confidence interval (CI) 1.9 to 8.08, and there was a trend toward attenuation of the ATPR response
to hypoxemia (0.05<p<0.10): mean difference 47 dyne-s-cm , 95% CI, -10 to 105.
Conclusion: In addition to causing pulmonary vasodilatation in the presence ofan activated RAS, our
results suggest that ANG II receptor blockade attenuates acute hypoxic pulmonary vasoconstriction
and that .ANG II may play a role in modulating this response in normal man.
(CHEST 1996; 110:698-703)
Key words: angiotensin II blockade; hypoxemia; pulmonary circulation
Abbreviations: ACE=angiotensin-converting enzyme; ANG II=angiotensin II; CI=confidence interval; CO=cardiac out¬
put; CSA=cross-sectional area; HPV=hypoxic pulmonary vasoconstriction; IIR=heart rate; MAP=mean arterial BP;
MPAP=mean pulmonary artery pressure; PAT=pulmonary acceleration time; PC\VP=pulmonary capillary wedge pressure;
PRA=plasma renin activity; RAS=renin angiotensin system; RIA=radioimmunoassay; SaOo=arterial oxygen saturation;
SV=stroke volume; SVT=aortic systolic velocity integral; SVR=systemic vascular resistance; TPR=total pulmonary vascular
resistance
Tit man, hypoxemia usually arises as a result of
pulmonary disease or adverse environmental con¬
ditions such as altitude. The effects of hypoxemia on
For editoriaJ comment see page 584
the pulmonary vasculature have been studied exten¬
sively since V011 Euler and Liljestrand1 first described
the phenomenon of hypoxic pulmonary vasoconstric-
*From die Department of Clinical Pharmacology, Ninewells Hos¬
pital and Medical School, University of Dundee, Dundee, Scot¬
land.
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tion (HPV). /Although HPV has beneficial effects, the
stimulus of chronic hypoxia results in an elevation of
pulmonary artery pressure leading to the development
of cor pulmonale.2-3
These patients have activation of the renin angio¬
tensin system (RAS),4 6 with elevated levels of angio¬
tensin II (ANG II). ANG II and hypoxia have both
been shown to be potent pulmonary vasoconstrictors in
man.' In vitro studies have shown that ANG II facil¬
itates HPV in the rat and potentiates this response in
dogs.8,9 Furthermore, tire use of angiotensin-convert-O '
ing enzyme (ACE)-inhibitors in chronically hypoxic
rats has been shown to attenuate the development of
pulmonary hypertension.
Clinical Investigations
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Studies in humans are rare, although recent data
have shown that pretreatment with tire long-acting
ACE inhibitor lisinopril blunts acute HPV in normal
volunteers compared to placebo.11 The effect of ACE
inhibition could in theory be due to lowering levels of
ANG II (a vasoconstrictor) or augmenting levels of
bradyldnin (a vasodilator) by suppressing the activity of
ldninase II, which normally contributes to the degra¬
dation of kinins.12
The purpose of this stud)' was to detennine the role
of ANG II in die pulmonary circulation during both
normoxemia and hypoxemia by competitive inhibition
of ANG II with its analogue, saralasin (l-sar-5-val-8-
ala-ANG II), which has been shown to be a compet¬
itive antagonist of ANG II in the presence of an acti¬




Eight healthy male volunteers, age (mean±SEM) 29±3 years,
were studied on 2 separate occasions. There was no abnormality
present on clinical history, examination, 12-lead ECG, echocardi¬
ography, biochemical screening, or hematologic screening. No
medications were permitted during and for 1 month prior to the
study. Informed written consent to the study protocol, previously
approved by the Tayside Committee for Medical Research Ethics,
was obtained.
Study Protocol
Subjects attended the laboratory,at the same time of the day on
2 separate occasions, at least 1 week apart. Subjects were pretreated
with 4 daily doses of furosemide, 40 mg, to activate the RAS such
that saralsin would function as a pure antagonist of ANGil devoid
ofpartial agonist activity. An indwelling IV cannula was inserted into
each antecubital fossa, one for infusion of saralasin or placebo and
the other for blood sampling. Subjects then rested in a supine po¬
sition for 30 min to obtain stable resting hemodynamics (To). They
then received either an infusion of 5% dextrose or saralasin 5, pg/
kg/min (Sigma Chemical Company; St Louis). They were restudied
after 20 minutes (Tj), and were then rendered hypoxemic by
breathing a variable mixture of oxygen and nitrogen sufficient to
render arterial oxygen saturation (SaOo) between 85 and 90% (To)
for 20 min adjusted for a further 20 min to achieve an SaOo of 75
to 80% (T3). The hypoxic gas mixture was produced from separate
cylinders of nitrogen and oxygen fitted with variable flow valves.
Gases were mixed in a 25-L Douglas bag, from which the subjects
breathed through a mouthpiece connected by a series of one-way
valves, while wearing an occlusive nose clip. Measurements of pul¬
monary and systemic hemodynamic variables and venous blood
samples for plasma renin activity (PRA) were taken at To, Tj, To,
and T3. Serum electrolytes were measured at To-
Measurements
Oxygenation: Arterial blood oxygen saturation was continuously
monitored by transcutaneous oximetry (CS1 503; Critjcare Systems
Inc; Waukesha, Wis).
Hemodynamics: Heart rate (HR) and mean arterial BP (MAP)
was measured by semiautomatic sphygmomanometer as tire mean
of three consecutive readings (Vital Signs Monitor; Critikon;
Tampa. Fla). Pulmonarv acceleration time (PAT) in milliseconds






















Figure 1. Pulmonary hemodynamic response to ANG II blockade
during normoxemia and hvpoxemia. Top: absolute Doppler MPAP
measured at baseline before infusion with normoxemia, during in¬
fusion of placebo or saralasin with normoxaemia, during infusion
with hvpoxemia (SaOo 85 to 90%), and during infusion with
hvpoxemia (SaOo 75 to 80%). Asterisk represents a significant
(p<0.05) difference between placebo and saralasin at each time
point. Bottom: absolute TPR measured at baseline before infusion
with normoxemia, during infusion of placebo or saralasin with nor¬
moxemia, during infusion with hypoxemia (SaOo S5 to 90%), and
during infusion with hypoxemia (SaOj 75 to 80%). Asterisk repre¬
sents a significant (p<0.05) difference between placebo and sarala¬
sin at each time point.
flow by pulsed-vvave Doppler echocardiography (Vingmed SD50;
Vingmed Sound; Horten, Norway) from the left third/fourth in¬
tercostal space. The mean of three consistent waveforms at each
time point was used for the purpose of analysis. Mean pulmonary
artery pressure (MPAP) (mm Hg) was calculated as MPAP=
73-(0.42xPAT).15 Aortic cross-sectional area (CSA) was measured
by M-mode echocardiography (Vingmed SD50). The aortic systolic
velocity integral (SVI) was measured by on-line computer-assisted
determination using pulsed-vvave Doppler echocardiography of
ascending aortic blood flow from the suprasternal notch. On-line
calculations of stroke volume (SV=S\TxCSA) and cardiac output
(CO) as the product of SV and HR were also made. Total pulmo¬
nary vascular resistance (TPR) was calculated as follows: TPR=
MPAP/COx80 dyne s-cm-0. We have shown previously the short-
term coefficients of variability for measurement of PAT and SM in
our hands to be 1.7% and 1.2%. respectively.14
Electrolytes: Samples for seruni electrolytes were collected in
chilled lithium-heparin tubes and were centrifuged at 4°C irnme
diatelv and separated plasma was stored at -20°C until measured
in one batch at die end of the study using an internal caesium
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standard flame photometer (Instrumentation Laboratory; Milan,
Italy).
RAS Activity: Samples for measurement of plasma renin activity
(PRA) were collected into chilled EDTA tubes. They were centri-
fuged at 4°C immediately and separated plasma was stored at -20°C
until assaved in one batch at the end of the study. PRA was assayed
using commercially available radioimmunoassay (RIA) kits (Sorin
Biomedica; Saluggia, Italy) that assayed PRA by measurement of
amount of angiotensin I generated per hour.
Data Analysis
Comparison of values between study days or between serial time
points on the same study day was made by multifactorial analysis of
variance.16 A probability value of p<0.05 (two-tailed) was consid¬
ered to be statistically significant. Data are presented in the text,
tables, and figures as means and SEM, and where a difference be¬




There was no significant difference in PAT, MPAP,O 7 7
or TPR at baseline (To) between study days. Infusion
of saralasin compared to tire placebo resulted in a sig¬
nificant (p<0.05) reduction in MPAP during normox-
emia (T'i), mean difference 4.6 mm Hg (95% CI, 1.25
to 8.0); at an SaC>2 of 85 to 90% (To), mean difference
6.1 mm Hg (95% CI, 1.4 to 10.8); and a significant
(p<0.0005) difference at an SaC>2 of 75 to 80% (T3),
mean difference 9.6 mm Hg (95% CI, 6.0 to 13.2),
respectively (Fig 1, top). Likewise saralasin infusion
compared to placebo resulted in a significant (p<0.05)
reduction in TPR at Tj, mean difference 76 dyne-s-cm
(95% CI, 29 to 123); at Tj, mean difference 72
dyne-s-cm-5 (95% CI, 8 to 136); and a significant
(p<0.0005) reduction at T3, mean difference 123
dyne-s-cm-5 (95% CI, 82 to 165), respectively (Fig 1,
bottom). Hypoxemia caused a significant (p<0.05) in¬
crease in MPAP and TPR at To and T3 compared to
baseline on both study days. Saralasin compared to
placebo significantly reduced PAT during nonnoxemia
and moderate and severe hypoxemia (Table 1).
In terms of change in MPAP (AMPAP) from base¬
line (To) to severe hypoxemia (T3), (lie AMPAP
response was significantly (p<0.005) attenuated by
saralasin infusion compared with placebo: mean dif¬
ference 7.3 mm Hg; 95% CI, 3.9 to 10.7. Likewise the
ATPR response from T0 to T3 was significantly (p <0.05)
attenuated by saralasin infusion compared with pla¬
cebo: mean difference 89 dyne-s-cm-5; 95% CI, 26 to
152. Because there was a significant fill in MPAP and
TPR at Tj compared with baseline (Tq) after saralasin
infusion compared to placebo, we also assessed the
AMPAP and ATPR response from Tj to T3. The
AMPAP response was likewise significandy (p<0.01)
attenuated by saralasin infusion compared with pla¬
cebo: mean difference 5.0 mm Hg; 95% CI, 1-9 to 8.08;
and there was a trend toward attenuation of the ATPR
response from Tj to T3 (0.05<p<0.10): mean differ¬
ence 47 dyne-s-cm-5; 95% CI, -10 to 105.
Systemic Hemodynamics
Aldiough, saralasin infusion compared to placebo
did not significantly alter systemic hemodynamic pa¬
rameters either at baselilie or during hypoxia, saralasin
infusion had significant effects on systemic hemody¬
namics compared with baseline measurements (Table
1). Compared to baseline (To), a significant (p<0.05)
increase in CO in response to hypoxemia (T3) was
noted on both study days. A fall in systemic vascular
resistance (SVR) in response to hypoxemia (T3) was
Table 1—Effects of ANC II Receptor Blockade on Systemic Ilemodt/namics and PAT*
Infusion
Preinfusion | I
SaO, >95% (T0) >95% (TP 85-90% (T2) 75-80% (T3)
HR, beats/min
P 71.0±4.8 68.6±4.2 73.1±4.3 73.8±5.6
S 67.2±3.8 64.1±3.5 6S.5±4.5 71.8±5.1
MAP, mm Hg
P 84.8±4.5 81.9±3.5 82.4±3.S S6.5±3.1
S S3.4±3.0 76.9±1.9I 79.4±3.3 77.4±4.2'
CO, L/min
P 5.45±0.48 5.20±0.25 5.69 ±0.3S 6.18±0.24)
S 5.36±0.34 5.06±0.17 5.42±0.36 6.10±0.39,
SVR, dyne-s-cnT5
I' ' 1,306±132 1,262±72 1,192±98 1,128±48
S 1,332± 80 1,251±54 1,260±69 l,0S2±73f
PAT, ms
P 146±2 146±3 125±2* 108±2f
S 152 ±2 15S±2,» 139±3,! 130±5,!
*Absolute values (mean±SEM) of HR, MAP, CO, SVR, and PAT at each level of oxygen after pretreatment with placebo (P) or saralasin (S).
^Significantly (p<0.05) different from baseline (To).
♦Significantly different between treatment with saralasin and placebo at that time point.
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also noted on both studv davs, although this reachedJ j ' O
statistical significance (p<0.05) only during saralasin
infusion. HR and MAP were unaffected by hypoxemia
on the placebo da}', although saralsin infusion resulted
in a significant (p<0.05) decrease in MAP at T3 and T1
compared to baseline (To).
Electrolytes
There was no significant difference in serum sodium
or potassium levels at baseline (To), between the study
days when patients received placebo or saralasin. Se¬
rum sodium level was 137.4±0.8 (placebo) vs
138.9±0.S (saralasin) mmol/L, and serum potassium
level was 3.97±0.10 (placebo) vs 3.89±0.0S (saralasin)
mmol/L.
HAS Activity
Saralasin infusion resulted in a significant (p<0.05)
increase in PRA at To and T3 compared to baseline
(T0): 5.25± 1.36 and 5.60± 1.31 vs 3.99±0.55 ng/mL/h,
respectively. Hypoxia alone was not associated with a
significant change in PRA at To and T3 compared to
baseline (To): 3.48±0.65 and 3.29±0.5S vs 3.S4±0.77
ng/mL/h, respectively. There was no significant dif¬
ference in PRA at any of die time points between die
2 stud}' days.
Discussion
Our results demonstrate that the ANGII antagonist
saralasin causes pulmonary vasodilatation in the pres¬
ence of an activated RAS. In this respect, we have
shown that absolute MPAP and TPR were significantly
lower during hypoxemia after saralasin compared to
placebo and similarly that the A MPAP and ATPR re¬
sponses from baseline to each level of hypoxemia were
also significantly attenuated by saralsin. There is also
evidence to suggest that ANG II blockade may atten-DO J
uate acute hypoxic pulmonary vasoconstriction re¬
flected by a significant reduction in the AMPAP and a
trend toward a reduction of die ATPR response from
Tj to severe hypoxemia (T3).
Saralasin is a highly soluble and stable ANG II an¬
alogue that was developed as an ANG II antagonist.1'
However, saralasin also possesses partial agonist-type
activity. It has been demonstrated that saralasin func¬
tions as an agonist in the presence of low renin
states,18'19 whereas elevated levels of PRA and ANG II
are associated with antagonism.20,21 Consequently, we
pretreated our study patients with diuretics to reduce
total body sodium concentration and extracellular vol¬
ume to achieve elevated PRA. We found PRA to be the
same after furosernide pretreatment on bodi studv
dai s suggesting comparable degrees ol RAS activation.
PRA was elevated at baseline in all patients 011 both
davs, compared with our own normal reference range
(0.2 to 2.8 ng/mL/h), allowing saralasin to function as
an ANG II antagonist rather than agonist. This an tag-tD o ci>
onistic activity is supported by the findings of a signif¬
icant reduction in MAP at Tj and T3 compared to
baseline (To) when patients received saralsin. We also
observed a significant increase in PRA at T2 and T3
compared to baseline (To), supportive of the antago¬
nistic activity of saralsin in which blockade of ANG II
receptors on renin secreting cells would be expected to
result in an increase in renin secretion due to inhibi¬
tion of ANG II mediated negative feedback, occurringo o
at the level of the juxtaglomerular apparatus.
Our results agree with animal studies suggesting a
possible role for ANG II in modulating HPV. Berkov8
suggested that ANG II was required to facilitate HPV
in die saline solution perfused rat lung, and studies in
dogs suggest that ANG II infusion augments HPV.9
Recently studies in man have shown that ANG II in¬
fusion augments HPV although not in a synergistic
manner.' The finding tiiat lisinopril pretreatment sig-
nificandy attenuated acute HPV in normal volunteers
suggested that ANG II plays an important role in
modulating HPV in normal man.11 Although theoret¬
ically this could have been due to increased levels of
bradykinin, tiiis agent has not been shown to produce
pulmonary vasodilatation in normal humans.22 Sarala¬
sin and lisinopril alleviate HPV to similar extents, pro¬
viding further evidence for a role of ANG II in mod¬
ulating HPV. Aldrough ANG II undoubtedly has
important pressor effects in the pulmonary circulation,
studies have suggested tiiat it is not the sole mediator
of HPV. McMurty23 has shown that ANG II is not re¬
quired for HPV in vitro, and studies in man have shown
that acute hypoxemia does not increase ANG II levels,
although this may not necessarily reflect tissue ANG II
activity in the lung.21 In this study, acute hypoxemia
had no effect on PRA and ANG II blockade with sar¬
alsin only attenuated and did not abolish HPV. This
supports the theory that ANG II has a role to play in
modulating HPV rather than being tire sole mediatoro o
of HPV.
How ANG II and hypoxia interact remains unclear,
although much interest has surrounded in vitro stud¬
ies showing that pulmonary but not mesenteric arterial
myocytes close potassium channels in response to hy¬
poxia.25 This results in membrane depolarization and
inward calcium flax through voltage-dependent cal¬
cium channels. ANG II is known to increase intracel¬
lular calcium through the inositol triphosphate path¬
way and it has recently been suggested that it max' act
directly on calcium channels through its receptor.-
It may be that one subtype of potassium channel acts
as a hypoxia sensor in tire pulmonary vasculature and
ANG II may modulate acute HPV via its effects on
calcium flax or on this potassium channel via mem-
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brane voltage changes, such that in the presence of
ANG II blockade, the hypoxic signal, with respect to
pulmonary vasoconstriction, is reduced.
We have used Doppler echocardiography to mea¬
sure hemodynamic changes in die pulmonary circula¬
tion. These noninvasive techniques have been shown
to be reproducible10 and a good correlation between
Doppler PAT and MPAP as measured by right heart
cadieter is well established.10'28"30 We looked at two
measures of pulmonary vasoconstriction; changes in
MPAP and TPR. A possible limitation of tiiis method
is that the use ofTPR does not account for any changes
in die postcapillary vascular bed, as assessed by pul¬
monary capillary wedge pressure (PCWP). In diis re¬
spect, we believe it is unediical to insert Swan-Ganz
catheters into normal volunteers for research purposes.
However, we believe diis extra information is not es¬
sential. It is known from previous work that hypoxemia
has no significant effects on PCWP, suggesting that
changes in TPR are reflective of changes in true pul¬
monary vascular resistance in precapillary arterioles
during hypoxia.01 To our knowledge, there is no infor¬
mation available regarding long-term dosing with
diuretics in normal volunteers; die only study available
looked at the acute hemodynamic consequences of IV
ethacrynic acid, which showed a reduction in PCWP.32
However, it would be difficult to extrapolate these
findings to long-term dosing, and although long-termO O O' O tD
diuretic therapy ma}' affect PCWP in normal volun¬
teers, it is important to note that patients were exposed
to bodi hypoxia and pretreatment with furosemide on
both study days, suggesting that diese stimuli are un¬
likely to be responsible for the changes observed be¬
tween study days. With respect to saralasin, its infusion
has not been shown to affect PCWP.33 We believe,
therefore, that the observed changes in TPR are a true
reflection of changes in pulmonary vascular tone.
We have shown for the first time (to our knowledge)
in man diat ANG II blockade with a specific compet¬
itive ANG II antagonist causes pulmonary vasodilata¬
tion and alleviates acute HPV in patients with an acti¬
vated RAS. This suggests the possibility diat ANG II
is a modulator of acute HPV in normal man. Although
one must be careful when extrapolating results from
normal volunteer studies, the ability to cause pulmo¬
nary vasodilatation and attenuate acute HPV, and
therefore the stimulus for pulmonary hypertension in
cor pulmonale, suggests that ANG II antagonists may
have a role to play in chronic hypoxic lung disease ei¬
ther to prevent or treat the cardiopulmonary conse¬
quences ol chronic hypoxemia. The availability of
orally active ANG II antagonists such as losartan may
therefore provide a novel therapeutic avenue for this
patient group.
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Abstract
Objectives: We examined the hypothesis that angiotensin II (ANG II) is a modulator of acute hypoxic pulmonary vasoconstriction
(HPV) by looking at the effect of losartan, a selective type 1 ANG II receptor antagonist, on acute HPV in man. Methods: Ten normal
volunteers were studied on two separate days. They either received pre-treatment with losartan 25, 50, 100, 100 mg respectively on four
consecutive days or matched placebo. They were then rendered hypoxaemic, by breathing an N2/02 mixture for 20 min to achieve an
Sa02 of 85-90% adjusted for a further 20 min to achieve an Sa02 of 75-80%. Pulsed wave Doppler echocardiography was used to
measure mean pulmonary artery pressure (MPAP), cardiac output and hence pulmonary vascular resistance (PVR). Results: Baseline
MPAP and PVR (during normoxaemia) were unaffected by losartan pre-treatment compared with placebo. However, losartan significantly
reduced MPAP at both levels of hypoxaemia compared with placebo: 14.7 ± 0.7 vs 19.0 ± 0.7 mmHg at an SaOz 85-90% (P < 0.01)
and 20.0 ± 0.7 vs 25.7 ± 0.8 mmHg at an Sa02 75-80% (P < 0.05) respectively. Similarly losartan significantly reduced PVR compared
to placebo: 191 ± 9 vs 246 + 10 dyne • s ■ era"5 at an Sa02 85-90% (P < 0.005) and 233 ± 12 vs 293 ± 18 dyne • s • cm-5 at an SaOz
75-80% (P < 0.05), respectively. Pre-treatment with losartan, however, had no significant effect on systemic vascular resistance although
losartan compared to placebo resulted in a significant (P < 0.05) reduction in mean arterial pressure at an Sa02 75-80%: 78 + 2 vs
87 + 2 mmHg. Conclusions: Losartan had no effect on baseline pulmonary haemodynamics but significantly attenuated acute hypoxic
pulmonary vasoconstriction, suggesting that angiotensin II plays a role in modulating this response in man via its effects on the type 1
angiotensin II receptor.
Keywords: Hypoxia; Pulmonary artery; RAAS; Angiotensin II; Losartan
1. Introduction
Hypoxic pulmonary vasoconstriction (HPV) is an im¬
portant homeostatic mechanism allowing blood to be di¬
verted from areas of alveolar hypoxia. Although this un¬
doubtedly has beneficial effects, chronic hypoxia results in
a continued stimulus to pulmonary vasoconstriction with
consequent vascular remodelling and over time the devel¬
opment of cor pulmonale [ 1 -3]. Interestingly, patients with
cor pulmonale have activation of the renin angiotensin
system (RAS) [4-6], with elevated levels of angiotensin II
(ANG II), itself a potent direct pulmonary vasoconstrictor.
Whilst in vivo studies have shown ANG II to be a pressor
agent in the pulmonary circulation [7] there is conflicting
evidence as to whether ANG II is involved in a facilitatory
capacity in modulating HPV [8,9].
There has been much research into pharmacological
manipulation of the hypoxic pulmonary vasoconstrictor
response although concern surrounds worsening of hypox¬
aemia by the use of vasodilators which could theoretically
have detrimental effects on ventilation perfusion matching.
Interestingly, the ANG II antagonist saralasin improved
systemic oxygenation presumably by redistributing pul¬
monary blood flow and improving ventilation perfusion
matching [10]. ACE inhibitors have been shown to attenu¬
ate the development of pulmonary hypertension in chroni¬
cally hypoxic rats [11]. A recent study in humans has
shown that ACE inhibition attenuated acute HPV [12].
However, this cannot solely be attributed to a reduction in
ANG II levels as ACE inhibitors affect many other sys¬
tems, in particular the kinins and prostanoids.
The purpose of this study, therefore, was to elucidate
the role of ANG II and in particular the type 1 ANG II
(AT,) receptor in modulating acute HPV by competitive
inhibition with losartan-potassium (DuP 753), a selective
orally active specific AT, receptor antagonist which shows
Corresponding author. Tel. ( + 44-1382) 660111; Fax ( + 44-1382)
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no affinity for other hormonal receptors and at a functional
level, excepting ANG II, does not alter the contractile
response to a variety of pressor stimuli [13]. Although
Jaiswal et al. [14] reported that in vitro losartan stimulates
prostacyclin release, this finding has not been reproduced
by other workers [15,16].
2. Methods
2.1. Subjects
Ten healthy male volunteers, age (mean ± s.e.m.) 26 + 5
years, were studied on two separate occasions. There was
no abnormality present on clinical history, examination, 12
lead ECG, echocardiography, biochemical or haemato-
logical screening. Informed written consent to the study
protocol, previously approved by the Tayside Committee
for Medical Research Ethics, was obtained.
2.2. Study protocol
Subjects attended the laboratory at the same time of the
day on two separate occasions, at least one week apart.
Subjects were pre-treated with four daily doses of losartan
(25 mg on day 1, 50 mg on day 2, 100 mg on days 3, 4) or
matched placebo in random order. They attended the labo¬
ratory 3 h after receiving their final dose such that the drug
would be studied at maximal effect [17]. An intravenous
cannula was inserted into the left forearm for blood sam¬
pling. Subjects then rested supine for at least 30 min to
obtain stable resting haemodynamics (T0). They were then
rendered hypoxaemic by breathing a variable mixture of
oxygen and nitrogen which rendered arterial oxygen satu¬
ration 85-90% (T,) for 20 min then adjusted for a further
20 min to achieve an arterial oxygen saturation of 75-80%
(T2). The hypoxic gas mixture was produced from separate
cylinders of nitrogen and oxygen fitted with variable flow
valves. Gases were mixed in a 25 litre Douglas bag, from
which the subjects breathed through a mouth-piece con¬
nected by a series of one-way valves, while wearing an
occlusive nose clip. Measurements of pulmonary and sys¬
temic haemodynamic variables, and venous blood samples
for plasma renin activity (PRA) and electrolyte assays,
were taken at T0, T,, and T2.
2.3. Measurements
2.3.1.1. (a) Oxygenation. Arterial blood oxygen saturation
was continuously monitored by transcutaneous oximetry
(CSI 503, Criticare Systems Inc, Waukesha, WI, USA).
2.3.1.2. (b) Haemodynamics. Heart rate (HR) was recorded
on an electrocardiograph trace and an average rate over 1
min was obtained. Mean arterial blood pressure (MAP)
was measured by semi-automatic sphygmomanometer
(Vital Signs Monitor, Critikon, Tampa, FL, USA). Pul¬
monary acceleration time (PAT) in milliseconds was mea¬
sured as previously described [18], from pulmonary arterial
flow by pulsed-wave Doppler echocardiography (Vingmed
SD50, Vingmed Sound, Horten, Norway) from the left
3rd/4th intercostal space. The mean of three consistent
waveforms at each time point was used for the purpose of
analysis. Mean pulmonary artery pressure (MPAP) in
mmHg was calculated as MPAP = 73 — (0.42 X PAT) [19].
Aortic cross-sectional area (CSA) was measured by M-
mode echocardiography (Vingmed SD50). The aortic sys¬
tolic velocity integral (SVI) was measured by on-line
computer assisted determination using pulsed-wave
Doppler echocardiography of ascending aortic blood flow
from the suprasternal notch. On-line calculations of stroke
volume (SV = SVI X CSA) and cardiac output (CO) as the
product of SV and HR were also made. Total pulmonary
vascular resistance (PVR) was calculated as: PVR =
MPAP/COX80 dyne-s-cm"5. We have previously
shown the short-term coefficients of variability for mea¬
surement of PAT and SVI in our hands to be 1.7% and
1.2% respectively [18].
2.3.1.3. (c) Electrolytes. Samples for serum electrolytes
were collected in chilled lithium-heparin tubes and were
centrifuged at 4°C immediately and separated plasma was
stored at — 20°C until measured in one batch at the end of
the study using an internal caesium standard flame pho¬
tometer (Instrumentation Laboratory, Milan, Italy).
2.3.1.4. (d) RAS activity. Samples for measurement of
plasma renin activity (PRA) were collected into chilled
EDTA tubes. They were centrifuged at 4°C immediately
and separated plasma was stored at — 20°C until assayed
in one batch at the end of the study. PRA was assayed
using commercially available RIA kits (Sorin Biomedica,
Saluggia, Italy) which assayed PRA by measurement of
amount of angiotensin I generated per hour. The intra-as-
say coefficient of variation for analysis of PRA was 7.6%.
2.4. Data analysis
Comparison of values between study days was made by
multifactorial analysis of variance (MANOVA) [20]. Com¬
parisons between serial time points on the same study day
were made using Duncan's multiple range test. A probabil¬
ity value of P < 0.05 (two-tailed) was considered to be
statistically significant. Data are presented in the text,
tables and figures as means and s.e.m.
3. Results
3.1. Pulmonary haemodynamics
There was no significant difference in absolute values
of MPAP or PVR at baseline during normoxaemia (T0).
Losartan compared to placebo resulted in a significant
(P<0.01) reduction in MPAP at an Sa02 of 85-90%
(Tj): mean difference 4.3 mmHg (95% CI 1.6-7.0) and a
significant (P<0.05) difference at an Sa02 of 75-80%
(T2): mean difference 5.6 mmHg (95% CI 2.8-8.5), re¬
spectively (Fig. 1A). Likewise losartan compared to
placebo resulted in a significant (P < 0.005) reduction in
PVR at T,: mean difference 55 dyne • s • cm-5 (95% CI
24—86) and a significant (P < 0.05) reduction at T2: mean
difference 60 dyne • s • cm-5 (95% CI 9-110), respec¬
tively (Fig. IB). Hypoxaemia was associated with a signif-
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Fig. 1. (A) Absolute Doppler mean pulmonary artery pressure (MPAP)
measured at (a) baseline during normoxaemia, (b) at an Sa02 85-90%
and (c) at an Sa02 75-80%. Asterix represents a significant (P < 0.05)
difference between placebo and losartan at each time point. (B) Absolute
pulmonary vascular resistance (PVR) measured at (a) baseline during
normoxaemia, (b) at an Sa02 85-90% and (c) at an Sa02 75-80%.
Asterix represents a significant (P < 0.05) difference between placebo
and losartan at each time point.
icant (P < 0.001) increase in MPAP and PVR at T, and T2
compared to baseline (T0) on both study days.
In terms of change in MPAP (AMPAP) from T0 to T,
and T0 to T2, the AMPAP response induced by hypox-
aemia was significantly (P < 0.01) attenuated by losartan
compared with placebo (Fig. 2A): mean difference 5.2
mmHg (95% CI 2.0-8.4) and 6.6 mmHg (95% CI 3.3-9.9)
respectively. Likewise the APVR response induced by
hypoxaemia from T0 to T, and T0 to T2 was significantly





Fig. 2. (A) Change in mean pulmonary artery pressure (AMPAP) from
baseline induced by hypoxaemia (a) at an Sa02 of 85-90% (i.e. T0 to T,)
and (b) at an Sa02 of 75-80% (i.e. T, to T2). The AMPAP represents
the mean of the individual changes. Asterix denotes that the hypoxic
pulmonary vasoconstrictor response was significantly (P < 0.01) attenu¬
ated by losartan (hatched bars) compared with placebo (clear bars) at an
Sa02 of 85-90% and at an SaO, of 75-80%. (B) Change in pulmonary
vascular resistance (APVR) induced by hypoxaemia (a) at an Sa02 of
85-90% and (b) at an Sa02 of 75-80%, compared to baseline. The
APVR represents the mean of the individual changes. Asterix denotes that
the hypoxic pulmonary vasoconstrictor response in man was significantly
(P < 0.01) attenuated by losartan (hatched bars) compared with placebo
(clear bars) at an Sa02 of 85-90% and at an Sa02 of 75-80%.
(Fig. 2B): mean difference 70 dyne • s • cm-5 (95% CI
26-152) and 78 dyne • s • cm"5 (95% CI 29-127).
3.2. Systemic haemodynamics
There was no significant difference between HR, CO
and SVR at each time point between the two study days
Table 1
Systemic haemodynamics
Sa02 > 95% (T0) Sa02 85-90% (T,) Sa02 75-80% (T2)
HR (bpm) P 58±2 64 ±2 70±3"
L 61 ±2 67 ±3 73 ±3"
MAP (mmHg) P 85 ±3 85 ±2 87 ±2
L 80 ±2 80 ±2 78±2 +
CO (1/min) P 5.52±0.17 6.17 ±0.11 7.18±0.37 *
L 5.39 ±0.24 6.22 ±0.33 6.96 ±0.36 *
SVR (dyne-s-cm-5) P 1232 ±42 1098 ±33 994 ±65 '
L 1209 ±39 1060 ±62 909 ±43 *
Significantly (P < 0.05) different from Sa02 > 95%.
+
Significantly (P < 0.05) different from placebo at the same time point.
Values are shown as means ± standard error of the mean after prior treatment with losartan or placebo at each level of oxygenation.
HR = heart rate; MAP = mean arterial pressure; CO = cardiac output; SVR = systemic vascular resistance.
P = placebo; L = losartan.
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Table 2
Serum electrolytes and plasma renin activity
Sa02 > 95% (T,) Sa02 85-90% (T,) Sa02 75-80% (T,)
Na+ (mmol/1) P 139.1 ±0.4 139.3 ±0. 139.3 ±0.4
L 139.2 ±0.4 139.7 ±0.3 139.3 ±0.3
K+ (mmol/1) P 4.08 ±0.09 4.09 ±0.12 4.01 ±0.10
L 4.15 ±0.06 4.11 ± 0.06 4.05 ±0.07
PRA (pmol/1 h" ' ) P 1.00 ±0.14 1.08 ± 0.19 0.84±0.12
L 7.48 ± 1.42+ 6.62± 1.18 + 6.46 ± 1.02 +
+
Significantly (P < 0.01) different from placebo at the same time point.
Values are shown as means ± standard error of the mean after prior treatment with losartan or placebo at each level of oxygenation.
Na+ = serum sodium; K+ = serum potassium; PRA = plasma renin activity.
P = placebo; L = losartan.
although severe hypoxaemia (at T2) resulted in a signifi¬
cant (P < 0.01) increase in CO and HR and a significant
decrease in SVR on both study days. There was no signifi¬
cant difference between study days with respect to MAP at
baseline (T0) or T,, although in the presence of severe
hypoxaemia (T2), MAP was significantly (P < 0.05) lower
following pre-treatment with losartan compared with
placebo: mean difference 9 ramHg (95% CI 2-16). Hy¬
poxaemia had no significant effects on MAP on either
study day (Table 1).
3.3. Electrolytes
There was no significant difference in serum sodium or
potassium following treatment with losartan or placebo at
any time point. Similarly, hypoxia had no significant ef¬
fects on serum sodium or potassium in comparison with
baseline (T0) on either study day (Table 2).
3.4. RAS activity
Pre-treatment with losartan resulted in a significant
(P < 0.01) increase in PRA compared to placebo at base¬
line (T0) at an Sa02 of 85-90% (T,) and at an Sa02 of
75-80% (T2). Hypoxia did not significantly affect PRA on
either study day in comparison with baseline (Table 2).
4. Discussion
We have demonstrated that the selective type 1 ANG II
blocker losartan attenuates acute hypoxic pulmonary vaso¬
constriction in man. In this respect both absolute MPAP
and absolute PVR were significantly lower during hypoxia
in those pre-treated with losartan compared to placebo. In
addition, to correct for any possible confounding baseline
effects, we have also shown that the delta-MPAP and
delta-PVR responses to each level of hypoxia were signifi¬
cantly attenuated by losartan. This supports the hypothesis
that ANG II may modulate the acute HPV response in man
via its effects on the AT, receptor.
Losartan is a potent, orally active drug which selec¬
tively blocks the AT, receptor [13] and as such provides us
with a specific tool for elucidating the role of ANG II in
HPV. It has been shown to produce concentration-depen¬
dent inhibition of angiotensin II induced vasoconstriction
in vitro and in vivo [17,21]. Studies using radioligand
membrane binding and autoradiography techniques have
shown heterogenicity of ANG II receptors in a variety of
different tissues [13]; however, the relative importance of
the AT, and AT2 receptor subtypes with respect to pul¬
monary pressor effects has not been previously docu¬
mented in man. Our results support the hypothesis that
ANG II has its effect primarily via the AT, receptor since
blockade of the AT, receptor significantly attenuated this
response. We also observed a significant increase in PRA
after treatment with losartan during both normoxaemia and
hypoxaemia. This is consistent with blockade of ANG II
receptors in the juxtaglomerular apparatus resulting in
renin secretion due to inhibition of ANG II mediated
negative feedback. Indeed, juxtaglomerular cell hypertro¬
phy and hyperplasia has been shown to occur as a conse¬
quence of losartan therapy in rhesus monkeys [22], In
contrast, if the AT2 receptor was as important in mediating
the acute HPV response then one would have expected a
nullification or a paradoxical increase in response after
treatment with losartan compared to placebo occurring as a
result of elevated ANG II levels. Although the pulmonary
and systemic vascular beds may respond differently to the
same stimulus, these results agree with findings in the
systemic circulation which have shown that none of the
established cardiovascular effects of ANG II can be at¬
tributed to the AT2 receptor [13].
Our findings are consistent with those in animal studies
suggesting an important role for ANG II in modulating
HPV. Berkov suggested that ANG II was required to
facilitate HPV in the saline perfused rat lung [8] and ANG
II infusion has been shown to augment HPV in dogs [23].
Studies in man have shown that ANG II infusion augments
HPV although not synergistically [24]. Interestingly, the
finding that pre-treatment with lisinopril attenuated acute
HPV in normal volunteers suggested an important role for
ANG II in modulating HPV in normal man [17], This
could theoretically have been due to increased bradykinin
levels although bradykinin infusion did not produce pul¬
monary vasodilation in normal volunteers [25]. In this
study we have shown that losartan attenuates HPV to a
similar degree as lisinopril, further implicating ANG II as
having an important role in modulating HPV. Although
ANG II undoubtedly has important pressor effects in the
pulmonary circulation, it is unlikely to be the sole mediator
of HPV. McMurty has shown that ANG II is not required
to produce HPV in vitro [9] and studies in man have
shown that acute hypoxaemia does not increase ANG II
levels [26]. This is consistent with the present study where
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we have shown that acute hypoxaemia had no significant
effect on PRA and that ANG II blockade with losartan
only attenuated rather than abolished HPV. This suggests
that, rather than being the sole mediator of HPV, ANG II
has an important role in modulating this response.
The mechanism whereby ANG II and hypoxaemia in¬
teract remains unclear, although in vitro studies have shown
that pulmonary but not mesenteric vascular smooth muscle
cells react to hypoxia by closing potassium channels [27],
The resultant membrane depolarisation results in an in¬
crease in intracellular calcium as a result of calcium influx
through voltage-dependent calcium channels and conse¬
quently smooth muscle contraction. ANG II is known to
increase intracellular calcium due to increased inositol
triphosphate production [28] and it has recently been sug¬
gested that it may act directly on calcium channels [29], It
may be that one subtype of potassium channel acts as a
hypoxia sensor in the pulmonary vasculature and that
ANG II may modulate acute HPV via its effect on calcium
flux or this potassium channel via membrane voltage
changes, such that in the absence of ANG II the hypoxic
signal, with respect to pulmonary vasoconstriction, is re¬
duced.
With respect to methodology, we have used Doppler-
echocardiography to measure haemodynamic changes in
the pulmonary circulation. These non-invasive techniques
have been shown to be highly reproducible [18] and the
close correlation between Doppler PAT and MPAP as
measured by right heart catheter, is well established
[19,30,31]. We looked at two measures of pulmonary
vasoconstriction; changes in MPAP and PVR. A possible
limitation of this methodology is that the use of total PVR
does not account for any changes in the post-capillary
vascular bed, as conventionally assessed by pulmonary
capillary wedge pressure (PCWP). In this respect we feel it
is unethical to insert Swan-Ganz catheters into normal
volunteers for research purposes particularly as volunteers
would have to be restudied on different days. The extra
information this would give us is, however, not essential.
Both groups were exposed to hypoxia and it is known
from previous work that hypoxaemia does not affect PCWP
and so effects on total PVR are reflective of changes in
true PVR in pre-capillary arterioles during hypoxia [32].
With respect to ANG II blockade, an acute dosing study
looking at the haemodynamic effects of losartan has shown
that it does not affect PCWP [33]. We believe therefore,
that the observed changes in total PVR are a true reflection
of changes in pulmonary vascular tone.
Thus, we have shown for the first time in man that
ANG II blockade with a type 1 ANG II antagonist attenu¬
ates acute HPV. This suggests that ANG II acts as an
important modulator of acute HPV in healthy humans via
its effects on the AT, receptor. One must be cautious when
extrapolating from normal volunteer studies to the clinical
situation. However, the ability of losartan to attenuate
HPV, the initial stimulus for pulmonary vascular remod¬
elling, suggests that it may delay or prevent progression
from chronic hypoxic lung disease to cor pulmonale.
Losartan may also have a role to play in the treatment of
cor pulmonale where vasoreactivity is still present. This
benefit may not only result from the interaction between
ANG II and hypoxia with respect to the pulmonary vascu¬
lar bed, but also as a consequence of blockade of the direct
pulmonary pressor effects of ANG II, particularly in pa¬
tients on oxygen therapy, where ANG II would be pre¬
dicted to exhibit proportionately greater pressor effects
[24],
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Abstract
Objectives: Angiotensin II (ANG II) is known to be a potent vasoconstrictor agent in the pulmonary circulation. Furthermore, type 1
ANG II receptor blockade with losartan attenuates acute hypoxic pulmonary vasoconstriction in normal subjects. The aim of this study
was therefore to evaluate the haemodynamic and endocrine sequelae of type 1 ANG II receptor blockade in patients with hypoxaemic cor
pulmonale. Methods: Nine patients with chronic obstructive pulmonary disease (COPD) age 67 + 3 years with pulmonary hypertension
and normal left ventricular systolic function were studied on two separate occasions in a double-blind, placebo-controlled, crossover
study. They were randomised to receive either 50 mg of oral losartan or matched placebo. Pulsed wave Doppler echocardiography was
used to measure cardiac output (CO), mean pulmonary artery pressure (MPAP) and hence systemic vascular resistance (SVR) and total
pulmonary vascular resistance (TPR). Haemodynamic measurements and venous blood samples were taken at baseline and after 2 and 4
h. Results: Maximal effects were observed at 4 h where losartan compared to placebo resulted in a significant reduction in both MPAP
(28.6 + 2.0 vs 32.4 + 1.5 mmHg) and TPR (428 ± 40 vs 510 ± 40 dyn • s • cm-5), respectively. Similarly losartan compared to placebo
resulted in a significant reduction in MAP (87 + 4.5 vs 93 + 3.2 mmHg) and SVR (1293 + 94 vs 1462 + 112 dyn-s-cm-5), and
significantly increased CO (5.58 + 0.43 vs 5.31 + 0.42 1/min). In addition, plasma aldosterone was significantly lower after treatment
with losartan compared to placebo: 76 + 23 vs 164 + 43 pg/ml respectively. Conclusions: Thus, selective type 1 ANG II receptor
blockade appears to have beneficial pulmonary and endocrine effects, suggesting a possible therapeutic role in the management of
hypoxaemic cor pulmonale.
Keywords: Angiotensin II; Losartan; Angiotensin receptor; Pulmonary hypertension; Human
The benefits of treating pulmonary hypertension in the
context of chronic hypoxic lung disease are unknown.
Oxygen therapy has been shown to reduce mean pul¬
monary artery pressure acutely [5], and reduce mortality in
patients with hypoxaemic cor pulmonale [3,4]. Whether
this is primarily due to improved systemic oxygenation or
a reduction in right ventricular afterload is not known.
Nevertheless, therapy that could either prevent or treat
pulmonary hypertension in these patients could conceiv¬
ably reduce both mortality and morbidity and have addi¬
tional benefits to oxygen therapy.
In the context of pulmonary hypertension, the role of
vasoactive peptides has been extensively investigated [6],
It is known that angiotensin II (ANG II) is a potent
Time for primary review 23 days.
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1. Introduction
Acute hypoxic pulmonary vasoconstriction (HPV) is an
important phenomenon present in a wide variety of differ¬
ent animal species allowing blood to be diverted from
areas of alveolar hypoxia, so maintaining ventilation perfu¬
sion matching. Although this undoubtedly has beneficial
effects, it can also have deleterious effects. In particular, in
chronic hypoxic lung disease, hypoxaemia provides a sus¬
tained stimulus to pulmonary vasoconstriction, resulting in
an elevation of mean pulmonary artery pressure [1], vascu¬
lar remodelling [2] and over time the development of cor
pulmonale and consequently a poor prognosis [3,4].
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pulmonary vasoconstrictor in man [7,8] and that patients
with hypoxaemic cor pulmonale have activation of the
renin-angiotensin-aldosterone system (RAAS) [9,10]. In¬
deed, ANG II has been shown to promote a growth
response in vascular smooth muscle cells [11], suggesting
the possibility that, in addition to acting as pressor agent,
ANG II could also contribute directly to vascular remod¬
elling. Interestingly angiotensin II converting enzyme in¬
hibitors (ACE inhibitors) have been shown to attenuate the
development of pulmonary hypertension in chronically
hypoxic rats [12], although there is conflicting evidence
from in vitro studies as to whether ANG II plays a
facilitatory role in modulating HPV [13,14], In normal
humans, however, ACE inhibition with lisinopril [15] and
type 1 ANG II receptor blockade with losartan [16] have
been shown to attenuate acute HPV. Subsequent studies in
patients with hypoxaemic cor pulmonale using ACE in¬
hibitors have shown variable pulmonary and systemic
haemodynamic benefit [17-21], Whether the beneficial
haemodynamic effects are a consequence of reducing ANG
II levels is unknown since ACE inhibitors also increase
levels of bradykinin, a vasodilator.
We have therefore evaluated for the first time the
effects of selective type 1 ANG II receptor blockade with
losartan, in patients with hypoxaemic cor pulmonale.
2. Methods
2.1. Subjects
Nine patients (6 male, 3 female), with clinically stable
cor pulmonale secondary to hypoxaemic cor pulmonale
(mean age + s.e.m. 67 + 3 years), were included in the
study after attending a screening visit to assess inclusion
criteria and characterise the study population. All had
spirometric evidence of obstructive airways disease
(FEV,/FVC < 70%) and arterial hypoxaemia whilst
breathing air (PaO, < 8.5 kPa) and had or gave a history
of having peripheral oedema. On echocardiography sub¬
jects were required to be in sinus rhythm, have normal left
ventricular function, no evidence of valvular heart disease
and a resting mean pulmonary artery pressure, whilst
Table I
Patient characterisitcs
FEV, (1) 0.78 + 0.09
FEV,% predicted (%) 30 + 2
FEV, /FVC 43 + 3
Pa 02 (kPa) on air 7.01 ±0.24
Pa CO, (kPa) on air 6.84 + 0.28
MPAP (mmHg) 32 + 2
The above values are expressed as means ± s.e.m. for respiratory func¬
tion and pulmonary huemodynamics in the patient group studied. FEV, =
forced expiratory volume in 1 s; FEV, /FVC = ratio of FEV, to forced
vital capacity; MPAP = mean pulmonary artery pressure.
breathing room air, of at least 25 mmHg. In addition, all
subjects had evidence of reversible, dynamic pulmonary
vasoconstriction as assessed by > 10% fall in MPAP on
breathing 60% oxygen for 30 min. All subjects were taking
inhaled bronchodilators (beta-agonist n = 9; anticholiner¬
gic n = 6) and inhaled steroids, five patients were taking
oral loop diuretics and 6 patients used domiciliary oxygen
for at least 15 h per day. Medications were unchanged
throughout the study period. The summary demographic
data for this patient group are given in Table 1.
2.2. Study protocol
All subjects gave informed written consent to the study
protocol previously approved by the Tayside Committee
for Medical Research Ethics and conforming with the
principles outlined in the Declaration of Helsinki. Subjects
were studied at the same time of the day on 2 separate
occasions at least 1 week apart in a randomised, double-
blind placebo-controlled, cross-over design. Patients taking
regular diuretics were asked to omit their morning dose of
diuretic on each visit. On each study day, an intravenous
cannula was sited in the right forearm for venous blood
sampling. Subjects then remained semi-recumbent
throughout and were studied whilst breathing room air.
Patients then received either 50 mg of oral losartan potas¬
sium (Merck Sharp and Dohme Ltd, Hertfordshire, UK) or
placebo. Haemodynamic parameters were measured and
blood samples were taken at baseline after subjects had
rested for at least 30 min to obtain stable resting hamody-
namics (ro), 2 h (7j) and 4 h (77) after administration of
either losartan or placebo.
2.3. Measurements
2.3.1. Oxygenation
Arterial blood oxygen saturation was continuously mon¬
itored by transcutaneous oximetry (CSI 503, Criticare Sys¬
tems Inc, Waukesha, WI, USA).
2.3.2. Systemic haemodynamics
Mean arterial blood pressure (MAP) and heart rate (HR)
were measured by semi-automatic sphygmomanometer
(Vital Signs Monitor, Critikon, Tampa, FL, USA) as the
mean of 3 consistent readings. Aortic cross-sectional area
(CSA) was measured by M-mode echocardiography
(Vingmed SD50). The aortic systolic velocity integral
(SVI) was measured by on-line computer-assisted determi¬
nation using pulsed-wave Doppler echocardiography of
ascending aortic blood flow from the suprasternal notch.
On-line calculations of stroke volume (SV = SVI X CSA)
and cardiac output (CO) as the product of SV and HR
were made. Total systemic vascular resistance (SVR) was
calculated as: SVR = MAP/CO X 80 dyn ■ s ■ cm"3. Re¬
producibility of our haemodynamic measurements includ-
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ing Doppler methodology was assessed in patients with cor
pulmonale by 3 repeat measurements over a 4 h period at 2
h intervals. This short-term co-efficient of variability for
MAP was 8.2%, CO was 9.6% and SVR was 5.3%.
2.3.3. Pulmonary haemodynamics
Pulmonary arterial flow was analysed by pulsed-wave
Doppler echocardiography (Vingmed SD50) from the sub¬
costal position to measure the pulmonary acceleration time
(PAT), being the time in milliseconds from the onset of
pulmonary flow to peak velocity. A stable pulsed-wave
Doppler signal was recorded with the mean of 3 consistent
waveforms at each time point used for the purpose of
analysis. Mean pulmonary artery pressure (MPAP) in
mmHg was then calculated using the regression equation
MPAP = 90 — (0.62 X PAT) as described by Dabestani for
pulmonary acceleration times < 110 ms [22].
Fig. 1 shows the correlation in our own hands between
measurements of PAT and MPAP made simultaneously
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Fig. I. Validation of Doppler-derived measures of mean pulmonary artery
pressure. Upper panel. Data comparing pulmonary acceleration time
(PAT) and simultaneously measured mean pulmonary artery pressure
(MPAP) during right heart catheterisation in patients with suspected
pulmonary hypertension. Lower panel. Data comparing catheter- and
Doppler-derived measures of mean pulmonary artery pressue (calculated
using Dabestani's regression equation MPAP = 73 —[0.42 X PAT]) during
right heart catheterisation in patients with suspected pulmonary hyper¬
tension.
undergoing right heart catheterisation after acute admission
to a coronary care unit, over a range of pulmonary artery
pressures (r = — 0.88, y=164 — 0.88 X , P< 0.0001, n
= 17). Using Dabestani's regression equation, MPAP = 73
— (0.42 X PAT) applicable to this range of pulmonary
acceleration times, a close correlation between Doppler
and catheter MPAP was also obtained (r = 0.88, y = 0.79
+ 4.2, P< 0.0001. n = 17). Total pulmonary vascular
resistance (TPR) was calculated as TPR = MPAP/CO X
80 dyn • s • cm-5. Reproducibility was assessed as before
and the short term co-efficient of variability for PAT was
3.2%, MPAP was 5.8% and TPR was 12.4%.
2.3.4. P. AAS activity and plasma creatinine
Samples for measurement of plasma renin activity
(PRA) were collected into chilled EDTA tubes and sam¬
ples for plasma aldosterone were collected in chilled
lithium-heparin tubes. They were centrifuged at 4°C imme¬
diately and separated plasma was stored at — 20°C until
assayed in one batch in duplicate at the end of the study.
PRA and plasma aldosterone were assayed using commer¬
cially available RIA kits (Sorin Biomedica, Saluggia, Italy).
PRA was assayed by measurement of amount of ANG I
generated per hour. The intra-assay coefficient of variation
for analysis of PRA was 6.50% and plasma aldosterone
was 8.77%.
2.4. Data analysis
Comparison of values between study days was made by
multifactorial analysis of variance (MANOVA) [23] and
where there was a significant difference the mean differ¬
ence and 95% confidence intervals for the mean difference
are given (95% CI). Comparisons between serial time
points on the same study day were made using Duncan's
multiple range test. A probability value of P < 0.05 (two-
tailed) was considered to be statistically significant. Data
are presented as means and s.e.m.
3. Results
3.1. Systemic haemodynamics
There were no significant differences in absolute values
of HR, SV, CO, MAP or SVR at baseline between study
days. Although there was no significant difference in either
MAP or SVR after treatment with losartan or placebo at 2
h, both MAP (P < 0.05, mean difference 5.7 mmHg, 95%
CJ 0.4-10.9) and SVR (P<0.01, mean difference 169
dyn s-cm"5, 95% CI 71-267) were significantly lower4
h after treatment with Iosartan compared to placebo (Fig.
2). Although losartan compared to placebo had no signifi¬
cant effects on SV, CO was significantly (P < 0.05) higher
4 h after losartan compared to placebo: mean difference
y=164-0.88x, r=-0.88, p<0.0001
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Fig. 2. Systemic haemodynamics. Upper panel: Mean arterial blood
pressure (MAP) measured at baseline, after 2 h and after 4 h. Lower
panel: Systemic vascular resistance (SVR) measured at baseline, after 2 h
and after 4 h. Treatment with losartan is represented by the bold triangles
whereas treatmenl with placebo is represented by the open circles. Values
are given as mean + s.e.m. " Represents a significant (P < 0.05) differ¬
ence between placebo and losartan at that time point whereas a +-sign





Fig. 3. Individual patient data on changes in vascular resistance. Upper
panel: Total pulmonary vascular resistance (TPR), measured at basline
and 4 h after acute administration of losartan 50 mg in 9 patients wih
hypoxaemic cor pulmonale. Lower panel: Systemic cascular resistance
(SVR), measured at basline and 4 h after acute administration of losartan
50 mg in 9 patients wih hypoxaemic cor pulmonale. Values are given as
mean + s.e.m. * Significant (P < 0.05) difference 4 h after administration
of losartan compared to baseline.
0.27 1/min (95% CI 0.04-0.50) (Table 2). Fig. 3 shows
the changes in SVR 4 h after administration of losartan
compared to placebo for individual patients. Whilst there
was no significant difference in HR between study days at
4 h. HR was significantly higher 4 h after treatment with




CO (1/min) P 5.47 ±0.42 5.56 + 0.49 5.31 ±0.42
L 5.26 + 0.32 5.37 + 0.46 5.58 ±0.43 *
SV (ml) P 79 + 7 79 + 7 75 + 7
L 76 + 6 78 + 6 76 + 6
HR (bpm) P 73 + 2 73 + 2 75 + 2
L 75 + 3 73 + 3 81 + 4 +
Values are given as mean + s.e.m. CO = cardiac output; SV = stroke
volume; HR = heart rate.P = placebo; L = losartan.
Significantly (P < 0.05) different from placebo at the same time point.
+
Significantly (P < 0.05) different from Tu.
3.2. Pulmonary haemodynamics
There was no significant difference in absolute values
of MPAP or TPR at baseline (T0) between study days.
Losartan compared to placebo resulted in a significant
(P<0.01) reduction in MPAP at 2 h (7)) (mean differ¬
ence 3.1 mmHg, 95% CI 1.6-4.6) and a significant (P <
0.05) reduction at 4 h (7*2) (mean difference 3.8 mmHg,
95% CI 0.3-7.3), respectively. Although there was no
significant difference in TPR between treatment with losar¬
tan and placebo at 2 h, TPR was significantly (P < 0.05)
lower 4 h after treatment with losartan compared to placebo:
mean difference 82 dyn•s•cm5 (95% CI 15-150). In
addition, both MPAP and TPR were significantly (P <
0.05) lower 4 h after treatment with losartan compared to
baseline (Fig. 4). Fig. 3 shows the changes in TPR 4 h
after administration of losartan compared to baseline for
individual patients.
3.3. RAAS activity and serum creatinine
There were no significant differences in absolute values
of PRA, plasma aldosterone or serum creatinine at baseline




















Fig. 4. Pulmonary haemodynamics. Upper panel: Doppler mean pul¬
monary artery pressure (MPAP) measured at baseline, after 2 h and after
4 h. Lower panel: Total pulmonary vascular reistance (TPR) measured at
baseline, after 2 h and after 4 h. Treatment with losartan is represented by
the bold triangles whereas treatment with placebo is represented by the
open circles. Values are given as mean + s.e..m. Represents a significant
(P<0.05) difference between placebo and losartan at that time point
whereas a +-sign represents a significant (P < 0.05) difference between
that timepoint and baseline.
between study days. Although there were no significant
differences between study days for PRA either at baseline
or 2 and 4 h after administration of losartan or placebo,
PRA was significantly increased 4 h after administration of
losartan compared to baseline. There were significant (P
Table 3


















164 + 43 +
76 + 23 * +
101+9
99 + 9
Values are given as mean + s.e.m. PRA = plasma renin activity.
Significantly (P < 0.05) different from placebo at the same time point.
+
Significantly (P < 0.05) different from T0.
< 0.05) falls in plasma aldosterone with time on both
study, but in addition losartan compared to placebo re¬
sulted in a significant (P < 0.05) reduction in plasma
aldosterone at 4 h (T2) (mean difference 89 pg/ml, 95%
CI 19-159). There were no significant differences in
plasma creatinine at baseline (7"0), 7, or T2 between study
days or with time on either study day (Table 3).
3.4. Oxygen saturation
There were no significant differences in oxygen satura¬
tion between days on which patients received placebo or
losartan at baseline (70) (91.4 ± 1.2 vs 91.1 + 1.1%), at T]
(90.7+ 1.1 vs 90.7+ 1.1%), or at T2 (90.7+ 1.2 vs 90.8
± 1.1%). respectively, or with time on either study day.
4. Discussion
We have demonstrated for the first time that the selec¬
tive type 1 ANG II receptor blocker, losartan, has benefi¬
cial pulmonary haemodynamic effects in hypoxaemic cor
pulmonale without altering oxygen saturation. In this re¬
spect both MPAP and TPR were significantly lower after
treatment with losartan compared to placebo, although this
effect was of small magnitude and of uncertain clinical
relevance. In addition, type 1 ANG II receptor blockade
appears to have beneficial endocrine effects reflected by
significantly lower levels of plasma aldosterone after treat¬
ment with losartan compared to placebo. We also noted a
significant reduction in both MAP and SVR as well as a
small but significant increase in cardiac output after treat¬
ment with losartan. This suggests that ANG II blockade
may have a therapeutic role in the management of hypox¬
aemic cor pulmonale.
Losartan a potent, orally active type 1 ANG II receptor
blocker (AT,) has provided us with a tool for elucidating
the role of ANG II in the pulmonary circulation in man. It
is a selective orally active selective AT, receptor antago¬
nist which shows no affinity for other hormonal receptors
and at a functional level excepting ANG II it does not alter
contractile response to a variety of different stimuli [24]
and has been shown to produce concentration-dependent
inhibition of ANG-II-induced vasoconstriction in vitro and
in vivo [25,26], Losartan undergoes an important first-pass
effect and is extensively transformed to its active metabo¬
lite, EXP 3174, reaching peak concentrations between 2
and 4 h after oral administration of losartan [27]. Early
studies in normal volunteers have confirmed antagonism of
pressor responses to exogenous administration of ANG I
and ANG II with approximately 60-70% inhibition of
control responses at maximum effect (3 h) [25,28]. Al¬
though the interaction of losartan with the eicosanoid
system has been observed in animals with high concentra-
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tions of the drug by some workers [29,30] it seems un¬
likely that this accounts for the observed effects to a
significant degree. Indeed, conflicting results surround evi¬
dence suggesting that losartan stimulates prostacyclin syn¬
thesis [29,31,32].
We examined the acute haemodynamic effects of a
single dose of oral losartan. Our patients had activation of
the RAAS system reflected by elevated levels of PRA at
baseline compared with our own normal reference range
(0.2-2.8 ng/ml/h). We also observed a significant in¬
crease in PRA 4 h after administration of losartan com¬
pared to baseline, consistent with blockade of the type 1
ANG II receptor in the juxtaglomerular apparatus, result¬
ing in renin secretion due to inhibition of ANG II mediated
negative feedback.
In terms of both systemic and pulmonary haemody¬
namic changes we observed maximal effect at 4 h Whether
the peak effect may have occurred after 4 h or if larger
doses of losartan would achieve greater pulmonary haemo¬
dynamic benefit or whether this would be limited by
systemic haemodynamic effects is not answered by this
study. Interestingly, acute dosing studies in patients with
congestive cardiac failure have shown no greater systemic
haemodynamic effects with doses of losartan of greater
than 25 mg of losartan and noted falls in MAP and SVR
after 2 h with peak effect observed between 4 and 12 h and
an effect still seen at 24 h [33], This study does however
suggest that ANG II contributes to the maintenance of both
pulmonary and systemic vascular tone in patients with
hypoxaemic cor pulmonale. Although ANG II has been
shown to have pressor effects in man [7,8], studies using
ACE inhibitors in patients with hypoxaemic cor pulmonale
have not consistently shown a pulmonary haemodynamic
benefit, possibly as a consequence of inclusion criteria
[17-21], We have, however, specifically excluded patients
who did not have demonstrable pulmonary vascular reac¬
tivity as assessed by the absence of a significant fall in
mean pulmonary artery pressure in response to acute oxy¬
gen administration. In this respect we feel it is important
that patients who are included in vasodilator trials have at
least some dynamic component to their pulmonary hyper¬
tension, a situation analogous to studying bronchodilator
therapy, where the degree of airway reversibility is estab¬
lished before evaluating the impact of therapy.
We observed a small but significant increase in cardiac
output after treatment with losartan compared to placebo,
and although HR was not significantly different between
study days, losartan significantly increased HR compared
to baseline. Although no significant increase in heart rate
has been observed in acute dosing studies with losartan in
patients with congestive cardiac failure, it is interesting
that an increase in HR was noted in studies performed in
normal volunteers pre-treated with oral frusemide [34].
This could possibly represent a reflex vagal withdrawal
response to an acute reduction in afterload or a direct
effect of losartan on the autonomic nervous system.
In terms of the methodology employed to measure
pulmonary haemodynamic changes, we have used the pul¬
monary acceleration time as a measure of mean pulmonary
artery pressure which we have sho reproducible in
both normal volunteer [35] and patient studies [36] and has
been shown to have a good correlation with catheter-de¬
rived measures in both our own hands and those of other
workers [22,37], although it is generally accepted that the
pulmonary acceleration time cannot be used to precisely
measure MPAP in a patient population [22]. We have
previously employed these methods to study the pul¬
monary vascular effects of vasoconstrictors [8] and va¬
sodilators [38], giving results which concur well with
invasive studies of the same agents [7,39] although some
sudies have shown a poor correlation between changes in
pulmonary acceleration time and catheter-measured MPAP
[40,41], Doppler echocardiography is also a well-validated
and reproducible measure of cardiac output [42], We do
not think that that the observed changes in TPR are likely
to be confounded by alterations in wedge pressure since in
cor pulmonale the increase in resistance is confined to the
precapillary vasculature.
In addition to beneficial pulmonary haemodynamic
changes, the inclusion of a placebo limb has allowed us to
examine the effects of ANG II receptor blockade on
plasma aldosterone levels. Plasma aldosterone is known to
increase following the assumption of the upright posture
and decrease following resumption of the supine posture
[43,44], an effect thought to be due to changes in both
aldosterone secretion and clearance [45]. As expected with
supine rest, plasma aldosterone levels fell on both study
days with falls on the placebo day similar to those seen in
normal volunteers [43], In addition, however, treatment
with losartan appears to have additional beneficial effects
with plasma aldosterone significantly lower 4 h after dos¬
ing. This reduction in plasma aldosterone is likely to
reflect a reduction in ANG-II-mediated aldosterone biosyn¬
thesis and secretion, and although ACE inhibitors have
been shown to have a similar effect, ANG II blockers may
theoretically produce greater aldosterone suppression since
bradykinin may indirectly potentiate aldosterone release
[46], By lowering plasma aldosterone, ANG II receptor
blockade may act to prevent excessive salt and water
retention, which may be an important precipitating factor
in acute exacerbations of cor pulmonale [47], The RAAS
also has significant trophic effects on vascular and cardiac
muscle [48], whether lowering aldosterone levels and in¬
hibiting the trophic effects of ANG II is sufficient to
inhibit these mitogenic effects is unknown but may be
important in arresting the cardiopulmonary remodelling
characterising this condition.
So to conclude, in addition to previous work demon¬
strating that ANG II receptor blockade can attenuate the
acute hypoxic pulmonary vasoconstrictor response, we have
now shown that the acute administration of losartan has
beneficial pulmonary haemodyna"' ?nd endocrine effects
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without worsening systemic oxygenation. Whether manip¬
ulating the renin-angiotensin-aldosterone system with
ACE inhibitors or angiotensin II blockade may be of
therapeutic value in hvpox ;emic cor pulmonale by inhibit¬
ing cardiopulmonary elling or reducing right ventric¬
ular afterload can only be answered by conducting large,
long-term follow-up studies.
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Background - Secretion of the vaso¬
constrictor peptide endothelin-1 from vas¬
cular endothelium is increased by various
stimuli. Whether hypoxaemia affects
plasma levels of endothelin-1 in humans
is unknown, but this may be important in
the haemodynamic response to hyp¬
oxaemia. The plasma endothelin-1 con¬
centrations in hypoxaemic humans has
therefore been measured.
Alethods — Plasma levels of endothelin-1
were measured by specific radio¬
immunoassay in 10 control subjects at rest
and following 30 minutes of acute hyp¬
oxaemia (SaO, 75-80%) induced by breath¬
ing a nitrogen/oxygen mixture, and in 10
patients with hypoxaemic cor pulmonale.
Results - The plasma endothelin-1 con¬
centration in control subjects was in¬
creased from a mean (SE) of 0-90 (0-11)
pmol/1 at baseline to 2-34 (0-34) pmol/1
during hypoxaemia. In patients with cor
pulmonale the plasma endothelin-1 con¬
centration was 2-96 (0-34) pmol/1, raised in
comparison with control subjects at rest
but similar to levels in controls during
hypoxaemia.
Conclusions - Plasma levels ofendothelin-
1 were increased by hypoxaemia in
humans. The raised levels observed in
patients with cor pulmonale may largely be
attributable to the effects of hypoxaemia,
although the pathophysiological sig¬
nificance of these observations remains to
be established.
(Thorax 1995;50:1308-1310)
Keywords: endothelin, cor pulmonale, hypoxaemia.
The endothelins are a group of structurally
similar peptides synthesised by vascular endo¬
thelium. These peptides act via two specific
receptors. Stimulation of the type A endothelin
receptor (ET^), the main subtype found on
vascular smooth muscle cells,1 results in pro¬
found and longlasting vasoconstriction, whilst
stimulation of the type B receptor (ETB) causes
release of vasodilator metabolites and transient
vasodilation.2 Interestingly, however, in rat pul¬
monary resistance vessels in vitro ETB ac¬
tivation may be important in mediating
endothelin-1 induced vasoconstriction.3 In
humans, endothelin-1 is the most potent vaso¬
constrictor substance known through its rel¬
atively selective activation of the ETA receptor.4
A role in the maintenance of vascular tone
is suspected but this remains speculative at
present.
Synthesis of this peptide is increased by a
number of humoral and physical stimuli, in¬
cluding hypoxia, which may be patho-
physiologically relevant.5 In vitro studies have
shown that acute hypoxia increases endothelin-
1 production by human endothelial cells6
whilst, in experimental animals in vivo, hypoxia
increases plasma concentrations of endothelin-
1.' The effect of hypoxaemia on endothelin-1
in humans is unknown but may be relevant in
the cardiovascular adaptations to hypoxaemia
and the circulatory abnormalities seen in con¬
ditions such as* cor pulmonale.
We have therefore studied the effects of hyp¬
oxaemia on plasma endothelin-1 levels in





Ten young male volunteers of mean (SE) 28-1
(2-2) years were smdied. None was taking pre¬
scribed medication and all had a normal clinical
history and examination, 12-lead electro¬
cardiogram, echocardiogram, and haemato-
logical and biochemical screen, and forced
expiratory volume in one second (FEV,) of
>90% predicted.
Cor pulmonale patients
Ten patients (six men) of mean (SE) age 73-4
(1 -7) years with clinically stable cor pulmonale
secondary to chronic obstructive pulmonary
disease were studied. All had obstructive pat¬
tern spirometry (FEV,/forced vital capacity
(FVC) <70%), arterial hypoxaemia while
breathing air (Pao, <8-0 kPa), and had or gave
a history of having peripheral oedema despite
normal left ventricular function (on echo¬
cardiogram or radionuclide ventriculography),
normal renal function (serum creatinine
<120mmol/l), and normal serum albumin
(>35 g/1). Patients with other significant cardio¬
vascular disease were excluded.
In this group, FEV, in litres was 0-75 (0-06)
(range 0-36-1-11), FEV, as % of predicted
33-8 (5-2) (range 19-61), Pao2 on air 6-30
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(0-34) kPa (range 4-35-7-80), and Paco, on
air 6-17 (0-50) kPa (range 3-84-8-80).
PROTOCOL
Informed consent was obtained to the protocol
previously approved by the Tayside committee
for medical research ethics. Baseline venous
blood samples were taken into chilled EDTA
tubes after 30 minutes supine rest while breath¬
ing air. Control subjects only were then
rendered hypoxaemic (steady state Sao, 75-
80% measured by pulse oximetry) for 30 min¬
utes by breathing a variable nitrogen/oxygen
mixture before taking a further blood sample.
ENDOTHELIN-1 ASSAY
Samples were centrifuged at 2000 rpm at 4°C
for 15 minutes and stored at —70°C. Assay
was carried out using a commercially available
radioimmunoassay kit (Nicholls Institute Diag¬
nostics, San Juan Capistrano, CA, USA) after
solid phase extraction on CI8 silica columns.
The lower limit of detection was 0-4 pmol/1
and the intra-assay coefficient of variation was
4-5%. The anti-endothelin antibody used was
100% specific for endothelin-1 and had cross-
reactivity of 96% with endothelin-3 and 7%
with proendothelin.
DATA ANALYSIS
After testing for normality of distribution, be¬
tween group comparisons were made by ana¬
lysis of variance followed by Duncan's multiple
range testing with p<0-05 considered sig¬
nificant.8 Results are expressed as mean (SE)
with 95% confidence intervals (CI) for sig¬
nificant differences.
Controls
Levels of endothelin-1 in 10 controls when normoxaemic (Cj) and following 30 minutes
hypoxaemia (9), and in 10 patients with cor pulmonale (/\) ■ Boxes indicate sample
means with standard error bars and asterisks indicate values significantly (p<0-05)
different from normoxaemic controls.
Results
The plasma endothelin-1 concentration in
normoxaemic controls was 0-90 (0-11) pmol/
1. After 30 minutes hypoxaemia it increased
significantly to 2-34 (0-34) pmol/1 (95% CI for
mean difference 0-41 to 2-48). In patients with
cor pulmonale the plasma endothelin-1 con¬
centration was 2-96 (0-34) pmol/1, significantly
greater than control subjects when norm¬
oxaemic (95% CI for mean difference 1-02 to
3-09) but not when hypoxaemic.
The plasma endothelin-1 concentration
therefore increased 2-6-fold in response to hyp¬
oxaemia in controls and was raised 3-3-fold in
patients with cor pulmonale compared with
normoxaemic controls. Results from individual
subjects with sample means are depicted in the
figure.
Discussion
These findings indicate that hypoxaemia in¬
creases plasma levels of endothelin-1 in
humans. In patients with cor pulmonale, endo-
thelin-1 was increased to levels comparable
to those in normal subjects rendered acutely
hypoxaemic. It is interesting to note that base¬
line levels in controls were similar to those
observed in other series," and that the increase
following hypoxaemia and in patients with cor
pulmonale is comparable to the rise seen in
normal subjects at high altitude.10
These observations in humans are largely
confirmatory of in vitro and animal studies
which have shown hypoxia to be a potent stim¬
ulus for endothelin-1 synthesis and gene
expression.6' In normal humans Therkelson et
al found that 15 minutes ofhypoxaemia caused
only a small increase in plasma endothelin-1
which was not statistically significant, perhaps
due to the shorter duration of the stimulus."
Abnormally high levels of endothelin-1 have
been described in a series of patients with
pulmonary hypertension of varying aetiology,
not all of whom were hypoxaemic,9 and thus
other stimuli may also be implicated. In the
present series, by excluding subjects with other
significant cardiovascular diseases such as hy¬
pertension and congestive heart failure, we feel
hypoxaemia is the most significant stimulus
responsible for increased endothelin-1 levels in
cor pulmonale. The in vitro evidence would
suggest that the increased endothelin-1 levels
observed were due to increased synthesis al¬
though, as endothelin-1 clearance mechanisms
in humans have not been fully characterised,5
the possibility of decreased removal cannot be
discounted.
The potent vasoactive properties of endo¬
thelin-1 may also be responsible for some of
the circulatory abnormalities seen during hyp¬
oxaemia, although plasma levels may not ac¬
curately reflect local concentrations and hence
vasoconstrictor activity. Whether endothelin-1
acts as a mediator of acute hypoxic pulmonary
vasoconstriction is unknown. Support for this
hypothesis might be drawn from studies using
endothelin receptor blockers which can at¬
tenuate acute hypoxic pulmonary vaso¬
constriction in rats12 and prevent development
1310 Cargill, Kiely, Clark, Lipworih
of pulmonary hypertension following chronic
hypoxia.13 These drugs now need to be tested
in humans where it is likely that endothelin-1
plays a significant part in the cardiovascular
response to hypoxaemia.
Manipulation of the endothelin system may
therefore be a useful measure in patients with
hypoxaemic lung disease, either to prevent or
treat the cardiopulmonary consequences of
chronic hypoxaemia.
The authors thank Gillian Pirie and Wendy Coutie for per¬
forming endothelin assays.
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Abstract
Objectives: Endothelin-1 levels are elevated in a number of conditions characterised by impaired cardiovascular performance and
abnormal vasoconstriction such as congestive cardiac failure and primary and secondary pulmonary hypertension. The aim of the present
study was to assess the effects of the vasoconstrictor peptide endothelin-1 on pulmonary and systemic haemodynamics and cardiovascular
performance in normal man. Methods: Ten healthy male volunteers were studied on two occasions in a randomised, double-blind,
placebo-controlled, cross-over study and received systemic infusions of either endothelin-1 (0.75, 1.5 and 3 pmol - kg" 1 • min" 1 for 30
min each) or saline placebo. Systemic and pulmonary haemodynamic parameters were monitored non-invasively by pulsed-wave Doppler,
as were parameters of left and right ventricular diastolic filling and inotropic state. Effects on renin-angiotensin and natriuretic peptide
system activity were also measured. Results: Endothelin-1 infusion produced dose-related falls in heart rate, stroke volume and cardiac
output. Systemic vascular resistance (SVR) increased from 1156 + 57 to 1738 + 115 dyn-s-cm"5, and total pulmonary vascular
resistance (TPR) increased from 142+ 12 to 329 + 22 dyn s-cm-5. Endothelin-l caused significant impairment of left and right
ventricular diastolic filling, even at a low dose which had no pulmonary or systemic pressor effects. Electromechanical and Doppler
acceleration indices of inotropic state were also significantly impaired. Activity of the renin-angiotensin system was suppressed by
endothelin-l whilst plasma levels of atrial natriuretic peptide (ANP) were unchanged. Conclusions: Thus, in addition to systemic and
pulmonary pressor effects our results suggest that endothelin-l impairs overall cardiovascular performance by causing diastolic
dysfunction and acting as a negatively inotropic agent. These effects were associated with compensatory changes in the renin-angiotensin
system.
Keywords: Endothelin; Vasoconstriction; Endothelium; Renin-angiotensin-aldosterone system; ANP; Human
1. Introduction
Endothelial function is an important regulator of vascu¬
lar tone although the physiological roles of the endothe-
lium-derived relaxing and constricting factors and their
functional antagonism remain the subject of much ongoing
research effort. In terms of vasoconstriction, the family of
peptides known as the endothelins have emerged as being
of major importance. These are a group of structurally
similar peptides synthesised by vascular endothelium which
act via two specific receptors. Stimulation of the type A
endothelin receptor (ETA) results in a gradual onset but
long-lasting vasoconstriction whilst stimulation of the type
B receptor (ETB), causes release of vasodilator metabolites
and transient vasodilatation but may also be involved in
the vasoconstrictor response [1]. ETA receptors are the
main subtype found on vascular smooth muscle cells [2]
and have also been localised to the heart and adrenal gland
[3], In vitro, endothelin-l is the most potent vasocon¬
strictor substance known through its relatively selective
activation of the G-protein-linked ETA receptor [4] as well
as being the most abundant endothelin isoform in human
plasma [5].
Release of endothelin-l from endothelial cells is stimu¬
lated by a variety of physical and chemical stimuli in vitro
[1] whilst in humans in vivo, hypoxia and angiotensin II
increase plasma concentrations of endothelin-l [6,7]. Ab¬
normalities of circulating endothelin-l concentrations have
also been observed in a number of conditions characterised
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by abnormal vasoconstriction such as hypertension [8],
congestive heart failure (CHF) [9], primary pulmonary
hypertension (PPH) [10]. and hypoxaemic cor pulmonale
[6], raising the possibility that endothelin-1 may play a
pathogenic role in both cardiovascular and cardiopul¬
monary disease. As the physiological effects of endothelin-
1 in man have not been fully studied, a precise understand¬
ing of this role remains elusive.
Although in previous in vivo studies in man, endothe¬
lial increased systemic blood pressure [11] and caused
renal vasoconstriction [12], the effects of endothelin-1 on
the pulmonary vasculature and cardiovascular performance
are not known. Furthermore, the design of some studies
[11] has not allowed for the prolonged action of endothe-
lin-1 and, as such, may have produced misleading informa¬
tion.
We have therefore evaluated the effects of systemic
endothelin-1 administration in healthy volunteers. This
study documents effects on systemic and pulmonary




Ten healthy, non-obese, male volunteers, age (mean +
s.e.m.) 26.1 + 1.4 years were studied. All had normal
clinical history and examination. 12-lead electrocardio¬
gram, echocardiogram and haematological and biochemi¬
cal screen. Subjects refrained from alcohol, tobacco and
caffeine for at least 12 h and had taken no medications for
at least 1 month before the study. Informed consent was
obtained to the study protocol previously approved by the
Tayside Committee for Medical Research Ethics and this
investigation conforms with the principles outlined in the
Declaration of Helsinki.
2.2. Protocol
Subjects were studied at the same time of day on 2
occasions at least 1 week apart in a randomised, double-
blind, cross-over design. Subjects were randomised prior
to commencement of the study with both subject and
echocardiographer (DGK) blinded with respect to the in-
fusate. After completion of the final study day and of all
measurements and calculations the active and placebo days
were revealed to allow statistical analysis to be performed.
On arrival at the clinical laboratory, intravenous cannulae
were sited in both forearms for infusion (left) and blood
sampling (right). Subjects then remained supine, turned
slightly on the left side throughout the study. After allow¬
ing at least 30 min rest to achieve baseline haemodynamic
parameters, infusion of either pharmaceutical grade human
endothelin-1 (Clinalfa AG; Laufelfingen, Switzerland) or
identical volume placebo (0.9% saline) was commenced in
random order. Endothelin-1 was infused at 0.75 pmol •
kg-' -min-1 for 30 min, then increased to 1.5 pmol •
kg-1 -min-1 for 30 min and then to 3.0 pmol-kg-1 •
min-1 for a further 30 min. Infusions were then discontin¬
ued and subjects monitored for a further 60 min. Measure¬
ments were made at baseline, at the end of each infusion
dose period and 30 and 60 min after stopping the infusion.
2.3. Measurements
For each Doppler-derived parameter, the mean of 3
consistent waveforms recorded at each time point was used
for the purpose of analysis.
2.3.1. Haemodynamic indices
Systolic (SBP), mean (MAP), diastolic arterial blood
pressure (DBP) and heart rate were measured using a
semi-automatic sphygmomanometer (Vital Signs Monitor;
Critikon. Tampa, FL, USA) and averaged over 3 sequential
readings. To measure cardiac output (CO), aortic cross-
sectional area (CSA) was first measured by M-mode
echocardiography (Vingmed SD50; Vingmed Sound,
Horten, Norway) from the left parasternal view at the level
of the aortic root. The aortic systolic Bow velocity integral
(SVI) was then measured by computer analysis of the
pulsed-wave Doppler profile of aortic blood flow from the
suprasternal notch. Stroke volume (SV = SVI X CSA) and
hence CO, as the product of SV and HR, were then
calculated on-line. Systemic vascular resistance (SVR) was
then calculated as SVR = MAP/CO X 80 dyn • s • cm-5.
Measurement of pulmonary flow acceleration time
(PAT) by pulsed-wave Doppler echocardiography
(Vingmed SD50) from the left 3rd/4th intercostal space
allowed calculation of mean pulmonary artery pressure
(MPAP) using the regression equation MPAP = 73 — (0.42
X PAT) which has been shown to have a good correlation
with MPAP measured simultaneously during cardiac
catheterisation in patients with pulmonary hypertension
[13]. Total pulmonary vascular resistance (TPR) was then
calculated as TPR = MPAP/CO X 80 dyn • s • cm-5. The
coefficients of variability (CV) for the Doppler measure¬
ments in this study were: SV 4.9%, CO 9.3%, MPAP
4.5%.
2.3.2. Lusitropic indices
From the apical window, pulsed-wave Doppler analysis
of mitral and tricuspid diastolic flow (Vingmed SD50) was
combined with simultaneous phonocardiography with the
microphone (Siemens AG; Munich, Germany) positioned
over the 2nd left intercostal space. Recordings were all
made during expiration with a display sweep speed of 100
mm/s. Transmitral and transtricuspid flow was analysed
after adjusting sample volume depth to yield maximal
E-wave velocities with clearly defined flow velocity en-
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velopes. Aortic and pulmonary components of the second
heart sound were identified on the phonocardiogram trace
by noting closure artefacts from superimposition of aortic
and pulmonary Doppler flow profiles.
From diastolic transmitral and transtricuspid flow, max¬
imal velocities of the early (Evmax) and atrial (Avmax)
components of flow were measured, and the E/A ratio
was calculated. The isovolumic relaxation time (IVRT)
was calculated for the left ventricle as the time in millisec¬
onds from the aortic component of the phonocardiogram
second heart sound to the onset of diastolic transmitral
flow, and for the right ventricle, the time from the pul¬
monary component of the phonocardiogram second heart
sound to the onset of diastolic transtricuspid flow. The CV
for these measurements were: mitral Evmax 12.2%, mitral
Avmax 17.2%, transmitral E/A ratio 12.4%, left ventricular
IVRT 13.8%, tricuspid Evraax 8.8%, tricuspid Avmax 14.2%,
transtricuspid E/A ratio 14.8%, right ventricular IVRT
29.1%.
2.3.3. Inotropic indices
Simultaneous lead II ECG, phonocardiogram (Siemens
AG) and pulsed-wave Doppler ascending aortic blood flow
(Vingmed SD50) were recorded as described. From these
recordings, the following variables were measured: aortic
peak acceleration (Accpeak), aortic mean acceleration
(Accmean) and electromechanical systole (QS2) from ECG
Q-wave to the second heart sound on phonocardiogram.
QSt was corrected for changes in HR according to stan¬
dard criteria [14] and is denoted QS2I. The CV values for
these measurements were: Accpeak 18.7%, Accmean 12.5%
and QS2I 3.5%.
2.3.4. Laboratory analyses
Following collection, all samples were kept on ice until
centrifugation at 3000 rpm for 15 min at 4°C. Plasma
sodium and potassium were measured using an internal
caesium standard flame photometer (Instrumentation Labo¬
ratory, Milan, Italy). Samples for plasma aldosterone assay
were collected into chilled lithium-heparin tubes and for
measurement of plasma renin activity (PRA) into chilled
EDTA tubes and stored at — 20°C until assayed in one
batch at the end of the study.
Assays were carried out using commercially available
radioimmunoassay kits which assayed aldosterone directly
(Sorin Biomedica, Saluggia, Italy) and PRA (Sorin
Biomedica) by measurement of amount of angiotensin I
generated per hour. For assay of atrial natriuretic peptide
(ANP), venous blood was collected into EDTA tubes
containing 4000 KIU aprotinin before centrifugation and
plasma kept at — 70°C until assayed in one batch at the
end of the study. After solid-phase extraction from plasma,
assay was performed using a commercially available ra¬
dioimmunoassay kit (Incstar Corporation, Wokingham,
Berkshire, UK). The intra-assay CV for these assays were:
PRA 7.6%, aldosterone 8.3%, ANP 8.0%.
Time (minutes) Time (mlnutesl
Fig. 1. Systemic and pulmonary haemodynamic changes in response to endothelin-1 (□) and placebo (O) infusions. The doses of endothelin-1 infused are
shown in diagramatic form on the jr-axis. Endothelin-1 was infused at 0.75 pmol kg~1 min~1 for 30 min, then increased to 1.5 pmol-kg-1 ■ min~1 for 30
min and then to 3.0 pmol• kg"1 -min-1 for a further 30 min. * Significant difference from placebo at the same time point. Significant difference from
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2.4. Data analysis
Comparisons were made between active and placebo
treatments for each treatment by repeated measures analy¬
sis of variance (ANOVA). Where the overall ANOVA was
significant, Duncan's multiple range testing was used to
determine differences at individual time points. A R-value
of less than 0.05 was considered significant and results are
expressed as means + s.e.m.
3. Results
There were no significant adverse effects during the
study although one subject felt transiently nauseous and
sweaty during maximal rate infusion of endothelin-1.
3.1. Haemodynamic effects
Baseline conditions on each study day were similar for
all haemodynamic parameters measured. Endothelin-1 had
significant systemic pressor effects compared with placebo,
where MAP was elevated following medium- and high-dose
endothelin-1 infusion and remained significantly greater
than placebo for 30 min after stopping the infusion (Fig.
1). Data for SBP and DBP are given in Table 1 where the
pattern of changes was similar. HR decreased during
medium and high dose endothelin-1 infusion compared
with placebo and remained significantly lower than placebo
for 30 min after stopping infusions (Fig. 1) whilst SV was
only significantly reduced during high dose endothelin-1
infusion (Table 1). CO also decreased during medium and
high dose endothelin infusion but was not significantly
different from placebo during the recovery period (Fig. 1).
Endothelin-1 significantly increased SVR during medium
and high dose infusion and remained greater than placebo
after 30 min recovery (Fig. 1). In the pulmonary circula¬
tion, both MPAP and TPR were increased by medium and
high dose infusion, remaining higher than placebo after 30



























Fig. 2. Changes in inotropic indices in response to endothelin-1 (□) and
placebo (O) infusions. The doses of endothelin-1 infused are shown in
diagramatic form on the a:-axis. Endothelin-1 was infused at 0.75 pmol-
kg ~1 • min ~1 for 30 min. then increased to 1.5 pmol • kg ~1 ■ min ~1 for 30
min and then to 3.0 pmol kg" 1-min~1 for a further 30 min. " Signifi¬
cant difference from placebo at the same time point. 1 Significant differ¬
ence from baseline during endothelin-1 infusion.
3.2. Inotropic effects
Aortic Accmean and Accpeak were similar at baseline on
each study day. Both parameters decreased during endothe¬
lin-1 infusion to levels significantly lower than placebo
during medium and high dose infusion for Accpeak (Fig. 2)
and at high dose only for Accmean (Fig. 2). Compared with
placebo, QS2I was significantly prolonged only during
high dose endothelin-1 infusion (Fig. 2).
Table 1
Systemic haemodynamics in response to endothelin-1 and placebo infusions
Time (min)
0 30 60 90 120 150
SBP (mmHg) Placebo 112±2.9 107 + 2.9 106 ±2.5 108 ±3.5 110 ± 2.8 110 ± 3.6
Active 108 + 2.5 107 + 2.2 109 + 2.1 114±3.5 *f 113 ±1.9 112 ±1.9
DBP (mmHg) Placebo 61+2.5 58 ±2.5 57 ±2.5 60 ±2.2 60 ± 1.7 61 + 2.2
Active 57 + 2.0 57+ 1.8 62 ±2.1 "f 67 ±3.2 *f 64 ± 1.8 * + 64 ±2.4 f
SV (ml) Placebo 90 + 4.0 89±4.2 88 ±3.6 86 ±3.2 87 ±4.7 89 ±4.4
Active 90 ±3.8 88±4.4 85 ±4.6 81 ±5.0 t 90 ±4.6 90 ±4.3
Absolute values (mean + s.e.m.) of systolic and diastolic blood pressure (SBP, DBP) and stroke volume (SV) during placebo and endothelin-1 infusion.
Significant difference from placebo at the same time point.
Significant difference from baseline during endothelin-1 infusion.

































Fig. 3. Echo-Doppler parameters of left (LV) and right (RV) ventricular filling in response to endothelin-1 (□) and placebo (O) infusions. The doses of
endothelin-1 infused are shown in diagramatic form on the x-axis. Endothelin-1 was infused at 0.75 pmol-kg-1 -min-1 for 30 min. then increased to 1.5
pmol • kg"1 • min~1 for 30 min and then to 3.0 pmo! - kg 1 ■ min~ 1 for a further 30 min. Significant difference from placebo at the same time point.
Significant difference from baseline during endothelin-1 infusion.
Table 2
Left and right ventricular filling parameters in response to endothelin-1 and placebo infusions
All units (m-s ') Time (min)
0 30 60 90 120 150
Mitral Placebo 70 + 4.1 69 + 4.3 71+4.0 68 ±3.4 70±3.2 68 ±4.0
F V^
max Active 71+3.9 71 +4.2 62 + 3.3 *t 59 + 3.4 *t 63 ±3.0 t 71 ±4.4
Mitral Placebo 42+1-9 42 ± 1.7 43+1.6 41 + 1.7 41 ±1.6 41 ± 1.8
AVmax Active 41 + 1.7 43 + 2.0 40+1.8 40 + 2.4 38 ±1.8 42 ±2.7
Tricuspid Placebo 47+1.7 45+1.2 47+1.3 46+1.3 46± 1.4 46± 1.2
F V
max Active 46 + 2.1 46 + 2.1 45+1.8 43+1.7 42 ±0.7 43 ± 1.0 T
Tricuspid Placebo 31 + 1.0 30+ 1.1 31 + 1.2 30 ±0.9 32± 1.1 31 ±0.8
A Vmax Active 30 + 0.9 32+ 1.4 31 + 1.0 31 ± 1.5 29 ±0.9 29± 1.3
Absolute values (mean + s.e.m.) of transmitral and transtricuspid E- and A-■wave maximal velocity during placebo and endothelin-1 infusion.
Significant difference from placebo at the same time point.
Significant difference from baseline during endothelin- 1 infusion.
Table 3
Serum electrolytes and atrial natriuretic peptide in response to endothelin-1 and placebo infusions
Time (min)
0 30 60 90 120 150
Na(mmoir') Placebo 138 + 0.7 138 + 0.6 138 + 0.8 138 + 0.6 136 ±0.8 138 ± 1.0
Active 137 + 0.7 138 + 0.7 137 + 0.9 137 ±0.8 137 ±0.6 138 ±0.6
K(mmol.r') Placebo 4.0 + 0.08 4.1 +0.04 4.1+0.06 4.1 ±0.05 4.0 ±0.06 4.1 ±0.08
Active 4.1+0.07 4.2 + 0.11 4.1 +0.08 4.2 ±0.06 4.2 ±0.08 4.2 ±0.09
ANP (pmol-I-1) Placebo 4.82+ 1.53 4.61 +0.59 4.36 + 0.43 4.05 ±0.49
Active 5.57 + 0.68 5.97 + 0.43 5.71+0.79 6.00 ±0.71
Absolute values (mean + s.e.m.) of serum sodium (Na), potassium (K) and atrial natriuretic peptide (ANP) during placebo and endothelin-1 infusion. There
were no significant differences between endothelin-1 and placebo treatments or with time.
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3.3. Lusitropic effects
All lusitropic parameters were similar at baseline on
each study day. Mitral and tricuspid E/A ratio decreased
during endothelin-1 infusion and were significantly differ¬
ent from placebo during high dose infusion only (Fig. 3).
These changes were due to falls in Evmax rather than
increases in Avmax (Table 2). IVRT was a more sensitive
marker of impaired ventricular filling where in the left
ventricle IVRT was prolonged by endothelin-1 even at the
lowest infusion rate compared with placebo (Fig. 3) whilst
in the right ventricle, IVRT during endothelin-1 infusion
was not significantly different from placebo but was pro¬
longed from baseline during medium and high dose infu¬
sion (Fig. 3).
3.4. Endocrine effects
Plasma sodium and potassium were similar at baseline
on both study days and did not change significantly during
either placebo or endothelin-1 infusion (Table 3). PRA was
similar at baseline on both days and fell significantly from
baseline after 90 min of placebo infusion (Fig. 4). The fall
during endothelin-1 infusion was however more rapid and
levels were significantly lower than baseline after low dose
infusion and continued to fall up to 60 min after stopping
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Fig. 4. Changes in renin-angiotensin system activity in response to
endothelin-1 (□) and placebo (O) infusions. The doses of endothelin-1
infused are shown in diagramatic form on the .v-axis. Endothelin-1 was
infused at 0.75 pmol-kg"'•min-1 for 30 min, then increased to 1.5
pmol • kg - 1 ■ min -1 for 30 min and then to 3.0 pmol ■ kg -1 ■ min -1 for a
further 30 min. Significant difference from placebo at the same time
point. ' Significant difference from baseline during active infusion.
during medium and high dose endothelin-1 infusion and
throughout the recovery period (Fig. 4). There was no
difference in plasma aldosterone either at baseline or fol¬
lowing endothelin-1 infusion compared with placebo. Lev¬
els fell significantly from baseline after 60 min of placebo
infusion and then began to plateau (Fig. 4). Levels also fell
following endothelin-1 infusion, reaching a significant
nadir at the medium dose (Fig. 4). No effect on plasma
ANP levels was observed during either placebo or en¬
dothelin-1 infusion (Table 3).
4. Discussion
Although endothelin-1 was initially characterised as a
vasoconstrictor, it is clear from the present study that in
addition to pressor effects, endothelin-1 may also have
direct effects on myocardial function in man. In compari¬
son with animal studies [15], these effects were observed
using relatively low doses of endothelin-1, although just
exceeding the previously highest reported dose in humans
[11]. We have administered endothelin-1 exogenously in a
range of doses, with the lowest dose achieving levels of
endothelin-1 found in pathophysiological states whilst the
higher doses will have achieved so-called 'pharmacologi¬
cal' concentrations. Unlike previous studies we have not
measured plasma endothelin-1 levels as this appears highly
variable between individuals during infusions of endothe¬
lin-1 [11], and as endothelin-1 has paracrine rather than
endocrine actions, plasma levels may not be comparable
with levels measured in pathological states. In these condi¬
tions plasma levels are likely to represent 'spillover' with
much higher levels of endothelin-1 found abluminally. It is
for these reasons that our dose range included infusions
that were known to achieve pathophysiological concentra¬
tions of endothelin-1 and greater. The relatively longer
infusion times in the present investigation have also al¬
lowed a clearer definition of the dose-related effects of
endothelin-1 than would be obtained with shorter dose
increments.
4.1. Study limitations
The parameters in this study were measured non-inva-
sively due to ethical considerations and as such have
associated limitations. Although our indices of inotropicity
and lusitropicity have previously been validated [16-18],
these measures can be affected to greater or lesser degrees
by loading conditions and we have alluded to this in the
text. Doppler echocardiography was used to measure
haemodynamic changes in the pulmonary circulation. Pul¬
monary acceleration time, which we have shown to be
reproducible in our own hands, was used to estimate mean
pulmonary artery pressure which has been shown to have a
good correlation with catheter-derived measures, although
in a patient population it cannot be accurately used to
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precisely estimate pulmonary artery pressure [13,19], Al¬
though estimation of changes in pulmonary artery pressure
over time may be accurate, some caution should be used
when taking these values for further calculations. We
looked at two measures of pulmonary vasoconstriction
changes in MPAP and TPR. A limitation of this methodol¬
ogy is that TPR neglects the downstream pressure of the
pulmonary circulation, namely left atrial pressure, as con¬
ventionally assessed by pulmonary capillary wedge pres¬
sure (PCWP). Although this may be increased if left
ventricular function is impaired, as was the case in this
study, the magnitude of the changes observed in the pul¬
monary vascular bed suggest an effect on the pre-capillary
vasculature. With respect to Doppler measures of cardiac
output, these are accepted as a relatively accurate measure
which can be made in most patients [20]; the major source
of error is generally accepted as measurement of the
annular diameter and this would be mitigated by the
cross-over design of the study. In addition, it remains
difficult to separate primary from secondary effects of
endothelin-1 on cardiopulmonary performance using this
protocol, although some of the data do support direct
effects on the heart.
4.2. Systemic and pulmonary haemodynamic effects
The haemodynamic effects of endothelin-1 in man are
not well characterised although our haemodynamic data
agree with findings from animal studies [15], Our study
confirms that endothelin-1 is a potent in vivo systemic
vasoconstrictor and it is interesting to note that MAP and
SVR were elevated compared to baseline for at least 30
min after stopping the infusion, indicating prolonged vaso¬
constriction. This is in keeping with in vitro data [21] and
with the observation that although plasma levels fall rapidly
after stopping endothelin-1 infusion, the increase in blood
pressure is maintained [11]. The relative bradycardia and
fall in CO during endothelin infusion may have been due
to a vagal reflex response to systemic vasoconstriction,
myocardial ischaemia or due to a direct effect on the
conducting system of the heart.
Most previous studies have neglected the action of
endothelin-1 on pulmonary haemodynamics. We have tried
to characterise these using non-invasive techniques which
we have previously employed to study the pulmonary
vascular effects of vasoconstrictors [22] and vasodilators
[23], giving results which concur well with invasive studies
of the same agents [24,25]. We have measured TPR and
not pulmonary vascular resistance (PVR) and as such have
neglected the downstream pressure of the pulmonary circu¬
lation. Our results suggest that endothelin-1 impairs dias¬
tolic function and acts as a negatively inotropic agent, and
as such have reasons to believe that left atrial pressure did
increase in these subjects. Although we cannot conclude
that PVR was increased in our subjects, the magnitude of
the changes in the pulmonary vascular bed is consistent
with a vasoconstrictor effect for endothelin-1, an effect
that would be predicted from in vitro and animal studies
[15,26]. At a receptor level, although still attributable to
endothelin-1, some debate exists about the role that activa¬
tion of the ETb receptor plays in producing pulmonary
vasoconstriction [27].
4.3. Inotropic and lusitropic effects
Our findings also support the hypothesis that endothe¬
lin-1 has negative inotropic effects and impairs ventricular
filling in humans and is similar to the findings of previous
animal studies [28], We have used echo-Doppler parame¬
ters and systolic time intervals to assess left ventricular
contractility as both QS2I and Accpe.lk are thought to be
relatively independent of loading conditions. In this re¬
spect, in vitro and in vivo work have shown that changes
in QS,I reflect inotropic influences and that load condi¬
tions only have a proportionately small effect on this
interval [29], although conflicting data exist regarding
Doppler-derived parameters of ascending aortic flow
[30,31]. Studies examining the effect of afterload on trans-
mitral flow patterns have been hampered by difficulties
involving sympathetic and neurohormonal activation; how¬
ever, the general consensus is that afterload decreases early
filling velocity and E/A ratio [32]. The IVRT also varies
with changes in afterload and prolongation of the IVRT is
directly related to the natural logarithm of aortic closing
pressure [33], Although the changes in IVRT and our
Doppler indices of left and right ventricular function can
be explained in part by increases in afterload, it is impor¬
tant to note that changes in left ventricular IVRT were
observed at low-dose endothelin-1 infusion which had no
significant pressor effects. This suggests that endothelin-1
may impair ventricular filling via a direct effect on the
myocardium as well as by increasing afterload.
Thus, in addition to a reflex response to vasoconstric¬
tion, the observed fall in CO and SV may also be due to a
direct effect of endothelin-1 on the myocardium possibly
mediated through the ETA receptor which is found on
cardiac muscle [3], although a secondary effect from my¬
ocardial ischaemia remains a possibility, despite the ab¬
sence of clinical or ECG evidence of ischaemia in these
subjects. Alternatively, endothelin-1 by directly affecting
myocyte calcium handling could lead to inefficient excita¬
tion-contraction coupling, an effect observed in vitro [34].
The changes in IVRT observed were of similar magnitude
to abnormalities associated with pulmonary heart disease
[35] and hypertensive heart disease [36]. Whether endothe¬
lin-1 contributes to the ill-defined syndrome of diastolic
heart failure is also unknown.
4.4. Endocrine effects
In terms of effects on the renin-angiotensin system
(RAS), endothelin-1 has been variously reported to have
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stimulatory and inhibitory actions [1], In vitro studies
would indicate that endothelin-1 inhibits renin release [37]
and stimulates aldosterone release in cell culture [38],
although in humans in vivo this effect may be offset by
renal vasoconstriction [12] increasing renin release and
hence aldosterone, as no effect on these parameters has
been reported [11,12]. The findings of the present study are
therefore of interest where the inclusion of a placebo limb
allows the prolonged, time-dependent fall in parameters of
RAS activity to be considered. We observed PRA to fall in
comparison with placebo after medium dose infusion, an
effect which continued throughout the remainder of the
study even when haemodynamic parameters had nor¬
malised. This therefore provides indirect evidence for a
direct effect on renin production rather than a phenomenon
secondary to renal vasoconstriction. The pattern with re¬
gard to aldosterone was different where, although not
significantly different from placebo, there was a biphasic
response during endothelin-1 infusion. This apparent disso¬
ciation of components of the RAS may be related to
increases in ACTH-mediated effects on aldosterone secre¬
tion. In addition, despite the increase in cardiac afterload,
no change in plasma ANP concentration was observed.
Contrary to a previous study in humans [11], we found
no significant effects on plasma electrolytes, a finding in
agreement with animal studies [15]. The possibility that
mild haemolysis was responsible for this finding has been
raised [11] and thus different peptide or infusion prepara¬
tion practices may have been responsible.
5. Conclusions
We have shown that endothelin-1, in addition to potent
pressor effects, has adverse effects on both inotropic and
lusitropic parameters. These new findings may be impor¬
tant in considering the pathophysiological role of endothe-
lin-1 in both cardiovascular and cardiopulmonary disease.
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Nitric oxide: an important role in the maintenance of systemic and
pulmonary vascular tone in man
David G. Kiely, Alison F. C. Lee, Allan D. Struthers & Brian J. Lipworth
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee DDI 9SY, Scotland, UK
Aims The aim of this study was to examine whether nitric oxide (NO) has an
important role in maintaining basal vascular tone in normal man by examining the
effects of nitric oxide inhibition using A/^-monomethyl-l-arginine (l-NMMA) on
systemic and pulmonary haemodynamics.
Methods Ten normal male volunteers 26 + 1.6 years were studied on two separate
occasions in a double-blind, placebo controlled crossover study. They were
randomised to receive either a continuous infusion of l-NMMA (4 mg kg 1 h ')
with a front loaded bolus (4 mg kg ) or volume matched placebo. Pulsed wave
Doppler echocardiography was used to measure cardiac output (CO), mean
pulmonary artery pressure (MPAP) and hence systemic vascular resistance (SVR)
and total pulmonary vascular resistance (TPR). Measurements were made prior to
infusion (t0) and after 4, 8, and 12 min (6, t2 and f3).
Results Infusion of l-NMMA significantly increased mean arterial blood pressure
(MAP), SVR and TPR and significantly reduced heart rate (HR), stroke volume
(SV) and CO compared to placebo. These effects were observed at f and persisted
during the entire infusion period.
Conclusions These results are consistent with a role for basal nitric oxide generation
in the maintenance of basal systemic and pulmonary vascular tone in normal man.
Keywords: nitric oxide, pulmonary circulation, systemic circulation
Introduction
Endothelial function is known to be an important determi¬
nant of vascular tone although the physiological roles of the
endothelium-derived relaxing and constricting factors and
their functional antagonism remain the subject of much
ongoing research effort. Much interest surrounds a potent
short acting vasodilator, nitric oxide, which is generated by
the vascular endothelium through the action of nitric oxide
synthase [1], Studies in animals using systemic infusions of
nitric oxide synthase inhibitors such as N°-monomethyl-l-
arginine (l-NMMA) have demonstrated an increase in mean
arterial pressure and systemic vascular resistance [2, 3],
Evidence in humans suggesting an important role for nitric
oxide generation in the maintenance of systemic vascular
tone comes from studies demonstrating that infusion of l-
NMMA into the brachial artery results in vasoconstriction
[4] and systemic infusions of l-NMMA increase systemic
vascular resistance [5].
There is however, some debate as to the role of nitric
oxide generation in the maintenance of the low pressure
pulmonary circulation where conflicting results exist suggest¬
ing the possibility of species specificity [6—10]. Interestingly,
studies in animals and humans have suggested that impaired
endothelial relaxing activity may contribute to the pathogen¬
esis of pulmonary hypertension [11, 12]. To date only
Stamler and his colleagues have examined the effects of
Correspondence: Dr David G. Kiely, Department of Clinical Pharmacology, Ninewells
Hospital and Medical School, Dundee DDI 9SY, Scotland, UK.
nitric oxide inhibition on pulmonary vascular tone in normal
man in a dose ranging study [6]. This study examines for
the first time in a placebo controlled manner the effects of
nitric oxide inhibition on pulmonary vascular tone in normal




Ten healthy, non-obese, male volunteers, age (mean +
s.e.mean) 26+1.6 years were studied. All had normal clin¬
ical history and examination, 12-lead electrocardiogram,
echocardiogram and haematological and biochemical screen.
Subjects refrained from alcohol, tobacco and caffeine for at
least 12 h and had taken no medications for at least 1 month
before the study. Informed consent was obtained to the
study protocol previously approved by the Tayside
Committee for Medical Research Ethics and this investigation
conforms with the principles outlined in the Declaration
of Helsinki.
Protocol
Subjects were studied at the same time of day on two
occasions in a randomized, double blind, cross-over design.
Subjects then remained supine, turned slightly on the left
side throughout the study. After allowing at least 30 min
rest to achieve baseline haemodynamic parameters they
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received either a continuous infusion of l-NMMA
(4 mg kg 1 h 1) with a front loaded bolus (4 mg kg 1)
given over 2 min or volume matched placebo (0.9% normal
saline). Measurements were made prior to infusion (t0) and
after 4, 8, and 12 min (q, f2 and 13).
Measurements
For each Doppler derived parameter, the mean of three
consistent waveforms recorded at each time point was used
for the purpose of analysis. MAP and HR were measured
by semi-automatic sphygmomanometer (Vital Signs
Monitor; Critikon, Tampa, FL, USA) and averaged over
three sequential readings. To measure CO, aortic cross-
sectional area (CSA) was first measured by M-mode
echocardiography (Vingmed SD50; Vingmed Sound,
Florten, Norway) from the left parasternal view at the level
of the aortic root. The aortic systolic flow velocity integral
(SVI) was then measured by computer analysis of the pulsed-
wave Doppler profile of aortic blood flow from the
suprasternal notch. Stroke volume (SV = SVIxCSA) and
hence CO, as the product of SV and HR, were then
calculated on-line. Measurement of pulmonary flow acceler¬
ation time (PAT) by pulsed-wave Doppler echocardiography
(Vingmed SD50) from the left 3rd/4th intercostal space
allowed calculation of mean pulmonary artery pressure
(MPAP) using the regression equation MPAP =
73 —(0.42 x PAT) which has been shown to have a good
correlation with MPAP measured simultaneously during
cardiac catheterisation in patients with pulmonary hyperten¬
sion in both our own hands [13] and those of other workers
[14]. The coefficients of variability (CV) for these Doppler
measurements in this study were HR: 12.8%; SV: 18.7%;




























Figure 1 Systemic and pulmonary pressor effects of l-NMMA
and placebo infusions in normal man. Asterisk (*) indicates
significant difference between infusion with i-NMMA and
placebo at that time point. Cross ( + ) indicates significant
difference from baseline during l-NMMA infusion.
Data analysis
Comparisons were made between active and placebo
treatments by repeated measures analysis of variance
(ANOVA). Where the overall ANOVA was significant,
Duncan's multiple range testing was used to determine
differences at individual time points. A P value of less than
0.05 was considered significant and results are expressed as
means+ s.e.mean and where a difference between means is
quoted, the 95% confidence (CI) for this difference is given.
Results
Acute administration of l-NMMA was not associated with
any adverse effects during the study. Baseline conditions on
each study day were similar for all haemodynamic parameters
measured. l-NMMA had significant pressor effects compared
with placebo, where both SVR (P=0.02); mean difference
479 dyn s cm"5 (95% CI 87-872) and TPR (P= 0.02); 63
dyn s cm D (95% CI 15-110) were elevated at 6 and these
effects persisted throughout the entire infusion period
(Figure 1). Although MAP was significantly increased during
infusion of I.-NMMA compared with placebo at q (P=
0.03); mean difference 5 mmHg (95% CI 1—10) an effect
that persisted throughout the entire infusion period, MPAP
was unchanged. In addition HR (P = 0.003); mean difference
9 beats min (95% CI 5-13) and CO (P= 0.02); mean
difference 1.741 min 1 (95% CI 0.33—3.15) were signifi¬
cantly lower during infusion with l-NMMA compared with
placebo at q an effect that persisted throughout the infusion
period (Table 1).
Discussion
Our results suggest that basal generation of NO is important
in the regulation of both systemic and normoxic pulmonary
vascular tone in normal man reflected by an increase in
both SVR and TPR during inhibition of nitric oxide
synthesis.
The systemic effects of NO inhibition in man are well
documented. Our results however suggest that in addition
that resting normoxic pulmonary vascular tone is dependent
on the continuous generation of nitric oxide. In this respect
infusion of l-NMMA resulted in a significant increase in
TPR which was sustained throughout the entire infusion
period. The lack of effect on MPAP is likely to reflect the
coexistent reduction in cardiac output Although this
phenomenon has been shown in some lower mammals [7,
8] it has not been demonstrated in either rat [9] or dog
models [10]. The results of this study support the findings
of Stamler et al. [6] who demonstrated a similar effect during
a dose ranging study in normal man. In addition, our results
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Table 1 Haemodynamic effects of l-
NMMA and placebo infusions in normal tg tj t2 t3
HR P 71 ±2 69 + 3 70 + 4 67 + 3
(beats min 1) L 68 + 4 60±4* + 59±3* + 57±3* +
SV P 102 ±5 104 + 6 101+4 111+6
(ml) L 100 + 6 95 ±6 + 91 ±5 + 90±7* +
CO P 6.92 + 0.47 6.91+0.48 6.66 + 0.44 7.21+0.56
(1 min-1) L 6.34 + 0.52 5.17 + 0.5*"1" 5.10±0.41* + 5.27 ±0.52* +
MAP P 87 + 3 89 + 3 89 + 3 87 + 3
(mmHg) L 90 + 3 94±3* + 95±3 + 94 ±2*+
MPAP P 11 + 1 11 + 1 12 + 1 11 + 1
(mmHg) L 10 + 1 12 + 1 12 + 2 12 + 1
Absolute values (mean + s.e.mean). Asterisk (*) indicates significant difference between infusion with
l-NMMA (L) and placebo (P) at that time point. Cross (+) indicates significant difference from
baseline during l-NMMA infusion.
suggest that these changes persist throughout a more
prolonged infusion period.
We chose to use a dose of l-NMMA based on findings
from previous in vivo studies conducted in man to ensure a
good profile of nitric oxide inhibition over the whole time
course of the study and found comparable systemic
haemodynamic effects. Previous work by Haynes et ah [5]
examined the maximal haemodynamic responses to
increments in doses of l-NMMA. He examined on separate
days doses of l-NMMA in ascending order (0.03, 0.1, 0.3,
1.0, 3.0 mg kg *) infused over 60 min and then 3 mg kg 1
l-NMMA infused over 20 min then the same dose infused
over 5 min via a peripheral cannula. Although, at doses
|
> 1 mg kg there was an apparent decrease in heart rate,
cardiac index and an increase in peripheral vascular resistance
no effect on blood pressure was observed until a dose of
3 mg kg 1 was given over 20 min when there were isolated
increases in both systolic and diastolic blood pressure but
these did not occur consistently at similar time points. He
and co-workers performed the definitive study using
3 mg kg 1 over 4 min and found maximal increases in mean
arterial blood pressure 10 min after the start of the infusion.
In a dose ranging study by Stamler et al. [6] the
haemodynamic responses to dosages of 0.01, 0.03, 0.1, 0.3
and 1.0 mg kg 1 min 1 each for 3 min via a central venous
catheter sheath were examined. Although an increase in
mean arterial blood pressure was observed at 0.1 mg kg 1
min 1 infused over 3 min no effects were observed on the
pulmonary vascular bed until the maximal rate of infusion
l.Omgkg ' min 1 given over 3 min. The discrepancy
between effects on the systemic and pulmonary vascular
beds may be explained by in vitro studies suggesting that l-
NMMA is a relatively ineffective inhibitor of NO synthase
in pulmonary blood vessels [15].
We used a front loaded infusion i.e. a combination of
bolus with a continuous infusion to give a good overall
profile of NO inhibition over the whole time course of the
study. We infused an initial 4 mg kg 1 bolus over 2 min (ie
2 mg kg 1 min 1 for 2 min) with a continuous infusion of
4 mg kg ' h 1 to ensure that we would achieve maximal
NO inhibition during the period under investigation. The
maximal haemodynamic changes in this study were noted
at 4 min and persisted throughout the entire infusion period.
We cannot comment whether haemodynamic changes
occurred earlier than 4 min since the time scale of
measurements was influenced partly by the time required
for signal acquisition and measurements to be made in
triplicate.
In addition for safety considerations we did not feel that
a dose escalation above the infusion rate used in this study
would be safe because of worries over limiting systemic
hypertension and worries over precipitating coronary vascular
spasm. The evidence from studies suggests that l-NMMA is
a relatively ineffective inhibitor ofNO synthase in pulmonary
blood vessels [15] and therefore to construct a dose response
curve based on the results of previous studies would have
meant doubling and quadrupling our dose of l-NMMA and
exposing our patients to unwanted risks.
With respect to methodology, we have used non-invasive
Doppler-echocardiography to measure haemodynamic
changes in the pulmonary circulation. These non-invasive
techniques have been shown to be reproducible [16] and
the close correlation between Doppler PAT and MPAP as
measured by right heart catheter, is well established both in
our own hands and those of other workers [13, 14, 17, 18],
Less, however, is known of the correlation between changes
in MPAP and PAT. Using regression equations incorporating
PAT, Chow et al. [19] examined patients before and after
pulmonary thromboendarterectomy and although statistically
significant the correlation between changes in PAT and
catheter measures of MPAP was weak (r= —0.41). Beard
et al. [20], however, showed a good correlation in 11 normal
subjects made hypoxic r= —0.73. In addition studies
performed in normal man using this non-invasive method¬
ology concur with results of invasive studies and we
therefore feel that the available evidence supports our view
that PAT can be used to assess changes in the pulmonary
vascular bed, particularly in normal volunteers where
repeated cardiac catheterisation is viewed by some including
ourselves as unethical. Doppler derived measures of cardiac
output have been shown to be reproducible and correlate
well with invasive measures [21], The major source of error
is generally accepted as measurement of the annular diameter
and this would be mitigated by the cross-over design of
this study.
There is a growing body of evidence suggesting that
endothelial dysfunction is important in the development of
hypoxic pulmonary hypertension. Endothelium dependent
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relaxation is reduced in chronically hypoxic rats [11] and in
man in end stage chronic hypoxic lung disease endothelium
dependent pulmonary artery relaxation is impaired and in
addition the contractile responses to pressor stimuli increased
[12]. These patients are known to have elevated levels of
pressor substances such as endothelin-1 |22], which has been
shown to be potent pressor agent in man in vivo [23], and
may have significantly greater pressor effects in the context
of a dysfunctional endothelium.
In addition to pressor effects we also noted a reduction
in HR, CO and SV. This may have been mediated via a
baroreceptor reflex and increase in left ventricular afterload
although a role for nitric oxide generation in the maintenance
of cardiac output remains a possibility.
To conclude, we have shown that basal nitric oxide
generation is important in maintaining basal vascular tone.
In disease states an imbalance of constricting and relaxing
factors may contribute to both systemic and pulmonary
vasoconstriction. The development of therapies which are
able to deliver relaxing factors such as nitric oxide to the
site of endothelial dysfunction holds promise, particularly in
chronic hypoxic lung disease where effective therapies
are limited.
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